



(11)

EP 2 780 039 B9

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)

Corrections, see

Description Paragraph(s) 74, 155, 185, 695, 699

Claims DE 19

Claims EN 19

Numerous spelling errors of minor importance

(51) Int Cl.:

A61K 47/50^(2017.01)

(86) International application number:

PCT/IB2012/056224

(87) International publication number:

WO 2013/072813 (23.05.2013 Gazette 2013/21)

(48) Corrigendum issued on:

18.04.2018 Bulletin 2018/16

(45) Date of publication and mention
of the grant of the patent:

29.11.2017 Bulletin 2017/48

(21) Application number: **12787111.9**

(22) Date of filing: **07.11.2012**

(54) **CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF**

ZYTOTOXISCHE PEPTIDE UND ANTIKÖRPERWIRKSTOFFKONJUGATE DAFÜR

PEPTIDES CYTOTOXIQUES ET CONJUGUÉS ANTICORPS-MÉDICAMENTS DE CEUX-CI

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **17.11.2011 US 201161561255 P**
27.07.2012 US 201261676423 P

(43) Date of publication of application:

24.09.2014 Bulletin 2014/39

(60) Divisional application:

17201829.3

(73) Proprietor: **Pfizer Inc.**

New York, NY 10017 (US)

(72) Inventors:

- **DOROSKI, Matthew David**
Mystic, Connecticut 06355 (US)
- **MADERNA, Andreas**
Stony Point, New York 10980 (US)

- **O'DONNELL, Christopher John**
Mystic, Connecticut 06355 (US)
- **SUBRAMANYAM, Chakrapani**
South Glastonbury, Connecticut 06073 (US)
- **VETELINO, Beth Cooper**
North Stonington, Connecticut 06359 (US)
- **DUSHIN, Russell George**
Old Lyme, Connecticut 06371 (US)
- **STROP, Pavel**
San Mateo, California 94402 (US)
- **GRAZIANI, Edmund, Idris**
Chestnut Ridge, NY 10977 (US)

(74) Representative: **Pfizer**

European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 (FR)

(56) References cited:

WO-A2-2005/081711 WO-A2-2007/008848
WO-A2-2008/052187

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 780 039 B9

- DORONINA SVETLANA O ET AL: "Novel peptide linkers for highly potent antibody-auristatin conjugate", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 19, no. 10, 1 October 2008 (2008-10-01), pages 1960-1963, XP008098503, ISSN: 1043-1802, DOI: 10.1021/BC800289A [retrieved on 2008-09-20]
- SVETLANA O. DORONINA ET AL: "Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity", BIOCONJUGATE CHEMISTRY, vol. 17, no. 1, 1 January 2006 (2006-01-01), pages 114-124, XP055009264, ISSN: 1043-1802, DOI: 10.1021/bc0502917

Remarks:


The file contains technical information submitted after the application was filed and not included in this specification

[0001] The present invention is directed to novel peptide-based compounds useful as payloads in antibody-drug-conjugates (ADC's), and payload-linker compounds useful in connection with ADC's. The present invention further relates to compositions including the aforementioned payloads, payload-linkers and ADC's, and methods for using these payloads, payload-linkers and ADC's, to treat pathological conditions including cancer.

[0002] Conjugation of drugs to antibodies, either directly or via linkers, involves a consideration of a variety of factors, including the identity and location of the chemical group for conjugation of the drug, the mechanism of drug release, the structural elements providing drug release, and the structural modification to the released free drug. In addition, if the drug is to be released after antibody internalization, the mechanism of drug release must be consonant with the intracellular trafficking of the conjugate.


[0003] While a number of different drug classes have been tried for delivery via antibodies, only a few drug classes have proved efficacious as antibody drug conjugates, while having a suitable toxicity profile. One such class is the auristatins, derivatives of the natural product dolastatin 10. Representative auristatins include (N-methylvaline-valine-dolaisoleuine-dolaproine-norephedrine) and (N-methylvaline-valine-dolaisoleuine-dolaproine-phenylalanine). However, there remains a need for additional auristatins with improved properties.

[0004] The present invention relates to cytotoxic pentapeptides and antibody drug conjugates thereof represented by formula:




or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,


W is



R¹ is hydrogen, C₁-C₈ alkyl, or C₁-C₈ haloalkyl, or R¹ is a linker or a linker-antibody such as



15 Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈heterocyclo-, -C₁-C₁₀alkylene-arylene-, -arylene-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo)-, -(C₃-C₈carbocyclo)-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo)- or -(C₃-C₈ heterocyclo)-C₁-C₁₀alkylene-;
Z is



-NH₂ or -NHL;

G is halogen, -OH, -SH or -S-C₁-C₆ alkyl;



L is an antibody;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R^{3A} and R^{3B} are defined as either of the following:

(i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or

(ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;



-S(=O)₂R', -SR' and arylene-R', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ heterocyclyl, C₁-C₁₀ alkylene-C₃-C₈ heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C₁-C₁₀ heterocyclyl;

R⁶ is hydrogen, -C₁-C₈ alkyl, -C₂-C₈ alkenyl, -C₂-C₈ alkynyl or -C₁-C₈ haloalkyl;

R¹² is hydrogen, C₁-C₄ alkyl, C₁-C₁₀ heterocyclyl or C₆-C₁₄ aryl;


R¹³ is C₁-C₁₀ heterocyclyl; and

R⁷ is F, Cl, I, Br, NO₂, CN and CF₃;

h is 1, 2, 3, 4 or 5; and


X is O

[0005] The present invention relates to cytotoxic pentapeptides and antibody drug conjugates thereof represented by formula:



or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is



R¹ is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;


R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;


R^{3A} and R^{3B} are defined as either of the following:

(i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, C₁ or halogen; and R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or hydrogen; or


(ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R⁵ is







10




20



40



Chemical structures of compounds 1 and 2 are shown. Compound 1 is a benzamide derivative with a cyclobutane ring and a wavy line indicating a variable group. Compound 2 is a benzamide derivative with a wavy line indicating a variable group.



-NH₂ or -NHL;

G is halogen, -OH, -SH or -S-C₁-C₆ alkyl;

L is an antibody;

R⁷ is F, Cl, I, Br, NO₂, CN and CF₃;

h is 1, 2, 3, 4 or 5; and

X is O.

[0006] Another aspect of the invention relates to pharmaceutical compositions including an effective amount of any one of the aforementioned compounds and/or any one of the aforementioned antibody drug conjugates and a pharmaceutically acceptable carrier or vehicle.

[0007] Another aspect of the invention relates to the aforementioned compounds and/or any one of the aforementioned antibody drug conjugates for use to treat cancer by administering to a patient in need thereof an effective amount of said compound and/or conjugate.

[0008] Another aspect of the invention relates to the aforementioned compounds and/or any one of the aforementioned antibody drug conjugates for use to treat cancer wherein said cancer includes a tumor, metastasis, or other disease or disorder characterized by uncontrolled cell growth wherein said cancer is selected from the group consisting of carcinomas of the bladder, breast, cervix, colon, gliomas, endometrium, kidney, lung, esophagus, ovary, prostate, pancreas, melanoma, stomach, and testes.

BRIEF DESCRIPTION OF THE FIGURES

[0009]

Figure 1 depicts a graph of anti-tumor activity of four conjugates (each administered at 1 mg/kg, Q4dx4) plotted as tumor volume over time.

Figure 2 depicts a graph of anti-tumor activity of six conjugates (each administered at 1 mg/kg, Q4dx4) plotted as drug-treated tumor volume/vehicle-treated tumor volume over time.

Figure 3 depicts the results of the testing of H(C)-#D54 and H(C)-vcMMAE at 1 mg/kg s

Figures 4A, 4B and 4C depict **[A]** results of testing of H(C)-#D54 and H(K)-MCC-DM1 in a MDA-MB-361-DYT2 mouse xenograft in vivo screening model; **[B]** results of the testing of H(C)-vcMMAE and H(C)-mcMMAF in a MDA-MB-361-DYT2 mouse xenograft in vivo screening model; and **[C]** a comparison of the calculated T/C for all four conjugates. Mice were treated q4dx4, starting on day 1.

Figures 5A, 5B, 5C, 5D, 5E and 5F depict the dose response results of the testing **[A]** H(C)-#D54, **[B]** H(C)-vcMMAE, **[C]** H(C)-mcMMAF and **[D]** H(K)-MCC-DM1 in a N87 mouse xenograft in vivo model; **[E]** a comparison of H(C)-#D54 and H(C)-vcMMAE; and **[F]** a comparison of T/C for all four conjugates. Mice were treated q4dx4, starting on day 1.

Figure 6 depicts the dose response results of the testing H(C)-#A115 at 1 mpk, 3 mpk and 10 mpk, in a N87 mouse xenograft in vivo model. Mice were treated q4dx4, starting on day 1.

Figure 7 shows data comparing humanized antibody hu08 conjugated to vc-0101 or mc-3377, tested in an in vivo xenograft model with PC3MM2 cells, a human prostate cancer cell line that expresses the IL-13R α 2 receptor.

Figures 8A through E show **[A]** the efficacy of rat-human chimeric anti-Notch ADCs dosed at 5mg/kg in HCC2429 lung xenografts; **[B and C]** the efficacy of rat-human chimeric anti-Notch ADCs dosed at 5mg/kg in MDA-MB-468 breast xenografts; **[D and E]** the efficacy of rat-human chimeric anti-Notch ADCs dosed at 5mg/kg in N87 gastric xenograft.

DETAILED DESCRIPTION

[0010] The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates comprising said cytotoxic pentapeptides, and to methods for using the same to treat cancer and other pathological conditions. The invention also relates to methods of using such compounds and/ conjugates in vitro, in situ, and in vivo for the detection, diagnosis or treatment of mammalian cells, or associated pathological conditions.

Definitions and Abbreviations

[0011] Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings. When trade names are used herein, the trade name includes the product formulation, the generic drug, and the active pharmaceutical ingredient(s) of the trade name product, unless otherwise indicated by context.

[0012] The term "antibody" (or "Ab") herein is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments that exhibit the desired biological activity. An intact antibody has primarily two regions: a variable region and a constant region. The variable region binds to and interacts with a target antigen. The variable region includes a complementary determining region (CDR) that recognizes and binds to a specific binding site on a particular antigen. The constant region may be recognized by and interact with the immune system (see, e.g., Janeway et al., 2001, Immuno. Biology, 5th Ed., Garland Publishing, New York). An antibody can be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2). The antibody can be derived from any suitable species. In some embodiments, the antibody is of human or murine origin. An antibody can be, for example, human, humanized or chimeric.

[0013] The terms "specifically binds" and "specific binding" refer to antibody binding to a predetermined antigen. Typically, the antibody binds with an affinity of at least about $1 \times 10^7 \text{ M}^{-1}$, and binds to the predetermined antigen with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.

[0014] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.

[0015] The term "monoclonal antibodies" specifically includes "chimeric" antibodies in which a portion of the heavy and/or light chain is identical to or homologous with the corresponding sequence of antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical to or homologous with the corresponding sequences of antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.

[0016] As used herein, "H(C)-" refers to trastuzumab (trade name HERCEPTIN®) which is a monoclonal antibody that interferes with the HER2/neu receptor, bound through one of its' cystine to compound of the invention. As used herein, "H(K)-" refers to trastuzumab which is a monoclonal antibody that interferes with the HER2/neu receptor, bound through one of its' lysines to compound of the invention.

[0017] An "intact antibody" is one which comprises an antigen-binding variable region as well as a light chain constant domain (C_L) and heavy chain constant domains, C_{H1} , C_{H2} , C_{H3} and C_{H4} , as appropriate for the antibody class. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof.

[0018] An intact antibody may have one or more "effector functions", which refers to those biological activities attributable to the Fc region (e.g., a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include complement dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis.

[0019] An "antibody fragment" comprises a portion of an intact antibody, preferably comprising the antigen-binding or variable region thereof. Examples of antibody fragments include Fab, Fab', $F(ab')_2$, and Fv fragments, diabodies, triabodies, tetrabodies, linear antibodies, single-chain antibody molecules, scFv, scFv-Fc, multispecific antibody fragments formed from antibody fragment(s), a fragment(s) produced by a Fab expression library, or an epitope-binding fragments

of any of the above which immuno specifically bind to a target antigen (e.g., a cancer cell antigen, a viral antigen or a microbial antigen).

[0020] The term "variable" in the context of an antibody refers to certain portions of the variable domains of the antibody that differ extensively in sequence and are used in the binding and specificity of each particular antibody for its particular antigen. This variability is concentrated in three segments called "hypervariable regions" in the light chain and the heavy chain variable domains. The more highly conserved portions of variable domains are called the framework regions (FRs). The variable domains of native heavy and light chains each comprise four FRs connected by three hypervariable regions.

[0021] The term "hypervariable region" when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" (e.g., residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (L3) in the heavy chain variable domain; Kabat et al. (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and/or those residues from a "hypervariable loop" (e.g., residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917). FR residues are those variable domain residues other than the hypervariable region residues as herein defined.

[0022] A "single-chain Fv" or "scFv" antibody fragment comprises the V.sub.H and V.sub.L domains of an antibody, wherein these domains are present in a single polypeptide chain. Typically, the Fv polypeptide further comprises a polypeptide linker between the V.sub.H and V.sub.L domains which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

[0023] The term "diabody" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a variable heavy domain (V_H) connected to a variable light domain (V_L) in the same polypeptide chain. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 0 404 097; WO 93/11161; and Hollinger et al., 1993, Proc. Natl. Acad. Sci. USA 90:6444-6448.

[0024] "Humanized" forms of non-human (e.g., rodent) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., 1986, Nature 321:522-525; Riechmann et al., 1988, Nature 332:323-329; and Presta, 1992, Curr. Op. Struct. Biol. 2:593-596.

[0025] As used herein, "isolated" means separated from other components of (a) a natural source, such as a plant or animal cell or cell culture, or (b) a synthetic organic chemical reaction mixture. As used herein, "purified" means that when isolated, the isolate contains at least 95%, and in another aspect at least 98%, of a compound (e.g., a conjugate) by weight of the isolate.

[0026] An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

[0027] An antibody which "induces apoptosis" is one which induces programmed cell death as determined by binding of annexin V, fragmentation of DNA, cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation, and/or formation of membrane vesicles (called apoptotic bodies). The cell is a tumor cell, e.g., a breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic or bladder cell. Various methods are available for evaluating the cellular events associated with apoptosis. For example, phosphatidyl serine (PS) translocation can be measured by

annexin binding; DNA fragmentation can be evaluated through DNA laddering; and nuclear/chromatin condensation along with DNA fragmentation can be evaluated by any increase in hypodiploid cells.

[0028] The term "therapeutically effective amount" refers to an amount of a drug effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may inhibit the growth of and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. For cancer therapy, efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR).

[0029] The term "substantial amount" refers to a majority, i.e. greater than 50% of a population, of a mixture or a sample.

[0030] The term "intracellular metabolite" refers to a compound resulting from a metabolic process or reaction inside a cell on an antibody-drug conjugate (ADC). The metabolic process or reaction may be an enzymatic process such as proteolytic cleavage of a peptide linker of the ADC. Intracellular metabolites include, but are not limited to, antibodies and free drug which have undergone intracellular cleavage after entry, diffusion, uptake or transport into a cell.

[0031] The terms "intracellularly cleaved" and "intracellular cleavage" refer to a metabolic process or reaction inside a cell on an ADC or the like, whereby the covalent attachment, e.g., the linker, between the drug moiety and the antibody is broken, resulting in the free drug, or other metabolite of the conjugate dissociated from the antibody inside the cell. The cleaved moieties of the ADC are thus intracellular metabolites.

[0032] The term "bioavailability" refers to the systemic availability (i.e., blood/plasma levels) of a given amount of a drug administered to a patient. Bioavailability is an absolute term that indicates measurement of both the time (rate) and total amount (extent) of drug that reaches the general circulation from an administered dosage form.

[0033] The term "cytotoxic activity" refers to a cell-killing, a cytostatic or an anti-proliferative effect of a ADC or an intracellular metabolite of said ADC. Cytotoxic activity may be expressed as the IC₅₀ value, which is the concentration (molar or mass) per unit volume at which half the cells survive.

[0034] A "disorder" is any condition that would benefit from treatment with a drug or antibody-drug conjugate. This includes chronic and acute disorders or diseases including those pathological conditions which predispose a mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include benign and malignant cancers; leukemia and lymphoid malignancies, neuronal, glial, astrocytic, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders; and inflammatory, angiogenic and immunologic disorders.

[0035] The terms "cancer" and "cancerous" refer to or describe the physiological condition or disorder in mammals that is typically characterized by unregulated cell growth. A "tumor" comprises one or more cancerous cells.

[0036] Examples of a "patient" include, but are not limited to, a human, rat, mouse, guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird and fowl. In an exemplary embodiment, the patient is a human.

[0037] The terms "treat" or "treatment," unless otherwise indicated by context, refer to therapeutic treatment and prophylactic measures to prevent relapse, wherein the object is to inhibit or slow down (lessen) an undesired physiological change or disorder, such as the development or spread of cancer. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already having the condition or disorder as well as those prone to have the condition or disorder.

[0038] In the context of cancer, the term "treating" includes any or all of inhibiting growth of tumor cells, cancer cells, or of a tumor; inhibiting replication of tumor cells or cancer cells, lessening of overall tumor burden or decreasing the number of cancerous cells, and ameliorating one or more symptoms associated with the disease.

[0039] In the context of an autoimmune disease, the term "treating" includes any or all of inhibiting replication of cells associated with an autoimmune disease state including, but not limited to, cells that produce an autoimmune antibody, lessening the autoimmune-antibody burden and ameliorating one or more symptoms of an autoimmune disease.

[0040] In the context of an infectious disease, the term "treating" includes any or all of: inhibiting the growth, multiplication or replication of the pathogen that causes the infectious disease and ameliorating one or more symptoms of an infectious disease.

[0041] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indication(s), usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.

[0042] As used herein, the terms "cell," "cell line," and "cell culture" are used interchangeably and all such designations include progeny. The words "transformants" and "transformed cells" include the primary subject cell and cultures or progeny derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same

function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

[0043] Unless otherwise indicated, the term "alkyl" by itself or as part of another term refers to a straight chain or branched, saturated hydrocarbon having the indicated number of carbon atoms (e.g., "C₁-C₈" alkyl refer to an alkyl group having from 1 to 8 carbon atoms). When the number of carbon atoms is not indicated, the alkyl group has from 1 to 8 carbon atoms. Representative straight chain C₁-C₈ alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl and n-octyl; while branched C₁-C₈ alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, and -2-methylbutyl; unsaturated C₂-C₈ alkyls include, but are not limited to, vinyl, allyl, 1-butenyl, 2-butenyl, isobutyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, 1-hexyl, 2-hexyl, 3-hexyl, acetylenyl, propynyl, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne and 3-methyl-1-butyne.

[0044] Unless otherwise indicated, "alkylene," by itself or as part of another term, refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of the stated number of carbon atoms, typically 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene (-CH₂-), 1,2-ethylene (-CH₂CH₂-), 1,3-propylene (-CH₂CH₂CH₂-), 1,4-butyne (-CH₂CH₂CH₂CH₂-), and the like. A "C₁-C₁₀" straight chain alkylene is a straight chain, saturated hydrocarbon group of the formula -(CH₂)₁₋₁₀-. Examples of a C₁-C₁₀ alkylene include methylene, ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, nonylene and decylene.

[0045] Unless otherwise indicated, the term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain hydrocarbon, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule. Up to two heteroatoms may be consecutive.

[0046] Unless otherwise indicated, the term "heteroalkylene" by itself or as part of another substituent means a divalent group derived from heteroalkyl (as discussed above). For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini.

[0047] Unless otherwise indicated, "aryl," by itself or as part of another term, means a substituted or unsubstituted monovalent carbocyclic aromatic hydrocarbon radical of 6-20, preferably 6-14, carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Typical aryl groups include, but are not limited to, radicals derived from benzene, substituted benzene, naphthalene, anthracene, biphenyl, and the like. A substituted carbocyclic aromatic group (e.g., an aryl group) can be substituted with one or more, preferably 1 to 5, of the following groups: C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from -H, C₁-C₈ alkyl and unsubstituted aryl. In some embodiments, a substituted carbocyclic aromatic group can further include one or more of: -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR'. "Arylene" is the corresponding divalent moiety.

[0048] "Substituted alkyl" means an alkyl in which one or more hydrogen atoms are each independently replaced with a substituent. Typical substituents include, but are not limited to, -X, -R, -O-, -OR-, -SR-, -S-, -NR₂, -NR₃, =NR, -CX₃, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, -NO₂, =N₂, -N₃, -NRC(=O)R, -C(=O)NR₂, -SO₃⁻, -SO₃H, -S(=O)₂R, -OS(=O)₂OR, -S(=O)₂NR, -S(=O)R, -OP(=O)(OR)₂, -P(=O)(OR)₂, -PO₃²⁻, PO₃H₂, -AsO₂H₂, -C(=O)R, -C(=O)X, -C(=S)R, -CO₂R, -CO₂⁻, -C(=S)OR, -C(=O)SR, -C(=S)SR, -C(=O)NR₂, -C(=S)NR₂, or -C(=NR)NR₂, where each X is independently a halogen: -F, -Cl, -Br, or -I; and each R is independently -H, C₁-C₂₀ alkyl, C₁-C₂₀ heteroalkyl, C₆-C₂₀ aryl, C₁-C₁₀ heterocyclyl, a protecting group or a prodrug moiety. Aryl, alkylene and heteroalkylene groups as described above may also be similarly substituted.

[0049] Unless otherwise indicated, "aralkyl" by itself or as part of another term, means an alkyl group, as defined above, substituted with an aryl group, as defined above.

[0050] Unless otherwise indicated, "C₁-C₁₀ heterocyclyl" by itself or as part of another term, refers to a monovalent substituted or unsubstituted aromatic or non-aromatic monocyclic, bicyclic or tricyclic ring system having from 1 to 10, preferably 3 to 8, carbon atoms (also referred to as ring members) and one to four heteroatom ring members independently selected from N, O, P or S, and derived by removal of one hydrogen atom from a ring atom of a parent ring system. One or more N, C or S atoms in the heterocyclyl can be oxidized. The ring that includes the heteroatom can be aromatic or nonaromatic. Unless otherwise noted, the heterocyclyl is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. Representative examples of a C₁-C₁₀ heterocyclyl include, but are not limited to, tetrahydrofuryl, oxetanyl, pyran, pyrrolidinyl, piperidinyl, piperazinyl, benzofuryl, benzothienyl, benzothiazolyl, indolyl, benzopyrazolyl, pyrrolyl, thiophenyl (thiopene), furanyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, quinolinyl including moieties such as 1,2,3,4-tetrahydro-quinolinyl, pyrimidinyl, pyridinyl, pyridonyl, pyrazinyl, pyridazinyl, isothiazolyl,

isoxazolyl, tetrazolyl, epoxide, oxetane and BODIPY (substituted or unsubstituted). A C₁-C₁₀ heterocyclyl can be substituted with up to seven groups including, but not limited to, C₁-C₈ alkyl, C₁-C₈ heteroalkyl, -OR', aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(=O)₂R', -S(O)R', halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; wherein each R' is independently selected from -H, C₁-C₈ alkyl, C₁-C₈ heteroalkyl and aryl. In some embodiments, a substituted heterocyclyl can also include one or more of: -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR'. "Heterocyclo" "C₁-C₁₀ heterocyclo" is the corresponding divalent moiety.

[0051] Unless otherwise indicated, "heteroalkyl" by itself or part of another term, means an alkyl group, as defined above, substituted with an aromatic heterocyclyl group, as defined above. Heteroalkalo is the corresponding divalent moiety.

[0052] Unless otherwise indicated, "C₃-C₈ carbocyclyl" by itself or as part of another term, is a 3-, 4-, 5-, 6-, 7- or 8-membered monovalent, substituted or unsubstituted, saturated or unsaturated non-aromatic monocyclic or bicyclic carbocyclic ring derived by the removal of one hydrogen atom from a ring atom of a parent ring system. Representative C₃-C₈ carbocyclyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, cycloheptyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrienyl, cyclooctyl, cyclooctadienyl, bicyclo(1.1.1.)pentane, and bicyclo(2.2.2.)octane. A C₃-C₈ carbocyclyl group can be unsubstituted or substituted with up to seven groups including, but not limited to, C₁-C₈ alkyl, C₁-C₈ heteroalkyl, -OR', aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(=O)₂R', -S(=O)R', -OH, -halogen, -N₃, -NH₂, -NH(R'), -N(R')₂ and -CN; where each R' is independently selected from -H, C₁-C₈ alkyl, C₁-C₈ heteroalkyl and aryl. "C₃-C₈ carbocyclo" is the corresponding divalent moiety.

[0053] The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

[0054] The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

[0055] "Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g., melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.

[0056] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms, McGraw-Hill Book Company, New York (1984); and Eliel and Wilen, Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., New York (1994). Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

[0057] An amino acid "derivative" includes an amino acid having substitutions or modifications by covalent attachment of a parent amino acid, such as, e.g., by alkylation, glycosylation, acetylation, phosphorylation, and the like. Further included within the definition of "derivative" is, for example, one or more analogs of an amino acid with substituted linkages, as well as other modifications known in the art.

[0058] A "natural amino acid" refers to arginine, glutamine, phenylalanine, tyrosine, tryptophan, lysine, glycine, alanine, histidine, serine, proline, glutamic acid, aspartic acid, threonine, cysteine, methionine, leucine, asparagine, isoleucine, and valine, unless otherwise indicated by context.

[0059] "Protecting group" refers to a moiety that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York, 1999, and Harrison and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996), which are incorporated herein by reference in their entirety. Representative hydroxy protecting groups include acyl groups, benzyl and trityl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers. Representative amino protecting groups include, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (Fmoc), nitro-veratryloxycarbonyl (NVOC), and the like.

[0060] Examples of a "hydroxyl protecting group" include, but are not limited to, methoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ether, benzyl ether, p-methoxybenzyl ether, trimethylsilyl ether, triethylsilyl ether, triisopropyl silyl ether, t-butylidimethyl silyl ether, triphenylmethyl silyl ether, acetate ester, substituted acetate esters,

pivaloate, benzoate, methanesulfonate and p-toluenesulfonate.

[0061] "Leaving group" refers to a functional group that can be substituted by another functional group. Such leaving groups are well known in the art, and examples include, but are not limited to, a halide (e.g., chloride, bromide, iodide), methanesulfonyl (mesyl), p-toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethylsulfonate.

[0062] The phrase "pharmaceutically acceptable salt," as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound. The compound typically contains at least one amino group, and accordingly acid addition salts can be formed with this amino group. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, malate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion.

[0063] "Pharmaceutically acceptable solvate" or "solvate" refer to an association of one or more solvent molecules and a compound or conjugate of the invention. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.


[0064] The terms "loading" or "drug loading" or "payload loading" represent or refer to the average number of payloads ("payload" and "payloads" are used interchangeably herein with "drug" and "drugs") per antibody in an ADC molecule. Drug loading may range from 1 to 20 drugs per antibody. This is sometimes referred to as the DAR, or drug to antibody ratio. Compositions of the ADCs described herein typically have DAR's of from 1-20, and in certain embodiments from 1-8, from 2-8, from 2-6, from 2-5 and from 2-4. Typical DAR values are 2, 4, 6 and 8. The average number of drugs per antibody, or DAR value, may be characterized by conventional means such as UV/visible spectroscopy, mass spectrometry, ELISA assay, and HPLC. The quantitative DAR value may also be determined. In some instances, separation, purification, and characterization of homogeneous ADCs having a particular DAR value may be achieved by means such as reverse phase HPLC or electrophoresis. DAR may be limited by the number of attachment sites on the antibody. For example, where the attachment is a cysteine thiol, an antibody may have only one or several cysteine thiol groups, or may have only one or several sufficiently reactive thiol groups through which a Linker unit may be attached. In some embodiments, the cysteine thiol is a thiol group of a cysteine residue that forms an interchain disulfide bond. In some embodiments, the cysteine thiol is a thiol group of a cysteine residue that does not form an interchain disulfide bond. Typically, fewer than the theoretical maximum of drug moieties are conjugated to an antibody during a conjugation reaction. An antibody may contain, for example, many lysine residues that do not react with a linker or linker intermediate. Only the most reactive lysine groups may react with a reactive linker reagent.

[0065] Generally, antibodies do not contain many, if any, free and reactive cysteine thiol groups which may be linked to a drug via a linker. Most cysteine thiol residues in the antibodies exist as disulfide bridges and must be reduced with a reducing agent such as dithiothreitol (DTT). The antibody may be subjected to denaturing conditions to reveal reactive nucleophilic groups such as lysine or cysteine. The loading (drug/antibody ratio) of an ADC may be controlled in several different manners, including: (i) limiting the molar excess of drug-linker relative to the antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification. Where more than one nucleophilic group reacts with a drug-linker then the resulting product is a mixture of ADC's with a distribution of one or more drugs moieties per antibody. The average number of drugs per antibody may be calculated from the mixture by, for example, dual ELISA antibody assay, specific for antibody and specific for the drug. Individual ADC's may be identified in the mixture by mass spectroscopy, and separated by HPLC, e. g., hydrophobic interaction chromatography.

[0066] Below is a list of abbreviations and definitions that may not otherwise be defined or described in this application: DMSO (refers to dimethyl sulfoxide), HRMS (refers to high resolution mass spectrometry), DAD (refers to diode array detection), TFA (refers to 2,2,2-trifluoroacetic acid or trifluoroacetic acid), TFF (refers to tangential flow filtration), EtOH (refers to ethanol), MW (refers to molecular weight), HPLC (refers to high performance liquid chromatography), prep HPLC (refers to preparative high performance liquid chromatography), etc. (refers to and so forth), trityl (refers 1,1',1"-ethane-1,1,1-triyltribenzene), THF (refers to tetrahydrofuran), NHS (refers to 1-Hydroxy-2,5-pyrrolidinedione), Cbz (refers to carboxybenzyl), eq. (refers to equivalent), *n*-BuLi (refers to *n*-butyllithium), OAc (refers to acetate), MeOH (refers to methanol), *i*-Pr (refers to isopropyl or propan-2-yl), NMM (refers to 4-methylmorpholine), and "-" (in a table refers to no data available at this time).

Compounds and Antibody Drug Conjugates Thereof


[0067] One aspect of the invention relates to a compound of formula I:



I

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is



R¹ is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;


R^{3A} and R^{3B} are either of the following:


(i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and

R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or


(ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R⁵ is





C_1 - C_{10} heterocyclyl, C_3 - C_8 carbocycl and C_6 - C_{14} aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of $-C_1$ - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')$ ₂, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl)- $C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')$ ₂, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')$ ₂, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl; or R^5 is



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')$ ₂, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl)- $C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')$ ₂, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')$ ₂, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$, $-SR'$ and arylene- R' , wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl, C_1 - C_8 heterocyclyl, C_1 - C_{10} alkylene- C_3 - C_8 heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl;


R^6 is hydrogen, $-C_1$ - C_8 alkyl, $-C_2$ - C_8 alkenyl, $-C_2$ - C_8 alkynyl, $-C_2$ - C_8 alkynyl or $-C_1$ - C_8 haloalkyl;

R^{12} is hydrogen, C_1 - C_4 alkyl, C_1 - C_{10} heterocyclyl or C_6 - C_{14} aryl;

R^{13} is C_1 - C_{10} heterocyclyl; and


X is O

[0068] Another aspect of the invention relates to compound of formula **Ila**:


**IIa**

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,


W is




R¹ is



Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈ heterocyclo-, -C₁-C₁₀ alkylene-arylene-, -arylene-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ carbocyclo)-, -(C₃-C₈ carbocyclo)-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ heterocyclo)- or -(C₃-C₈ heterocyclo)-C₁-C₁₀ alkylene-;
Z is





or -NH₂;

G is halogen, -OH, -SH or -S-C₁-C₆ alkyl;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;


R^{3A} and R^{3B} are either of the following:

(i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl or halogen; and

R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or

(ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R⁵ is



10



30

35


X is O

40



50

55



R^1 is hydrogen, C_1 - C_8 alkyl or C_1 - C_8 haloalkyl;

R^2 is hydrogen, C_1 - C_8 alkyl or C_1 - C_8 haloalkyl;


R^{3A} and R^{3B} are either of the following:

(i) R^{3A} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; and


R^{3B} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; or

(ii) R^{3A} and R^{3B} taken together are either C_2 - C_8 alkylene, which C_2 - C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1 - C_8 heteroalkylene, which C_1 - C_8 heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R^5 is




or





optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, $-O-(C_1-C_8\text{alkyl})$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl;

R^{11} is



Y is $-C_2-C_{20}$ alkylene-, $-C_2-C_{20}$ heteroalkylene-, C_3-C_8 carbocyclo-, -arylene-, $-C_3-C_8$ heterocyclo-, $-C_1-C_{10}$ alkylene-arylene-, -arylene- $-C_1-C_{10}$ alkylene-, $-C_1-C_{10}$ alkylene- $(C_3-C_8$ carbocyclo)-, $-(C_3-C_8$ carbocyclo)- $-C_1-C_{10}$ alkylene-, $-C_1-C_{10}$ alkylene- $(C_3-C_8$ heterocyclo)-, or $-(C_3-C_8$ heterocyclo)- $-C_1-C_{10}$ alkylene-;
 Z is




G is halogen, -OH, -SH, or $-S-C_1-C_6$ alkyl;

R^7 is independently selected for each occurrence from the group consisting of F, Cl, I, Br, NO_2 , CN and CF_3 ;

h is 1, 2, 3, 4 or 5; and

X is O.


[0070] Another aspect of the invention relates to compound of formula **IIb**:




IIb

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is





R¹ is



Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈ heterocyclo-, -C₁-C₁₀ alkylene-arylene-, -arylene-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ carbocyclo)-, -(C₃-C₈ carbocyclo)-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀ alkylene-;

Z is



L is an antibody;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R^{3A} and R^{3B} are either of the following:


(i) R^{3A} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; and

R^{3B} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; or

(ii) R^{3A} and R^{3B} taken together are either C_2 - C_8 alkylene, which C_2 - C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1 - C_8 heteroalkylene, which C_1 - C_8 heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;


(ii)

R^5 is



C_1 - C_{10} heterocyclyl, C_3 - C_8 carbocycl and C_6 - C_{14} aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of $-C_1$ - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')_2$, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl;

or R^5 is



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')_2$, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$,

halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$, $-SR'$ and arylene- R' , wherein each R' is independently selected from the group consisting of hydrogen, C_1-C_8 alkyl, C_1-C_8 heterocyclyl, C_1-C_{10} alkylene- C_3-C_8 heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1-C_{10} heterocyclyl;


R^6 is hydrogen, $-C_1-C_8$ alkyl, $-C_2-C_8$ alkenyl, $-C_2-C_8$ alkynyl or $-C_1-C_8$ haloalkyl;

R^{12} is hydrogen, C_1-C_4 alkyl, C_1-C_{10} heterocyclyl or C_6-C_{14} aryl;

R^{13} is C_1-C_{10} heterocyclyl; and

X is O


[0071] Another aspect of the invention relates to compound of formula **IIIb**:



IIIb

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is



R^1 is hydrogen, C_1-C_8 alkyl or C_1-C_8 haloalkyl;

R^2 is hydrogen, C_1-C_8 alkyl or C_1-C_8 haloalkyl;

R^{3A} and R^{3B} are either of the following:


(i) R^{3A} is C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_3-C_8 carbocyclyl, or halogen; and

R^{3B} is C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_3-C_8 carbocyclyl, or halogen; or

(ii) R^{3A} and R^{3B} taken together are either C_2-C_8 alkylene, which C_2-C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1-C_8 heteroalkylene, which C_1-C_8 heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

(ii)

R^5 is




or



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -O-(C₁-C₈ alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH,


halogen, -N₃, -NH₂, -NH(R'), -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR, wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl and unsubstituted aryl;

R^{11} is



Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈heterocyclo-, -C₁-C₁₀alkylene-arylene-, -arylene-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo)-, -(C₃-C₈carbocyclo)-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀alkylene-;


Z is



5

10

15




L is an antibody;

X is O.

[0072] Another aspect of the invention relates to compound of formula **IIc**:

20

25

**IIc**

30


or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

R^{1'} is

35

40


45



Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈ heterocyclo-, -C₁-C₁₀ alkylene-arylene-, -arylene-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ carbocyclo)-, -(C₃-C₈ carbocyclo)-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀ alkylene-;


Z' is

55



5

10



15


L is an antibody;

D is absent;

R^{2'} is hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, or is absent if  is present;R^{3A'} and R^{3B'} are either of the following:

20

(i) R^{3A'} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and R^{3B'} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen, or R^{3B'} is C₂-C₄ alkylene and forms a saturated 5 to 6 member ring as indicated

by  ; or

25


(ii) R^{3A'} and R^{3B'} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

(ii)


30

R⁵ is

35




40




45


50



55



C₁-C₁₀ heterocyclyl, C₃-C₈ carbocycl and C₆-C₁₄ aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of -C₁-C₈ alkyl, -C₁-C₈ alkyl-N(R')₂, -C₁-C₈ alkyl-C(O)R', -C₁-C₈ alkyl-C(O)OR', -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C₁-C₁₀ heterocyclyl; or R⁵ is



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -C₁-C₈ alkyl-N(R')₂, -C₁-C₈ alkyl-C(O)R', -C₁-C₈ alkyl-C(O)OR', -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R', -SR' and arylene-R', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ heterocyclyl, C₁-C₁₀alkylene-C₃-C₈heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C₁-C₁₀ heterocyclyl;


R⁶ is hydrogen, -C₁-C₈ alkyl, -C₂-C₈ alkenyl, -C₂-C₈ alkynyl or -C₁-C₈ haloalkyl;

R¹² is hydrogen, C₁-C₄ alkyl, C₁-C₁₀ heterocyclyl or C₆-C₁₄ aryl;

R¹³ is C₁-C₁₀ heterocyclyl; and

X is O


[0073] Another aspect of the invention relates to compound of formula **IIIc**:



IIIc

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is



R¹ is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R^{3A} and R^{3B} are either of the following:


(i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and

R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or


(i) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

(ii)

R⁵ is




or




optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -NH₂, -NH(R'), -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR', wherein each

R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl and unsubstituted aryl;
R^{11'} is




Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈ heterocyclo-, -C₁-C₁₀ alkylene-
arylene-, -arylene-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ carbocyclo)-, -(C₃-C₈ carbocyclo)-C₁-C₁₀ alkylene-,
-C₁-C₁₀ alkylene-(C₃-C₈ heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀ alkylene-;
Z' is



or -NH-;
L is an antibody;
X is O.

[0074] Another aspect of the invention relates to compound of formula **IId**:



IId

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

L is an antibody;

[linker] is a divalent linker;

D is absent;

R^{2'} is hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, or is absent if  is present;

R^{3A'} and R^{3B'} are either of the following:


(i) R^{3A'} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and

R^{3B'} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen, or R^{3B'} is C₂-C₄ alkylene and forms a saturated 5 to 6 member ring as indicated by ; or

(ii) R^{3A'} and R^{3B'} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

(ii)

R⁵ is




C₁-C₁₀ heterocyclyl, C₃-C₈ carbocyclyl and C₆-C₁₄ aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of -C₁-C₈ alkyl, -C₁-C₈ alkyl-N(R')₂, -C₁-C₈ alkyl-C(O)R', -C₁-C₈ alkyl-C(O)OR', -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR', wherein each R' is independently

selected from the group consisting of hydrogen, C₁-C₈ alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C₁-C₁₀ heterocyclyl;
or R⁵ is

5

10



15

optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -C₁-C₈ alkyl-N(R')₂, -C₁-C₈ alkyl-C(O)R', -C₁-C₈ alkyl-C(O)OR', -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R', -SR' and arylene-R', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈heterocyclyl, C₁-C₁₀alkylene-C₃-C₈heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C₁-C₁₀ heterocyclyl;

20

R⁶ is hydrogen, -C₁-C₈ alkyl, -C₂-C₈ alkenyl, -C₂-C₈ alkynyl or -C₁-C₈ haloalkyl;

R¹² is hydrogen, C₁-C₄ alkyl, C₁-C₁₀ heterocyclyl or C₆-C₁₄ aryl;

R¹³ is C₁-C₁₀ heterocyclyl; and


25

X is O

[0075] Another aspect of the invention relates to compound of formula formula **III**d:

30

35



IIId


40

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is

45

50



55

R¹ is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R^{3A} and R^{3B} are either of the following:


(i) R^{3A} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; and

R^{3B} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; or


(ii) R^{3A} and R^{3B} taken together are either C_2 - C_8 alkylene, which C_2 - C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1 - C_8 heteroalkylene, which C_1 - C_8 heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

(i)

R^5 is



or




optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, $-O-(C_1-C_8\text{alkyl})$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl;

[linker] is a divalent linker;


L is an antibody;

X is O.


[0076] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein the compound is represented by



[0077] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein W is



[0078] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein W is



[0079] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R¹ is hydrogen.

[0080] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R¹ is C₁-C₈ alkyl.

[0081] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R¹ is methyl.

[0082] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R² is hydrogen.

[0083] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R² is C₁-C₈ alkyl.

[0084] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R² is methyl.

[0085] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R¹ is hydrogen; and R² is methyl.

[0086] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R¹ is methyl; and R² is methyl.

[0087] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, or C₃-C₈ carbocyclyl, ; and R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen.

[0088] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} is hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl; and R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen.

[0089] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} is halogen.

[0090] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} is C₁-C₈ alkyl.

[0091] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} is methyl.

[0092] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3B} is C₁-C₈ alkyl.

[0093] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3B} is methyl.

[0094] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3B} is isopropyl.

[0095] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3B} is C₃-C₈ carbocyclyl.

[0096] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3B} is cyclohexyl.

[0097] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} is C_1 - C_8 alkyl; and R^{3B} is C_1 - C_8 alkyl.

[0098] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} is methyl; and R^{3B} is methyl.

[0099] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} and R^{3B} taken together are C_2 - C_8 alkylene or C_1 - C_8 heteroalkylene.

[0100] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} and R^{3B} taken together are C_2 - C_8 alkylene.

[0101] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} and R^{3B} taken together are $-CH_2CH_2-$.


[0102] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} and R^{3B} taken together are $-CH_2CH_2CH_2-$.

[0103] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} and R^{3B} taken together are $-CH_2CH_2CH_2CH_2-$.


[0104] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} and R^{3B} taken together are C_1 - C_8 heteroalkylene.

[0105] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^{3A} and R^{3B} taken together are $-CH_2OCH_2-$.


[0106] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0107] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0108] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0109] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0110] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0111] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0112] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0113] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0114] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0115] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0116] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0117] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0118] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0119] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is




[0120] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is



[0121] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is



In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^5 is



In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^6 is hydrogen.

[0122] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^6 is C_1 - C_8 alkyl.

[0123] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^6 is methyl.

[0124] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein X is O.

[0125] In certain embodiments, the present invention relates to any of the aforementioned compounds, or a pharmaceutically acceptable salt or solvate thereof, and attendant definitions, wherein the compound is selected from the group consisting of:

N^2 -[(1-Aminocyclopentyl)carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N^2 -[(1-Aminocyclopentyl)carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N^2 -[(1-Aminocyclopropyl)carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

1-Amino-N-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]cyclohexanecarboxamide;

2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N²-[(3-Aminooxetan-3-yl)carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-Dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-Dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-Dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[1-(bicyclo[4.2.0]octa-1,3,5-trien-7-yl)-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[bicyclo[4.2.0]octa-1,3,5-trien-7-yl(carboxy)methyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-Methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

2-methyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(methylamino)-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-2-amino-1-benzyl-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-oxo-2-(propylamino)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(diethylamino)-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(tert-butylamino)-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

3-methyl-D-isovalyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

3-methyl-L-isovalyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

L-isovalyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

D-isovalyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

1,2-dimethyl-L-prolyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

1,2-dimethyl-D-prolyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide;

Methyl N-[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-[(2S)-2-methylpiperidin-2-yl]carbonyl)-L-valyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]-L-phenylalaninate;

Methyl N-[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-[(2R)-2-methylpiperidin-2-yl]carbonyl)-L-valyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]-L-phenylalaninate;

N-[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-[(2S)-2-methylpiperidin-2-yl]carbonyl)-L-valyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]-L-phenylalanine;

N-[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-[(2R)-2-methylpiperidin-2-yl]carbonyl)-L-valyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]-L-phenylalanine;

(2S)-N-[(2S)-1-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide;

(2R)-N-[(2S)-1-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide;

2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

(2S)-N-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide;

(2R)-N-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide;

1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-aminophenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-aminophenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-(1,2,3,4-tetrahydroquinolin-6-yl)propan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-aminophenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2R,4S)-4-carboxy-1-phenylpentan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-(bicyclo[1.1.1]pent-1-ylamino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(1R)-2-methoxy-2-oxo-1-(1-phenylcyclopropyl)ethyl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(1S)-2-methoxy-2-oxo-1-(1-phenylcyclopropyl)ethyl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1R)-1-[(7R)-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]-2-methoxy-2-oxoethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-[(7S)-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]-2-methoxy-2-oxoethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-[(7R)-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]-2-methoxy-2-oxoethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-me-

thyl-L-valinamide;

N,N,2-trimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,N,2-trimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(R)-carboxy(1-phenylcyclopropyl)methyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

difluoro{2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(3R,4R,7S)-7-benzyl-15-{2-[(3,5-dimethyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}-4-methyl-5,8,13-trioxo-2-oxa-6,9,12-triazapentadecan-3-yl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamidato}boron;

2-methyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[(N-[(3-aminooxetan-3-yl)carbonyl]-L-valyl)(methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(3R,4R,7S,12S)-7-benzyl-14-[3-chloro-4-(propan-2-yloxy)phenyl]-4-methyl-12-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)benzyl]-5,8,14-trioxo-2,9-dioxo-6,13-diazatetradecan-3-yl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-[(4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylphenyl]amino)-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-(prop-2-en-1-yloxy)propan-2-yl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-[(1H-1,2,3-triazol-4-ylmethyl)amino]propan-2-yl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(1H-imidazol-4-yl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;


N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1R)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;

1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-(piperazin-1-yl)propan-2-yl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide;


1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-amino-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide; and

2-methyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide.


[0126] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^1 is



[0127] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^1 is



[0128] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^1 is



[0129] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Y is C_2 - C_{20} alkylene.

[0130] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Y is $-(CH_2)_p-$; and p is 1-10.

[0131] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 1. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 2. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 3. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 4. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 5. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 6. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 7. In certain embodiments, the present invention relates to any of the aforementioned compounds


and attendant definitions, wherein p is 8. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 9. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein p is 10.

[0132] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Y is C₂-C₂₀ heteroalkylene.


[0133] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Y is -(CH₂CH₂O)_qCH₂CH₂-; and q is 1-10.

[0134] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 1. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 2. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 3. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 4. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 5. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 6. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 7. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 8. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 9. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein q is 10.


[0135] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is




[0136] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is




[0137] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is




[0138] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is



[0139] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is



[0140] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is



[0141] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^7 is F or Cl; and h is 4 or 5.

[0142] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^7 is F; and h is 3, 4 or 5.





[0143] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein R^7 is F; and h is 5.


[0144] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is $-NH_2$.

[0145] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein G is Cl. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein G is Br. In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein G is I.


[0146] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein the compound is selected from the group consisting of the compounds of **Table 18B**.

[0147] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein the compound is selected from the group consisting of:







and




[0148] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is



[0149] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is




[0150] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is




[0151] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is -NHL.

[0152] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is



[0153] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein Z is



[0154] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein L is H(C)-.

[0155] In certain embodiments, the present invention relates to any of the aforementioned compounds and attendant definitions, wherein L is an antibody selected from a murine antibody for the treatment of ovarian cancer such as oregovomab (OVAREX®); a murine IgG_{2a} antibody for the treatment of colorectal cancer such as edrecolomab (PANOREX®); an anti-EGFR IgG chimeric antibody for the treatment of epidermal growth factor positive cancers, such as head and neck cancer, for instance cetuximab (ERBITUX®); a humanized antibody for the treatment of sarcoma, such as a Humanized Monoclonal Antibody to the Vitronectin Receptor ($\alpha_v\beta_3$) like Vitaxin®; a humanized IgG₁ antibody for the treatment of chronic lymphocytic leukemia (CLL) such as alemtuzumab (CAMPATH I/H®); SMART ID10 which is a humanized anti-HLA-DR antibody for the treatment of non-Hodgkin's lymphoma; 131I Lym-1 (ONCOLYM®) which is a radiolabeled murine anti-HLA-Dr10 antibody for the treatment of non-Hodgkin's lymphoma; a humanized anti-CD2 mAb for the treatment of Hodgkin's Disease or non-Hodgkin's lymphoma such as ALLOMUNE®; labetuzumab (CEACIDE®) which is a humanized anti-CEA antibody for the treatment of colorectal cancer; bevacizumab (AVASTIN®) which is a humanized anti-VEGF-A mAb for the treatment of brain, colon, kidney, or lung cancer; lbratumab tiuxetan (ZEVALIN®) which is an anti-CD20 monoclonal antibody to the treatment of non-Hodgkin's lymphoma; ofatumumab (ARZERRA®) which is a human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia; panitumumab (VECTIBIX®) which is a human anti-EGFR monoclonal antibody for the treatment of colon cancer; rituximab (RITUXAN®) which is an anti-CD20 chimeric monoclonal antibody for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; tositumomab (BEXXAR®) which is an anti-CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma; trastuzumab (HERCEPTIN®) which is an anti-HER2 receptor monoclonal antibody for the treatment of breast and stomach cancer; ipilimumab (YERVOY®) which is an anti-CTLA4 human monoclonal antibody for the treatment of melanoma; gemtuzumab and inotuzumab ozogamicin.

[0156] In another specific embodiment, L includes antibodies selected from anti-I-13 antibodies, including anti-I-13 antibodies used in the treatment of cancer, for instance anti-IL-13R α 2 antibodies.

[0157] In yet another specific embodiment, L includes antibodies selected from anti-Notch antibodies, including anti-Notch antibodies used in the treatment of cancer.



[0158] In certain embodiments, the antibody L is bound to the linker via a sulfur bond or via a sulfur-sulfur bond.




[0159] Another aspect of the invention relates to an antibody drug conjugate comprising any of the aforementioned compounds.

[0160] Another aspect of the invention relates to an antibody drug conjugate comprising an antibody and any one of the aforementioned compounds.


[0161] In certain embodiments, the present invention relates to any of the aforementioned antibody drug conjugates and attendant definitions, wherein the compound is covalently bound to the antibody.

[0162] In certain embodiments, the present invention relates to any of the aforementioned antibody drug conjugates and attendant definitions, wherein the compound in said antibody drug conjugate is selected from the group consisting of the compounds of **Table 18B**,





and



[0163] In certain embodiments, the present invention relates to any of the aforementioned antibody drug conjugates and attendant definitions, wherein the antibody drug conjugate comprises between 2, 3, 4, 5, 6, 7, 8, 9 or 10 compounds of the invention.

[0164] In certain embodiments, the present invention relates to any of the aforementioned antibody drug conjugates and attendant definitions, wherein the antibody drug conjugate comprises 3 or 4 compounds of the invention.

The Antibody Unit (Ab)

[0165] As noted above, the term "antibody" (or "Ab") herein is used in the broadest sense and specifically covers intact monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments that exhibit the desired biological activity. In addition, while certain aspects of the invention described herein refer to antibody drug conjugates, it is further envisioned that the antibody portion of the conjugate might be replaced with anything that specifically binds or reactively associates or complexes with a receptor, antigen or other receptive moiety associated with a given target-cell population. For example, instead of containing an antibody a conjugates of the invention could contain a targeting molecule that binds to, complexes with, or reacts with a receptor, antigen or other receptive moiety of a cell population sought to be therapeutically or otherwise biologically modified. Example of such molecules include smaller molecular weight proteins, polypeptide or peptides, lectins, glycoproteins, non-peptides, vitamins, nutrient-transport molecules (such as, but not limited to, transferrin), or any other cell binding molecule or substances. In certain aspects, the antibody or other such targeting molecule acts to deliver a drug to the particular target cell population with which the antibody or other targeting molecule interacts.

[0166] Heteroatoms that may be present on an antibody unit include sulfur (in one embodiment, from a sulfhydryl group of an antibody), oxygen (in one embodiment, from a carbonyl, carboxyl or hydroxyl group of an antibody) and nitrogen (in one embodiment, from a primary or secondary amino group of an antibody). These hetero atoms can be present on the antibody in the antibody's natural state, for example a naturally-occurring antibody, or can be introduced into the antibody via chemical modification.

[0167] In one embodiment, an antibody unit has a sulfhydryl group and the antibody unit bonds via the sulfhydryl group's sulfur atom.

[0168] In another embodiment, the antibody has lysine residues that can react with activated esters (such esters include, but are not limited to, N-hydroxysuccinimide, pentafluorophenyl, and p-nitrophenyl esters) and thus form an amide bond consisting of the nitrogen atom of the antibody unit and a carbonyl.

[0169] In yet another aspect, the antibody unit has one or more lysine residues that can be chemically modified to introduce one or more sulfhydryl groups. The reagents that can be used to modify lysines include, but are not limited to, N-succinimidyl S-acetylthioacetate (SATA) and 2-Iminoethanol hydrochloride (Traut's Reagent).

[0170] In another embodiment, the antibody unit can have one or more carbohydrate groups that can be chemically

modified to have one or more sulfhydryl groups.

[0171] In yet another embodiment, the antibody unit can have one or more carbohydrate groups that can be oxidized to provide an aldehyde group (see, e.g., Laguzza, et al., 1989, J. Med. Chem. 32(3):548-55). The corresponding aldehyde can form a bond with a reactive site such as, for example, hydrazine and hydroxylamine. Other protocols for the modification of proteins for the attachment or association of drugs are described in Coligan et al., Current Protocols in Protein Science, vol. 2, John Wiley & Sons (2002) (incorporated herein by reference).

[0172] When the conjugates comprise non-immunoreactive protein, polypeptide, or peptide units instead of an antibody, useful non-immunoreactive protein, polypeptide, or peptide units include, but are not limited to, transferrin, epidermal growth factors ("EGF"), bombesin, gastrin, gastrin-releasing peptide, platelet-derived growth factor, IL-2, IL-6, transforming growth factors ("TGF"), such as TGF- α and TGF- β , vaccinia growth factor ("VGF"), insulin and insulin-like growth factors I and II, somatostatin, lectins and apoprotein from low density lipoprotein.

[0173] Useful polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of immunized animals. Useful monoclonal antibodies are homogeneous populations of antibodies to a particular antigenic determinant (e.g., a cancer cell antigen, a viral antigen, a microbial antigen, a protein, a peptide, a carbohydrate, a chemical, nucleic acid, or fragments thereof). A monoclonal antibody (mAb) to an antigen-of-interest can be prepared by using any technique known in the art which provides for the production of antibody molecules by continuous cell lines in culture.

[0174] Useful monoclonal antibodies include, but are not limited to, human monoclonal antibodies, humanized monoclonal antibodies, antibody fragments, or chimeric monoclonal antibodies. Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. USA. 80:7308-7312; Kozbor et al., 1983, Immunology Today 4:72-79; and Olsson et al., 1982, Meth. Enzymol. 92:3-16).

[0175] The antibody can also be a bispecific antibody. Methods for making bispecific antibodies are known in the art and are discussed infra.

[0176] The antibody can be a functionally active fragment, derivative or analog of an antibody that immunospecifically binds to target cells (e.g., cancer cell antigens, viral antigens, or microbial antigens) or other antibodies that bind to tumor cells or matrix. In this regard, "functionally active" means that the fragment, derivative or analog is able to elicit anti-anti-idiotypic antibodies that recognize the same antigen that the antibody from which the fragment, derivative or analog is derived recognizes. Specifically, in an exemplary embodiment the antigenicity of the idiotype of the immunoglobulin molecule can be enhanced by deletion of framework and CDR sequences that are C-terminal to the CDR sequence that specifically recognizes the antigen. To determine which CDR sequences bind the antigen, synthetic peptides containing the CDR sequences can be used in binding assays with the antigen by any binding assay method known in the art (e.g., the BIA core assay) (for location of the CDR sequences, see, e.g., Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md.; Kabat E et al., 1980, J. Immunology 125(3):961-969).

[0177] Other useful antibodies include fragments of antibodies such as, but not limited to, F(ab')₂ fragments, Fab fragments, Fvs, single chain antibodies, diabodies, triabodies, tetrabodies, scFv, scFv-FV, or any other molecule with the same specificity as the antibody.

[0178] Additionally, recombinant antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are useful antibodies. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as for example, those having a variable region derived from a murine monoclonal and human immunoglobulin constant regions. (See, e.g., U.S. Pat. No. 4,816,567; and U.S. Pat. No. 4,816,397, which are incorporated herein by reference in their entirety.) Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, e.g., U.S. Pat. No. 5,585,089, which is incorporated herein by reference in its entirety.) Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in International Publication No. WO 87/02671; European Patent Publication No. 0 184 187; European Patent Publication No. 0 171 496; European Patent Publication No. 0 173 494; International Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; European Patent Publication No. 012 023; Berter et al., 1988, Science 240:1041-1043; Liu et al., 1987, Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al., 1987, J. Immunol. 139:3521-3526; Sun et al., 1987, Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al., 1987, Cancer. Res. 47:999-1005; Wood et al., 1985, Nature 314:446-449; and Shaw et al., 1988, J. Natl. Cancer Inst. 80:1553-1559; Morrison, 1985, Science 229:1202-1207; Oi et al., 1986, BioTechniques 4:214; U.S. Pat. No. 5,225,539; Jones et al., 1986, Nature 321:552-525; Verhoeyan et al., 1988, Science 239:1534; and Beidler et al., 1988, J. Immunol. 141:4053-4060; each of which is incorporated herein by reference in its entirety.

[0179] Completely human antibodies are particularly desirable and can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a

portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, 1995, *Int. Rev. Immunol.* 13:65-93. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., U.S. Pat. Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; each of which is incorporated herein by reference in its entirety. Other human antibodies can be obtained commercially from, for example, Abgenix, Inc. (now Amgen, Freemont, Calif.) and Medarex (Princeton, N.J.).

[0180] Completely human antibodies that recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (See, e.g., Jespers et al., 1994, *Biotechnology* 12:899-903). Human antibodies can also be produced using various techniques known in the art, including phage display libraries (see, e.g., Hoogenboom and Winter, 1991, *J. Mol. Biol.* 227:381; Marks et al., 1991, *J. Mol. Biol.* 222:581; Quan and Carter, 2002, *The rise of monoclonal antibodies as therapeutics*, In *Anti-IgE and Allergic Disease*, Jardieu and Fick, eds., Marcel Dekker, New York, N.Y., Chapter 20, pp. 427-469).

[0181] In other embodiments, the antibody is a fusion protein of an antibody, or a functionally active fragment thereof, for example in which the antibody is fused via a covalent bond (e.g., a peptide bond), at either the N-terminus or the C-terminus to an amino acid sequence of another protein (or portion thereof, preferably at least 10, 20 or 50 amino acid portion of the protein) that is not from an antibody. Preferably, the antibody or fragment thereof is covalently linked to the other protein at the N-terminus of the constant domain.

[0182] Antibodies include analogs and derivatives that are either modified, i.e., by the covalent attachment of any type of molecule as long as such covalent attachment permits the antibody to retain its antigen binding immunospecificity. For example, but not by way of limitation, derivatives and analogs of the antibodies include those that have been further modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular antibody unit or other protein, etc. Any of numerous chemical modifications can be carried out by known techniques including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis in the presence of tunicamycin, etc. Additionally, the analog or derivative can contain one or more unnatural amino acids.

[0183] Antibodies can have modifications (e.g., substitutions, deletions or additions) in amino acid residues that interact with Fc receptors. In particular, antibodies can have modifications in amino acid residues identified as involved in the interaction between the anti-Fc domain and the FcRn receptor (see, e.g., International Publication No. WO 97/34631, which is incorporated herein by reference in its entirety).

[0184] Antibodies immunospecific for a cancer cell antigen can be obtained commercially or produced by any method known to one of skill in the art such as, e.g., chemical synthesis or recombinant expression techniques. The nucleotide sequence encoding antibodies immunospecific for a cancer cell antigen can be obtained, e.g., from the GenBank database or a database like it, literature publications, or by routine cloning and sequencing.

[0185] In a specific embodiment, known antibodies for the treatment of cancer can be used. Antibodies immunospecific for a cancer cell antigen can be obtained commercially or produced by any method known to one of skill in the art such as, e.g., recombinant expression techniques. The nucleotide sequence encoding antibodies immunospecific for a cancer cell antigen can be obtained, e.g., from the GenBank database or a database like it, the literature publications, or by routine cloning and sequencing. Examples of antibodies available for the treatment of cancer include, but are not limited to, OVAREX® which is a murine antibody for the treatment of ovarian cancer; PANOREX® (Glaxo Wellcome, NC) which is a murine IgG_{2a} antibody for the treatment of colorectal cancer; Cetuximab ERBITUX® (Imclone Systems Inc., NY) which is an anti-EGFR IgG chimeric antibody for the treatment of epidermal growth factor positive cancers, such as head and neck cancer; Vitaxin® (MedImmune, Inc., MD) which is a humanized antibody for the treatment of sarcoma; CAMPATH 1/H® (Leukosite, MA) which is a humanized IgG₁ antibody for the treatment of chronic lymphocytic leukemia (CLL); SMART ID10 (Protein Design Labs, Inc., CA) which is a humanized anti-HLA-DR antibody for the treatment of non-Hodgkin's lymphoma; ONCOLYM® (Techniclone, Inc., CA) which is a radiolabeled murine anti-HLA-Dr10 antibody for the treatment of non-Hodgkin's lymphoma; ALLOMUNE® (BioTransplant, CA) which is a humanized anti-CD2 mAb for the treatment of Hodgkin's Disease or non-Hodgkin's lymphoma; CEACIDE® (Immunomedics, NJ) which is a humanized anti-CEA antibody for the treatment of colorectal cancer; AVASTIN® (Genentech/Roche, CA) which is a humanized anti-VEGF-A mAb for the treatment of brain, colon, kidney, or lung cancer; ZEVALIN® (Spectrum Pharmaceuticals, NV) which is an anti-CD20 monoclonal antibody to the treatment of non-Hodgkin's lymphoma; ARZERRA® (GSK, UK) which is a human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia; VECTIBIX® (Amgen, CA) which is a human anti-EGFR monoclonal antibody for the treatment of colon cancer; RITUXAN® (Genentech/BioGen, CA) which is an anti-CD20 chimeric monoclonal antibody for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; BEXXAR® (GSK, UK) which is an anti-CD20 monoclonal antibody for the treatment of

non-Hodgkin's lymphoma; HERCEPTIN® (Genentech, CA) which is an anti-HER2 receptor monoclonal antibody for the treatment of breast and stomach cancer; YERVOY® (BMS, NJ) which is an anti-CTLA4 human monoclonal antibody for the treatment of melanoma; MYLOTARG® (Wyeth/Pfizer, NY) which is anti-CD33 humanized monoclonal antibody conjugated to calicheamicin for the treatment of acute myelogenous leukemia; and, inotuzumab ozogamicin (Wyeth/Pfizer, NY) which is an anti-CD22 humanized monoclonal antibody conjugated to calicheamicin for the treatment of acute lymphocytic leukemia and non-Hodgkin's lymphoma.

[0186] In another specific embodiment, anti-IL13 antibodies, including anti-IL13 antibodies used in the treatment of cancer, can be used.

[0187] In another specific embodiment, anti-Notch antibodies, including anti-Notch antibodies used in the treatment of cancer, can be used.

[0188] In attempts to discover effective cellular targets for cancer diagnosis and therapy, researchers have sought to identify transmembrane or otherwise tumor-associated polypeptides that are specifically expressed on the surface of one or more particular type(s) of cancer cell as compared to on one or more normal non-cancerous cell(s). Often, such tumor-associated polypeptides are more abundantly expressed on the surface of the cancer cells as compared to on the surface of the non-cancerous cells. The identification of such tumor-associated cell surface antigen polypeptides has given rise to the ability to specifically target cancer cells for destruction via antibody-based therapies.

Synthesis of Compounds and Antibody Drug Conjugates Thereof


[0189] The compounds and conjugates of the invention can be made using the synthetic procedures outlined below in the Exemplification.

[0190] As described in more detail below, the compounds and conjugates of the invention can be prepared using a section of a linker unit having a reactive site for binding to the compound.

Linker

[0191] A linker (sometimes referred to as "[linker]" herein) is a bifunctional compound which can be used to link a drug and an antibody to form an antibody drug conjugate (ADC). Such conjugates are useful, for example, in the formation of immunoconjugates directed against tumor associated antigens. Such conjugates allow the selective delivery of cytotoxic drugs to tumor cells.


[0192] In one embodiment, the linker has the formula: is




wherein

Y is C₂-C₂₀ alkylene or C₂-C₂₀ heteroalkylene; C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈heterocyclo-, -C₁-C₁₀alkylene-arylene-, -arylene-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo)-, -(C₃-C₈carbocyclo)-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀alkylene-;

Z is





or -NH₂;

R⁷ is independently selected for each occurrence from the group consisting of F, Cl, I, Br, NO₂, CN and CF₃;

R¹⁰ is hydrogen, -C₁-C₁₀alkyl, -C₃-C₈carbocycle, aryl, -C₁-C₁₀heteroalkyl, -C₃-C₈heterocyclo, -C₁-C₁₀alkylene-aryl, -arylene-C₁-C₁₀alkyl, -C₁-C₁₀alkylene-(C₃-C₈carbocycle), -(C₃-C₈ carbocycle)-C₁-C₁₀alkyl, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo), and -(C₃-C₈ heterocyclo)-C₁-C₁₀alkyl, where aryl on R₁₀ comprising aryl is optionally substituted with [R₇]_h; and

h is 1, 2, 3, 4 or 5.

[0193] In an ADC the linker serves to attach the payload to the antibody.

[0194] In one aspect, a second section of the linker unit is introduced which has a second reactive site e.g., an electrophilic group that is reactive to a nucleophilic group present on an antibody unit (e.g., an antibody). Useful nucleophilic groups on an antibody include but are not limited to, sulfhydryl, hydroxyl and amino groups. The heteroatom of the nucleophilic group of an antibody is reactive to an electrophilic group on a linker unit and forms a covalent bond to a linker unit. Useful electrophilic groups include, but are not limited to, maleimide and haloacetamide groups. The electrophilic group provides a convenient site for antibody attachment.


[0195] In another embodiment, a linker unit has a reactive site which has a nucleophilic group that is reactive to an electrophilic group present on an antibody. Useful electrophilic groups on an antibody include, but are not limited to, aldehyde and ketone carbonyl groups. The heteroatom of a nucleophilic group of a linker unit can react with an electrophilic group on an antibody and form a covalent bond to the antibody. Useful nucleophilic groups on a linker unit include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide. The electrophilic group on an antibody provides a convenient site for attachment to a linker unit.

[0196] Amino functional groups are also useful reactive sites for a linker unit because they can react with carboxylic acid, or activated esters of a compound to form an amide linkage. Typically, the peptide-based compounds of the invention can be prepared by forming a peptide bond between two or more amino acids and/or peptide fragments. Such peptide bonds can be prepared, for example, according to the liquid phase synthesis method (see, e.g., Schroder and Lubke, "The Peptides", volume 1, pp 76-136, 1965, Academic Press) that is well known in the field of peptide chemistry.


[0197] As described in more detail below, the conjugates can be prepared using a section of the linker having a reactive site for binding to a compound of the invention and introducing another section of the linker unit having a reactive site for an antibody. In one aspect, a linker unit has a reactive site which has an electrophilic group that is reactive with a nucleophilic group present on an antibody unit, such as an antibody. The electrophilic group provides a convenient site for antibody attachment. Useful nucleophilic groups on an antibody include but are not limited to, sulfhydryl, hydroxyl and amino groups. The heteroatom of the nucleophilic group of an antibody is reactive to an electrophilic group on a Linker unit and forms a covalent bond to a linker unit. Useful electrophilic groups include, but are not limited to, maleimide and haloacetamide groups.

[0198] In another embodiment, a linker unit has a reactive site which has a nucleophilic group that is reactive with an electrophilic group present on an antibody unit. The electrophilic group on an antibody provides a convenient site for attachment to a linker unit. Useful electrophilic groups on an antibody include, but are not limited to, aldehyde and ketone carbonyl groups. The heteroatom of a nucleophilic group of a linker unit can react with an electrophilic group on an antibody and form a covalent bond to the antibody. Useful nucleophilic groups on a linker unit include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.


[0199] As used herein, "mc-" previously known as "MalC-" refers to




As used herein, "mcValCitPABC-" previously known as "MalCValCitPABC-" refers to




[0200] As used herein, "MalPegXC2-" refers to




[0201] As used herein, "AmPegXC2-" refers to




[0202] As used herein, "mcValCitPABCAmPegXC2-" refers to




[0203] As used herein, "MalPegXC2ValCitPABC-" refers to




[0204] As used herein, "2BrAcPegXC2" refers to




[0205] As used herein, "mv-" refers to




[0206] As used herein, "mb-" refers to




[0207] As used herein, "me-" refers to




[0208] As used herein, "MalC6-" refers to




[0209] As used herein, "PFPCOPegXC2ValCitPABC-" refers




[0210] As used herein, "PFPCOPegXC2AmPegYC2-" refers to




[0211] As used herein, "PFPCOPegXC2AlaAlaAsnPABC-" refers to




[0212] As used herein, "PFPCOPegXC2-" refers to




[0213] As used herein, "PFPCOPegXC2AmPegYC2PABC-" refers to




[0214] As used herein, "mcGly-" refers to




[0215] As used herein, "AzCOC2Ph4AmCOPeg2C2-" refers to



[0216] As used herein, "AzCOC2Ph4AmPeg1C1-" refers to



[0217] As used herein, "AcLysValCitPABC-" refers to



Conjugation with Transglutaminase


[0218] In certain embodiments, a compound of the invention may be covalently crosslinked to an Fc-containing or Fab-containing polypeptide engineered with an acyl donor glutamine-containing tag (e.g., Gln-containing peptide tags or Q-tags) or an endogenous glutamine made reactive (i.e., the ability to form a covalent bond as an acyl donor in the presence of an amine and a transglutaminase) by polypeptide engineering (e.g., via amino acid deletion, insertion, substitution, mutation, or any combination thereof on the polypeptide), in the presence of transglutaminase, provided that the compound of the invention comprises an amine donor agent (e.g., small molecule comprising or attached to a reactive amine), thereby forming a stable and homogenous population of an engineered Fc-containing polypeptide conjugate with the amine donor agent being site-specifically conjugated to the Fc-containing or Fab-containing polypeptide through the acyl donor glutamine-containing tag or the exposed/accessible/reactive endogenous glutamine. For

example, compounds of the invention may be conjugated as described in International Patent Application Serial No. PCT/IB2011/054899, whose entire contents are incorporated herein by reference. In certain embodiments, to facilitate conjugation of the compound of the invention to an Fc-containing or Fab-containing polypeptide engineered with an acyl donor glutamine-containing tag or an endogenous glutamine made reactive by polypeptide engineering in the presence of transglutaminase, Z is NH₂.

Conjugation to the Human Light Chain Kappa Domain Constant Region


[0219] In certain embodiments, a compound of the invention may be covalently attached to the side chain of K¹⁸⁸ of the human light chain kappa domain constant region (CL_K) (full light chain numbering according to Kabat). K¹⁸⁸ may also be termed CL_K K80, when counting only the human kappa constant region, for example, of SEQ ID NOs: 1, 2, 3 and 4).

[0220] For example, compounds of the invention may be conjugated as described in US Patent Application Serial Number 13/180,204, or WO2012/007896 whose entire contents are incorporated herein by reference. In certain embodiments, to facilitate conjugation to K¹⁸⁸ CL_K (CL_K-K80), Z is



R⁷ is independently selected for each occurrence from the group consisting of F, Cl, I, Br, NO₂, CN and CF₃; and h is 1, 2, 3, 4 or 5.

[0221] In certain embodiments, to facilitate conjugation to K¹⁸⁸ CL_K (CL_K-K80), Z is



[0222] The present invention further provides antibody drug conjugates comprising an antibody, or antigen binding portions thereof, comprising a constant kappa domain covalently conjugated to a toxin of the invention, characterized in that at least one toxin of the invention is covalently conjugated to K80 of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO: 4 (**Table 1**). In some aspects, the number of toxins of the invention covalently conjugated to the at K80 may be a range whose lower limit is selected from the group consisting of about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, and about 2.0, and whose upper limit is selected from the group consisting of about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5. In some aspects, p is about 2.

[0223] Conjugation of the toxin with the constant light domain of an antibody is particularly desirable to minimize, or prevent, any interference with binding of the Fc portion of the antibody to Fc receptors (such as FcγR and FcRn) or binding of the antibody to its respective target. Conversely, conjugation of the respective toxin to the Fc portion of an antibody may decrease the antibody half-life *in vivo* and/or its capacity to interact with the immune system (effector function). Conjugation of the toxin in the variable heavy chain (VH) or variable light chain (VL) region of the antibody carries a risk of diminishing the binding of the antibody to its cognate.

[0224] Furthermore, whereas conjugation to CL_K-K80 is reliable and robust, conjugation to other antibody surface lysines, each of slightly different reactivity and pI can result in a heterogeneous sample of conjugated antibodies that can release conjugated molecules at inopportune or irregular times, such as during circulation and prior to delivery of the Effector Moiety to the target by antibody recognition.

[0225] In addition, the present invention provides for known polymorphisms of the kappa chain V/A at position 45 and A/L at position 83 (giving the 3 identified human constant kappa polymorphisms Km(1):V45/L83 (SEQ ID NO:2), Km(1,2):A45/L83 (SEQ ID NO:3), and Km(3) A45/V83 (SEQ ID NO:4)). The variability of residues at positions 45 and 83 in SEQ ID NO:1 may be selected so as to only provide for any one, two or all three of the Km(1), Km(1,2), and Km(3) polymorphisms.




Table 1

SEQ ID NO	DESCRIPTION	SEQUENCE
1	hLC constant region GENUS	TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDN $\times$ LQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HK $\times$ YACEVTH QGLSSPVTKS FNRGEC
2	h LC constant region Km(1) polymorphism (V45/L83)	TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNVLQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKLYACEVTH QGLSSPVTKS FNRGEC
3	h LC constant region Km(1,2) polymorphism A45/L83	TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKLYACEVTH QGLSSPVTKS FNRGEC
4	h LC constant region Km(3) polymorphism A45/V83	TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYLSST LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGEC


Wherein x at position 45 is A or V, and x at position 83 is L or V.

[0226] In certain embodiments, the invention provides for a composition comprising a compound of the invention covalently conjugated to an antibody (or antigen binding portion thereof), wherein at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% of the compound of the invention in the composition is conjugated to the antibody or antigen binding portion thereof at K¹⁸⁸ CL κ .




[0227] In certain embodiments, the compounds of the invention




and



may be conjugated to the combining site of a catalytic antibody, such as aldolase antibodies, or antigen binding portion thereof. Aldolase antibodies contain combining site portions that, when unencumbered (for example by conjugation), catalyze an aldol addition reaction between an aliphatic ketone donor and an aldehyde acceptor. The contents of US Patent Application Publication No. US 2006/205670 are incorporated herein by reference, in particular pages 78-118 describing linkers, and paragraphs [0153]-[0233] describing antibodies, useful fragments, variants and modifications thereof, h38C2, combining sites and complementary determining regions (CDRs), and related antibody technology (**Table 2**, and exemplary compounds below):



and



[0228] The term "combining site" includes the CDRs and the adjacent framework residues that are involved in antigen binding.

Table 2

SEQ ID NO	DESCRIPTION	SEQUENCE
5	<u>h38C2 VL</u>	ELQMTQSPSS LSASVGDRV ITCRSSQSLL HTYGSPYLNW YLQKPGQSPK LLIYKVSNR SGVPSRFSGS GSGTDFTLTI SSLQPEDFAV YFCSQGTHLP YTFGGGKVE IK


(continued)

SEQ ID NO	DESCRIPTION	SEQUENCE
6	<u>h38C2 VH</u>	EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMSWVRQS PEKGLEWVSE IRLRSDNYAT HYAESVKGRF TISRDNSKNT LYLQMNSLRA EDTGIYYCKT YFYSFSYWGQ GTLVTVSS
7	<u>h38C2 LC</u>	ELQMTQSPSS LSASVGDRVIT ITCRSSQSLL HTYGSPYLNW YLQKPGQSPK LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAV YFCSQGTHLP YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
8	<u>h38C2 HC</u>	EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMSWVRQS PEKGLEWVSE IRLRSDNYAT HYAESVKGRF TISRDNSKNT LYLQMNSLRA EDTGIYYCKT YFYSFSYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVPEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK

Conjugation with linkers comprising succinimides, including ring-opened versions

[0229] In certain embodiments, the present invention includes a compound of the invention conjugated via a succinimide-based linker or a ring-opened succinimide-based linker. The stability of the succinimide-cysteine linkage has become an area of increasing interest. Succinimides can be transferred both *in vitro* and *in vivo* to exogenous thiol nucleophiles, presumably through a retro-Michael reaction resulting in a maleimide that is subsequently attacked by a thiol. It is believed that hydrolysis of the ring results in a species that is resistant to the retro-Michael reaction. This renders the resulting conjugate more stable and potentially more efficacious. Conditions may be optimized to forcibly open the succinimide ring on the conjugate. Basic conditions resulted in facile hydrolysis of the ring. For instance, linkers containing a polyethylene glycol (PEG) chain can be hydrolysed at pH 9.2 at 37°C in approximately 12h, and linkers

containing an alkyl chain, such as "mc" may require a higher temperature and longer reaction time in order to drive the ring-opening to completion.



Example of forced hydrolysis of maleimide-based conjugates

[0230] In order to assess the stability of these conjugates and prioritize samples for *in vivo* evaluation, an assay was developed that involves the treatment of the maleimide-linked conjugates with excess aqueous glutathione (GSH) or plasma. Aliquots of the reaction mixture were analyzed at various timepoints to determine the loading of the conjugate, using the methodology described above. The results (Table 24) indicate that the drug-antibody linkage is slowly cleaved in a GSH-dependent manner. As expected, the rate of cleavage is highly dependent upon the hydrolysis of the succinimide ring. Importantly, these results appear to translate to improved PK exposure, as measured by an increase in area-under-curve (AUC) of the conjugate and by an increase in the conjugate/Ab exposure ratio.

Method for assessing the stability of ADCs

[0231] The ADC sample (30 μ g) in PBS is mixed with glutathione (GSH) solution to produce final concentration of GSH of 0.5 mM and 3 mg/mL protein concentration. A control sample (without GSH) was likewise prepared from 30 μ g ADC diluted to 3 mg/mL in PBS. The GSH-treated ADC sample and the control ADC sample were incubated at 37°C and were sampled at 0, 3, and 6 days. Aliquots were reduced with excess TCEP, acidified by adding 0.1% formic acid solution with 10% acetonitrile and analyzed by for loading by LC/MS as described below.

[0232] Sample analysis: Analysis was performed using an Agilent 1100 capillary HPLC coupled with Waters Xevo G2 Q-TOF mass spectrometer. The analytes were loaded onto a Zorbax Poroshell 300SB C8 column (0.5 mm X 75 mm, maintained at 80°C) with 0.1% formic acid, and eluted using a gradient of 20-40% buffer B (80% acetonitrile, 18% 1-propanol, 2% water with 0.1% formic acid) at a flow rate of 20 (μ L/min over 5.5 minutes. Mass spectrometric detection was carried out in positive, sensitivity mode with capillary voltage set at 3.3 kV. Data analysis was performed with MaxEnt 1 function in MassLynx and intensities were used for loading calculation based on the previously described formula.

Compositions and Methods of Administration

[0233] In other embodiments, another aspect of the invention relates to pharmaceutical compositions including an effective amount of a compound of the invention and/or antibody drug conjugate thereof and a pharmaceutically acceptable carrier or vehicle. In certain embodiments, the compositions are suitable for veterinary or human administration.

[0234] The present pharmaceutical compositions can be in any form that allows for the composition to be administered to a patient. For example, the composition can be in the form of a solid or liquid. Typical routes of administration include, without limitation, parenteral, ocular and intra-tumor. Parenteral administration includes subcutaneous injections, intravenous, intramuscular or intrasternal injection or infusion techniques. In one aspect, the compositions are administered parenterally. In a specific embodiment, the compositions are administered intravenously.

[0235] Pharmaceutical compositions can be formulated so as to allow a compound of the invention and/or antibody drug conjugate thereof to be bioavailable upon administration of the composition to a patient. Compositions can take the form of one or more dosage units, where for example, a tablet can be a single dosage unit, and a container of a compound of the invention and/or antibody drug conjugate thereof in liquid form can hold a plurality of dosage units.

[0236] Materials used in preparing the pharmaceutical compositions can be non-toxic in the amounts used. It will be evident to those of ordinary skill in the art that the optimal dosage of the active ingredient(s) in the pharmaceutical composition will depend on a variety of factors. Relevant factors include, without limitation, the type of animal (e.g., human), the particular form of the a compound of the invention and/or antibody drug conjugate thereof, the manner of administration, and the composition employed.

[0237] The pharmaceutically acceptable carrier or vehicle can be solid or particulate, so that the compositions are, for example, in tablet or powder form. The carrier(s) can be liquid. In addition, the carrier(s) can be particulate.

[0238] The composition can be in the form of a liquid, e.g., a solution, emulsion or suspension. In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.

[0239] The liquid compositions, whether they are solutions, suspensions or other like form, can also include one or more of the following: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which can serve as the solvent or suspending medium, polyethylene glycols, glycerin, cyclodextrin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, phosphates or amino acids and agents for the adjustment of tonicity such as sodium chloride or dextrose. A parenteral composition can be enclosed in ampoule, a disposable syringe or a multiple-dose vial made of glass, plastic or other material. Physiological saline is an exemplary adjuvant. An injectable composition is preferably sterile.

[0240] The amount of a compound of the invention and/or antibody drug conjugate thereof that is effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances.

[0241] The compositions comprise an effective amount of a compound of the invention and/or antibody drug conjugate thereof such that a suitable dosage will be obtained. Typically, this amount is at least about 0.01% of a compound of the invention and/or antibody drug conjugate thereof by weight of the composition. In an exemplary embodiment, pharmaceutical compositions are prepared so that a parenteral dosage unit contains from about 0.01% to about 2% by weight of the amount of a compound of the invention and/or antibody drug conjugate thereof.

[0242] For intravenous administration, the composition can comprise from about 0.01 to about 100 mg of a compound of the invention and/or antibody drug conjugate thereof per kg of the patient's body weight. In one aspect, the composition can include from about 1 to about 100 mg of a compound of the invention and/or antibody drug conjugate thereof per kg of the patient's body weight. In another aspect, the amount administered will be in the range from about 0.1 to about 25 mg/kg of body weight of a compound of the invention and/or antibody drug conjugate thereof.

[0243] Generally, the dosage of a compound of the invention and/or antibody drug conjugate thereof administered to a patient is typically about 0.01 mg/kg to about 20 mg/kg of the patient's body weight. In one aspect, the dosage administered to a patient is between about 0.01 mg/kg to about 10 mg/kg of the patient's body weight. In another aspect, the dosage administered to a patient is between about 0.1 mg/kg and about 10 mg/kg of the patient's body weight. In yet another aspect, the dosage administered to a patient is between about 0.1 mg/kg and about 5 mg/kg of the patient's body weight. In yet another aspect the dosage administered is between about 0.1 mg/kg to about 3 mg/kg of the patient's body weight. In yet another aspect, the dosage administered is between about 1 mg/kg to about 3 mg/kg of the patient's body weight.

[0244] A compound of the invention and/or antibody drug conjugate thereof can be administered by any convenient route, for example by infusion or bolus injection. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer a compound of the invention and/or antibody drug conjugate thereof. In certain embodiments, more than one compound of the invention and/or antibody drug conjugate thereof is administered to a patient.

[0245] In specific embodiments, it can be desirable to administer one or more compounds of the invention and/or antibody drug conjugates thereof locally to the area in need of treatment. This can be achieved, for example, and not by way of limitation, by local infusion during surgery; topical application, e.g., in conjunction with a wound dressing after surgery; by injection; by means of a catheter; or by means of an implant, the implant being of a porous, non-porous, or gelatinous material, including membranes, such as silastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a cancer, tumor or neoplastic or pre-neoplastic tissue. In another embodiment, administration can be by direct injection at the site (or former site) of a manifestation of an autoimmune disease.

[0246] In yet another embodiment, the compound of the invention and/or antibody drug conjugate thereof can be delivered in a controlled release system, such as but not limited to, a pump or various polymeric materials can be used. In yet another embodiment, a controlled-release system can be placed in proximity of the target of the compound of the invention and/or antibody drug conjugate thereof, e.g., the liver, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in the review by Langer (*Science* 249:1527-1533 (1990)) can be used.

[0247] The term "carrier" refers to a diluent, adjuvant or excipient, with which a compound or antibody drug conjugate

thereof is administered. Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin. The carriers can be saline, and the like. In addition, auxiliary, stabilizing and other agents can be used. In one embodiment, when administered to a patient, the compound or conjugate and pharmaceutically acceptable carriers are sterile. Water is an exemplary carrier when the compound or conjugate are administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

[0248] The present compositions can take the form of solutions, pellets, powders, sustained-release formulations, or any other form suitable for use. Other examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.

[0249] In an embodiment, the compound of the invention and/or antibody drug conjugate thereof are formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to animals, particularly human beings. Typically, the carriers or vehicles for intravenous administration are sterile isotonic aqueous buffer solutions. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally comprise a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where a compound of the invention and/or antibody drug conjugate thereof is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the compound of the invention and/or antibody drug conjugate thereof is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.

[0250] The composition can include various materials that modify the physical form of a solid or liquid dosage unit. For example, the composition can include materials that form a coating shell around the active ingredients. The materials that form the coating shell are typically inert, and can be selected from, for example, sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients can be encased in a gelatin capsule.

[0251] Whether in solid or liquid form, the present compositions can include a pharmacological agent used in the treatment of cancer.

Therapeutics Uses of Compounds and Antibody Drug Conjugates Thereof

[0252] Another aspect of the invention relates to the compounds of the invention and antibody drug conjugates thereof for use to treat cancer.

[0253] The compounds of the invention and/or antibody drug conjugates thereof are useful for inhibiting the multiplication of a tumor cell or cancer cell, causing apoptosis in a tumor or cancer cell, or for treating cancer in a patient. The compounds of the invention and/or antibody drug conjugates thereof can be used accordingly in a variety of settings for the treatment of animal cancers. Said conjugates can be used to deliver a compound of the invention to a tumor cell or cancer cell. Without being bound by theory, in one embodiment, the antibody of the conjugate binds to or associates with a cancer-cell or a tumor-cell-associated antigen, and the conjugate can be taken up (internalized) inside a tumor cell or cancer cell through receptor-mediated endocytosis or other internalization mechanism. The antigen can be attached to a tumor cell or cancer cell or can be an extracellular matrix protein associated with the tumor cell or cancer cell. In certain embodiments, once inside the cell, one or more specific peptide sequences are enzymatically or hydrolytically cleaved by one or more tumor cell or cancer cell-associated proteases, resulting in release of a compound of the invention from the conjugate. The released compound of the invention is then free to migrate within the cell and induce cytotoxic or cytostatic activities. The conjugate also can be cleaved by an intracellular protease to release a compound of the invention. In an alternative embodiment, the compound of the invention is cleaved from conjugate outside the tumor cell or cancer cell, and the compound of the invention subsequently penetrates the cell.

[0254] In certain embodiments, the conjugates provide conjugation-specific tumor or cancer drug targeting, thus reducing general toxicity of the compounds of the invention.

[0255] In another embodiment, the antibody unit binds to the tumor cell or cancer cell.

[0256] In another embodiment, the antibody unit binds to a tumor cell or cancer cell antigen which is on the surface of the tumor cell or cancer cell.

[0257] In another embodiment, the antibody unit binds to a tumor cell or cancer cell antigen which is an extracellular matrix protein associated with the tumor cell or cancer cell.

[0258] The specificity of the antibody unit for a particular tumor cell or cancer cell can be important for determining those tumors or cancers that are most effectively treated.

[0259] Particular types of cancers that can be treated with a compound of the invention and/or antibody drug conjugate thereof, include but are not limited to, carcinomas of the bladder, breast, cervix, colon, endometrium, kidney, lung,

esophagus, ovary, prostate, pancreas, skin, stomach, and testes; and blood born cancers including but not limited to leukemias and lymphomas.

[0260] *Multi-Modality Therapy for Cancer.* Cancers, including, but not limited to, a tumor, metastasis, or other disease or disorder characterized by uncontrolled cell growth, can be treated or inhibited by administration of a compound of the invention and/or antibody drug conjugate thereof.

[0261] In other embodiments, methods for treating cancer are provided, including administering to a patient in need thereof an effective amount of a compound of the invention and/or antibody drug conjugate thereof and a chemotherapeutic agent. In one embodiment the chemotherapeutic agent is that with which treatment of the cancer has not been found to be refractory. In another embodiment, the chemotherapeutic agent is that with which the treatment of cancer has been found to be refractory. A compound of the invention and/or antibody drug conjugate thereof can be administered to a patient that has also undergone surgery as treatment for the cancer.

[0262] In some embodiments, the patient also receives an additional treatment, such as radiation therapy. In a specific embodiment, the compound of the invention and/or antibody drug conjugate thereof is administered concurrently with the chemotherapeutic agent or with radiation therapy. In another specific embodiment, the chemotherapeutic agent or radiation therapy is administered prior or subsequent to administration of a compound of the invention and/or antibody drug conjugate thereof.


[0263] A chemotherapeutic agent can be administered over a series of sessions. Any one or a combination of the chemotherapeutic agents, such a standard of care chemotherapeutic agent(s), can be administered.

[0264] Additionally, methods of treatment of cancer with a compound of the invention and/or antibody drug conjugate thereof are provided as an alternative to chemotherapy or radiation therapy where the chemotherapy or the radiation therapy has proven or can prove too toxic, e.g., results in unacceptable or unbearable side effects, for the subject being treated. The patient being treated can, optionally, be treated with another cancer treatment such as surgery, radiation therapy or chemotherapy, depending on which treatment is found to be acceptable or bearable.

[0265] The compounds of the invention and/or antibody drug conjugates thereof can also be used in an in vitro or ex vivo fashion, such as for the treatment of certain cancers, including, but not limited to leukemias and lymphomas, such treatment involving autologous stem cell transplants. This can involve a multi-step process in which the animal's autologous hematopoietic stem cells are harvested and purged of all cancer cells, the animal's remaining bone-marrow cell population is then eradicated via the administration of a high dose of a compound of the invention and/or antibody drug conjugate thereof with or without accompanying high dose radiation therapy, and the stem cell graft is infused back into the animal. Supportive care is then provided while bone marrow function is restored and the patient recovers.

Released Species



[0266] Further embodiments of the invention include the chemical species released, inside or in the vicinity of the cancer cell or tumor cell by what is believed to be enzymatic and/or hydrolytic cleavage by one or more cancer cell or tumor cell-associated proteases. Such compounds include the species described herein, and also include compounds such as those described in the structure:



IV



or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is




Y is C₂-C₂₀ alkylene or C₂-C₂₀ heteroalkylene; C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈heterocyclo-, -C₁-C₁₀alkylene-arylene-, -arylene-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo)-, -(C₃-C₈carbocyclo)-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀alkylene-;

Z'' is



or -NHZ''' ;

Z''' is



G is halogen, -OH, -SH or -S-C₁-C₆ alkyl;


R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R^{3A} and R^{3B} are defined as either of the following:

- (i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and
R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or


(ii) R^{3A} and R^{3B} taken together are either C_2-C_8 alkylene, which C_2-C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1-C_8 heteroalkylene, which C_1-C_8 heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R^5 is



C_1-C_{10} heterocyclyl, C_3-C_8 carbocyclyl and C_6-C_{14} aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of $-C_1-C_8$ alkyl, $-C_1-C_8$ alkyl- $N(R')_2$, $-C_1-C_8$ alkyl- $C(O)R'$, $-C_1-C_8$ alkyl- $C(O)OR'$, $-O-(C_1-C_8$ alkyl), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1-C_8 alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1-C_{10} heterocyclyl;

or R^5 is



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -C₁-C₈ alkyl-N(R')₂, -C₁-C₈ alkyl-C(O)R', -C₁-C₈ alkyl-C(O)OR', -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R', -SR' and arylene-R', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈heterocyclyl, C₁-C₁₀alkylene-C₃-C₈heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C₁-C₁₀ heterocyclyl;

R⁶ is hydrogen, -C₁-C₈ alkyl, -C₂-C₈ alkenyl, -C₂-C₈ alkynyl or -C₁-C₈ haloalkyl;

R¹² is hydrogen, C₁-C₄ alkyl, C₁-C₁₀ heterocyclyl or C₆-C₁₄ aryl;

R¹³ is C₁-C₁₀ heterocyclyl; and


R⁷ is independently selected for each occurrence from the group consisting of F, Cl, I, Br, NO₂, CN and CF₃;

R¹⁰ is hydrogen, -C₁-C₁₀alkyl, -C₃-C₈carbocycle, aryl, -C₁-C₁₀heteroalkyl, -C₃-C₈heterocyclo, -C₁-C₁₀alkylene-aryl, -arylene-C₁-C₁₀alkyl, -C₁-C₁₀alkylene-(C₃-C₈carbocycle), -(C₃-C₈ carbocycle)-C₁-C₁₀alkyl, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo), and -(C₃-C₈ heterocyclo)-C₁-C₁₀alkyl, where aryl on R₁₀ comprising aryl is optionally substituted with [R₇]_h;


h is 1, 2, 3, 4 or 5; and

X is O.

[0267] Of particular interest are compounds of formula IV having the structures:



and



[0268] The invention is further described in the following examples, which are not intended to limit the scope of the invention.

EXEMPLIFICATION

[0269] Experiments were generally carried out under inert atmosphere (nitrogen or argon), particularly in cases where oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate (generally Sure-Seal™ products from the Aldrich Chemical Company, Milwaukee, Wisconsin). Products were generally dried under vacuum before being carried on to further reactions or submitted for biological testing. Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatography-mass spectrometry (GCMS) instrumentation. Chemical shifts for nuclear magnetic resonance (NMR) data are expressed in parts per million (ppm, δ) referenced to residual peaks from the deuterated solvents employed.

[0270] For syntheses referencing procedures in other Examples or Methods, reaction Protocol (length of reaction and temperature) may vary. In general, reactions were followed by thin layer chromatography (TLC) or mass spectrometry, and subjected to work-up when appropriate. Purifications may vary between experiments: in general, solvents and the solvent ratios used for eluants/gradients were chosen to provide appropriate R_f S or retention times.

[0271] Optical rotations were performed on a Perkin-Elmer polarimeter 343 (Serial number 9506).

[0272] HRMS were performed on an Agilent 6220 TOF LC/MS.

[0273] Compound names were generated with ACD Labs software.

HPLC and LC-MS Conditions Used for Analysis

[0274] *Protocol A:* Column: Phenomenex Luna C18 (2), 150 x 3.0 mm, 5 μ m; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% B over 1.5 minutes, 5% to 100% B over 8.5 minutes, then 100% B for 1 minute; Flow rate: 0.75 mL/minute. Temperature: 25°C; Detection: DAD 215 nm, 254 nm; MS (+) range 150-2000 daltons; Injection volume: 10 μ L; Instrument: Agilent 1200 LCMS.

[0275] *Protocol B:* Column: Phenomenex Luna C18 (2), 150 x 3.0 mm, 5 μ m; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 50% B over 1.5 minutes, 50% to 100% B over 6.5 minutes, then 100% B over 3 minutes; Flow rate: 0.75 mL/minute. Temperature: 25°C; Detection: DAD 215 nm; MS (+) range 150-2000 daltons; Injection volume: 10 μ L; Instrument: Agilent 1200 LCMS.

[0276] *Protocol C:* Column: Phenomenex Luna C18 (2), 150 x 3.0 mm, 5 μ m; Mobile phase A: 0.02% trifluoroacetic acid in water (v/v); Mobile phase B: 0.02% trifluoroacetic acid in methanol (v/v); Gradient: 50% to 100% B over 10 minutes; Flow rate: 0.75 mL/minute. Temperature: not controlled; Detection: DAD 215 nm, 254 nm; Injection volume: 10 μ L; Instrument: Agilent 1100 HPLC.

[0277] *Protocol D:* Column: Phenomenex Luna C18 (2), 150 x 3.0 mm, 5 μ m; Mobile phase A: 0.02% trifluoroacetic acid in water (v/v); Mobile phase B: 0.02% trifluoroacetic acid in methanol (v/v); Gradient: 5% to 100% B over 8 minutes; Flow rate: 0.75 mL/minute. Temperature: not controlled; Detection: DAD 215 nm, 254 nm; Injection volume: 10 μ L; Instrument: Agilent 1100 HPLC.

[0278] *Protocol E:* Column: Phenomenex Lux Amylose-2, 250 x 4.6 mm, 5 μ m; Mobile phase A: heptane; Mobile phase B: ethanol (denaturated); Gradient: 5% to 100% B over 10 minutes; Flow rate: 1.5 mL/minute. Temperature: not controlled; Detection: DAD 215 nm, 254 nm; MS (+) range 150-1500 daltons; Injection volume: 10 μ L; Instrument: Agilent 1100 LCMS.

[0279] *Protocol F:* Column: Waters Acquity UPLC BEH, C18, 2.1 x 50 mm, 1.7 μ m; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% B over 0.1 minute, 5% to 95% B over 0.7 minute, 95% B over 0.1 minute; Flow rate: 1.25 mL/minute. Temperature: 60°C; Detection: 200-450nm; MS (+) range 100-1200 daltons; Injection volume: 5 μ L; Instrument: Waters Acquity.

[0280] *Protocol G:* Column: Phenomenex Luna C18 (2), 150 x 3.0 mm, 5 μ m; Mobile phase A: 0.02% trifluoroacetic acid in water (v/v); Mobile phase B: 0.02% trifluoroacetic acid in acetonitrile (v/v); Gradient: 0% to 100% B over 8.5

minutes; Flow rate: 1.5 mL/minute. Temperature: not controlled; Detection: DAD 210 nm; Injection volume: 10 µL; Instrument: Agilent 1100 HPLC.

[0281] *Protocol H:* Column: Phenomenex Gemini-NX, C18, 4.6 x 50 mm, 3 µm, 110 Å; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 0% to 100% B over 4.10 minutes, linear then 100% B over 0.4 minute; Flow rate: 1.5 mL/minute. Temperature: 60°C; Detection: DAD 200-450 nm; MS (+) range 100-2000 daltons; Injection volume: 5 µL; Instrument: Agilent.

[0282] *Protocol I:* Column: Atlantis T3, 75 x 3.0 mm, 3 µm; Mobile phase A: 0.05% trifluoroacetic acid in water (v/v); Mobile phase B: acetonitrile; Gradient: 5% to 95% B over 5.75 minutes; Flow rate: 1.2 mL/minute. Temperature: 45°C; Detection: DAD 215 nm, 230 nm, 254 nm; MS (+) range: 150-1200 daltons; Injection volume: 5 µL; Instrument: Agilent 1100 LCMS.

[0283] *Protocol J:* Column: Phenomenex Luna Phenyl-Hexyl, 150 x 3.0 mm, 5 µm; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% B over 1.5 minutes, 5% to 100% B over 8.5 minutes, then 100% B over 1 minute; Flow rate: 0.75 mL/minute. Temperature: 25°C; Detection: DAD 215 nm, 254 nm; MS (+) range 150-2000 daltons; Injection volume: 10 µL; Instrument: Agilent 1200 LCMS.

[0284] *Protocol K:* Column: Symmetry-C18, 50 x 2.1 mm, 3.5 µm; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in methanol (v/v); Gradient: 10% to 90% B over 6.5 minutes; Flow rate: 0.7 mL/minute. Temperature: room temperature; Detection: DAD 215 nm; MS (+) range 100-1500 daltons; Injection volume: 3 µL; Instrument: Waters 996 PDA.

[0285] *Protocol L:* Column: XBridge C-18, 150 x 4.6 mm, 3.5 µm; Mobile phase A: 5 mM aqueous ammonium acetate solution; Mobile phase B: acetonitrile; Gradient: 10% B over 3 minutes then 10% to 80% B over 14 minutes; Flow rate: 0.7 mL/minute. Temperature: room temperature; Detection: DAD 215 nm; MS (+) range 100-1500 daltons; Injection volume: 3 µL; Instrument: Waters 996 PDA.

[0286] *Protocol M:* Column: Phenomenex Luna, 150 x 3.0 mm, 5 µm; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in methanol (v/v); Gradient: 50% B over 1.5 minutes, 50% to 80% B over 8.5 minutes, then 80% B over 10 minutes; Flow rate: 0.75 mL/minute. Temperature: 45°C; Detection: DAD 215 nm, 254 nm; MS (+) range 90-2000 daltons; Injection volume: 10 µL; Instrument: Agilent 1200 LCMS.

[0287] *Protocol N:* Column: Phenomenex Luna C18 (2), 150 x 3.0 mm, 5 µm; Mobile phase A: 0.02% trifluoroacetic acid in water (v/v); Mobile phase B: 0.02% trifluoroacetic acid in acetonitrile (v/v); Gradient: 0% to 100% B over 23.5 minutes; Flow rate: 1.5 mL/minute. Temperature: not controlled; Detection: DAD 210 nm; Injection Volume: 10 µL; Instrument: Agilent 1100 HPLC

[0288] *Protocol O:* Column: Column: Agilent Poroshell 300SB-C8, 75 x 2.1 mm, 2.6 µm; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 20% B to 45% B over 4 minutes; Flow rate: 1.0 mL/minute. Temperature: 60 °C; Detection: 220 nm; MS (+) range 400-2000Da; Injection volume: 10 µL; Instrument: Agilent 1100 LC, Waters MicromassZQ MS. Deconvolution was performed using MaxEnt1.

[0289] *Protocol P:* Column: Column: TSK-gel G3000SWxl, 300 x 7.8 mm, 10 µm; Mobile phase: Phosphate buffer saline (PBS, IX), pH 7.4 with 2% acetonitrile; Isocratic; Flow rate: 1 mL/minute. Temperature: room temperature; Injection Volume: 5 µL; Instrument: Agilent 1100 HPLC.

[0290] *Protocol Q:* Column: Waters Acquity UPLC HSS T3, C18, 2.1 x 50 mm, 1.7 µm; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% B over 0.1 minute, 5% to 95% B over 2.5 minutes, 95% B over 0.35 minute; Flow rate: 1.25 mL/minute. Temperature: 60 °C; Detection: 200-450nm; MS (+) range 100-2000 daltons; Injection volume: 5 µL; Instrument: Waters Acquity.

[0291] *Protocol Q1:* Column: Waters Acquity UPLC HSS T3, C18, 2.1 x 50 mm, 1.7 µm; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% B over 0.1 minute, 5% to 95% B over 1.5 minute, 95% B over 0.35 minute; Flow rate: 1.25 mL/minute. Temperature: 60 °C; Detection: 200-450nm; MS (+) range 100-2000 daltons; Injection volume: 5 µL; Instrument: Waters Acquity.

[0292] *Protocol Q2:* Column: Xtimate C18, 2.1 x 30 mm, 3 µm; Mobile phase A: 0.1% trifluoroacetic acid in water (v/v); Mobile phase B: 0.1% trifluoroacetic acid in acetonitrile (v/v); Gradient: 10% to 80% B over 0.9 minutes, 80% B over 0.6 minutes; 100 % B for 0.5 minutes; Flow rate: 1.2 mL/minute. Detection: DAD 220 nM; Temperature: 25°C; Injection volume: 1 µL; Instrument: Agilent.

[0293] *Protocol Q3:* Column: Xtimate C18, 2.1 x 30 mm, 3 µm; Mobile phase A: 0.1% trifluoroacetic acid in water (v/v); Mobile phase B: 0.1% trifluoroacetic acid in acetonitrile (v/v); Gradient 0% to 60% B over 0.9 minutes, 60% B over 0.6 minutes; 100% B for 0.5 minutes; Flow rate: 1.2mL/minute. Detection: DAD 220 nM; Temperature: 25°C; Injection volume: 1 µL; Instrument: Agilent.

[0294] *Protocol R:* Column: Phenomenex Luna, 150 x 3.0 mm, 5 µm; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in methanol (v/v); Gradient: 5% B over 1.5 minutes, 5% to 100% B over 8.5 minutes, then 100% B over 1 minute; Flow rate: 0.75 mL/minute. Temperature: 45 °C; Detection: DAD 215 nm, 254 nm; MS (+) range 150-2000 daltons; Injection volume: 10 µL; Instrument: 305 RP Agilent 1200 LCMS.

[0295] *Protocol S:* Column: Phenomenex Luna, 150 x 3.0 mm, 5 µm; Mobile phase A: 0.1% trifluoroacetic acid in

water (v/v); Mobile phase B: 0.1% trifluoroacetic in acetonitrile (v/v); Gradient: 5% B over 1.5 minutes, 5% to 95% B over 8.5 minutes, then 100% B over 1 minute; Flow rate: 1.0 mL/minute. Temperature: not controlled; Detection: DAD 210 nm; MS (+) range 150-2000 daltons; Injection volume: 10 μ L; Instrument: 305 RP Agilent 1100 HPLC.

[0296] *Protocol T:* Column: Atlantis dC18, 50 x 4.6 mm, 5 μ m; Mobile phase A: 0.05% trifluoroacetic acid in water (v/v); Mobile phase B: 0.05% trifluoroacetic acid in acetonitrile (v/v); Gradient: 5% to 95% B over 4.0 minutes; then hold at 95% B over 1 minute; Flow rate: 2 mL/minute. Temperature: room temperature; Detection: DAD 215 nm; MS (+) range 160 -1000 daltons; Injection volume: 3 μ L; Instrument: Waters 996 PDA.

[0297] *Protocol U:* Column: Phenomenex Luna C18 (2), 150 x 3.0 mm, 5 μ m; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% B over 1.5 minutes, 5% to 100% B over 8.5 minutes, then 100% B for 1 minute; Flow rate: 0.75 mL/minute. Temperature: 45 °C; Detection: DAD 215 nm, 254 nm; MS (+) range 150-2000 daltons; Injection volume: 10 μ L; Instrument: Agilent 1200 LCMS.

[0298] *Protocol V:* Column: HPLC-V Ultimate XB- C18, 50 x 3.0 mm, 3 μ m; Mobile phase A: 0.225 % trifluoroacetic acid in water (v/v); Mobile phase B: 0.225 % trifluoroacetic acid in acetonitrile (v/v); Gradient: 30% to 90% B over 6 minutes; Flow rate: 1.2 mL/minute. Temperature: 40 °C; Detection: DAD 220 nm; Injection volume: 1 μ L; Instrument: SHIMADZU.

[0299] *Protocol W:* Column: HPLC-V Ultimate XB- C18, 50 x 3.0 mm, 3 μ m; Mobile phase A: 0.1 % trifluoroacetic acid in water (v/v); Mobile phase B: 0.1 % trifluoroacetic acid in acetonitrile (v/v); Gradient: 10% to 80% B over 6 minutes; Flow rate: 1.2 mL/minute. Temperature: 40°C; Detection: DAD 220 nm; Injection volume: 3 μ L; Instrument: SHIMADZU.

[0300] *Protocol X:* Column: YMC-pack ODS-A, 150 x 4.6 mm, 5 μ m; Mobile phase A: 0.1 % trifluoroacetic acid in water (v/v); Mobile phase B: 0.1 % trifluoroacetic acid in acetonitrile (v/v); Gradient: 10% to 80% B over 6 minutes; Flow rate: 1.2 mL/minute. Detection: DAD 220 nm. Temperature: 40°C; Injection volume: 3 μ L; Instrument: SHIMADZU.

[0301] *Protocol Y:* Column: YMC-pack ODS-A, 150 x 4.6 mm, 5 μ m; Mobile Phase A: 0.1% trifluoroacetic acid in water (v/v); Mobile Phase B: 0.1% trifluoroacetic acid in acetonitrile (v/v); Gradient: 0% to 95% B over 10 minutes, then 95% B for 5 minutes; Flow rate: 1.5 mL/minute; Detection: DAD 220 nm; Instrument: Agilent 1100.

[0302] *Protocol Z:* Column: Xtimate C18, 2.1 x 30 μ m, 3 μ m; Mobile Phase A: 0.1% trifluoroacetic acid in water (v/v); Mobile phase B: 0.1% trifluoroacetic acid in acetonitrile (v/v); Gradient: 0% to 60% B over 2 minutes; Flow rate: 1.2 ml/min. Temperature: 50°C; Detection: 220 nm, MS (+) range 100 -1000 daltons; Injection volume: 1 μ L; Instrument: SHIMADZU.

[0303] *Protocol AB:* Column: Phenomenex Luna C18 (2), 150 x 2.0 mm, 5 μ m; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% to 100% B over 10 minutes, then 100% B for 2 minute; Flow rate: 0.5 mL/minute. Temperature: 25°C; Detection: DAD 210 nm, 254 nm; MS (+) range 150-2000 daltons; Injection volume: 5 μ L; Instrument: Agilent 1100 LCMS.

[0304] *Protocol BB:* Column: Phenomenex Luna C18 (2), 150 x 2.0 mm, 5 μ m; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% B over 2.0 minutes, 5% to 100% B over 12 minutes, and 100% B for 2 minute, then 100% to 5% B over 1.5 min; Flow rate: 0.75 mL/minute. Temperature: 25°C; Detection: DAD 215 nm, 254 nm; MS (+) range 150-2000 daltons; Injection volume: 5 μ L; Instrument: Agilent.

[0305] *Protocol CB:* Column: Waters XBridge C18, 4.6 x 50 mm, 5 μ m; Mobile phase A: 0.03% ammonium hydroxide in water (v/v); Mobile phase B: 0.03% ammonium hydroxide in acetonitrile (v/v); Gradient: 5% to 95 % B over 4.0 minutes, then 95% B for 1 minute; Flow rate: 2 mL/minute. Temperature: 25°C; Detection: DAD 215 nm, MS (+) range 160-1000 daltons; Injection volume: 4 μ L; Instrument: Waters ZQ/Alliance 2795 HPLC.

[0306] *Protocol DB:* Column: Waters Atlantis dC18, 4.6 x 50 mm, 5 μ m; Mobile phase A: 0.05% trifluoroacetic acid in water (v/v); Mobile phase B: 0.05% trifluoroacetic acid in acetonitrile (v/v); Gradient: 5.0% to /95% B over 4.0 minutes, then 95% B for 1 minute. Flow rate: 2 mL/minute. Temperature: 25 °C; Detection: DAD 215 nm, MS (+) range 160-1000 daltons; Injection volume: 4 μ L; Instrument: Waters ZQ/Alliance 2795 HPLC.

[0307] *Protocol EB:* Column: XBridge RP18, 2.1 x 50 mm, 5 μ m; Mobile phase A: 0.02% ammonium hydroxide in water (v/v); Mobile phase B: 0.02% ammonium hydroxide in acetonitrile (v/v); Gradient 10% to 80% B% over 6 minutes, then 80% for 2 minutes; Flow rate: 1.2 mL/minute. Detection: DAD 220 nm.; Temperature: 50 °C.

[0308] *Protocol FB:* Column: Phenomenex Luna C18 (2), 150 x 2.0 mm, 5 μ m; Mobile phase A: 0.1% formic acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient: 5% B over 2.0 minutes, 5% to 100% B over 10 minutes, and 100% B for 2 minute; Flow rate: 0.50 mL/minute. Temperature: 25 °C; Detection: DAD 215 nm, 254 nm; MS (+) range 150-2000 daltons; Injection volume: 5 μ L; Instrument: Agilent 1200 LCMS.

[0309] In some instances some minor alterations to analysis LC-MS and HPLC conditions were made such as but not limited a change in gradient or flow rate which is indicated by the symbol *.

HPLC Conditions Used for Purification

[0310] *Method A:* Column: Phenomenex Lux Amylose-2, 250 x 21.2 mm, 5 μ m; Mobile phase A: Heptane; Mobile phase B: Ethanol (denatured); Gradient: 5% to 100% B over 6 min; Flow Rate: 27 mL/minute; Detection: DAD 210-360

nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx.

[0311] Method B: Column: Phenomenex Luna C18(2), 150 x 21.2 mm, 5 µm; Mobile phase A: 0.02% acetic acid in water; Mobile phase B: 0.02% acetic acid in acetonitrile; Gradient: 5% B over 1.5 minutes, 5% to 45% B over 8.5 minutes; Flow rate: 27 mL/minute; Detection: DAD 215 nm, 254 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx.

[0312] Method C: Column: Phenomenex Luna C18, 100 x 30 mm, 10 µm; Mobile phase A: 0.02% trifluoroacetic acid in water (v/v); Mobile phase B: 0.02% trifluoroacetic acid in methanol (v/v); Gradient: 10% to 90% B over 20 minutes; Flow rate: 20 mL/minute. Temperature: not controlled; Detection: DAD 210 nm, 254 nm; Injection Volume: variable; Instrument: Gilson.

[0313] Method D: Column: Phenomenex Synergi Max-RP, 150 x 21.2 mm, 4 µm; Mobile phase A: 0.1% formic acid in water; Mobile phase B: 0.1% formic acid in acetonitrile; Gradient: 30% B for 1.5 minutes, 30% to 60% B over 8.5 minutes, 60 to 100% B over 0.5 minutes then 100% B over 2 minutes; Flow rate: 27 mL/minute; Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx.

[0314] Method E1: Column: Phenomenex Luna C18(2), 150 x 21.2 mm, 5 µm; Mobile phase A: 0.1% formic acid in water; Mobile phase B: 0.1% formic acid in acetonitrile; Gradient: 40% B for 1.5 minutes, 40% to 80% B over 8.5 minutes, 80 to 100% B over 0.5 minute then 100% B over 2 minutes; Flow rate: 27 mL/minute; Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx LCMS.

[0315] Method E2: Column: Phenomenex Luna Phenyl-hexyl, 150 x 21.2 mm, 5 µm. The rest of the Protocols are identical to those described for Method E1.

[0316] Method F: Column: Phenomenex Synergi Max-RP, 150 x 21.2 mm, 4 µm; Mobile phase A: 0.1% formic acid in water; Mobile phase B: 0.1% formic acid in methanol; Gradient: 44% B for 1.5 minutes, 44% to 77% B over 8.5 minutes, then 77% B over 10 minutes; Flow rate: 27 mL/minute; Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx LCMS.

[0317] Method G: Column: PrincetonSFC 2-ethylpyridine, 250 x 21.2 mm, 5 µm; Mobile phase A: heptane; Mobile phase B: ethanol (denaturated); Gradient: 1% B for 1.5 minutes, 1% to 50% B over 8.5 minutes; Flow rate: 27 mL/minute; Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx LCMS.

[0318] Method H: Column: Phenomenex Luna C18(2), 150 x 21.2 mm, 5 µm; Mobile phase A: 0.02% acetic acid in water; Mobile phase B: 0.02% acetic acid in acetonitrile; Gradient: 20% B over 1.5 minutes, 20% to 60% B over 10.5 minutes; Flow rate: 27 mL/minute; Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx LCMS.

[0319] Method I: Column: Phenomenex Luna C18(2), 150 x 21.2 mm, 5 µm; Mobile phase A: 0.1% formic acid in water; Mobile phase B: 0.1% formic acid in methanol; Gradient: 40% B over 1.5 minutes, 40% to 70% B over 8.5 minutes then 70% B over 10 minutes; Flow rate: 27 mL/minute; Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx LCMS.

[0320] Method J: Column: Phenomenex Luna C18, 100 x 30 mm, 5 µm; Mobile phase A: 0.02% trifluoroacetic acid in water (v/v); Mobile phase B: 0.02% trifluoroacetic acid in acetonitrile (v/v); Gradient: 10% to 90% B over 20 minutes; Flow rate: 20 mL/minute. Temperature: not controlled; Detection: DAD 210 nm, 254 nm; Injection Volume: variable; Instrument: Gilson.

[0321] Method K: Column: Phenomenex Luna C18(2), 150 x 21.2 mm, 5 µm; Mobile phase A: 0.1% formic acid in water; Mobile phase B: 0.1% formic acid in acetonitrile; Gradient: 20% B for 1.5 minutes, 20% to 50% B over 8.5 minutes, 50 to 100% B over 0.5 minute then 100% B over 2 minutes; Flow rate: 27 mL/minute; Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx LCMS.

[0322] Method L: Column: Phenomenex Luna C18(2), 150 x 21.2 mm, 5 µm; Mobile phase A: 0.1% formic acid in water; Mobile phase B: 0.1% formic acid in acetonitrile; Gradient: 30% B for 1.5 minutes, 30% to 50% B over 8.5 minutes, 50 to 100% B over 0.5 minute then 100% B over 2 minutes; Flow rate: 27 mL/minute; Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx LCMS.

[0323] Method M: Column: Waters Sunfire, C18, 19x100 mm, 5 µm; Mobile phase A: 0.05% trifluoroacetic acid in water (v/v); Mobile phase B: 0.05% trifluoroacetic acid in acetonitrile (v/v); Gradient: 0 to 100% over 8.5 minutes. Flow rate 25 mL/minute. Detection: DAD 215 nm MS (+) range 160-1000 daltons; Instrument: Waters FractionLynx.

[0324] Method N: Column: Waters Sunfire, C18, 19x100 mm, 5 µm; Mobile phase A: 0.05% formic acid in water (v/v); Mobile phase B: 0.05% formic acid in acetonitrile (v/v); Gradient: 0 to 100% over 8.5 minutes. Flow rate 25 mL/minute. Detection: DAD 215 nm MS (+) range 160-1000 daltons; Instrument: Waters FractionLynx.

[0325] Method O: Column: Phenomenex Luna C18, 21.2x150 mm, 5 µm; Mobile phase A: 0.1% formic acid in water (v/v) acid in water (v/v); Mobile phase B: 0.1% formic acid in acetonitrile (v/v); Gradient(v/v); Gradient 20% B over 1.5 minutes, 20% to 40% B over 8.5 minutes, 40 to 100% B over 0.5 minutes, then hold 100% B for 1.5 minutes. Flow rate: 27 mL/minute. Detection: DAD 210-360 nm; MS (+) range 150-2000 daltons; Instrument: Waters FractionLynx.

[0326] Method P: Column: Phenomenex Gemini C18, 21.2x250mm, 5 µm; Mobile phase A: 0.225 % ammonia hydroxide in water (pH 10) (v/v); Mobile phase B: 0.225% ammonia hydroxide in acetonitrile (v/v); Gradient: 45% to 85%

B over 10 minutes. Flow rate 35 mL/minute. Detection: DAD 220 nm MS (+) range 100-1200 daltons; Instrument: Shimadzu MS Trigger.

[0327] *Method Q:* Column: Phenomenex Synergi C18, 50x250 mm, 10 μ m; Mobile phase A: 0.1% trifluoroacetic acid in water (v/v) Mobile phase B: Acetonitrile; Gradient 10% to 40% B over 25 minutes. Flow rate 100 mL/minute. Detection: UV/Vis 220 nm; Instrument: Shimadzu LC-8A.

[0328] *Method R:* Column: Phenomenex Luna C18 (2), 250 x 21.2 mm, 5 μ m; Mobile phase A: 0.1% TFA in water (v/v); Mobile phase B: 0.1% TFA in acetonitrile (v/v); Gradient: 10% to 100% over 30 minutes; Flow rate variable. Temperature: 25°C; Detection: DAD 215 nm, 254 nm; MS (+) range 150 - 2000 daltons; Injection volume: 1.8 mL; Instrument: Agilent 1100 Prep HPLC.

[0329] In some instances some minor alterations to purification conditions were made such as but not limited to a change in gradient or flow rate which is indicated by the symbol *.

General Procedures

[0330] *General Procedure A:* Fmoc removal using diethylamine or piperidine. To a solution of the Fmoc-containing compound in dichloromethane or *N,N*-dimethylformamide (also referred to as DMF), was added an equal volume of diethylamine or piperidine. Reaction progress was monitored by LC-MS (or HPLC or TLC). Solvents were removed *in vacuo*, and in some cases the residue was azeotroped one to four times with heptane. Residue was usually diluted with dichloromethane and a small amount of methanol before being reduced down onto silica and purified by chromatography on silica gel, eluting with methanol in dichloromethane (or other appropriate mixture of solvents) to afford the desired material (or crude material was used as is).

[0331] *General Procedure B:* Boc removal or *t*-Bu ester cleavage using trifluoroacetic acid. To a solution of the Boc-containing compound or *tert*-butyl ester-containing compound in dichloromethane at 0°C (or at room temperature) was added trifluoroacetic acid, to afford a ratio of 1:4 trifluoroacetic acid:dichloromethane. Reaction progress was monitored by LC-MS (or HPLC or TLC). Solvents were removed *in vacuo*. The residue was azeotroped three times with heptane to afford the desired material.

[0332] *General Procedure C:* Boc removal or *tert*-butyl ester (also refers to *t*-Bu ester) cleavage using hydrochloric acid in dioxane. To either a solution of Boc-containing compound or *tert*-butyl ester-containing compound in dioxane (or in some cases no solution, or other relevant solvent) was added a 4 M solution of hydrochloric acid in dioxane. Reaction progress was monitored by LC-MS (or HPLC or TLC). The reaction was concentrated *in vacuo* and in some cases azeotroped one to four time with heptanes.

[0333] *General Procedure D:* coupling with *O*-(7-azabenzotriazol-1-yl)-*N,N,N'*-tetramethyluronium hexafluorophosphate (HATU). To a stirring solution of the amine (1.0 eq.) and acid (1.0-2.0 eq.) in dichloromethane, *N,N*-dimethylformamide (also referred to as DMF), or a mixture of both, HATU (1.0-2.0 eq.) was added followed by triethylamine (2.0-4.0 eq.) or diisopropylethylamine (2.0-4.0 eq., also referred to as Hunig's base). Reaction progress was monitored by LC-MS (or HPLC or TLC); the reaction was usually completed within three hours. Solvents were removed *in vacuo*. The residue was purified by silica gel or reverse phase chromatography or in some cases azeotroped three times with heptanes, diluted with a small amount of ethyl acetate before being reduced down onto silica or C18 bonded silica and purified by silica gel or reverse phase chromatography.

[0334] *General Procedure E:* coupling with *N*-[6-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)hexanoyl]-*L*-valyl-*N*⁵-carbamoyl-*N*-[4-({[(4-nitrophenoxy)carbonyl]oxy)methyl}phenyl)-*L*-ornithinamide (MalcValCitPABC-PNP). To a mixture of the payload amine (1 eq.) and *N*-[6-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)hexanoyl]-*L*-valyl-*N*⁵-carbamoyl-*N*-[4-({[(4-nitrophenoxy)carbonyl]oxy)methyl}phenyl)-*L*-ornithinamide (MalcValCitPABC-PNP, Eur. Pat. Appl. (1994), EP624377, 1.0-2.0 eq.) in *N,N*-dimethylformamide or dimethylacetamide (also referred to as DMA), pyridine (0.0-4.0 eq.), diisopropylethylamine (0.0-4.0 eq.), 2,6-dimethylpyridine (0.0-4.0 eq., also referred to as 2,6-Ludidine) and 1-hydroxybenzotriazole hydrate (0.01-1.1 eq. also referred to as HOBT) or 3*H*-[1,2,3]triazolo[4,5-*b*]pyridin-3-ol (0.01-1.1 eq., also referred to as HOAT) was added. After stirring at 40 °C-50°C for 1-48 hours, the reaction mixture was concentrated *in vacuo* and azeotroped three times with heptane. The crude material was purified by reverse phase chromatography according to the specified method to afford the desired material.

[0335] *General procedure F:* conjugation of commercial HERCEPTIN® antibody with linker-payload via internal disulfides. Commercially available HERCEPTIN® antibody (Genentech Inc) was dialyzed into Dulbecco's Phosphate Buffered Saline (DPBS, Lonza). The dialyzed antibody was reduced with addition of *x* equivalents of tris(2-carboxyethyl)phosphine hydrochloride (TCEP, 5 mM in distilled water) and diluted to 15 mg/mL final antibody concentration using DPBS, 5mM 2,2',2''',2'''-(ethane-1,2-diyl)dinitrilo)tetraacetic acid (EDTA), pH 7.0-7.4 (Buffer A). The reaction was incubated at 37 °C for 1-2 hours and then cooled to room temperature. Conjugation was performed by addition of *y* equivalents of linker-payload (5-10 mM in dimethylacetamide (DMA)). DMA was added to achieve 10-20% (v/v) total organic solvent component in final reaction mixture, and Buffer A added to achieve 10 mg/mL final antibody concentration. The reaction was incubated for 1-2 hours at room temperature. The reaction mixture was then buffer exchanged into DPBS (pH 7.4)

using GE Healthcare Sephadex G-25 M buffer exchange columns per manufacturer's instructions. Crude material was purified by size exclusion chromatography (SEC) using GE AKTA Explorer system with GE Superdex column and PBS (pH 7.4) eluent.

[0336] *General procedure G:* Conjugation reactions were performed in the upper portion of a centrifugal ultrafiltration device such as Amicon Ultra 50k Ultracel filters (*part #UFC805096*, GE). A 132 mM stock solution of L-cysteine was prepared in PBS containing 50 mM EDTA. This solution (50 μ L) was added to a mixture of the respective mutant antibody (5 mg) in 950 μ L of PBS containing 50 mM EDTA. The final cysteine concentration in the reaction mixture was 6.6 mM. After allowing the reaction to stand at room temperature (about 23°C) for 1.5 hours the reaction tube was centrifuged to concentrate the material to approximately 100 μ L. The mixture was diluted to 1 mL with PBS containing 50 mM EDTA. This process was repeated 4 times in order to remove all the cysteine reductant. The resulting material was diluted to 1 mL in PBS containing 50 mM EDTA and treated with 16 μ L of a 5 mM solution of the maleimide linker-payload (from **Table 18A** in dimethyl acetamide (DMA) (approximately 5 equivalents). After standing at room temperature (about 23°C) for 1.5 hours the reaction tube was centrifuged to concentrate the material to approximately 100 μ L. The mixture was diluted to 1 mL with PBS. This process was repeated 2 times in order to remove the excess maleimide reactant. The antibody conjugates were generally purified by size exclusion chromatography (SEC) using GE AKTA Explorer system with a GE Superdex200 column and PBS (pH7.4) eluent. The loading of the drug onto the intended site of conjugation was determined using a variety of methods including mass spectrometry (MS), reverse phase HPLC, and hydrophobic interaction chromatography (HIC), as has been described elsewhere. The reported value (in **Tables 19A** and **19B**) is generally obtained by LC-MS under reducing conditions.

[0337] *General procedure H:* A 20 mM TCEP solution (generally 50 to 100 molar equivalents) was added to the antibody (typically 5 mg) such that the final antibody concentration was 5 mg/mL in PBS containing 50 mM EDTA. After allowing the reaction to stand at 37°C for 1.5 hours, the antibody was buffer exchanged into PBS containing 50 mM EDTA using a 50 kD MW cutoff spin concentration device (3 x 3 mL wash, 10x concentration per cycle). Alternative methods such as TFF or dialysis are also useful in particular circumstances. The resulting antibody was re-suspended in 1 mL of PBS containing 50 mM EDTA and treated with a freshly prepared 50 mM solution of DHA (dehydroascorbate) in 1:1 PBS/EtOH (final DHA concentration is typically 1 mM) and allowed to stand at 4 °C overnight. The antibody/DHA mixture was buffer exchanged into PBS containing 50 mM EDTA using a 50 kD MW cutoff spin concentration device (3 x 3 mL wash, 10x concentration per cycle). The resulting antibody was re-suspended in 1 mL of PBS containing 50 mM EDTA and treated with 10 mM maleimide linker-payload in DMA (typically 5-10 equivalents). After standing for 1.5 hours, the material was buffer exchanged (as above) into 1 mL of PBS (3 x 3 mL washes, 10x concentration per cycle). Purification by SEC (as described previously) was performed as needed to remove any aggregated material.

[0338] *General procedure I:* The initial conjugation of the linker-payload was performed using the previously described method (General Procedure F). The resulting antibody-drug-conjugate was buffer exchanged into a 50 mM borate buffer (pH 9.2) using an ultrafiltration device (50 kD MW cutoff). The resulting solution was heated to either 37°C for 24 hours (for the maleimide-Peg linkers) or to 45°C for 48 hours (for the maleimide-caproyl linkers). The resulting solution was cooled, buffer-exchanged into PBS, and purified by SEC (as described previously) in order to remove any aggregated material. LCMS analysis of the material indicated that the succinimide ring had completely opened (90% or more). Note that in examples where a methyl ester is present in the payload, the ester is hydrolyzed to the carboxylic acid under the described conditions.

[0339] *General procedure J:* The pentafluorophenyl esters were conjugated to the shown antibody following the procedure previously outlined in WO2012007896 A1.

[0340] *General procedure K:* The conjugation of amino-alkyl linkers was accomplished via enzyme-mediated ligation as described in WO2012059882 A2.

[0341] *General Procedure L.* N-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (prepared in the same manner as #136) was coupled to the relevant amino acid or amine moiety using HATU (1.0-2.0 eq.) in the presence of Hunig's base (1.-5.0 eq.) in a solution of DMF, dichloromethane, or in some cases a solution of both (or a solution of one or more solvents). Reaction was monitored by LC-MS (or TLC or HPLC). Reaction was concentrated *in vacuo* and purified usually by silica chromatography or by prep HPLC. Fmoc protection was then removed as described in general procedure A followed by concentration *in vacuo* and purified by silica chromatography or by prep HPLC.

[0342] *General Procedure M.* #151 was coupled to the relevant amine using HATU (1.0-2.0 eq., or other appropriate coupling reagent) in the presence of Hunig's base (1.0-5.0 eq.) in a solution of DMF, dichloromethane, or in some cases a solution of both (or a solution of one or more solvents). Reaction was monitored by LC-MS (or TLC or HPLC). Reaction was concentrated *in vacuo*. Boc de-protection was then performed as described in general procedure B, concentrated *in vacuo* and purified by silica chromatography or by prep HPLC.

[0343] *General Procedure N.* 1-(9H-fluoren-9-yl)-3-oxo-2,7,10,13,16,19,22-hepta-oxa-4-azapentacosan-25-oic acid (or other appropriate Fmoc-AmPegXC2-COOH) was coupled to the relevant cytotoxic pentapeptide (or the cytotoxic pentapeptide containing a protecting group on a reactive moiety other than the N-terminus) using HATU (1.0-2.0 eq.,

or other appropriate coupling reagent) in the presence of Hunig's base (1.0-5.0 eq. or other appropriate base) in a solution of DMF, dichloromethane, or in some cases a solution of both (or a solution of one or more solvents). Reaction was monitored by LC-MS (or TLC or HPLC). Reaction was concentrated *in vacuo*. Fmoc de-protection was performed according to general procedure A. In some cases a second de-protection was performed in order to remove a protecting group on a reactive moiety on the cytotoxic pentapeptide using general procedure B (or other relevant procedure known in the literature based on the protecting group). The reaction was concentrated *in vacuo* and purified by silica chromatography or by prep HPLC.

[0344] *General Procedure O.* The appropriate Fmoc-AmPegXC2-COOH is coupled to the relevant cytotoxic pentapeptide (or the cytotoxic pentapeptide containing a protecting group on a reactive moiety other than the N-terminus) and Fmoc de-protection is performed according to general procedure N. The reaction is concentrated *in vacuo* and then purified by silica chromatography or prep HPLC (or the crude material can be used as is). The appropriate PABC sequence (such as mcValCitPABC, or derivative of) is then installed according to general procedure E. In some cases if a protecting group is present on cytotoxic pentapeptide portion of the molecule de-protection is then performed using general procedure A or general procedure B (or other relevant procedure known in the literature based on the protecting group). The reaction is concentrated *in vacuo* and purified by silica chromatography or by prep HPLC.

[0345] *General Procedure P.* Followed procedure E replacing mcValCitPABC-PNP, with MalPeg3C2ValCitPABC-PNP (prepared in a similar manner to mcValCitPABC-PNP).

[0346] *General Procedure Q.* The appropriate Fmoc-AmPegXC2-COOH is coupled to the relevant cytotoxic pentapeptide (or the cytotoxic pentapeptide containing a protecting group on a reactive moiety other than the N-terminus) and Fmoc de-protection is performed as described in general procedure N. The reaction is concentrated *in vacuo* and then purified by silica chromatography or by prep HPLC (or the crude material can be used as is). To a stirring solution of this residue in DMF at 0°C (or a slightly higher temperature in some cases) bromoacetic acid (1.0-2.0 eq.) was added followed by Hunig's base (1.0-5.0 eq.) and HATU (1.0-2.0 eq.) The reaction was allowed to warm to room temperature and stir at room temperature while being monitored by LC-MS (or TLC or HPLC). Reaction was concentrated *in vacuo* and purified by prep HPLC.

[0347] *General Procedure R.* Followed procedure E replacing mcValCitPABC-PNP, with N-(6-((9H-fluoren-9-ylmethoxy)carbonyl)amino)hexanoyl)-L-valyl-N-5-~carbamoyl-N-[4-((4-nitrophenoxy)carbonyl)oxy)methyl]phenyl]-L-ornithinamide (prepared in a similar manner to mcValCitPABC-PNP). Fmoc de-protection was then performed (general procedure B) followed by prep HPLC purification.

[0348] *General Procedure S.* To a stirring solution of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanal (1.0-3.0 eq.) in methanol the relevant cytotoxic pentapeptide (1.0 eq) was added followed by formic acid. The reaction was allowed to stir at room temperature for 1-40 minutes followed by the addition of sodium (cyano-kappaC)(trihydro)borate(1-) (3.0-6.0 eq., also referred to as sodium cyanoborohydride). The reaction was monitored by LC-MS (or TLC or HPLC). In some cases additional 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanal (1.0-3.0 eq.) was added. The reaction was concentrated *in vacuo* followed by purification using prep HPLC.

[0349] *General procedure T.* 4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilinium is prepared as described in the literature (Bioorganic and Medicinal Chemistry Letters. 2012, vol. 22, #13, 4249 - 4253) which is then coupled to bis(pentafluorophenyl) 3,3'-[ethane-1,2-diylbis(oxy)]dipropionate using HATU in dichloromethane followed by coupling to the desired cytotoxic pentapeptide. Material is then purified by prep HPLC.

[0350] *General procedure U.* Fmoc-ValCitPABC-PNP is coupled to the desired cytotoxic pentapeptide following general procedure E and then Fmoc is removed following general procedure A. This residue is then coupled to [2-oxo-2-((4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]phenyl)amino)ethoxy]acetic acid (which is prepared by coupling 4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilinium with 1,4-dioxane-2,6-dione following general procedure D). Material is then purified by prep HPLC.

[0351] *General procedure V.* Bis(pentafluorophenyl) 3,3'-[ethane-1,2-diylbis(oxy)]dipropionate or bis(pentafluorophenyl) 4,7,10,13,16-pentaaxanonadecane-1,19-dioate is coupled to the desired cytotoxic pentapeptide (or in some cases coupled to the desired cytotoxic pentapeptide containing a protecting group on a reactive moiety other than the N-terminus) following general procedure D. If a protecting group is present, the protecting group is then removed (using relevant procedures described in the literature). Material is then purified by prep HPLC.

[0352] *General procedure W.* 4-(((4-nitrophenoxy)carbonyl)oxy)methyl]phenyl 1-(9H-fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azatridecan-13-oate is coupled to the desired cytotoxic pentapeptide following general procedure E. Fmoc is removed following general procedure A. Bis(pentafluorophenyl) 3,3'-[ethane-1,2-diylbis(oxy)]dipropionate is coupled to this residue following general procedure D. Material is then purified by prep HPLC.

[0353] *General procedure X1.* N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-L-alanyl-N-1-~[4-(((4-nitrophenoxy)carbonyl)oxy)methyl]phenyl]-N-4-trityl-L-aspartamide is coupled to the desired cytotoxic pentapeptide following general procedure E. Fmoc is removed following general procedure A and trityl protecting group is removed following general procedure B. Bis(pentafluorophenyl) 3,3'-[ethane-1,2-diylbis(oxy)]dipropionate is coupled to this residue following general procedure D. Material is purified by prep HPLC.

[0354] *General procedure X2.* N-{3-[2-(3-ethoxy-3-oxopropoxy)ethoxy]propanoyl}-L-valyl-N~5~-carbamoyl-N-[4-(((4-nitrophenoxy)carbonyl)oxy)methyl]phenyl]-L-ornithinamide is coupled to the desired cytotoxic pentapeptide following general procedure E. Ethyl ester is removed using lithium hydroxide in THF and water. NHS ester is then formed by coupling residue with 1-hydroxypyrrolidine-2,5-dione using N,N'-dicyclohexylcarbodiimide in THF. Material is purified by prep HPLC.

[0355] *General procedure X3.* N-[(9H-fluoren-9-ylmethoxy)carbonyl]-D-valyl-N~5~-carbamoyl-N-[4-(((2-carboxypropan-2-yl)carbamoyl)oxy)methyl]phenyl]-L-ornithinamide is coupled to **#50** following general procedure D in DMSO and acetonitrile. Fmoc is removed following general procedure A followed by coupling with bis(pentafluorophenyl) 3,3'-[ethane-1,2-diylbis(oxy)]dipropionate using Hunig's base in acetonitrile. Material is purified by prep HPLC.

[0356] *General procedure X4.* N-[1-(9H-fluoren-9-yl)-3,5,12-trioxo-2,7,10-trioxa-4-azadodecan-12-yl]-2-methylalanine is coupled to **#250** following general procedure D in acetonitrile. Fmoc is removed following general procedure A followed by coupling with bis(pentafluorophenyl) 3,3'-[ethane-1,2-diylbis(oxy)]dipropionate using Hunig's base in acetonitrile. Material is purified by prep HPLC.

[0357] *General procedure X5.* L-valyl-N~5~-carbamoyl-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide is coupled to N~2~-acetyl-N~6~-((tert-butoxycarbonyl)-L-lysine following general procedure D. This resulting residue is coupled with bis(4-nitrophenyl)carbonate with Hunig's base in DMF, followed by coupling with the desired cytotoxic pentapeptide following general procedure E. Boc de-protection is then performed following general procedure B in acetonitrile. Residue is purified by prep HPLC.

[0358] In some instances minor alterations to reaction conditions were made such as but not limited to order of reagent and reactant addition and or the amount of reagent or reactant which is indicated by the symbol *. Furthermore, these general procedures are provided as exemplary only and are non-limiting.

[0359] In addition to the General Procedures provided above, relevant dolastatin and auristatin references include the following: Petit et al. J. Am. Chem. Soc. 1989, 111, 5463; Petit et al. AntiCancer Drug Design 1998, 13, 243 and references cited therein; Petit et al. J. Nat. Prod. 2011, 74, 962; WO 96/33212; WO 95/09864; EP 0695758; WO 07/8848; WO 01/18032; WO 09/48967; WO 09/48967; WO 09/117531; WO 08/8603; US 7,750,116; US 5,985,837; and US 2005/9751.

MS Analysis and Sample Preparation

[0360] Samples were prepped for LC-MS analysis by combining about 20 μ L of sample (approximately 1 mg/mL of ADC in PBS) with 20 μ L of 20 mM dithiothreitol (DTT). After allowing the mixture to stand at room temperature for 5 minutes, the samples were analyzed according to protocol O.

[0361] The following calculation was performed in order to establish the total loading (DAR) of the conjugate:


$$\text{Loading} = 2 * [\text{LC1}/(\text{LC1} + \text{LC0})] + 2 * [\text{HC1}/(\text{HC0} + \text{HC1} + \text{HC2} + \text{HC3})] + 4 * [\text{HC2}/(\text{HC0} + \text{HC1} + \text{HC2} + \text{HC3})] + 6 * [\text{HC3}/(\text{HC0} + \text{HC1} + \text{HC2} + \text{HC3})]$$

Where the indicated variables are the relative abundance of: LC0 = unloaded light chain, LC1 = single loaded light chain, HC0 = unloaded heavy chain, HC1 = single loaded heavy chain, HC2 = double loaded heavy chain, and HC3 = triple loaded heavy chain.

[0362] LC-MS conditions used are Protocol F for retention time below one minute and Protocol H for the remaining experiments unless otherwise indicated.

Preparation of N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)-1-carboxy-2-methoxy-4-methylhexan-3-yl]-N-methyl-L-valinamide (#8)

[0363]



[0364] Step 1. Synthesis of benzyl [(2*S*,3*S*)-1-hydroxy-3-methylpentan-2-yl]methylcarbamate (**#1**). To a solution of *N*-[(benzyloxy)carbonyl]-*N*-methyl-L-isoleucine (52.37 g, 187.5 mmol, 1 eq.) in tetrahydrofuran (524 mL, 0.35 M) was added borane-tetrahydrofuran complex (1 M in tetrahydrofuran, 375 mL, 375 mmol, 2 eq.) slowly over 1 hour and the reaction was allowed to stir for 18 hours at room temperature. The reaction was cooled to 0 °C and water (30 mL) was added over 30 minutes. The reaction mixture was diluted with 1 M aqueous sodium carbonate solution (100 mL) and *tert*-butyl methyl ether (250 mL). The aqueous layer was back-extracted with *tert*-butyl methyl ether (100 mL). The combined organic layers were washed with 1 M aqueous sodium carbonate solution (100 mL), washed with brine (200 mL), dried over magnesium sulfate, filtered, and concentrated *in vacuo* to provide **#1** (48.44 g, 97% yield) as a pale yellow oil, which was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers: δ 7.26-7.41 (m, 5H), [5.06 (AB quartet, *J*_{AB}=12.9 Hz, Δ*v*_{AB}=22.8 Hz) and 5.06 (AB quartet, *J*_{AB}=9.0 Hz, Δ*v*_{AB}=9.0 Hz), total 2H], [4.65 (t, *J*=5.3 Hz) and 4.59 (t, *J*=5.4 Hz), total 1H], 3.67-3.80 (m, 1H), 3.51-3.60 (m, 1H), 3.41-3.51 (m, 1H), 2.75 and 2.71 (2 s, total 3H), 1.49-1.64 (br m, 1H), 1.24-1.37 (br m, 1H), 0.90-1.02 (br m, 1H), 0.74-0.87 (m, 6H).

[0365] Step 2. Synthesis of benzyl methyl[(2*S*,3*S*)-3-methyl-1-oxopentan-2-yl]carbamate (**#2**). To a solution of **#1** (8.27 g, 31.2 mmol, 1 eq.) in dimethyl sulfoxide (41.35 mL, 0.75 M), was added triethylamine (8.70 mL, 64.0 mmol, 2.05 eq.) and the mixture was cooled to 0 °C. Sulfur trioxide pyridine complex (10.18 g, 63.96 mmol, 2.05 eq.) was then added portion-wise, while keeping the internal temperature below 8 °C. The reaction was allowed to reach room temperature and was stirred for 18 hours. The reaction was poured into water (100 mL) and *tert*-butyl methyl ether (100 mL). The aqueous layer was back-extracted with *tert*-butyl methyl ether (50 mL) and the combined organic layers were washed with brine (100 mL), dried over magnesium sulfate, filtered, concentrated *in vacuo* and purified by silica gel chromatography (Gradient: 10% to 60% ethyl acetate in heptane) to provide **#2** (7.14 g, 87%) as a colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 9.61 (s, 1H), 7.26-7.42 (m, 5H), 5.01-5.13 (m, 2H), 4.04-4.12 (m, 1H), 2.86 and 2.82 (2 s, total 3H), 1.94-2.11 (br m, 1H), 1.26-1.42 (br m, 1H).

[0366] Step 3. Synthesis of *tert*-butyl (3*R*,4*S*,5*S*)-4-[[[(benzyloxy)carbonyl](methyl)amino]-3-hydroxy-5-methylheptanoate (**#3**). Lithium diisopropylamine was prepared by adding *n*-butyllithium (2.5 M solution in tetrahydrofuran, 35.9 mL, 89.8 mmol, 1.4 eq.) to a solution of diisopropylamine (13.8 mL, 96.3 mmol, 1.5 eq.) in tetrahydrofuran (50 mL, 1.3 M) at -78 °C. After 1 hour, *tert*-butyl acetate (15.7 mL, 116 mmol, 1.8 eq.) was added drop-wise and the reaction mixture was stirred for an additional 1.5 hours while being allowed to slowly warm to -20 °C. The reaction mixture was recooled to -78 °C and a solution of the aldehyde **#2** (16.9 g, 64.2 mmol, 1 eq.) in tetrahydrofuran (10 mL) was added. The reaction mixture was stirred for 1.5 hours and then quenched by addition of water (100 mL). After extraction with diethyl ether (2 x 100 mL), the combined organic layers were dried over sodium sulfate, filtered, concentrated *in vacuo* and purified by silica gel chromatography (Gradient: 0% to 20% acetone in heptane) to provide **#3** (8.4 g, 34%) as a colorless oil. LC-MS: *m/z* 402.4 [M+Na⁺], retention time = 3.91 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers: δ 7.27-7.39 (m, 5H), 5.01-5.12 (m, 2H), [4.93 (d, *J*=7.2 Hz) and 4.98 (br d, *J*=7.2 Hz), total 1H], 4.03-4.15 (br m, 1H), 3.68-3.85 (br m, 1H), 2.65 and 2.72 (2 br s, total 3H), 2.28-2.37 (m, 1H), 2.09-2.17 (m, 1H), 1.74-1.90 (br m, 1H), 1.41-1.51 (m, 1H), 1.39 (s, 9H), 0.92-1.01 (m, 1H), 0.77-0.92 (m, 6H).

[0367] Step 4. Synthesis of *tert*-butyl (3*R*,4*S*,5*S*)-4-[[[(benzyloxy)carbonyl](methyl)amino]-3-methoxy-5-methylheptanoate (**#@2**). To a solution of **#3** (8.4 g, 22 mmol, 1 eq.) in 1,2-dichloroethane (25 mL, 0.88 M) were added molecular

sieves (4 Å, 0.7 g) and Proton sponge (1,8-bis(dimethylamino)naphthalene) (13.4 g, 59.2 mmol, 2.7 eq.), followed by trimethyloxonium tetrafluoroborate (9.10 g, 61.6 mmol, 2.8 eq.). After stirring overnight, the reaction mixture was filtered through Celite. The filtrate was concentrated *in vacuo* and the residue was purified by silica gel chromatography (Gradient: 0% to 40% 1:1 acetone:ethyl acetate in heptane) to give **#@2** (8.7 g, 68%) as a colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers: δ 7.28-7.40 (m, 5H), 5.01-5.13 (m, 2H), 3.89-4.08 (br m, 1H), 3.70-3.82 (m, 1H), 3.18 and 3.26 (2 s, total 3H), 2.66 and 2.71 (2 br s, total 3H), 2.44-2.53 (m, 1H, assumed; partially obscured by solvent peak), 2.17-2.24 (m, 1H), 1.71-1.86 (br m, 1H), 1.39 and 1.39 (2 s, total 9H), 1.31-1.40 (m, 1H), 0.94-1.08 (m, 1H), 0.76-0.91 (m, 6H).

[0368] Step 5. Synthesis of *tert*-butyl (3*R*,4*S*,5*S*)-3-methoxy-5-methyl-4-(methylamino)heptanoate, hydrochloride salt (**#4**). To a solution of **#@2** (13.37 g, 33.98 mmol, 1 eq.) in methanol (134 mL, 0.1 M) and concentrated hydrochloric acid (3.1 mL, 37.4 mmol, 1.1 eq.) was added 10% palladium on carbon (50% wet) (0.1 wt%; 1.34 g, 3.40 mmol). The mixture was hydrogenated at 45 psi for 3 hours, then purged with nitrogen, filtered through Celite and concentrated *in vacuo* to provide **#4** (9.20 g, 92%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 9.65 (br s, 1H), 8.97 (br s, 1H), 3.98-4.04 (m, 1H), 3.40 (s, 3H), 3.06-3.13 (br m, 1H), 2.82 (br dd, *J*=6, 5 Hz, 3H), 2.74-2.80 (m, 1H), 2.68 (dd, half of ABX pattern, *J*=16.3, 4.2 Hz, 1H), 2.00-2.10 (br m, 1H), 1.73-1.84 (m, 1H), 1.46 (s, 9H), 1.38-1.45 (m, 1H), 1.13 (d, *J*=7.0 Hz, 3H), 0.99 (t, *J*=7.4 Hz, 3H).

[0369] Step 6. Synthesis of *tert*-butyl (3*R*,4*S*,5*S*)-4-[[*N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-L-valyl](methylamino)-3-methoxy-5-methylheptanoate (**#5**). To a mixture of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-L-valine (18.53 g, 54.60 mmol, 1.3 eq.) and 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (9.58 g, 54.6 mmol, 1.3 eq.) in 2-methyltetrahydrofuran (118.00 mL, 0.34 M) was added *N*-methylmorpholine (6.52 mL, 59.1 mmol, 1.5 eq.) followed by **#4** (11.80 g, 39.9 mmol, 1 eq.). After 3 hours, the reaction was quenched with water (50 mL) and stirred for 15 minutes. The aqueous layer was separated and back-extracted with 2-methyltetrahydrofuran (50 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate solution (50 mL), dried over magnesium sulfate, filtered, and concentrated *in vacuo* to give a colorless oil, which was purified by silica gel chromatography (Gradient: 5% to 40% ethyl acetate in heptane) to give **#5** (26.2 g, 91%) as a colorless foam. LC-MS (Protocol I) *m/z* 581.3 [M+H⁺] 604.3 [M+Na⁺], retention time = 4.993 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), possibly a mixture of rotamers, characteristic major signals: δ 7.88 (d, *J*=7.4 Hz, 2H), 7.71 (d, *J*=7.4 Hz, 2H), 7.62 (d, *J*=8.6 Hz, 1H), 7.41 (dd, *J*=7.4, 7.4 Hz, 2H), 7.27-7.34 (m, 2H), 4.13-4.32 (m, 4H), 3.70-3.82 (br m, 1H), 3.24 (s, 3H), 2.92 (br s, 3H), 2.54 (dd, *J*=15.7, 2.4 Hz, 1H), 2.17 (dd, *J*=15.4, 9.4 Hz, 1H), 1.95-2.07 (m, 1H), 1.70-1.83 (br m, 1H), 1.40 (s, 9H), 0.83-0.94 (m, 9H), 0.69 (t, *J*=7.2 Hz, 3H).

[0370] Step 7A. Synthesis of *tert*-butyl (3*R*,4*S*,5*S*)-3-methoxy-5-methyl-4-[methyl(L-valyl)amino]heptanoate (**#6**). To a solution of **#5** (26 g, 42 mmol, 1 eq.) in tetrahydrofuran (260 mL, 0.16 M) was added diethylamine (22 mL) over 30 minutes. The reaction was stirred for about 6 hours and the suspension was then filtered through Celite and washed with additional tetrahydrofuran (25 mL). The filtrate was concentrated *in vacuo* to provide a pale yellow oil, which was redissolved in 2-methyltetrahydrofuran (50 mL) and concentrated again to ensure complete removal of diethylamine. The crude oil of **#6** (>15.25 g) was taken into the next step without further purification.

[0371] Step 7B. Synthesis of (3*R*,4*S*,5*S*)-4-[[*N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-L-valyl] (methyl amino)-3-methoxy-5-methylheptanoic acid (**#@5**). According to general procedure B, from **#5** (1.62 g, 2.79 mmol, 1 eq.), dichloromethane (10 mL, 0.3 M) and trifluoroacetic acid (3 mL) was synthesized **#@5** (1.42 g, 97%) as a solid which was used without further purification. LC-MS *m/z* 525.3 [M+H⁺] 547.3 [M+Na⁺] retention time = 0.95 minute; ¹H NMR (400 MHz, DMSO-*d*₆), characteristic signals: δ 7.89 (d, *J*=7.6 Hz, 2H), 7.71 (d, *J*=7.4 Hz, 2H), 7.59 (d, *J*=8.8 Hz, 1H), 7.41 (dd, *J*=7.6, 7.4 Hz, 2H), 7.28-7.34 (m, 2H), 4.14-4.32 (m, 4H), 3.24 (s, 3H), 2.92 (br s, 3H), 2.51-2.57 (m, 1H, assumed; partially obscured by solvent peak), 2.20 (dd, *J*=15.9, 9.5 Hz, 1H), 1.95-2.06 (m, 1H), 1.70-1.83 (br m, 1H), 1.22-1.36 (br m, 1H), 0.84-0.93 (m, 9H), 0.70 (t, *J*=7.3 Hz, 3H).


[0372] Step 8. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*-methyl-L-valyl-*N*-[(3*R*,4*S*,5*S*)-1-*tert*-butoxy-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#7**). To a mixture of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*-methyl-L-valine (19.54 g, 55.29 mmol, 1.3 eq.) and **#6** (15.25 g, 42.54 mmol, 1 eq.) in 2-methyltetrahydrofuran (152 mL, 0.28 M) was added 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) (9.71 g, 55.3 mmol, 1.3 eq.). After 10 minutes, *N*-methylmorpholine (6.6 mL, 60 mmol, 1.4 eq.) was slowly added, while keeping the internal temp below 25 °C. The reaction was stirred for 4 hours and was then quenched by the addition of water (50 mL). After stirring for 15 minutes, the aqueous layer was separated and back-extracted with 2-methyltetrahydrofuran (50 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate solution (100 mL), then were dried over magnesium sulfate, filtered, and concentrated *in vacuo*. The resulting yellow foam was purified by silica gel chromatography (Gradient: 5% to 35% ethyl acetate in heptane) to give **#7** (32 g, 97%). ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 7.89 (d, *J*=7.4 Hz, 2H), 7.62 (d, *J*=7.4 Hz, 2H), 7.41 (br dd, *J*=7.4, 7.4 Hz, 2H), 7.29-7.34 (m, 2H), 4.52-4.69 (br m, 1H), 3.70-3.82 (br m, 1H), 3.22 and 3.25 (2 br s, total 3H), 2.94 and 2.96 (2 br s, total 3H), 2.78 and 2.81 (2 br s, total 3H), 2.11-2.23 (m, 1H), 1.90-2.10 (m, 2H), 1.68-1.83 (br m, 1H), 1.40 (s, 9H), 1.21-1.33 (br m, 1H).

[0373] Step 9. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*-methyl-L-valyl-*N*-[(2*R*,3*S*,4*S*)-1-carboxy-2-meth-

oxy-4-methylhexan-3-yl]-*N*-methyl-L-valinamide (**#8**). To **#7** (32 g, 46 mmol, 1 eq.) in dichloromethane (160 mL, 0.29 M) was added drop-wise over 10 minutes trifluoroacetic acid (17.4 mL, 231 mmol, 5 eq.). After 6 hours, the same amount of trifluoroacetic acid was added and the reaction was continued for 18 hours. The reaction mixture was diluted with toluene (320 mL) and concentrated *in vacuo* to provide **#8** (35.8 g, 97%) as a pinkish oil, which was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 7.90 (d, *J*=7.0 Hz, 2H), 7.62 (d, *J*=7.4 Hz, 2H), 7.41 (br dd, *J*=7.4, 7.0 Hz, 2H), 7.29-7.35 (m, 2H), 4.54-4.68 (br m, 1H), [4.09 (d, *J*=11 Hz) and 4.22 (d, *J*=10.9 Hz), total 1H], 3.74-3.84 (br m, 1H), 3.22 and 3.24 (2 br s, total 3H), 2.94 and 2.96 (2 br s, total 3H), 2.78 and 2.80 (2 br s, total 3H), 2.13-2.24 (m, 1H), 1.89-2.10 (br m, 2H), 1.70-1.81 (br m, 1H).

Preparation of (2*R*,3*R*)-3-[(2*S*)-1-(*tert*-Butoxycarbonyl)pyrrolidin-2-yl]-3-methoxy-2-methylpropanoic acid (#11**; "Boc-Dap-acid")**

[0374]



[0375] Step 1. Synthesis of *tert*-butyl (2*S*)-2-[(1*R*,2*S*)-1-hydroxy-2-methylbut-3-en-1-yl]pyrrolidine-1-carboxylate (#9**).** To a solution of *tert*-butyl (2*S*)-2-formylpyrrolidine-1-carboxylate (10 g, 50 mmol, 1 eq.) in dichloromethane (120 mL, 0.42 M) was added potassium (2*Z*)-2-buten-1-yltrifluoroborate (9.76 g, 60.2 mmol, 1.2 eq.) followed by tetra-*n*-butylammonium bromide (3.24 g, 5.02 mmol, 0.1 eq.) and water (60 mL). After 13 hours, the reaction was diluted with dichloromethane (150 mL) and water (150 mL). The aqueous layer was separated and back-extracted with dichloromethane (100 mL). The combined organic layers were washed with aqueous sodium chloride solution (5% wt, 200 mL), washed with water (200 mL), and concentrated *in vacuo* to afford **#9** (~13 g) as an orange oil, which was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 5.61-5.86 (br m, 1H), 4.97-5.09 (m, 2H), 3.80-3.98 (br m, 2H), 3.45-3.67 (br m, 1H), 3.21-3.29 (m, 1H), 2.14-2.26 (m, 1H), 1.80-2.04 (m, 3H), 1.65-1.76 (m, 1H), 1.47 (s, 9H), 1.12 (d, *J*=6.6 Hz, 3H).

[0376] Step 2. Synthesis of *tert*-butyl (2*S*)-2-[(1*R*,2*S*)-1-methoxy-2-methylbut-3-en-1-yl]pyrrolidine-1-carboxylate (#10**).** Sodium hydride (60% in mineral oil, 3.38 g, 84.4 mmol, 1.1 eq.) was combined with hexane (40 mL), and the mixture was subjected to rapid mechanical stirring for 5 minutes. The solids were allowed to settle and the hexane was removed. This procedure was repeated twice to remove mineral oil. *N,N*-Dimethylformamide (59 mL, 1.3 M) was added and the mixture was cooled to 0 °C; methyl iodide (5 mL; 81 mmol, 1.05 eq.) was then added drop-wise, followed by drop-wise addition of a solution of **#9** (19.6 g, 76.8 mmol, 1 eq.) in *N,N*-dimethylformamide (59 mL) over 5 minutes, while keeping the temperature between 0 °C and 5 °C. The reaction was stirred at 0 °C for 2 hours. The reaction was quenched with saturated aqueous ammonium chloride solution (150 mL), poured into aqueous sodium chloride solution (5% wt, 300 mL), and the mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with 10% aqueous sodium chloride solution (2 x 300 mL), washed with water (200 mL), and concentrated *in vacuo*. The resulting water-wet oil was re-concentrated from ethyl acetate (150 mL) and purified by silica gel chromatography (Gradient: 2% to 10% ethyl acetate in heptane) to afford **#10** (15.0 g, 73%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃), presumed to be a mixture of rotamers: δ 5.60-5.83 (m, 1H), 4.91-5.06 (m, 2H), 3.81-3.95 (br m, 1H), 3.43 (s, 3H), 3.36-3.61 (m, 2H), 3.19-3.31 (m, 1H), 2.09-2.21 (m, 1H), 1.86-2.02 (br m, 2H), 1.62-1.85 (br m, 2H), 1.47 and 1.49 (2 s, total 9H), 1.09 (d, *J*=6.6 Hz, 3H).


[0377] Step 3. Synthesis of (2*R*,3*R*)-3-[(2*S*)-1-(*tert*-butoxycarbonyl)pyrrolidin-2-yl]-3-methoxy-2-methylpropanoic acid (#11**).** To **#10** (25.0 g, 92.8 mmol, 1 eq.) in *tert*-butanol (100 mL, 0.93 M) was immediately added water (30.00 mL) followed by *N*-methylmorpholine-*N*-oxide (25.97 g, 192.1 mmol, 2.07 eq.) and osmium tetroxide (235.93 mg, 928.04 μmol, 0.01 eq.) After 12 hours, the mixture was concentrated *in vacuo* using water (20 mL) to azeotropically remove residual *tert*-butanol. The residue was partitioned between ethyl acetate (500 mL) and water (500 mL) plus brine (150 mL). The aqueous layer was re-extracted with ethyl acetate (250 mL). The combined organic layers were washed with aqueous sodium chloride solution (10 wt%, 200 mL), washed with water (150 mL), and concentrated *in vacuo* to afford a water-wet pale brown oil that was re-concentrated from ethyl acetate (100 mL) to remove any remaining water. This crude diol (34.76 g) was used without further purification.

[0378] To the crude diol (34.76 g, ≤92.8 mmol, 1 eq.) in acetonitrile (347 mL, 0.1 M) and water (174 mL) was added sodium permanganate (2.03 g, 5.73 mmol, 0.05 eq.). The mixture was cooled to 0 °C and sodium periodate (51.46 g, 240.6 mmol, 2.1 eq.) was added portion-wise over 30 minutes, while keeping the internal temperature below 5 °C. The reaction was stirred at 0 °C for 4 hours and was then poured into a solution of sodium thiosulfate pentahydrate (65.40 g, 263.5 mmol, 2.3 eq.) in water (100 mL). The mixture was filtered through Celite and the filtrate was concentrated *in*

vacuo. The residue was partitioned between ethyl acetate (200 mL) and water (200 mL). The aqueous layer was back-extracted with ethyl acetate (250 mL), and the combined organic layers were washed with a 10% aqueous citric acid solution. As the desired product was very soluble in water, all the aqueous layers were combined, treated with Celite (100 g) and concentrated *in vacuo* to yield an off-white paste. Ethyl acetate (150 mL) was added and the mixture was re-concentrated to remove any residual water; this operation was repeated one more time. The paste was treated with ethyl acetate (150 mL) and placed *in vacuo* at 50 °C for 10 minutes and filtered (repeated twice). These filtrates were combined with the previous organic layer (from the citric acid wash), concentrated, diluted with ethyl acetate (200 mL) and filtered through Celite to remove solids. Finally, this filtrate was concentrated to yield **#11** (22.9 g, 69% over two steps) as a yellowish/brown foam. LCMS (Protocol I): m/z 310.1 [M+Na⁺], 232.1 [(M - 2-methylprop-1-ene) ÷ H⁺], 188.1 [(M - Boc)+H⁺], retention time = 3.268 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), characteristic signals: δ 3.61-3.85 (br m, 2H), 3.20-3.45 (br m, 4H), 3.03-3.17 (br m, 1H), 1.59-1.93 (br m, 4H), 1.40 (br s, 9H), 1.02-1.18 (br m, 3H).

Preparation of (2R,3R)-3-Methoxy-2-methyl-N-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]-3-[(2S)-pyrrolidin-2-yl]propanamide, trifluoroacetic acid salt (#19) and (2R,3R)-3-methoxy-2-methyl-N-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]-3-[(2S)-pyrrolidin-2-yl]propanethioamide, trifluoroacetic acid salt (#18)

[0379]



[0380] Step 1. Synthesis of *N*α-(*tert*-butoxycarbonyl)-L-phenylalaninamide (#12). To a solution of Boc-Phe-OH (30.1 g, 113 mmol, 1 eq.) in tetrahydrofuran (378 mL, 0.3 M) cooled to -10 °C were added *N*-methylmorpholine (13.6 mL, 124 mmol, 1.09 eq.), and ethyl chloroformate (11.8 mL, 124 mmol, 1.09 eq.). After 20 minutes, a 30% aqueous ammonium hydroxide solution (45 mL, 350 mmol, 3.1 eq.) was added. The mixture was stirred at room temperature for 18 hours before being concentrated *in vacuo*. The residue was diluted with ethyl acetate and washed sequentially with 1 N aqueous potassium bisulfate solution, water and brine. The organic layer was then dried over sodium sulfate, filtered, and concentrated *in vacuo*. The white solid was dissolved (this required heating with stirring) in ethyl acetate (about 400 mL); the solution was then allowed to cool to room temperature before adding hexane (~1000 mL). After a few minutes, a white material started to precipitate from the reaction mixture. The solid was collected by filtration, washed with heptane (2 x ~150 mL), and dried under vacuum for 18 hours to give **#12** (24.50 g, 82%) as a solid. LC-MS: m/z 263.2 [M-H⁺], 309.2 [M+HCO₂⁻], retention time = 1.85 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, major rotamer: δ 7.35 (br s, 1H), 7.22-7.30 (m, 5H), 7.00 (br s, 1H), 6.78 (d, *J*=8.6 Hz, 1H), 4.09 (ddd, *J*=10, 9, 4.5 Hz, 1H), 2.95 (dd, *J*=13.8, 4.4 Hz, 1H), 2.72 (dd, *J*=13.7, 10.1 Hz, 1H), 1.30 (s, 9H).

[0381] Step 2. Synthesis of *tert*-butyl [(2S)-1-amino-3-phenyl-1-thioxopropan-2-yl]carbamate (#13). To a solution of **#12** (14.060 g, 53.192 mmol, 1 eq.) in tetrahydrofuran (180 mL, 0.296 M), was added 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-dithione (Lawesson's reagent) (12.70 g, 31.40 mmol, 0.59 eq.) and the reaction was refluxed for 90 minutes. The reaction was cooled to room temperature and quenched by addition of saturated aqueous sodium bicarbonate solution. The mixture was extracted twice with ethyl acetate and the combined organic layers were dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was dissolved in ethyl acetate, concentrated *in vacuo* onto silica and purified by silica gel chromatography (Gradient: 0% to 100% ethyl acetate in heptane), affording **#13** (11.50 g, 77%) as a white solid. LC-MS: m/z 279.4 [M-H⁺], 225.2 [(M - 2-methylprop-1-ene)+H⁺], 181.2 [(M - Boc)+H⁺]; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, major rotamer: δ 9.60 (br s, 1H), 9.19 (br s, 1H), 7.23-7.32 (m, 5H), 6.82 (d, *J*=8.8 Hz, 1H), 4.44 (ddd, *J*=9.4, 9.1, 4.4 Hz, 1H), 3.00 (dd, *J*=13.7, 4.5 Hz, 1H), 2.79 (dd, *J*=13.6, 9.9 Hz, 1H), 1.29 (s, 9H).

[0382] Step 3. Synthesis of *tert*-butyl [(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]carbamate (#14). To a mixture of **#13**

(5.65 g, 20.2 mmol, 1 eq.) in acetone (101 mL, 0.2 M) was added bromoacetaldehyde diethyl acetal (8.76 mL, 58.2 mmol, 2.89 eq.) and 2 drops of 4 M hydrochloric acid in dioxane. The mixture was degassed with nitrogen three times before being heated to reflux. After 2 hours, the reaction was cooled to room temperature and concentrated *in vacuo*. The residue was dissolved in ethyl acetate, washed with saturated aqueous sodium bicarbonate solution and washed with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The resulting crude orange oil was diluted with ethyl acetate before being concentrated *in vacuo* onto silica and purified by silica gel chromatography (Gradient: 0% to 35% ethyl acetate in heptane) and then by reverse phase chromatography (Method A) to give **#14** (625 mg, 10%); HPLC (Protocol E): *m/z* 304.5 [M+H⁺], 248.9 [(M - 2-methylprop-1-ene)+H⁺], retention time = 7.416 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, major rotamer: δ 7.75 (d, *J*=3.3 Hz, 1H), 7.75 (br d, *J*=8.6 Hz, 1H), 7.61 (br d, *J*=3.1 Hz, 1H), 7.25-7.30 (m, 5H), 4.99 (ddd, *J*=10.5, 8.9, 4.5 Hz, 1H), 3.29-3.36 (m, 1H, assumed; partially obscured by water signal), 2.98 (dd, *J*=13.8, 10.6 Hz, 1H), 1.31 (s, 9H).

[0383] Step 4. Synthesis of (1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethanamine, hydrochloride salt (**#15**). According to general procedure C, from **#14** (1.010 g, 3.318 mmol, 1 eq.), dioxane (10 mL, 0.33 M) and a 4 M solution of hydrochloric acid in dioxane (20 mL, 80 mmol, 20 eq.) was synthesized **#15** (775 mg, 97%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.95-9.07 (br m, 3H), 7.86 (d, *J*=3.2 Hz, 1H), 7.73 (d, *J*=3.2 Hz, 1H), 7.18-7.28 (m, 3H), 7.10-7.15 (m, 2H), 4.98-5.07 (m, 1H), 3.49 (dd, *J*=13.3, 4.9 Hz, 1H), 3.18 (dd, *J*=13.4, 10.2 Hz, 1H).

[0384] Step 5. Synthesis of *tert*-butyl (2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidine-1-carboxylate (**#16**). To a solution of **#11** (280 mg, 0.974 mmol, 1 eq.) and **#15** (460 mg, 1.44 mmol, 1.48 eq.) in *N,N*-dimethylformamide (3 mL, 0.32 M) at 0°C was added diethylphosphoryl cyanide (DEPC) (93% purity, 212 μL, 1.30 mmol, 1.34 eq.), followed by triethylamine (367 μL, 2.63 mmol, 2.7 eq.). After 2 hours at 0°C, the reaction mixture was warmed to room temperature for 18 hours. The reaction mixture was then diluted with ethyl acetate:toluene (2:1, 30 mL) and was washed successively with 1 M aqueous sodium bisulfate solution (35 mL) and 50% saturated aqueous sodium bicarbonate solution (4 x 25 mL). The organic layer was dried over sodium sulfate, filtered, concentrated *in vacuo*, and purified by silica gel chromatography (12% to 100% ethyl acetate in heptane) to give **#16** as a light amber oil (374 mg, 81%). LC-MS: *m/z* 474.4 [M+H⁺], 374.4 [(M - 2-methylprop-1-ene)+H⁺] retention time = 3.63 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), characteristic signals: δ 8.66 (d, *J*=8.5 Hz, 1H), 7.78 (d, *J*=3.3 Hz, 1H), 7.64 (d, *J*=3.3 Hz, 1H), 7.21-7.31 (m, 4H), 7.14-7.20 (m, 1H), 5.40 (ddd, *J*=11.4, 8.5, 4.0 Hz, 1H), 3.23 (br s, 3H), 2.18 (dq, *J*=9.7, 6.7 Hz, 1H), 1.06 (d, *J*=6.6 Hz, 3H).


[0385] Step 6A. Synthesis of *tert*-butyl (2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidine-1-carboxylate (**#17**). A mixture of **#16** (350 mg, 0.739 mmol, 1 eq.) and 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-dithione (Lawesson's reagent) (324 mg, 0.776 mmol, 1.05 eq.) in toluene (6 mL, 0.1 M) was warmed to 100°C. After 10 minutes, the mixture was cooled to room temperature. Insoluble material was removed by filtration and the filtrate was concentrated *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 12% to 80% ethyl acetate in heptane) and then by reverse phase chromatography (Method E2) to give **#17** (120 mg, 33%); HPLC (Protocol J): *m/z* 490.2 [M+H⁺], retention time = 10.069 minutes; [α]_D²⁰ - 110 (c 0.24, MeOH); ¹H NMR (400 MHz, CD₃OD), characteristic signals: δ 7.78 (d, *J*=3.3 Hz, 1H), 7.51 (d, *J*=3.3 Hz, 1H), 7.32-7.37 (m, 2H), 7.24-7.30 (m, 2H), 7.17-7.23 (m, 1H), 6.52-6.61 (br m, 1H), 3.62 (br dd, *J*=15, 4 Hz, 1H), 3.37 (s, 3H), 2.98-3.09 (br m, 1H), 2.53-2.64 (br m, 1H), 1.60-1.78 (m, 2H), 1.49 (s, 9H), 1.27 (d, *J*=6.5 Hz, 3H).

[0386] Step 6B. Synthesis of (2*R*,3*R*)-3-methoxy-2-methyl-*N*-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]-3-[(2*S*)-pyrrolidin-2-yl]propanethioamide, trifluoroacetic acid salt (**#18**). According to general procedure B, from **#17** (198 mg, 0.404 mmol, 1 eq.), dichloromethane (6 mL, 0.07 M) and trifluoroacetic acid (2 mL) was synthesized **#18** (185 mg, 91%), which was used without further purification. LC-MS: *m/z* 390.1 [M+H⁺], retention time = 0.57 minutes; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.91 (d, *J*=8.2 Hz, 1H), 9.07-9.20 (br m, 1H), 7.86-8.00 (br m, 1H), 7.83 (d, *J*=3.2 Hz, 1H), 7.69 (d, *J*=3.3 Hz, 1H), 7.27-7.36 (m, 4H), 7.21-7.26 (m, 1H), 6.33 (ddd, *J*=11.3, 8.3, 4.4 Hz, 1H), 3.76-3.82 (m, 1H), 3.56 (dd, *J*=14.6, 4.3 Hz, 1H), 3.45 (s, 3H), 3.28 (dd, *J*=14.6, 11.3 Hz, 1H), 3.02-3.12 (br m, 1H), 2.89-3.00 (br m, 1H), 2.72-2.89 (m, 2H), 1.69-1.83 (br m, 1H), 1.43-1.58 (m, 2H), 1.20-1.33 (m, 1H), 1.22 (d, *J*=6.6 Hz, 3H).

[0387] Step 7. Synthesis of (2*R*,3*R*)-3-methoxy-2-methyl-*N*-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]-3-[(2*S*)-pyrrolidin-2-yl]propanamide, trifluoroacetic acid salt (**#19**). According to general procedure B, from **#16** (607 mg, 1.28 mmol, 1 eq.), dichloromethane (10 mL, 0.13 M) and trifluoroacetic acid (2 mL) was synthesized **#19** (640 mg, quantitative), which was used in the next step without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.96-9.07 (br m, 1H), 8.89 (d, *J*=8.8 Hz, 1H), 7.87-8.00 (br m, 1H), 7.80 (d, *J*=3.2 Hz, 1H), 7.66 (d, *J*=3.3 Hz, 1H), 7.28-7.34 (m, 4H), 7.20-7.27 (m, 1H), 5.43 (ddd, *J*=11.3, 8.6, 4.2 Hz, 1H), 3.42-3.50 (m, 2H), 3.36 (s, 3H), 3.04-3.14 (br m, 1H), 2.99 (dd, *J*=14.2, 11.5 Hz, 1H), 2.92-3.02 (m, 1H), 2.78-2.88 (br m, 1H), 2.34-2.42 (m, 1H), 1.73-1.84 (br m, 1H), 1.55-1.68 (m, 1H), 1.38-1.53 (m, 2H), 1.15 (d, *J*=6.9 Hz, 3H).

Preparation of (2R,3R)-3-Methoxy-2-methyl-N-(2-phenylethyl)-3-[(2S)-pyrrolidin-2-yl]propanethioamide, hydrochloride salt (#23) and (2R,3R)-3-methoxy-2-methyl-N-(2-phenylethyl)-3-[(2S)-pyrrolidin-2-yl]propanamide, hydrochloride salt (#24)

[0388]



[0389] Step 1A. Synthesis of *tert*-butyl (2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidine-1-carboxylate (#20). To **#11** (22 g, 77 mmol, 1 eq.) in dichloromethane (383 mL, 0.2 M) and *N,N*-dimethylformamide (30 mL) were added diisopropylethylamine (26.9 mL, 153 mmol, 2 eq.), 2-phenylethylamine (11.6 mL, 91.9 mmol, 1.2 eq.) and HATU (39.0 g, 99.5 mmol, 1.3 eq.). The reaction was stirred for 18 hours and then concentrated *in vacuo*. The residue was taken up in ethyl acetate (700 mL) and washed sequentially with 1 M aqueous hydrochloric acid solution (2 x 200 mL) and brine. The organic layer was dried over sodium sulfate, filtered and evaporated *in vacuo*. The crude material was taken up in dichloromethane and filtered. The filtrate was purified by silica gel chromatography (Gradient: 0% to 100% ethyl acetate in heptane) to give **#20** (24 g, 80%) as an off-white solid. LC-MS: *m/z* 392.2 [M+2H⁺], 291.1 [(M - Boc)+H⁺], retention time = 0.88 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers: δ 7.80-7.89 (br m, 1H), 7.23-7.29 (m, 2H), 7.15-7.23 (m, 3H), 3.72-3.82 and 3.55-3.62 (2 br m, total 1H), 3.45-3.55 (br m, 1H), 3.31-3.44 (br m, 2H), 3.29 (s, 3H), 3.12-3.25 (br m, 1H), 2.98-3.12 (br m, 1H), 2.71 (t, *J*=7.1 Hz, 2H), 2.09-2.19 (m, 1H), 1.71-1.83 (br m, 2H), 1.60-1.70 (br m, 1H), 1.49-1.60 (br m, 1H), 1.41 (s, 9H), 1.03 (d, *J*=6.8 Hz, 3H).

[0390] Step 1B. Synthesis of dipyridinium-1-ylpentathiodiphosphonate (#21). Phosphorous pentasulfide (4.45 g, 2.19 mmol, 1 eq.) was added to pyridine (56 mL, 0.36 M) at 80 °C and the mixture was heated at reflux (115 °C) for 1 hour. The mixture was cooled to room temperature and the product was collected by filtration to give **#21** as a yellow solid (4.57 g, 60%); mp: 165-167 °C (decomposition); ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.78-8.84 (m, 4H), 8.22-8.30 (m, 2H), 7.76-7.83 (m, 4H).


[0391] Step 2A. Synthesis of *tert*-butyl (2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidine-1-carboxylate (#22). A mixture of **#20** (1.200 g, 3.073 mmol, 1 eq.) and **#21** (1.40 g, 3.69 mmol, 1.2 eq.) in acetonitrile (15 mL, 0.20 M) was subjected to microwave radiation at 100 °C for 30 minutes. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate (150 mL), and washed sequentially with 0.5 M aqueous hydrochloric acid solution (100 mL) and brine (2 x 50 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 20% to 80% ethyl acetate in heptane) to give **#22** (670 mg, 54%) as a white wax-like solid; mp: 107-109 °C; LC-MS: *m/z* 407.4 [M+H⁺], 351.3 [(M - 2-methylprop-1-ene)+H⁺], 307.3 [(M - Boc)+H⁺], retention time = 0.99 minutes; ¹H NMR (400 MHz, CD₃CN), presumed to be a mixture of rotamers: δ 8.28 (br s, 1H), 7.19-7.33 (m, 5H), 3.81-4.05 (br m, 2H), 3.60-3.81 (br m, 2H), 3.38-3.51 (br m, 1H), 3.36 (s, 3H), 3.02-3.17 (br m, 1H), 2.89-3.02 (m, 2H), 2.50-2.62 (br m, 1H), 1.71-1.85 (br m, 2H), 1.53-1.66 (br m, 2H), 1.45 (br s, 9H), 1.23 (d, *J*=6.7 Hz, 3H).

[0392] Step 3. Synthesis of (2R,3R)-3-methoxy-2-methyl-N-(2-phenylethyl)-3-[(2S)-pyrrolidin-2-yl]propanethioamide, hydrochloride salt (#23). According to procedure C, from **#22** (325 mg, 0.799 mmol, 1 eq.), dioxane (5 mL, 0.2 M) and a 4 M hydrochloric acid solution in dioxane (4 mL, 16 mmol, 20 eq.) was synthesized **#23** (274 mg, quantitative) as a white foam; LC-MS: 308.2 [M+H⁺], retention time = 0.55 minutes.

[0393] Step 2B. Synthesis of (2R,3R)-3-methoxy-2-methyl-N-(2-phenylethyl)-3-[(2S)-pyrrolidin-2-yl]propanamide, hydrochloride salt (#24). To **#20** (7.00 g, 17.9 mmol, 1 eq.) in dioxane (50 mL, 0.36 M) and methanol (2 mL) was added a 4 M solution of hydrochloric acid in dioxane (20 mL, 80 mmol, 4.4 eq.). After stirring for 18 hours, the mixture was concentrated to afford **#24** (5.86 g, quantitative) as a gum, which was used without further purification; LC-MS: 292.2 [M+H⁺], retention time = 0.47 minutes.

Reference Example Preparation of N-Methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#26)

[0394]




[0395] Step 1. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*-methyl-L-valyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#25**)

[0396] According to general procedure D, from **#8** (480 mg, 0.753 mmol, 1 eq.), dichloromethane (10 mL, 0.07 M), *N,N*-dimethylformamide (2 mL), the amine **#18** (401 mg, 0.941 mmol, 1.25 eq.), HATU (372 mg, 0.979 mmol, 1.3 eq.) and triethylamine (367 μ L, 2.64 mmol, 3.5 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 30% acetone in heptane) to afford **#25** (711 mg, 75%) as a solid. LC-MS: *m/z* 1009.7 [M+H⁺], retention time = 1.15 minutes; HPLC (Protocol B): *m/z* 505.3 [M+2H⁺]/2, retention time = 10.138 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.54 (br d, *J*=8 Hz) and 10.81 (br d, *J*=8 Hz), total 1H], 7.89 (br d, *J*=7 Hz, 2H), [7.80 (d, *J*=3.3 Hz) and 7.83 (d, *J*=3.2 Hz), total 1H], [7.64 (d, *J*=3.2 Hz) and 7.69 (d, *J*=3.2 Hz), total 1H], 7.62 (br d, *J*=7 Hz, 2H), 7.37-7.44 (m, 2H), 7.28-7.35 (m, 4H), 7.20-7.27 (m, 2H), 7.12-7.18 (m, 1H), 6.27-6.35 and 6.40-6.48 (2 m, total 1H), [1.14 (d, *J*=6.4 Hz) and 1.17 (d, *J*=6.3 Hz), total 3H].

[0397] Step 2. Synthesis of *N*-methyl-L-valyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#26**). According to general procedure A, from **#25** (701 mg, 0.694 mmol) in dichloromethane (10 mL, 0.07 M) and diethylamine (10 mL) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane) to give a glass-like solid. Diethyl ether and heptane were added and the mixture was concentrated *in vacuo*, producing **#26** (501 mg, 92%) as a white solid. HPLC (Protocol A): *m/z* 787.4 [M+H⁺], retention time = 7.229 minutes, (purity > 97%); ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.54 (br d, *J*=8 Hz) and 10.81 (br d, *J*=8 Hz), total 1H], [7.99 (br d, *J*=9 Hz) and 8.00 (br d, *J*=9 Hz), total 1H], [7.80 (d, *J*=3.3 Hz) and 7.83 (d, *J*=3.3 Hz), total 1H], [7.65 (d, *J*=3.2 Hz) and 7.69 (d, *J*=3.3 Hz), total 1H], 7.29-7.34 (m, 2H), 7.19-7.28 (m, 2H), 7.13-7.19 (m, 1H), [6.31 (ddd, *J*=11, 8, 4.5 Hz) and 6.45 (ddd, *J*=11.5, 8, 4.5 Hz), total 1H], [4.57 (dd, *J*=8.9, 8.7 Hz) and 4.63 (dd, *J*=8.7, 8.7 Hz), total 1H], 3.16, 3.21, 3.24 and 3.25 (4 s, total 6H), 2.96 and 3.03 (2 br s, total 3H), [1.14 (d, *J*=6.6 Hz) and 1.17 (d, *J*=6.4 Hz), total 3H].

Preparation of N²-[(1-Aminocyclopentyl)carbonyl]-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (#30**)**

[0398]



[0399] Step 1. Synthesis of *tert*-butyl (3*R*,4*S*,5*S*)-4-[[*N*-[(1-[(9*H*-fluoren-9-ylmethoxy)carbonyl] amino] cyclopentyl)carbonyl]-*L*-valyl](methylamino)-3-methoxy-5-methylheptanoate (**#27**). To **#6** (287 mg, 0.801 mmol, 1 eq.) in dichloromethane (4 mL, 0.2 M) were added 1-[(9*H*-fluoren-9-ylmethoxy)carbonyl]amino)cyclopentanecarboxylic acid (309 mg, 0.879 mmol, 1.1 eq.), diisopropylethylamine (281 μ L, 1.60 mmol, 2 eq.) and HATU (376 mg, 0.960 mmol, 1.2 eq.). The mixture was stirred for 18 hours and diluted with ethyl acetate (15 mL). The reaction mixture was washed with 1 M aqueous hydrochloric acid solution (2 x 5 mL) and with brine (5 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by silica gel chromatography (Gradient: 0% to 60% ethyl acetate in heptane) to provide **#27** (502 mg, 91%) as a white foam. LC-MS: *m/z* 692.3 [M+H⁺], 714.3 [M+Na⁺], 636.3 [(M - 2-methylprop-1-ene)+H⁺], retention time = 1.13 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), characteristic signals: δ 7.89 (br d, *J*=7.4 Hz, 2H), 7.67-7.75 (m, 2H), 7.60 (br s, 1H), 7.38-7.44 (m, 2H), 7.30-7.36 (m, 2H), 7.21 (br d, *J*=8.8 Hz, 1H), 4.44-4.59 (m, 2H), 4.17-4.27 (m, 3H), 3.68-3.78 (br m, 1H), 3.21 (s, 3H), 2.88 (br s, 3H), 2.09-2.20 (m, 2H), 1.39 (s, 9H).


[0400] Step 2. Synthesis of (3*R*,4*S*,5*S*)-4-[[*N*-[(1-[(977-fluoren-9-ylmethoxy)carbonyl]amino) cyclopentyl)carbonyl]-*L*-valyl](methylamino)-3-methoxy-5-methylheptanoic acid (**#28**). To a solution of **#27** (500 mg, 0.723 mmol) in dichloromethane (7 mL, 0.1 M) was added trifluoroacetic acid (3 mL). The reaction mixture initially became orange, then darkened over time. After stirring for 18 hours, the solvent was removed *in vacuo* to give **#28** (460 mg, quantitative) as a dark brown glass, which was used without further purification. LC-MS: *m/z* 636.3 [M+H⁺].

[0401] Step 3. Synthesis of *N*²-[(1-[(9*H*-fluoren-9-ylmethoxy)carbonyl]amino)cyclopentyl]carbonyl]-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide (**#29**). According to general procedure D, from **#28** (50 mg, 0.079 mmol, 1 eq.) dichloromethane (3 mL, 0.03 M), *N,N*-dimethylformamide (0.5 mL), amine **#18** (44 mg, 0.087 mmol, 1.1 eq.), triethylamine (33.0 μ L, 0.237 mmol, 3 eq.) and HATU (36 mg, 0.95 mmol, 1.2 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 30% acetone in heptane) to give **#29** (59 mg, 67%) as a solid. LC-MS: *m/z* 1007.5 [M+H⁺], retention time = 1.11 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.54 (br d, *J*=8 Hz) and 10.80 (br d, *J*=8 Hz), total 1H], 7.89 (br d, *J*=7 Hz, 2H), [7.80 (d, *J*=3.3 Hz) and 7.82 (d, *J*=3.1 Hz), total 1H], 7.68-7.75 (m, 2H), [7.64 (d, *J*=3.2 Hz) and 7.68 (d, *J*=3.2 Hz), total 1H], 7.38-7.44 (m, 2H), 7.27-7.36 (m, 4H), 7.12-7.25 (m, 4H), [6.30 (ddd, *J*=11, 8, 4.5 Hz) and 6.39-6.48 (m), total 1H], [4.50 (br dd, *J*=8, 8 Hz) and 4.54-4.59 (m), total 1H], 4.17-4.29 (m, 3H), 2.89 and 2.96 (2 br s, total 3H), [1.13 (d, *J*=6.5 Hz) and 1.16 (d, *J*=6.4 Hz), total 3H].

[0402] Step 4. Synthesis of *N*²-[(1-aminocyclopentyl)carbonyl]-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl] pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide (**#30**). According to general procedure A, from **#29** (54 mg, 0.054 mmol) in dichloromethane (6 mL, 0.9 mM) and diethylamine (4 mL) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane) to give example **#30** (26 mg, 61%) as a solid. HPLC (Protocol A): retention time = 7.233 minutes, *m/z* 785.4 [M+H⁺], (purity > 72%). ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.54 (br d, *J*=8 Hz) and 10.82 (br d, *J*=8 Hz), total 1H], 8.19-8.27 (m, 1H), [7.80 (d, *J*=3.2 Hz) and 7.83 (d, *J*=3.2 Hz), total 1H], [7.65 (d, *J*=3.3 Hz) and 7.69 (d, *J*=3.3 Hz), total 1H], 7.28-7.33 (m, 2H), 7.20-7.27 (m, 2H), 7.14-7.19 (m, 1H), [6.31 (ddd, *J*=11, 8, 4.5 Hz) and 6.44 (ddd, *J*=11, 8, 4 Hz), total 1H], [4.53 (dd, *J*=9, 8 Hz) and 4.60 (dd, *J*=9, 7.5 Hz), total 1H], 3.24 and 3.25 (2 s, total 3H), 3.17 and 3.21 (2 s, total 3H), 2.93 and 3.00 (2 br s, total 3H), [1.14 (d, *J*=6.5 Hz) and 1.17 (d, *J*=6.5 Hz), total 3H].

Preparation of 2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-((2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino)-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#34)

[0403]



[0404] Step 1. Synthesis of *N*-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3R,4S,5S)-1-*tert*-butoxy-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#31**). To a solution of **#6** (70% pure, 3.13 g, 6.1 mmol, 1 eq.) in dichloromethane (40 mL, 0.15 M) were added *N*-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanine (1.99 g, 6.12 mmol, 1 eq.), diisopropylethylamine (2.67 mL, 15.3 mmol, 2.5 eq.) and HATU (2.79 g, 7.35 mmol, 1.2 eq.). The reaction mixture was stirred for 18 hours, diluted with ethyl acetate, washed with 1 M aqueous hydrochloric acid solution and washed with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo* onto silica. The material was then purified by silica gel chromatography (Gradient: 0% to 45% ethyl acetate in heptane) to provide **#31** (3.65 g, 90%) as a solid. LC-MS: *m/z* 665.5 [M+H⁺], 688.5 [M+Na⁺], 610.5 [(M - 2-methylprop-1-ene)+H⁺]; HPLC (Protocol C): retention time = 9.455 (purity > 94%); ¹H NMR (400 MHz, DMSO-*d*₆), characteristic signals: δ 7.89 (d, *J*=7.4 Hz, 2H), 7.67-7.74 (m, 2H), 7.39-7.48 (m, 3H), 7.31-7.36 (m, 2H), 7.29 (br d, *J*=8.8 Hz, 1H), 4.47-4.60 (br m, 1H), 4.47 (dd, *J*=8.6, 8.0 Hz, 1H), 4.18-4.28 (m, 3H), 3.69-3.79 (br m, 1H), 3.21 (s, 3H), 2.88 (br s, 3H), 2.15 (dd, *J*=15.5, 9.3 Hz, 1H), 1.91-2.01 (m, 1H), 1.67-1.81 (br m, 1H), 1.39 (s, 9H), 1.36 (br s, 3H), 1.30 (s, 3H), 0.75 (d, *J*=6.6 Hz, 3H), 0.66-0.73 (br m, 3H).

[0405] Step 2. Synthesis of *N*-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(2R,3S,4S)-1-carboxy-2-methoxy-4-methylhexan-3-yl]-*N*-methyl-L-valinamide (**#32**). According to general procedure B, from **#31** (500 mg, 0.751 mmol) in dichloromethane (7 mL, 0.1 M) and trifluoroacetic acid (3 mL) was synthesized **#32** as a glass (458 mg, quantitative), which was used in the next step without further purification. LC-MS: *m/z* 611.4 [M+2H⁺], 632.2 [M+Na⁺], retention time = 0.94 minute.


[0406] Step 3. Synthesis of *N*-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3R,4S,5S)-3-methoxy-1-((2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino)-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#33**). According to general procedure D, from **#32** (53.0 mg, ≤0.083 mmol, 1 eq.), dichloromethane (4 mL, 0.02 M), *N,N*-dimethylformamide (1 mL), amine **#18** (43.8 mg, 0.0870 mmol, 1 eq.), triethylamine (36 μL, 0.26 mmol, 3 eq.) and HATU (39.5 mg, 0.104 mmol, 1.2 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 30% acetone in heptane) to give **#33** (60 mg, 69% over two steps). LC-MS: *m/z* 981.4 [M+H⁺], retention time = 1.090 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.54 (br d, *J*=8 Hz) and 10.80 (br d, *J*=8 Hz), total 1H], 7.86-7.91 (m, 2H), [7.80 (d, *J*=3.3 Hz) and 7.82 (d, *J*=3.3 Hz), total 1H], 7.68-7.74 (m, 2H), [7.64 (d, *J*=3.2 Hz) and 7.68 (d, *J*=3.3 Hz), total 1H], 7.38-7.44 (m, 2H), 7.20-7.36 (m, 6H), 7.12-7.17 (m, 1H), 6.27-6.34 and 6.40-6.47 (2 m, total 1H), 3.22 and 3.24 (2 s, total 3H), 3.14 and 3.18 (2 s, total 3H), 2.90 and 2.97 (2 br s, total 3H), 1.37 (br s, 3H), 1.31 (2 br s, total 3H), [1.13 (d, *J*=6.6 Hz) and 1.16 (d, *J*=6.5 Hz), total 3H].

[0407] Step 4. Synthesis of 2-methylalanyl-*N*-[(3R,4S,5S)-3-methoxy-1-((2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino)-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#34**). According to general procedure A, from **#33** (55 mg, 0.055 mmol, 1 eq.) in dichloromethane (6 mL, 0.009 M) and diethylamine (4 mL) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 5% methanol in dichloromethane) to give **#34** (25 mg, 60%) as a solid. HPLC (Protocol A): *m/z* 759.4 [M+H⁺], retention time = 7.088 minutes, (purity > 75%). ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.54 (br d, *J*=8 Hz) and 10.81 (br d, *J*=8 Hz), total 1H], 8.01-8.08 (m, 1H), [7.80 (d, *J*=3.1 Hz) and 7.83 (d, *J*=3.3 Hz), total 1H], [7.65 (d, *J*=3.2 Hz) and 7.69 (d, *J*=3.2 Hz), total 1H], 7.29-7.33 (m,

2H), 7.20-7.27 (m, 2H), 7.13-7.19 (m, 1H), 6.27-6.35 and 6.40-6.48 (2 m, total 1H), [4.49 (dd, $J=9$, 8 Hz) and 4.56 (dd, $J=9$, 8 Hz), total 1H], 3.24 and 3.25 (2 s, total 3H), 3.17 and 3.21 (2 s, total 3H), 2.92 and 2.99 (2 br s, total 3H), 1.20 and 1.21 (2 s, total 3H), 1.12 and 1.13 (2 s, total 3H), 0.75-0.81 (m, 3H).

Reference Example Preparation of N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#36)

[0408]




[0409] Step 1. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#35). To a mixture of **#23** (337 mg, 0.983 mmol, 1 eq.) in dichloromethane (8 mL, 0.1 M) and *N,N*-dimethylformamide (1 mL) were added **#8** (564 mg, 0.885 mmol, 0.9 eq.), diisopropylethylamine (383 mg, 2.95 mmol, 3 eq.) and HATU (472 mg, 1.18 mmol, 1.2 eq.). After 2 hours, the mixture was diluted with dichloromethane, washed sequentially with 0.1 M aqueous hydrochloric acid and with brine, dried over magnesium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by reverse phase chromatography (Method G) to give **#35** (600 mg, 66%); LC-MS: m/z 926.6 $[M+H]^+$, retention time = 1.16 minutes; ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ [9.94 (br t, $J=5$ Hz) and 10.16-10.23 (br m), total 1H], 7.90 (d, $J=7.2$ Hz, 2H), [7.71 (br d, $J=7$ Hz) and 8.06 (br d, $J=8$ Hz), total 1H], 7.60-7.65 (m, 2H), 7.41 (br dd, $J=7$, 7 Hz, 2H), 7.15-7.36 (m, 7H), 3.29 (s, 3H), 1.16-1.22 (m, 3H).

[0410] Step 2. Synthesis of N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#36). According to general procedure A, from **#35** (465 mg, 0.502 mmol, 1 eq.) in dichloromethane (5 mL, 0.1 M) and diethylamine (5 mL) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane) to give **#36** (310 mg, 88%) as a solid. LC-MS: m/z 704.6 $[M+H]^+$, retention time = 0.74 minutes; HRMS: m/z calculated for $C_{38}H_{66}N_5O_5S$: 704.4779, found: 704.477 $[M+H]^+$; ^1H NMR (400 MHz, CD_3OD), presumed to be a mixture of rotamers, characteristic signals: δ 7.23-7.30 (m, 4H), 7.15-7.22 (m, 1H), [4.68 (d, $J=8.6$ Hz) and 4.74 (d, $J=8.0$ Hz), total 1H], 3.39 and 3.40 (2 s, total 3H), 3.12 and 3.22 (2 br s, total 3H), [2.82 (d, $J=6.0$ Hz) and 2.84 (d, $J=6.0$ Hz), total 1H], 2.29 and 2.30 (2 s, total 3H), [1.27 (d, $J=6.8$ Hz) and 1.29 (d, $J=6.6$ Hz), total 3H], [0.84 (t, $J=7.4$ Hz) and 0.87 (t, $J=7.4$ Hz), total 3H].

Reference Example Preparation of N-methyl-L-valyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#41) and Reference Example N-Methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[[[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#42)

[0411]



[0412] Step 1. Synthesis of methyl *N*-[(2*R*,3*R*)-3-[(2*S*)-1-(*tert*-butoxycarbonyl)pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-*L*-phenylalaninate (**#37**). To a mixture of **#11** (2.7 g, 9.4 mmol, 1 eq.) in dichloromethane (30 mL, 0.3 M) and *N,N*-dimethylformamide (3 mL) were added diisopropylethylamine (3.30 mL, 18.8 mmol, 2 eq.), *L*-phenylalanine methyl ester hydrochloride (2.03 g, 9.40 mmol, 1.2 eq.) and HATU (4.79 g, 12.2 mmol, 1.3 eq.). The reaction was stirred for 18 hours and then concentrated *in vacuo*. The residue was taken up in ethyl acetate (100 mL) and washed sequentially with 1 M hydrochloric acid (2 x 50 mL) and brine. The organic layer was dried over sodium sulfate, filtered and evaporated *in vacuo*. The crude material was taken up in dichloromethane and filtered. The filtrate was purified by silica gel chromatography (Gradient: 0% to 100% ethyl acetate in heptane) to give **#37** (2.76 g, 65%) as an off-white solid. LC-MS: *m/z* 449.3 [M+H⁺], 349.2 [(M - Boc)+H⁺] retention time = 0.88 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 8.28 (d, *J*=8.2 Hz, 1H), 7.14-7.29 (m, 5H), 4.50 (ddd, *J*=10.9, 8.1, 4.4 Hz, 1H), 3.64 (s, 3H), 3.23 (s, 3H), 2.15-2.24 (m, 1H), 1.56-1.76 (m, 2H), 1.31-1.55 (m, 11H), 1.02 (d, *J*=6.6 Hz, 3H).

[0413] Step 2. Synthesis of methyl *N*-[(2*R*,3*R*)-3-[(2*S*)-1-(*tert*-butoxycarbonyl)pyrrolidin-2-yl]-3-methoxy-2-methylpropanethioyl]-*L*-phenylalaninate (**#38**). A mixture of **#37** (1.52 g, 3.39 mmol, 1 eq.) and **#21** (1.68 g, 4.41 mmol, 1.3 eq.) in acetonitrile (12 mL, 0.28 M) was subjected to microwave radiation at 100 °C for 1 hour. The mixture was partitioned between water and ethyl acetate. The aqueous layer was back-extracted with ethyl acetate. The combined organic layers were washed with 10% aqueous citric acid solution and with brine, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The material was dissolved in a small amount of ethyl acetate and concentrated onto silica *in vacuo*. Purification by silica gel chromatography (Gradient: 0% to 30% ethyl acetate in heptane) provided **#38** (680 mg, 43%); LC-MS: *m/z* 465.2 [M+H⁺], 487.3 [M+Na⁺], 365.2 [(M - Boc)+H⁺], retention time = 0.97 minutes; HPLC (Protocol B): 465.2 [M+H⁺], 487.2 [M+Na⁺], 365.2 [(M - Boc)+H⁺], retention time = 7.444 minutes (purity > 98%); ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 10.23 (br d, *J*=7.5 Hz, 1H), 7.17-7.28 (m, 5H), 5.24 (ddd, *J*=11, 7.5, 4.5 Hz, 1H), 3.66 (s, 3H), 3.28 (s, 3H), 3.21 (dd, *J*=14.3, 4.4 Hz, 1H), 3.07 (dd, *J*=14.2, 11.2 Hz, 1H), 2.65-2.74 (m, 1H), 1.54-1.71 (m, 2H), 1.37 (s, 9H), 1.17 (d, *J*=6.4 Hz, 3H).

[0414] Step 3. Synthesis of methyl *N*-[(2*R*,3*R*)-3-methoxy-2-methyl-3-[(2*S*)-pyrrolidin-2-yl]propanethioyl]-*L*-phenylalaninate, hydrochloride salt (**#39**). According to general procedure C, at 0 °C from **#38** (660 mg, 1.42 mmol, 1 eq.), dioxane (10 mL, 0.14 M) and 4 M hydrochloric acid solution in dioxane (20 mL, 80 mmol, 60 eq.) was synthesized **#39** (590 mg) as an off-white solid, which was used in the next step without further purification. LC-MS: *m/z* 365.2 [M+H⁺], retention time = 0.58 minutes; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.67 (d, *J*=7.7 Hz, 1H), 9.42-9.54 (br m, 1H), 8.21-8.33 (br m, 1H), 7.20-7.35 (m, 5H), 5.25 (ddd, *J*=11.1, 7.6, 4.4 Hz, 1H), 3.76 (dd, *J*=8.9, 3.0 Hz, 1H), 3.68 (s, 3H), 3.39 (s, 3H), 3.24 (dd, *J*=14.2, 4.5 Hz, 1H), 3.13 (dd, *J*=14.3, 11.0 Hz, 1H), 2.93-3.09 (m, 3H), 2.85-2.93 (m, 1H), 1.72-1.84 (m, 1H), 1.36-1.60 (m, 3H), 1.22 (d, *J*=6.6 Hz, 3H).

[0415] Step 4. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*-methyl-*L*-valyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide (**#40**). According to general procedure D, from **#8** (247 mg, 0.387


mmol, 1 eq.), **#39** (186 mg, ≤ 0.450 mmol, 1.2 eq.), dichloromethane (10 mL, 0.04 M), *N,N*-dimethylformamide (2 mL), HATU (176 mg, 0.464 mmol, 1.2 eq.) and triethylamine (189 μ L, 1.35 mmol, 3.5 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 25% acetone in heptane) to give **#40** (410 mg, 90% over 2 steps) as an off-white solid. LC-MS: *m/z* 984.7 [M+H⁺], 1006.7 [M+Na⁺], retention time = 1.15 minutes; HPLC (Protocol C): retention time = 9.683 minutes (purity > 99%); ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.19 (br d, *J*=7 Hz) and 10.49 (br d, *J*=8 Hz), total 1H], 7.90 (d, *J*=7.5 Hz, 2H), 7.60-7.65 (m, 2H), 7.38-7.45 (m, 2H), 7.29-7.35 (m, 2H), 7.14-7.28 (m, 5H), [5.20 (ddd, *J*=11, 7, 4 Hz) and 5.35-5.43 (m), total 1H], 3.65 and 3.69 (2 s, total 3H), [1.15 (d, *J*=6.5 Hz) and 1.18 (d, *J*=6.4 Hz), total 3H].

[0416] Step 5A. Synthesis of *N*-methyl-L-valyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, trifluoroacetic acid salt (**#41**). To a solution of **#40** (401 mg, 0.407 mmol, 1 eq.) in tetrahydrofuran (10 mL, 0.03 M) was added a solution of lithium hydroxide (24.4 mg, 1.02 mmol, 2.5 eq.) in water (5 mL). After 4 hours, the reaction was concentrated *in vacuo* and then azeotroped three times with heptane. The crude material was dissolved in dimethyl sulfoxide (7 mL) and purified by reverse phase chromatography (Method C, 7 injections of 1 mL). The appropriate fractions were concentrated (Genevac) before being diluted with a small amount of methanol in dichloromethane. The mixture was concentrated *in vacuo* to a glass-like solid. Diethyl ether was then added, followed by heptane, and the mixture was concentrated *in vacuo* to afford **#41** (180 mg, 59%) as a white solid. LC-MS: *m/z* 748.6 [M+H⁺], retention time = 0.68 minutes; HPLC (Protocol A): 748.4 [M+H⁺], retention time = 6.922 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 12.9 and 13.1 (2 v br s, total 1H), [10.12 (br d, *J*=8 Hz) and 10.45 (br d, *J*=8 Hz), total 1H], 8.75-8.90 (m, 2H), 8.62-8.73 (br m, 1H), 7.13-7.29 (m, 5H), [5.20 (ddd, *J*=11, 7.5, 4 Hz) and 5.40 (ddd, *J*=11.5, 8, 4 Hz), total 1H], 4.55-4.73 (m, 2H), 3.23 and 3.25 (2 s, total 3H), 3.16 and 3.18 (2 s, total 3H), 2.97 and 3.01 (2 br s, total 3H), 1.13-1.20 (m, 3H), 0.73-0.81 (m, 3H).

[0417] Step 5B. Synthesis of *N*-methyl-L-valyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#42**). According to general procedure A, from **#40** (561 mg, 0.570 mmol, 1 eq.), dichloromethane (10 mL, 0.057 M) and diethylamine (10 mL) was synthesized **#42** (348 mg, 80%) as a white solid after silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane). LC-MS: *m/z* 762.7 [M+H⁺], retention time = 0.74 minutes; HPLC (Protocol A): 762.4 [M+H⁺], retention time = 7.315 minutes (purity > 95%); ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.20 (br d, *J*=7.5 Hz) and 10.50 (br d, *J*=8 Hz), total 1H], 7.95-8.03 (m, 1H), 7.15-7.29 (m, 5H), [5.20 (ddd, *J*=11, 7.5, 5 Hz) and 5.39 (ddd, *J*=11, 7.5, 4 Hz), total 1H], [4.57 (dd, *J*=8.8, 8.7 Hz) and 4.61 (dd, *J*=8.7, 8.6 Hz), total 1H], 3.65 and 3.69 (2 s, total 3H), 3.24 and 3.25 (2 s, total 3H), 3.16 and 3.17 (2 s, total 3H), 2.96 and 2.99 (2 br s, total 3H), 2.69-2.79 (m, 1H), 2.62-2.68 (m, 1H), 2.14 and 2.15 (2 br s, total 3H), [1.15 (d, *J*=6.6 Hz) and 1.18 (d, *J*=6.5 Hz), total 3H], [0.75 (t, *J*=7.4 Hz) and 0.76 (t, *J*=7.3 Hz), total 3H].

Preparation of 2-Methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, hydrochloride salt (#44**) and 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, hydrochloride salt (**#45**)**

[0418]




[0419] Step 1. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#43**). To a solution of **#32** (321 mg, 0.881 mmol, 1 eq.) in dichloromethane (5 mL, 0.1 M) and *N,N*-dimethylformamide (1 mL) were added **#39** (484 mg, <0.769 mmol, 0.9 eq.), HATU (353 mg, 0.881 mmol, 1 eq.) and diisopropylethylamine (463 μL , 2.64 mmol, 3 eq.). After stirring for 18 hours, the mixture was diluted with dichloromethane, washed with water and with brine, dried over magnesium sulfate, filtered, and concentrated onto silica *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 0% to 30% acetone in heptane) to give **#43** (574 mg, 68% over two steps) as a white solid. LC-MS: m/z 956.6 $[\text{M}+\text{H}^+]$, retention time = 4.49 minutes; ^1H NMR (400 MHz, CD_3OD), presumed to be a mixture of rotamers, characteristic signals: δ 7.80 (d, $J=7.5$ Hz, 2H), 7.64-7.72 (m, 2H), 7.16-7.35 (m, 7H), [5.43 (dd, $J=11$, 4.5 Hz) and 5.58 (dd, $J=11.5$, 4 Hz), total 1H], 3.72 and 3.75 (2 s, total 3H), 3.34 and 3.35 (2 s, total 3H), 3.26 and 3.29 (2 s, total 3H), 3.05 and 3.11 (2 br s, total 3H), 1.39 and 1.40 (2 s, total 3H), [1.24 (d, $J=6.7$ Hz) and 1.29 (d, $J=6.4$ Hz), total 3H].

[0420] Step 2A. Synthesis of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, hydrochloride salt (**#44**). To a solution of **#43** (100 mg, 0.105 mmol, 1 eq.) in tetrahydrofuran (5 mL, 0.02 M) was added a solution of lithium hydroxide (10 mg, 0.417 mmol, 3 eq.) in water (3 mL). After 3 hours, the reaction was concentrated *in vacuo* and purified by reverse phase chromatography (Method C) to give a trifluoroacetic acid salt, which was dissolved in methanol, treated with a 4 M hydrochloric acid solution in dioxane, and concentrated *in vacuo* to give **#44** (56 mg, 71%) as a white solid. LC-MS: m/z 720.6 $[\text{M}+\text{H}^+]$, retention time = 0.67 minutes; HPLC (Protocol D): retention time = 8.851 minutes; ^1H NMR (400 MHz, CD_3OD), presumed to be a mixture of rotamers, characteristic signals: δ 7.17-7.31 (m, 5H), 3.34 and 3.35 (2 s, total 3H), 3.10 and 3.16 (2 br s, total 3H), 1.62 and 1.64 (2 s, total 3H), 1.53 and 1.55 (2 s, total 3H), [1.26 (d, $J=6.5$ Hz) and 1.30 (d, $J=6.5$ Hz), total 3H], 0.84-0.91 (m, 3H).

[0421] Step 2B. Synthesis of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, hydrochloride salt (**#45**). According to general procedure A, from **#43** (176 mg, 0.184 mmol, 1 eq.), dichloromethane (4 mL, 0.05 M) and diethylamine (4 mL) was synthesized the crude desired material, which was purified by reverse phase chromatography (Method C). The resulting trifluoroacetic acid salt was dissolved in methanol, treated with a 4 M solution of hydrochloric acid in dioxane, and concentrated *in vacuo* to give **#45** (100 mg, 70%) as a white solid. LC-MS: m/z 734.6 $[\text{M}+\text{H}^+]$, retention time = 0.72 minutes; ^1H NMR (400 MHz, CD_3OD), presumed to be a mixture of rotamers, characteristic signals: δ 7.18-7.31 (m, 5H), 5.41-5.47 and 5.55-5.62 (2 m, total 1H), 3.73 and 3.76 (2 s, total 3H), 3.35 and 3.36 (2 s, total 3H), 3.10 and 3.15 (2 br s, total 3H), 1.62 and 1.64 (2 s, total 3H), 1.53 and 1.55 (2 s, total 3H), [1.25 (d, $J=6.6$ Hz) and 1.29 (d, $J=6.5$ Hz), total 3H], 0.84-0.91 (m, 3H).

Preparation of N^2 -[(1-Aminocyclopentyl)carbonyl]- N -[(3 R ,4 S ,5 S)-3-methoxy-1-[(2 S)-2-[(1 R ,2 R)-1-methoxy-2-methyl-3-oxo-3-[(1 S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (#47)

[0422]




[0423] Step 1. Synthesis of N^2 -[(1-[(9 H -fluoren-9-ylmethoxy)carbonyl]amino)cyclopentyl]-carbonyl]- N -[(3 R ,4 S ,5 S)-3-methoxy-1-[(2 S)-2-[(1 R ,2 R)-1-methoxy-2-methyl-3-oxo-3-[(1 S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (#46). To a solution of #19 (353 mg, 0.944 mmol, 1 eq.) in dichloromethane (10 mL, 0.094 M) were added #28 (600 mg, 0.944 mmol, 0.9 eq.), diisopropylethylamine (498 μ L, 2.83 mmol, 3 eq.) and HATU (444 mg, 1.13 mmol, 1.2 eq.). After stirring for two days, the mixture was concentrated *in vacuo* and the residue was diluted with ethyl acetate (60 mL), washed with 1 M aqueous hydrochloric acid solution and with brine, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was diluted with dichloromethane and filtered. The filtrate was concentrated under reduced pressure onto silica and purified by silica gel chromatography (Gradient: 40% to 100% ethyl acetate in heptane) to give #46 (644 mg, 69%) as a white solid. LC-MS: m/z 991.8 [M+H⁺], retention time = 1.07 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 7.89 (br d, J =7.4 Hz, 2H), [7.77 (d, J =3.3 Hz) and 7.79 (d, J =3.3 Hz), total 1H], 7.66-7.76 (m, 2H), [7.62 (d, J =3.3 Hz) and 7.65 (d, J =3.3 Hz), total 1H], 7.37-7.44 (m, 2H), 7.11-7.36 (m, 7H), [5.38 (ddd, J =11, 8, 4 Hz) and 5.48-5.57 (m), total 1H], 3.13, 3.17, 3.18 and 3.24 (4 s, total 6H), 2.90 and 3.00 (2 br s, total 3H), [1.05 (d, J =6.6 Hz) and 1.09 (d, J =6.8 Hz), total 3H].

[0424] Step 2. Synthesis of N^2 -[(1-aminocyclopentyl)carbonyl]- N -[(3 R ,4 S ,5 S)-3-methoxy-1-[(2 S)-2-[(1 R ,2 R)-1-methoxy-2-methyl-3-oxo-3-[(1 S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (#47). To a mixture of #46 (500 mg, 0.504 mmol, 1 eq.) in tetrahydrofuran (8 mL, 0.06 M) was added diethylamine (4 mL). After stirring for 18 hours, the reaction mixture was concentrated *in vacuo* and the residue was purified by silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane) to give #47 (374 mg, 96%) as a white solid. LC-MS: m/z 769.6 [M+H⁺], retention time = 0.70 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [8.64 (br d, J =8.4 Hz) and 8.87 (br d, J =8.6 Hz), total 1H], [8.22 (br d, J =9.4 Hz) and 8.26 (br d, J =9.4 Hz), total 1H], [7.77 (d, J =3.3 Hz) and 7.80 (d, J =3.3 Hz), total 1H], [7.63 (d, J =3.1 Hz) and 7.66 (d, J =3.3 Hz), total 1H], 7.13-7.31 (m, 5H), [5.39 (ddd, J =11.1, 8.5, 4.2 Hz) and 5.54 (ddd, J =11.7, 8.8, 4.1 Hz), total 1H], [4.53 (dd, J =9.2, 7.6 Hz) and 4.64 (dd, J =9.2, 6.6 Hz), total 1H], 3.16, 3.20, 3.21 and 3.25 (4 s, total 6H), 2.93 and 3.03 (2 br s, total 3H), [1.05 (d, J =6.8 Hz) and 1.10 (d, J =6.6 Hz), total 3H], 0.73-0.80 (m, 3H).

Preparation of N^2 -[(1-Aminocyclopropyl)carbonyl]- N -[(3 R ,4 S ,5 S)-3-methoxy-1-[(2 S)-2-[(1 R ,2 R)-1-methoxy-2-methyl-3-oxo-3-[(1 S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (#51) and 1-amino- N -[(2 S)-1-[(3 R ,4 S ,5 S)-3-methoxy-1-[(2 S)-2-[(1 R ,2 R)-1-methoxy-2-methyl-3-oxo-3-[(1 S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methylamino)-3-methyl-1-oxobutan-2-yl]cyclohexanecarboxamide (#52)

[0425]



[0426] Step 1. Synthesis of (2*R*,3*R*)-3-methoxy-2-methyl-*N*-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]-3-[(2*S*)-pyrrolidin-2-yl]propanamide, trifluoroacetic acid salt and (3*R*,4*S*,5*S*)-4-[[*N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*L*-valyl](methylamino)-3-methoxy-5-methylheptanoic acid (**#48**). To a solution of **#16** (1.0 g, 2.11 mmol, 1 eq.) and **#5** (1.22 g, 2.11 mmol, 1 eq.) in dichloromethane (20 mL, 0.1 M) at 0 °C was added trifluoroacetic acid (6 mL). After 3 hours, the mixture was concentrated *in vacuo* to give the mixture **#48** (1.8 g), which was used in the next step without further purification; LC-MS (Protocol K): *m/z* 374.2 [M+H⁺], retention time = 2.093 minutes, 525.2 [M+H⁺], retention time = 4.875 minutes.

[0427] Step 2. Synthesis of *N*²-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide (**#49**). To a solution of **#48** (1.8 g, ≤2.1 mmol, 1 eq.) and diethyl cyanophosphonate (DEPC) (0.51 g, 3.2 mmol, 1.5 eq.) in 1,2-dimethoxyethane (30 mL, 0.07 M) at 0 °C was added triethylamine (1.47 mL, 10.6 mmol, 5 eq.). After stirring at room temperature for 2 hours, the mixture was concentrated *in vacuo* and the residue was purified by silica gel chromatography (10% to 50% ethyl acetate in petroleum ether) to give **#49** (0.8 g, 45%). *R*_f 0.6 (10% methanol in dichloromethane); LC-MS (Protocol K): *m/z* 881.3 [M+H⁺], 903.3 [M+Na⁺], retention time = 4.837 minutes.

[0428] Step 3. Synthesis of *N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide (**#50**). According to general procedure A, from **#49** (0.70 g, 0.79 mmol, 1 eq.), dichloromethane (15 mL, 0.05 M) and diethylamine (10 mL) was synthesized **#50** (160 mg, 30%) after purification by silica gel chromatography (Gradient: 0% to 5% methanol in dichloromethane). *R*_f 0.4 (10% methanol in dichloromethane); LC-MS (Protocol K): *m/z* 658.3 [M+H⁺], 680.3 [M+Na⁺], retention time = 2.760 minutes.


[0429] Step 4A. Synthesis of *N*²-[(1-aminocyclopropyl)carbonyl]-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide (**#51**). To a solution of **#50** (100 mg, 0.15 mmol, 1 eq.), bromotris(dimethylamino)phosphonium hexafluorophosphate (Brop, 70 mg, 0.18 mmol, 1.2 eq.) and diisopropylethylamine (0.08 mL, 0.45 mmol, 3 eq.) in dichloromethane (15 mL, 0.01 M) at 0 °C was added 1-aminocyclopropanecarboxylic acid (18 mg, 0.18 mmol, 1.2 eq.). After 2 hours, the mixture was quenched with water and extracted twice with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 0% to 5% methanol in dichloromethane) to give **#51** (45 mg, 34%). *R*_f 0.5 (10% methanol

in dichloromethane). LC-MS (Protocol L): m/z 741.44 $[M+H]^+$; ^1H NMR (300 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ [8.64 (br d, $J=8$ Hz) and 8.88 (br d, $J=8$ Hz), total 1H], [8.16 (br d, $J=9$ Hz) and 8.22 (br d, $J=10$ Hz), total 1H], [7.77 (d, $J=3.5$ Hz) and 7.79 (d, $J=3.5$ Hz), total 1H], [7.63 (d, $J=3.5$ Hz) and 7.65 (d, $J=3$ Hz), total 1H], 7.10-7.32 (m, 5H), 5.33-5.60 (m, 1H), 3.16, 3.20, 3.21 and 3.26 (4 s, total 6H), 2.93 and 3.02 (2 br s, total 3H), [1.05 (d, $J=6.3$ Hz) and 1.10 (d, $J=6.3$ Hz), total 3H].

[0430] Step 4B. Synthesis of 1-amino-N-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methylamino)-3-methyl-1-oxobutan-2-yl]cyclohexanecarboxamide (**#52**). To a solution of **#50** (120 mg, 0.18 mmol, 1 eq.), Brop (84 mg, 0.21 mmol, 1.2 eq.) and diisopropylethylamine (0.1 mL, 0.54 mmol, 3 eq.) in dichloromethane (15 mL, 0.009 M) at 0 °C was added 1-aminocyclohexanecarboxylic acid (31 mg, 0.21 mmol, 1.2 eq.). After 2 hours, the mixture was quenched with water and extracted twice with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 0% to 5% methanol in dichloromethane) to give **#52** (50 mg, 35%). R_f 0.6 (10% methanol in dichloromethane). LC-MS (Protocol K): m/z 783.79 $[M+H]^+$; ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ [8.64 (br d, $J=8$ Hz) and 8.87 (br d, $J=9$ Hz), total 1H], 8.18-8.28 (m, 1H), [7.77 (d, $J=3.5$ Hz) and 7.80 (d, $J=3.3$ Hz), total 1H], [7.63 (d, $J=3.3$ Hz) and 7.66 (d, $J=3.3$ Hz), total 1H], 7.12-7.31 (m, 5H), 5.35-5.43 and 5.49-5.57 (2 m, total 1H), [4.51 (dd, $J=9$, 8 Hz), and 4.61 (dd, $J=9$, 7 Hz), total 1H], 3.16, 3.19, 3.21 and 3.25 (4 s, total 6H), 2.93 and 3.02 (2 br s, total 3H), [1.05 (d, $J=6.8$ Hz) and 1.10 (d, $J=6.8$ Hz), total 3H].

Preparation of 2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#54**)**

[0431]




[0432] Step 1. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#53**). According to general procedure D, from **#32** (2.05 g, 2.83 mmol, 1 eq.) in dichloromethane (20 mL, 0.1 M) and *N,N*-dimethylformamide (3 mL), the amine **#19** (2.5 g, 3.4 mmol, 1.2 eq.), HATU (1.29 g, 3.38 mmol, 1.2 eq.) and triethylamine (1.57 mL, 11.3 mmol, 4 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 55% acetone in heptane), producing **#53** (2.42 g, 74%) as a solid. LC-MS: m/z 965.7 $[M+H]^+$, 987.6 $[M+Na]^+$, retention time = 1.04 minutes; HPLC (Protocol A): m/z 965.4 $[M+H]^+$, retention time = 11.344 minutes (purity > 97%); ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ 7.86-7.91 (m, 2H), [7.77 (d, $J=3.3$ Hz) and 7.79 (d, $J=3.2$ Hz), total 1H], 7.67-7.74 (m, 2H), [7.63 (d, $J=3.2$ Hz) and 7.65 (d, $J=3.2$ Hz), total 1H], 7.38-7.44 (m, 2H), 7.30-7.36 (m, 2H), 7.11-7.30 (m, 5H), [5.39 (ddd, $J=11.4$, 8.4, 4.1 Hz) and 5.52 (ddd, $J=11.7$, 8.8, 4.2 Hz), total 1H], [4.49 (dd, $J=8.6$, 7.6 Hz) and 4.59 (dd, $J=8.6$, 6.8 Hz), total 1H], 3.13, 3.17, 3.18 and 3.24 (4 s, total 6H), 2.90 and 3.00 (2 br s, total 3H), 1.31 and 1.36 (2 br s, total 6H), [1.05 (d, $J=6.7$ Hz) and 1.09 (d, $J=6.7$ Hz), total 3H].

[0433] Step 2. Synthesis of 2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#54**). According to general procedure A, from **#53** (701 mg, 0.726 mmol) in dichloromethane (10 mL, 0.07 M) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 10% methanol

in dichloromethane). The residue was diluted with diethyl ether and heptane and was concentrated *in vacuo* to afford **#54** (406 mg, 75%) as a white solid. LC-MS: m/z 743.6 $[M+H]^+$, retention time = 0.70 minutes; HPLC (Protocol A): m/z 743.4 $[M+H]^+$, retention time = 6.903 minutes, (purity > 97%); ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ [8.64 (br d, $J=8.5$ Hz) and 8.86 (br d, $J=8.7$ Hz), total 1H], [8.04 (br d, $J=9.3$ Hz) and 8.08 (br d, $J=9.3$ Hz), total 1H], [7.77 (d, $J=3.3$ Hz) and 7.80 (d, $J=3.2$ Hz), total 1H], [7.63 (d, $J=3.3$ Hz) and 7.66 (d, $J=3.2$ Hz), total 1H], 7.13-7.31 (m, 5H), [5.39 (ddd, $J=11, 8.5, 4$ Hz) and 5.53 (ddd, $J=12, 9, 4$ Hz), total 1H], [4.49 (dd, $J=9, 8$ Hz) and 4.60 (dd, $J=9, 7$ Hz), total 1H], 3.16, 3.20, 3.21 and 3.25 (4 s, total 6H), 2.93 and 3.02 (2 br s, total 3H), 1.21 (s, 3H), 1.13 and 1.13 (2 s, total 3H), [1.05 (d, $J=6.7$ Hz) and 1.10 (d, $J=6.7$ Hz), total 3H], 0.73-0.80 (m, 3H).

Preparation of 2-Methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, acetic acid salt (#56)

[0434]




[0435] Step 1. Synthesis of *N*-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#55**). To a solution of **#24** (104 mg, 0.256 mmol, 1 eq.) in dichloromethane (10 mL, 0.094 M) were added **#32** (156 mg, 0.256 mmol, 0.9 eq.), diisopropylethylamine (135 μ L, 0.768 mmol, 3 eq.) and HATU (120 mg, 0.307 mmol, 1.2 eq.). After stirring for 18 hours, the mixture was concentrated *in vacuo* and the residue was diluted with ethyl acetate (10 mL), washed with 1 M aqueous hydrochloric acid solution (2 x 5 mL) and with brine, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was diluted with dichloromethane and filtered. The filtrate was concentrated under reduced pressure onto silica and purified by silica gel chromatography (Gradient: 0% to 100% ethyl acetate in heptane) to give **#55** (44 mg, 19%) as a white solid. LC-MS: m/z 884.5 $[M+2H]^+$, retention time = 1.04 minutes.

[0436] Step 2. Synthesis of 2-methylalanyl-*N*-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, acetic acid salt (**#56**). To a mixture of **#55** (44 mg, 0.050 mmol, 1 eq.) in tetrahydrofuran (1 mL, 0.05 M) was added diethylamine (0.5 mL). After stirring for 18 hours, the reaction mixture was concentrated *in vacuo* and the residue was purified by reverse phase chromatography (Method B) to give **#56** (16.2 mg, 49%) as a solid. LC-MS: m/z 660.8 $[M+H]^+$, retention time = 2.23 minutes; HPLC (Protocol A): m/z 660.5 $[M+H]^+$, 682.4 $[M+Na]^+$, retention time = 6.865 minutes.

Preparation of 2-Methylalanyl-*N*-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (#60)

[0437]



[0438] Step 1. Synthesis of 1-(1-phenylcyclopropyl)methanamine **#1**. To a solution of 1-phenylcyclopropanecarbonitrile (50 g, 0.34 mol, 1 eq.) in tetrahydrofuran (500 mL, 0.7 M) at 0 °C was added lithium aluminum hydride (23 g, 0.35 mol, 1.03 eq.). The reaction mixture was stirred at 0 °C for one hour and then at reflux for one hour. The reaction mixture was then cooled down and quenched with water (23 mL) and a 15% aqueous sodium hydroxide solution (69 mL). The mixture was filtered and concentrated *in vacuo* to afford **#1** (36 g, 72%). LC-MS: *m/z* 148.1 [M+H⁺], retention time = 0.86 minutes; ¹H NMR (400 MHz, CDCl₃) δ 7.2-7.4 (m, 5H), 2.78 (s, 2H), 1.19 (br s, 2H), 0.72-0.84 (m, 4H).

[0439] Step 2. Synthesis of *tert*-butyl (2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidine-1-carboxylate (**#57**). According to general procedure D, from **#11** (2.15 g, 7.48 mmol, 1.1 eq.) in dichloromethane (20 mL, 0.3 M) and *N,N*-dimethylformamide (4 mL), 1-(1-phenylcyclopropyl)methanamine **#1** (1.001 g, 6.799 mmol, 1 eq.), HATU (3.10 g, 8.16 mmol, 1.2 eq.) and triethylamine (2.84 mL, 20.4 mmol, 3 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 100% ethyl acetate in heptane), producing **#57** (1.93 g, 68%) as a solid. HPLC (Protocol A at 45 °C): *m/z* 417.3 [M+H⁺], retention time = 10.575 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers: δ 7.75-7.81 (m, 1H), 7.20-7.27 (m, 4H), 7.12-7.19 (m, 1H), 3.33-3.62 and 3.71-3.80 (br multiplets, total 4H), 3.28 (s, 3H), 2.97-3.17 (br m, 2H), 2.14-2.24 (m, 1H), 1.67-1.80 (br m, 2H), 1.45-1.65 (m, 2H), 1.41 (s, 9H), 1.00 (d, *J*=6.6 Hz, 3H), 0.67-0.93 (m, 4H).

[0440] Step 3. Synthesis of (2*R*,3*R*)-3-methoxy-2-methyl-*N*-[(1-phenylcyclopropyl)methyl]-3-[(2*S*)-pyrrolidin-2-yl]propanamide, hydrochloride salt (**#58**). According to general procedure C, from **#57** (566 mg, 1.36 mmol, 1 eq.) in dioxane (4 mL, 0.3 M) and 4 M hydrochloric acid solution in dioxane (4 mL, 16 mmol, 11.7 eq.) was synthesized **#58** (466 mg, 97%); LC-MS: *m/z* 318.2 [M+H⁺], 339.2 [M+Na⁺], retention time = 0.56 minute; ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.53 (br s, 1H), 8.48 (br s, 1H), 8.11 (br dd, *J*=5.7, 5.6 Hz, 1H), 7.23-7.30 (m, 4H), 7.14-7.21 (m, 1H), 3.58 (dd, *J*=7.5, 3.9 Hz, 1H), 3.50 (dd, *J*=13.7, 6.3 Hz, 1H), 3.34 (s, 3H), 3.21-3.29 (br m, 1H), 3.18 (dd, *J*=13.8, 5.0 Hz, 1H), 3.04-3.13 (br m, 2H), 2.42-2.50 (m, 1H), 1.56-1.89 (m, 4H), 1.04 (d, *J*=6.9 Hz, 3H), 0.71-0.91 (m, 4H).


[0441] Step 4. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#59**). According to general procedure D, from **#32** (550 mg, 0.902 mmol, 1 eq.), **#58** (350 mg, 0.992 mmol, 1.1 eq.) dichloromethane (10 mL, 0.08 M) and *N,N*-dimethylformamide (2 mL), HATU (446 mg, 1.17 mmol, 1.3 eq.) and triethylamine (0.503 mL, 3.61 mmol, 4 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 30% acetone in heptane), producing **#59** (618 mg, 69%) as an off-white solid. LC-MS: *m/z* 908.7 [M+H⁺], 930.7 [M+Na⁺], retention time = 1.07 minutes; HPLC (Protocol B at 45 °C): *m/z* 908.5 [M+H⁺], retention time = 8.721 minutes (purity > 97%); ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 7.89 (d, *J*=7.5 Hz, 2H), 7.38-7.44 (m, 2H), 7.30-7.36 (m, 2H), [4.49 (dd, *J*=8.5, 7.8 Hz) and 4.59 (dd, *J*=8.7, 6.9 Hz), total 1H], 4.18-4.26 (m, 3H), 3.93-4.01 (br m, 1H), 3.23 and 3.26 (2 s, total 3H), 3.16 and 3.16 (2 s, total 3H), 2.91 and 3.05 (2 br s, total 3H), 1.36 and 1.37 (2 br s, total 3H), 1.30 and 1.32 (2 br s, total 3H), [1.00 (d, *J*=6.7 Hz) and 1.02 (d, *J*=6.6 Hz), total 3H], 0.67-0.78 (m, 7H).

[0442] Step 5. Synthesis of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#60**). According to general procedure A, from **#59** (605 mg, 0.666 mmol, 1 eq.) dichloromethane (10 mL, 0.067 M) and diethylamine (10 mL) was synthesized **#60** (379 mg, 83%); HPLC (Protocol A at 45 °C) *m/z* 685.5 [M+H⁺], retention time = 7.072 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [8.03 (br d, *J*=9.6 Hz) and 8.07 (br d, *J*=9.4 Hz), total 1H], [7.74 (br dd, *J*=7, 4 Hz) and 7.99 (br dd, *J*=5.9, 5.7 Hz), total 1H], 7.20-7.27 (m, 4H), 7.11-7.17 (m, 1H), [4.49 (dd, *J*=9, 7 Hz) and 4.58 (dd, *J*=9, 7.5 Hz), total 1H], 3.96-4.04 (br m, 1H),

3.24 and 3.27 (2 s, total 3H), 3.18 and 3.19 (2 s, total 3H), 2.93 and 3.07 (2 br s, total 3H), 1.20 and 1.21 (2 s, total 3H), 1.12 and 1.14 (2 s, total 3H), [1.00 (d, $J=6.7$ Hz) and 1.03 (d, $J=6.7$ Hz), total 3H].

Preparation of 2-Methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#66)

[0443]



[0444] Step 1. Synthesis of cyclohepta-2,4,6-trien-1-ylacetone (#61). To a solution of anhydrous acetonitrile (3.12 mL, 56.2 mmol, 1 eq.) in tetrahydrofuran (281 mL, 0.2 M) was added lithium diisopropylamide (1.8 M in heptane/ethylbenzene/tetrahydrofuran, 31.2 mL, 56.2 mmol, 1 eq.) at -78 °C. After 20 minutes at -78 °C, tropylium tetrafluoroborate (10 g, 56 mmol, 1 eq.) was added. After 10 minutes, the reaction was concentrated *in vacuo* and the residue was diluted with ethyl acetate and washed with water. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo* to provide a brown oil, which was purified by silica gel chromatography (Gradient: 0% to 10% ethyl acetate in heptane) to provide #61 (1.88 g, 25%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 6.69-6.71 (m, 2H), 6.27-6.32 (m, 2H), 5.28-5.33 (m, 2H), 2.61 (d, $J=7.2$ Hz, 2H), 2.26-2.34 (m, 1H).

[0445] Step 2. Synthesis of 2-(cyclohepta-2,4,6-trien-1-yl)ethanamine (#62). To a suspension of lithium aluminum hydride (911 mg, 24.0 mmol, 1.4 eq.) in anhydrous diethyl ether (75 mL, 0.23 M) at 0 °C was slowly added, drop-wise over 15 minutes, a solution of #61 (2.25 g, 17.2 mmol, 1 eq.) in diethyl ether (15 mL). The reaction was warmed to room temperature. After 5 hours, the reaction was cooled to 0 °C and quenched by addition of water (1 mL), then filtered through a small pad of Celite and washed with methanol. The filtrate was dried over sodium sulfate, filtered, and concentrated *in vacuo* to provide #62 (1.683 g, 73%) as a golden oil. LC-MS: m/z 136.1 [M+H⁺], retention time = 0.23 minutes; ¹H NMR (400 MHz, CDCl₃) δ 6.64-6.67 (m, 2H), 6.16-6.21 (m, 2H), 5.16-5.21 (m, 2H), 2.84-2.89 (m, 2H), 1.86-1.92 (m, 2H), 1.62-1.70 (m, 1H).

[0446] Step 3. Synthesis of tert-butyl (2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidine-1-carboxylate (#63). To a solution of #11 (3.57 g, 12.4 mmol, 1 eq.) in dichloromethane (100 mL, 0.1 M) and *N,N*-dimethylformamide (4 mL) was added HATU (5.36 g, 13.7 mmol, 1.1 eq.). After 20 minutes, triethylamine (5.20 mL, 37.3 mmol, 3 eq.) was added, followed by #62 (1.68 g, 12.4 mmol, 1 eq.), and the mixture was stirred for 18 hours. The reaction was concentrated *in vacuo* and the residue was taken up in ethyl acetate and washed with water (50 mL). The aqueous layer was back-extracted with ethyl acetate (3 times) and the combined organic layers were dried, filtered, and concentrated *in vacuo* to provide a brown oil, which was purified by silica gel chromatography (Gradient: 0% to 100% ethyl acetate in heptane) to provide #63 (2.95 g, 59% yield) as a viscous oil. LC-MS: m/z 405.4 [M+H⁺], 427.4 [M+Na⁺], retention time = 0.75 minutes; ¹H NMR (400 MHz, CDCl₃), presumed to be a mixture of rotamers: δ 6.63-6.68 (m, 2H), 6.16-6.23 (m, 2H), 5.19 (br dd, $J=9.0, 5.8$ Hz, 2H), 3.51-3.63 and 3.71-3.90 (2 br multiplets, total 3H), 3.42 (s, 3H), 3.18-3.29 and 3.34-3.47 (2 br multiplets, total 3H), 2.27-2.45 (br m, 1H), 1.6-2.00 (m, 7H), 1.47 and 1.50 (2 br s, total 9H), 1.16-1.29 (br m, 3H).

[0447] Step 4. Synthesis of (2R,3R)-N-[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanamide, hydrochloride salt (#64)

[0448] Intermediate #63 (400 mg, 0.989 mmol, 1 eq.) was treated with a 4 M solution of hydrochloric acid in dioxane (10 mL, 40 mmol, 40 eq.). After 1 hour, the reaction mixture was concentrated *in vacuo* and the residue was taken up


in dichloromethane and washed with 1 M sodium hydroxide solution. The aqueous layer was back-extracted with dichloromethane and the combined organic layers were dried over sodium sulfate, filtered, and concentrated *in vacuo* to provide **#64** (301 mg, quantitative) as a brown oil, which slowly began to solidify upon standing. LC-MS: *m/z* 305.3 [M+H⁺], retention time = 0.54 minutes; HPLC (Protocol G): retention time = 4.848 minutes; ¹H NMR (400 MHz, CDCl₃), characteristic signals: δ 6.64-6.67 (m, 2H), 6.16-6.22 (m, 2H), 6.08-6.14 (br m, 1H), 5.16-5.22 (m, 2H), 3.44 (s, 3H), 3.31 (dd, *J*=6.3, 4.5 Hz, 1H), 2.98-3.04 (m, 1H), 2.94 (ddd, *J*=10.5, 7.2, 5.6 Hz, 1H), 2.81 (ddd, *J*=10.5, 7.7, 6.7 Hz, 1H), 2.57 (qd, *J*=7.1, 4.5 Hz, 1H), 1.90-1.97 (m, 2H), 1.49-1.55 (m, 1H), 1.18 (d, *J*=7.1 Hz, 3H).

[0449] Step 5. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#65**). According to general procedure D, from **#32** (678 mg, 0.937 mmol, 1 eq.) in dichloromethane (9.37 mL, 0.1 M), the amine **#64** (300 mg, 0.985 mmol, 1.1 eq.), HATU (427 mg, 1.12 mmol, 1.2 eq.) and diisopropylethylamine (494 μL, 2.81 mmol, 3 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 50% acetone in heptane), producing **#65** (546 mg, 65%) as a solid. LC-MS: *m/z* 896.7 [M+H⁺], 918.7 [M+Na⁺], retention time = 1.06 minutes.

[0450] Step 6. Synthesis of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#66**). To a solution of **#65** (540 mg, 0.603 mmol, 1 eq.) in dichloromethane (10 mL, 0.06 M) was added triethylamine (10 mL) and the reaction mixture was stirred for 2 hours. The mixture was concentrated *in vacuo* and the residue was purified by silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane) to give **#66** (347 mg, 85%) as a colorless solid. HPLC (Protocol A at 45 °C): *m/z* 674.5 [M+H⁺], retention time = 7.015 minutes. ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [8.03 (br d, *J*=9 Hz) and 8.05 (br d, *J*=9 Hz), total 1H], [7.77 (br dd, *J*=5.5, 5.5 Hz) and 7.98 (br dd, *J*=5.5, 5.5 Hz), total 1H], 6.54-6.65 (m, 2H), 6.10-6.19 (m, 2H), 5.11-5.19 (m, 2H), [4.48 (dd, *J*=9, 8 Hz) and 4.54 (dd, *J*=9, 7.5 Hz), total 1H], 3.94-4.04 (br m, 1H), 3.26 and 3.29 (2 s, total 3H), 3.17 and 3.19 (2 s, total 3H), 2.93 and 3.06 (2 br s, total 3H), 1.20 and 1.21 (2 s, total 3H), 1.12 and 1.13 (2 s, total 3H), [1.04 (d, *J*=6.8 Hz) and 1.07 (d, *J*=6.7 Hz), total 3H].

Preparation of 2-Methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#69**) and 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#70**)

[0451]



[0452] Step 1. Synthesis of methyl *N*-[(2*R*,3*R*)-3-methoxy-2-methyl-3-[(2*S*)-pyrrolidin-2-yl]propanoyl]-*L*-phenylalaninate, hydrochloride salt (**#67**). According to general procedure C, from **#37** (2.39 g, 5.33 mmol, 1 eq.), dioxane (10 mL, 0.53 M) and a 4 M hydrochloric acid solution in dioxane (10 mL, 40 mmol, 7.5 eq.) was synthesized **#67** (2.21 g) as a white solid, which was used in the next step without further purification. LC-MS: *m/z* 349.2 [M+H⁺], retention time = 0.53 minutes; ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.45-9.58 (br m, 1H), 8.63 (d, *J*=8.1 Hz, 1H), 8.51-8.62 (br m, 1H), 7.25-7.33 (m, 4H), 7.18-7.25 (m, 1H), 4.50 (ddd, *J*=10.8, 8.1, 4.5 Hz, 1H), 3.65 (s, 3H), 3.54 (dd, *J*=6.8, 4.5 Hz, 1H), 3.20 (s, 3H), 3.11 (dd, *J*=13.8, 4.5 Hz, 1H), 2.99-3.14 (br m, 3H), 2.89 (dd, *J*=13.8, 10.9 Hz, 1H), 2.44-2.50 (m, 1H, assumed; partially obscured by solvent peak), 1.77-1.89 (m, 1H), 1.60-1.73 (m, 2H), 1.46-1.57 (m, 1H), 1.05 (d, *J*=6.8 Hz, 3H).


[0453] Step 2. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide (**#68**). According to general procedure D, from **#32** (353 mg, 0.488 mmol, 1 eq.) in dichloromethane (10 mL, 0.04 M), amine **#67** (271 mg, <0.588 mmol, 1.3 eq.), HATU (223 mg, 0.586 mmol, 1.2 eq.) and diisopropylethylamine (238 μL, 1.71 mmol, 3.5 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 40% acetone in heptane), affording **#68** (404 mg, 88% over two steps) as a solid. LC-MS: *m/z* 940.7 [M+H⁺], 962.7 [M+Na⁺], retention time = 1.04 minutes; HPLC (Protocol C): retention time = 9.022 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [8.25 (br d, *J*=8 Hz) and 8.48 (br d, *J*=8 Hz), total 1H], 7.89 (d, *J*=7.4 Hz, 2H), 7.67-7.75 (m, 2H), 7.38-7.44 (m, 2H), 7.31-7.36 (m, 2H), 7.14-7.24 (m, 5H), 4.43-4.69 (m, 3H), 4.17-4.26 (m, 3H), 3.91-3.99 (br m, 1H), 3.63 and 3.65 (2 s, total 3H), 3.19 and 3.24 (2 s, total 3H), 3.14 and 3.15 (2 s, total 3H), 2.90 and 2.99 (2 br s, total 3H), 1.36 and 1.37 (2 br s, total 3H), 1.30 and 1.32 (2 s, total 3H), [1.02 (d, *J*=6.8 Hz) and 1.06 (d, *J*=6.6 Hz), total 3H].

[0454] Step 3A. Synthesis of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide, trifluoroacetic acid salt (**#69**). To a solution of **#68** (143 mg, 0.152 mmol, 1 eq.) in tetrahydrofuran (5 mL, 0.02 M) was added a solution of lithium hydroxide (9.10 mg, 0.378 mmol, 2.5 eq.) in water (3 mL). After 5 hours, the reaction was concentrated *in vacuo*, azeotroped three times with heptane, dissolved in dimethyl sulfoxide (2.2 mL) and purified by reverse phase chromatography (Method C) to give **#69** (56 mg, 52%). HPLC (Protocol A at 45 °C): 704.4 [M+H⁺], retention time = 6.623 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 8.08-8.22 and 8.37-8.49 (2 m, total 5H), 7.12-7.28 (m, 5H), 3.18, 3.20 and 3.24 (3 s, total 6H), 2.95 and 3.04 (2 br s, total 3H), 1.52 and 1.53 (2 s, total 3H), 1.39 and 1.41 (2 s, total 3H), [1.02 (d, *J*=6.8 Hz) and 1.05 (d, *J*=6.6 Hz), total 3H], 0.74-0.81 (m, 3H).

[0455] Step 3B. Synthesis of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide (**#70**). According to general procedure A, from **#68** (240 mg, 0.255 mmol, 1 eq.), dichloromethane (10 mL, 0.026 M) and diethylamine (10 mL) was synthesized **#70** (120 mg, 65%) as a white solid/glass mix after silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane). HPLC (Protocol A at 45 °C): *m/z* 762.7 [M+H⁺], 740.4 [M+Na⁺], retention time = 6.903 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [8.26 (d, *J*=8.1 Hz) and 8.49 (d, *J*=8.3 Hz), total 1H], [8.03 (d, *J*=9.5 Hz) and 8.07 (d, *J*=9.5 Hz), total 1H], 7.14-7.27 (m, 5H), 3.63 and 3.67 (2 s, total 3H), 3.16, 3.18, 3.20 and 3.25 (4 s, total 6H), 2.92 and 3.01 (2 br s, total 3H), 1.20 and 1.22 (2 s, total 3H), 1.12 and 1.13 (2 s, total 3H), [1.02 (d, *J*=6.8 Hz) and 1.06 (d, *J*=6.7 Hz), total 3H], 0.74-0.80 (m, 3H).

Preparation of N²-[(3-Aminooxetan-3-yl)carbonyl]-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-*L*-valinamide, acetic acid salt (#75**)**

[0456]



[0457] Step 1. Synthesis of 3-[(*tert*-butoxycarbonyl)amino]oxetane-3-carboxylic acid (**#71**). To 1-amino-3-oxetane-3-carboxylic acid (1.00 g, 8.54 mmol, 1 eq.) in dioxane (15 mL, 0.5 M) was added a solution of sodium hydroxide (1.55 g, 38.7 mmol, 4.5 eq.) in water (15 mL) followed by di-*tert*-butyl dicarbonate (2.09 g, 9.29 mmol, 1.1 eq.). A white solid formed. The reaction was stirred for 18 hours and then concentrated *in vacuo*. The residue was taken up in ethyl acetate and washed with 1 M aqueous hydrochloric acid solution and with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo* to give **#71** (633 mg, 38%) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$), presumed to be a mixture of rotamers: δ 12.93 (br s, 1H), 7.59 and 7.93 (2 br s, total 1H), 4.71-4.78 (m, 2H), 4.47 (d, $J=6.4$ Hz, 2H), 1.30 and 1.38 (2 s, total 9H).

[0458] Step 2. Synthesis of N^2 -[(9H-fluoren-9-ylmethoxy)carbonyl]- N -[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (**#72**). To **#5** (9.47 g, 18.0 mmol, 1 eq.) and **#24** (5.90 g, 18.0 mmol, 1 eq.) in dichloromethane (250 mL, 0.072 M) were added diisopropylethylamine (9.52 mL, 54.2 mmol, 3 eq.) and HATU (8.49 g, 21.7 mmol, 1.2 eq.). The reaction was stirred for 18 hours and then concentrated *in vacuo*. The residue was taken up in ethyl acetate (300 mL) and was washed with 1 M aqueous hydrochloric acid solution (2 x 100 mL) and with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was taken up in dichloromethane (250 mL) and filtered. The filtrate was concentrated *in vacuo* onto silica and purified by silica gel chromatography (Gradient: 0% to 50% acetone in heptane) to provide **#72** (11.61 g, 81%) as a light yellow solid. LC-MS: m/z 797.6 [$\text{M}+\text{H}^+$], 819.6 [$\text{M}+\text{Na}^+$], retention time = 1.06 minutes; ^1H NMR (400 MHz, $\text{DMSO}-d_6$), presumed to be a mixture of rotamers, characteristic signals: δ 3.26 and 3.28 (2 s, total 3H), 3.18 and 3.20 (2 s, total 3H), 2.95 and 3.10 (2 br s, total 3H), 1.01-1.09 (m, 3H), 0.67-0.78 (m, 3H).

[0459] Step 3. Synthesis of N -[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (**#73**). To **#72** (5.16 g, 6.47 mmol, 1 eq.) in tetrahydrofuran (10 mL, 0.65 M) was added diethylamine (10 mL). After 2 hours, the reaction was concentrated *in vacuo* and the residue was purified by silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane) to give **#73** (2414 mg, 65%). LC-MS: m/z 576.5 [$\text{M}+\text{H}^+$], retention time = 0.64 minutes; ^1H NMR (400 MHz, $\text{DMSO}-d_6$), presumed to be a mixture of rotamers, characteristic signals: δ 7.80-7.88 and 7.99-8.10 (2 m, total 1H), 7.14-7.31 (m, 5H), 3.17 and 3.18 (2 s, total 3H), 2.87 and 3.03 (2 br s, total 3H), 1.02-1.08 (m, 3H).


[0460] Step 4. Synthesis of N^2 -[(3-[(*tert*-butoxycarbonyl)amino]oxetan-3-yl)carbonyl]- N -[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (**#74**). To **#73** (100 mg, 0.174 mmol, 1 eq.) in dichloromethane (4 mL, 0.04 M) and N,N -dimethylformamide (0.5 mL) was added **#71** (45.2 mg, 0.208 mmol, 1.2 eq.), followed by diisopropylethylamine (92 μL , 0.521 mmol, 3 eq.) and HATU (102 mg, 0.260 mmol, 1.5 eq.). After 16 hours, the reaction was concentrated *in vacuo* and the residue was taken up in ethyl acetate (6 mL) and washed with 1 M aqueous hydrochloric acid solution (2 x 2 mL) and with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by reverse phase chromatography (Method C) to give **#74** (140 mg), which was used in the next step without further purification. LC-MS: m/z 774.7 [$\text{M}+\text{H}^+$], 796.6 [$\text{M}+\text{Na}^+$], retention time = 0.91 minute.

[0461] Step 5. Synthesis of N^2 -[(3-aminooxetan-3-yl)carbonyl]- N -[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-meth-

oxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, acetic acid salt (**#75**). To **#74** (140 mg, ≤ 0.181 mmol, 1 eq.) in dichloromethane (3 mL, 0.06 M) was added trifluoroacetic acid (1 mL). After 1 hour, the reaction was concentrated *in vacuo* and the residue was taken up in ethyl acetate (6 mL) and washed with saturated aqueous sodium bicarbonate solution (2 mL) and with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. Half of the crude material was purified by reverse phase chromatography (Method B) to give **#75** (16 mg, 26%, over two steps). LC-MS: m/z 674.6 $[M+H]^+$, retention time = 0.68 minutes; HPLC (Protocol A at 45 °C): m/z 674.5 $[M+H]^+$, retention time = 7.128 minutes; ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ 7.80-7.87 and 8.02-8.07 (2 m, total 2H), 7.23-7.30 (m, 2H), 7.14-7.22 (m, 3H), 4.28-4.33 (m, 2H), 3.96-4.04 (br m, 1H), 3.17 and 3.19 (2 s, total 3H), 2.96 and 3.10 (2 br s, total 3H), [1.04 (d, $J=7.0$ Hz) and 1.07 (d, $J=6.6$ Hz), total 3H].

Preparation of N,2-Dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#79**) and N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#80**)**

[0462]



[0463] Step 1. Synthesis of methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[N-[(9H-fluoren-9-ylmethoxy) carbonyl]-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanethiyl]-L-phenylalaninate (**#76**). According to general procedure D, from **#5** (260 mg, 0.648 mmol, 1 eq.), **#39** (340 mg, <0.629 mmol, 1 eq.), dichloromethane (10 mL, 0.065 M), HATU (296 mg, 0.778 mmol, 1.2 eq.) and diisopropylethylamine (339 μ L, 1.94 mmol, 3 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 40% acetone in heptane) to give **#76** (466 mg, 83% over two steps) as a solid. LC-MS: m/z 871.5 $[M+H]^+$, 893.5 $[M+Na]^+$, retention time = 1.10 minutes; HPLC (Protocol C): retention time = 9.249 minutes (purity > 99%); ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ [10.19 (br d, $J=7.4$ Hz) and 10.49 (br d, $J=7.8$ Hz), total 1H], 7.89 (br d, $J=7.4$ Hz, 2H), 7.68-7.75 (m, 2H), 7.54-7.60 (m, 1H), 7.41 (br dd, $J=7.4$, 7.4 Hz, 2H), 7.28-7.36 (m, 2H), 7.15-7.28 (m, 5H), [5.20 (ddd, $J=10.9$, 7.3, 4.4 Hz) and 5.34-5.43 (m), total 1H], 3.65 and 3.69 (2 s, total 3H), 3.24 and 3.25 (2 s, total 3H), 3.17 (br s, 3H), 2.93 and 2.98 (2 br s, total 3H), [1.15 (d, $J=6.6$ Hz) and 1.18 (d, $J=6.6$ Hz), total 3H].

[0464] Step 2. Synthesis of methyl N-[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(L-valyl)amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanethiyl]-L-phenylalaninate (**#77**). According to general procedure A, from **#76** (460 mg, 0.528 mmol, 1 eq.) tetrahydrofuran (8 mL, 0.07 M) and diethylamine (8 mL) was synthesized **#77** (399 mg), which was used in the next step without further purification; LC-MS m/z 649.5 $[M+H]^+$, retention time = 0.73 minutes; ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic product signals: δ [10.20 (d, $J=7.4$ Hz) and 10.49 (d, $J=7.4$ Hz), total 1H], 7.15-7.28 (m, 5H), [5.20 (ddd, $J=10.9$, 7.2, 4.5 Hz) and 5.34-5.42 (m), total 1H], 3.65 and 3.68 (2 s, total 3H), 3.24 and 3.25 (2 s, total 3H), 3.15 and 3.15 (2 s, total 3H), 2.83 and 2.88 (2 br s, total 3H), [1.15 (d, $J=6.6$ Hz) and 1.18 (d, $J=6.6$ Hz), total 3H].


[0465] Step 3. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*,2-dimethylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#78**). According to general procedure D, from **#77** (399 mg, <0.52 mmol, 1 eq.), *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*,2-dimethylalanine (213 mg, 0.628 mmol, 1.2 eq.), dichloromethane (5 mL, 0.1 M), HATU (239 mg, 0.628 mmol, 1.2 eq.) and diisopropylethylamine (282 μ L, 1.62 mmol, 3.1 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 50% acetone in heptane), providing **#78** (231 mg, 46% over two steps). LC-MS: m/z 970.7 [M+H⁺], 992.6 [M+Na⁺], retention time = 1.11 minutes; HPLC (Protocol C): retention time = 9.260 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.19 (d, *J*=7.4 Hz) and 10.47 (d, *J*=7.8 Hz), total 1H], 7.89 (d, *J*=7.4 Hz, 2H), 7.61-7.67 (m, 2H), 7.41 (br dd, *J*=7.4, 7.4 Hz, 2H), 7.14-7.36 (m, 8H), [5.20 (ddd, *J*=11, 7, 5 Hz) and 5.38 (ddd, *J*=11, 8, 4 Hz), total 1H], [4.41 (dd, *J*=8.6, 8.4 Hz) and 4.46 (dd, *J*=8.2, 8.2 Hz), total 1H], 3.65 and 3.68 (2 s, total 3H), 3.23 and 3.24 (2 s, total 3H), 3.13 (br s, 3H), 2.88 and 2.93 (2 br s, total 3H), 2.84 and 2.85 (2 s, total 3H), 1.31 and 1.32 (2 s, total 3H), [1.15 (d, *J*=6.6 Hz) and 1.18 (d, *J*=6.4 Hz), total 3H].

[0466] Step 4A. Synthesis of *N*,2-dimethylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-3-[(2*S*)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#79**). According to general procedure A, from **#78** (223 mg, 0.230 mmol, 1 eq.), dichloromethane (6 mL, 0.04 M) and diethylamine (6 mL) was synthesized **#79** (146 mg, 85%) as a white solid after silica gel chromatography (Gradient: 0% to 5% methanol in heptane then 0% to 10% methanol in dichloromethane). HPLC (Protocol A at 45 °C): 749.4 [M+H⁺], retention time = 7.315 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.20 (d, *J*=7.6 Hz) and 10.50 (d, *J*=8.0 Hz), total 1H], 7.79-7.88 (m, 1H), 7.15-7.29 (m, 5H), [5.20 (ddd, *J*=11, 7, 4 Hz) and 5.38 (ddd, *J*=11, 8, 4 Hz), total 1H], [4.50 (dd, *J*=8.8, 8.6 Hz) and 4.56 (dd, *J*=9, 8 Hz), total 1H], 3.65 and 3.69 (2 s, total 3H), 3.24 and 3.25 (2 s, total 3H), 3.16 (br s, 3H), 2.93 and 2.97 (2 br s, total 3H), 2.10 and 2.11 (2 s, total 3H).

[0467] Step 4B. Synthesis of *N*,2-dimethylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, trifluoroacetic acid salt (**#80**). To a solution of **#78** (170 mg, 0.175 mmol, 1 eq.) in tetrahydrofuran (3 mL, 0.04 M) was added a solution of lithium hydroxide (12.6 mg, 0.525 mmol, 3 eq.) in water (1.5 mL). After stirring overnight, the solvent was removed *in vacuo*. The residue was azeotroped three times with heptane. The residue was then diluted with dimethyl sulfoxide (2.2 mL) and purified by reverse phase chromatography (Method C) to afford **#80** (74 mg, 58%) as a solid. LC-MS: m/z 734.6 [M+H⁺], retention time = 0.69 minutes; HPLC (Protocol A at 45 °C): 734.4 [M+H⁺], retention time = 6.903 minutes (purity > 96%); ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ 12.9 and 13.1 (2 v br s, total 1H), [10.12 (d, *J*=7.4 Hz) and 10.46 (d, *J*=7.8 Hz), total 1H], 8.77-8.89 (br m, 2H), [8.47 (d, *J*=8.6 Hz) and 8.51 (d, *J*=8.6 Hz), total 1H], 7.21-7.29 (m, 4H), 7.14-7.21 (m, 1H), [5.16-5.23 (m) and 5.38 (ddd, *J*=11.3, 8.2, 3.9 Hz), total 1H], [4.51 (dd, *J*=9.0, 9.0 Hz) and 4.57 (dd, *J*=9.4, 8.6 Hz), total 1H], 3.24 and 3.24 (2 s, total 3H), 3.18 and 3.19 (2 s, total 3H), 2.96 and 3.00 (2 br s, total 3H), 1.51 and 1.53 (2 s, total 3H), 1.40 and 1.42 (2 s, total 3H), 1.14-1.19 (m, 3H), 0.74-0.81 (m, 3H).

Preparation of *N*,2-Dimethylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (#84**)**

[0468]



[0469] Step 1. Synthesis of *N*²-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#81**). According to general procedure D, from **#5** (620 mg, 1.18 mmol, 1 eq.) dichloromethane (10 mL, 0.1 M), amine **#18** (604 mg, 1.42 mmol, 1.2 eq.), diisopropylethylamine (618 μ L, 3.54 mmol, 3 eq.) and HATU (539 mg, 1.42 mmol, 1.2 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 30% acetone in heptane) to give **#81** (737 mg, 58%). HPLC (Protocol C): retention time = 9.235 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.54 (br d, *J*=8 Hz) and 10.81 (br d, *J*=8 Hz), total 1H], 7.89 (d, *J*=7.6 Hz, 2H), [7.80 (d, *J*=3.3 Hz) and 7.83 (d, *J*=3.1 Hz), total 1H], 7.70-7.75 (m, 2H), [7.64 (d, *J*=3.1 Hz) and 7.68 (d, *J*=3.3 Hz), total 1H], 7.55-7.60 (m, 1H), 7.38-7.44 (m, 2H), 7.13-7.35 (m, 7H), [6.31 (ddd, *J*=11, 8, 4.5 Hz) and 6.40-6.48 (m), total 1H], 3.23 and 3.24 (2 s, total 3H), 3.17 and 3.22 (2 s, total 3H), 2.94 and 3.01 (2 br s, total 3H), [1.14 (d, *J*=6.4 Hz) and 1.17 (d, *J*=6.2 Hz), total 3H].


[0470] Step 2. Synthesis of *N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#82**). According to general procedure A, from **#81** (733 mg, 0.818 mmol, 1 eq.) in dichloromethane (7 mL, 0.1 M) and diethylamine (7 mL) was synthesized **#82** (670 mg), which was used in the next step without further purification. LC-MS: *m/z* 674.5 [M+H⁺], retention time = 1.29 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic product signals: δ [10.55 (br d, *J*=8 Hz) and 10.84 (br d, *J*=8 Hz), total 1H], [7.64 (d, *J*=3.1 Hz) and 7.69 (d, *J*=3.3 Hz), total 1H], 7.13-7.33 (m, 5H), 6.27-6.35 and 6.38-6.47 (2 m, total 1H), 3.23 and 3.25 (2 s, total 3H), 3.15 and 3.19 (2 s, total 3H), 2.84 and 2.91 (2 br s, total 3H).

[0471] Step 3. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*,2-dimethylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#83**). According to general procedure D, from **#82** (670 mg, $\leq$ 0.818 mmol, 1 eq.), dichloromethane (5 mL, 0.16 M), *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-*N*,2-dimethylalanine (304 mg, 0.896 mmol, 1.1 eq.), HATU (372 mg, 0.978 mmol, 1.2 eq.) and diisopropylethylamine (440 μ L, 2.53 mmol, 3.1 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 30% acetone in heptane) to give **#83** (556 mg, 69% over two steps). LC-MS: *m/z* 994.7 [M+H⁺], retention time = 0.69 minutes; HPLC (Protocol C): retention time = 9.333 minutes (purity > 98%); ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.53 (br d, *J*=8 Hz) and 10.80 (br d, *J*=8 Hz), total 1H], 7.86-7.91 (m, 2H), [7.80 (d, *J*=3.3 Hz) and 7.82 (d, *J*=3.2 Hz), total 1H], [7.64 (d, *J*=3.2 Hz) and 7.68 (d, *J*=3.2 Hz), total 1H], 7.62-7.66 (m, 2H), 7.38-7.44 (m, 2H), 7.28-7.36 (m, 5H), 7.19-7.26 (m, 2H), 7.12-7.17 (m, 1H), [6.31 (ddd, *J*=11, 8, 4.5 Hz) and 6.44 (ddd, *J*=11, 8.5, 4.5 Hz), total 1H], [4.42 (dd, *J*=9, 8 Hz) and 4.48 (dd, *J*=8, 8 Hz), total 1H], 3.22 and 3.24 (2 s, total 3H), 3.13 and 3.17 (2 s, total 3H), 2.89 and 2.97 (2 br s, total 3H), 2.84 and 2.85 (2 s, total 3H), [1.13 (d, *J*=6.4 Hz) and 1.16 (d, *J*=6.4 Hz), total 3H].

[0472] Step 4. Synthesis of *N*,2-dimethylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#84**). According to general procedure A, from **#83** (552 mg, 0.555 mmol, 1 eq.) in dichloromethane (10 mL, 0.05 M) and diethylamine (10 mL) was synthesized the crude desired material, which was diluted with methanol, concentrated *in vacuo* onto silica, and purified by silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane) to give **#84** (406 mg, 95%) as a white solid. LC-MS: *m/z* 772.8 [M+H⁺], retention time = 1.35 minutes; HPLC (Protocol A): 774.4 [M+H⁺], retention time = 7.390 minutes; ¹H NMR (400 MHz, DMSO-*d*₆), presumed to be a mixture of rotamers, characteristic signals: δ [10.54 (br d, *J*=8 Hz) and 10.81 (br d, *J*=8 Hz), total 1H], 7.78-7.84 (m, 2H), [7.65 (d, *J*=3.1 Hz) and 7.69 (d, *J*=3.3 Hz), total 1H], 7.29-7.34 (m, 2H), 7.20-7.28 (m, 2H), 7.14-7.19 (m, 1H), 6.27-6.35 and 6.40-6.48 (2 m, total 1H), [4.51 (dd, *J*=9, 8 Hz) and 4.57 (dd, *J*=9, 8 Hz), total 1H], 3.24 and 3.25 (2 s, total 3H), 3.16 and 3.21 (2 s, total 3H), 2.94 and 3.00 (2 br s, total 3H), 2.09 and 2.10 (2 s, total 3H), 1.08 and 1.09 (2 s, total 3H), 0.73-0.80 (m, 3H).

N,2-Dimethylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-1-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[[[(1*S*)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (#88**)**

[0473]



[0474] Step 1. Synthesis of N^2 -[(9H-fluoren-9-ylmethoxy)carbonyl]- N -[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino} propyl] pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (**#85**). To a mixture of **#5** (5.48 g, 10.4 mmol, 1 eq.) and **#19** (3.90 g, 10.4 mmol, 1 eq.) in dichloromethane (50 mL, 0.2M) was added diisopropylethylamine (5.51 mL, 31.3 mmol, 3 eq.) followed by HATU (4.91 g, 12.5 mmol, 1.2 eq.). After stirring overnight, the reaction mixture was concentrated *in vacuo*. The residue was taken up in ethyl acetate (100 mL) and washed with 1 M aqueous hydrochloric acid solution (2 x 30 mL) and with brine (30 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was taken up in dichloromethane and filtered; the filtrate was purified by silica gel chromatography (Gradient: 0% to 50% acetone in heptane) to afford **#85** (7.20 g, 78%) as a solid. LC-MS: m/z 880.6 $[\text{M}+\text{H}^+]$, retention time = 1.07 minutes.

[0475] Step 2. Synthesis of N -[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino} propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (**#86**). According to general procedure A, from **#85** (5.00 g, 5.68 mmol, 1 eq.) in tetrahydrofuran (10 mL, 0.56 M) and diethylamine (3 mL) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0% to 10% methanol in dichloromethane) to give **#86** (2.952 g, 79%) as a solid. LC-MS: m/z 658.5 $[\text{M}+\text{H}^+]$, 680.5 $[\text{M}+\text{Na}^+]$ retention time = 0.66 minute; ^1H NMR (400 MHz, $\text{DMSO}-d_6$), presumed to be a mixture of rotamers, characteristic signals: δ [8.64 (br d, $J=8.4$ Hz) and 8.90 (br d, $J=8.8$ Hz), total 1H], [7.77 (d, $J=3.3$ Hz) and 7.80 (d, $J=3.3$ Hz), total 1H], [7.63 (d, $J=3.3$ Hz) and 7.66 (d, $J=3.3$ Hz), total 1H], 7.12-7.31 (m, 5H), [5.39 (ddd, $J=11.2, 8.4, 4.2$ Hz) and 5.54 (ddd, $J=11.9, 8.9, 4.0$ Hz), total 1H], 3.15, 3.19, 3.20 and 3.26 (4 s, total 6H), 2.86 and 2.98 (2 br s, total 3H), [1.06 (d, $J=6.6$ Hz) and 1.11 (d, $J=6.6$ Hz), total 3H].


[0476] Step 3. Synthesis of N -(*tert*-butoxycarbonyl)- N ,2-dimethylalanyl- N -[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino} propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (**#87**). To a mixture of **#86** (80.3 mg, 0.122 mmol, 1 eq.) in dichloromethane (4 mL, 0.03 M) was added N -(*tert*-butoxycarbonyl)- N ,2-dimethylalanine (29.1 mg, 0.134 mmol, 1.1 eq.) followed by diisopropylethylamine (64 μL , 0.365 mmol, 3 eq.) and HATU (71.7 mg, 0.183 mmol, 1.5 eq.). After stirring overnight, the reaction mixture was concentrated *in vacuo*. The residue was taken up in ethyl acetate (6 mL) and washed with 1 M aqueous hydrochloric acid solution (2 x 2 mL) and with brine. The organic solvent was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was taken up in dichloromethane and filtered; the filtrate was concentrated *in vacuo* onto silica and purified by silica gel chromatography (Gradient: 0% to 50% acetone in heptane) to afford **#87** (58 mg, 50%) as a white solid. LC-MS: m/z 857.7 $[\text{M}+\text{H}^+]$, 879.7 $[\text{M}+\text{Na}^+]$, retention time = 0.99 minute; ^1H NMR (400 MHz, $\text{DMSO}-d_6$), presumed to be a mixture of rotamers, characteristic signals: δ [8.64 (br d, $J=8$ Hz) and 8.87 (br d, $J=9$ Hz), total 1H], [7.77 (d, $J=3.3$ Hz) and 7.80 (d, $J=3.3$ Hz), total 1H], [7.63 (d, $J=3.2$ Hz) and 7.66 (d, $J=3.2$ Hz), total 1H], 7.13-7.31 (m, 5H), [6.95 (br d, $J=8$ Hz) and 7.06 (br d, $J=8$ Hz), total 1H], 5.35-5.42 and 5.51-5.58 (2 m, total 1H), 3.15, 3.19, 3.20 and 3.26 (4 s, total 6H), 2.94 and 3.03 (2 br s, total 3H), 2.83 and 2.84 (2 s, total 3H), [1.05 (d, $J=6.7$ Hz) and 1.11 (d, $J=6.7$ Hz), total 3H].

[0477] Step 4. Synthesis of N ,2-dimethylalanyl- N -[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino} propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (**#88**). To a mixture of **#87** (58 mg, 0.068 mmol, 1 eq.) in dichloromethane (8 mL) was added trifluoroacetic acid (2 mL). After stirring overnight, the reaction mixture was concentrated *in vacuo*. The residue was taken up in ethyl acetate (10 mL), washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered, and concentrated *in vacuo* to give **#88** (52 mg, quantitative). LC-MS 757.6 $[\text{M}+\text{H}^+]$, retention time = 0.69 minute; ^1H NMR (400 MHz, $\text{DMSO}-d_6$), presumed to be a mixture of rotamers, characteristic signals: δ [8.64 (br d, $J=8.6$ Hz) and 8.87 (br d, $J=8.6$ Hz), total 1H], 7.80-7.85 (m, 1H), [7.77 (d, $J=3.3$ Hz) and 7.80 (d, $J=3.1$ Hz), total 1H], [7.63 (d, $J=3.1$ Hz) and 7.66 (d, $J=3.3$ Hz), total 1H], 7.20-7.31 (m, 4H), 7.13-7.19 (m, 1H), [5.39 (ddd, $J=11, 8.5, 4$ Hz) and 5.49-5.56 (m),

total 1H], [4.51 (dd, $J=9$, 8 Hz) and 4.61 (dd, $J=9$, 8 Hz), total 1H], 3.16, 3.20, 3.21 and 3.25 (4 s, total 6H), 2.94 and 3.03 (2 br s, total 3H), 2.10 and 2.10 (2 s, total 3H), 1.16 (br s, 3H), 1.04-1.12 (m, 6H), 0.72-0.80 (m, 3H).

Reference Example Preparation of N^2 -(3-Amino-2,2-dimethylpropanoyl)- N -[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide, trifluoroacetic acid salt (#95)

[0478]




[0479] Step 1. Synthesis of 3-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2,2-dimethylpropanoic acid (**#93**). To 3-amino-2,2-dimethylpropanoic acid, hydrochloride salt (250 mg, 1.63 mmol, 1 eq.) in dichloromethane (4 mL, 0.4 M) was added diisopropylethylamine (859 μ L, 4.88 mmol, 3 eq.) followed by (9H-fluoren-9-ylmethoxy)carbonyl chloride (473 mg, 1.79 mmol, 1.1 eq.). The reaction was stirred for 18 hours and then concentrated *in vacuo*. The residue was taken up in ethyl acetate (3 mL) and washed with 1 M aqueous hydrochloric acid solution (2 x 1 mL) and with brine. The organic layer was dried over sodium sulfate, filtered, and purified by silica gel chromatography (Gradient: 0% to 100% ethyl acetate in heptane) to give **#93** (250 mg, 45%) as an oil. ^1H NMR (400 MHz, DMSO- d_6) δ 12.22 (s, 1H), 7.89 (d, $J=7.4$ Hz, 2H), 7.72 (d, $J=7.4$ Hz, 2H), 7.38-7.44 (m, 2H), 7.27-7.35 (m, 3H), 4.18-4.30 (m, 3H), 3.16 (d, $J=6.2$ Hz, 2H), 1.05 (s, 6H).

[0480] Step 2. Synthesis of N^2 -(3-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2,2-dimethylpropanoyl]- N -[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (**#94**). To **#86** (100 mg, 0.152 mmol, 1 eq.) in dichloromethane (4 mL, 0.038 M) and N,N -dimethylformamide (0.5 mL) was added **#93** (51.6 mg, 0.152 mmol, 1 eq.) followed by diisopropylethylamine (80.0 μ L, 0.457 mmol, 3 eq.) and HATU (89.8 mg, 0.229 mmol, 1.5 eq.). The reaction was stirred for 18 hours and then concentrated *in vacuo*. The residue was taken up in ethyl acetate (6 mL) and was washed with 1 M aqueous hydrochloric acid solution (2 x 2 mL) and with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was taken up in dichloromethane (250 mL) and filtered; the filtrate was concentrated *in vacuo* onto silica and purified by silica gel chromatography (Gradient: 0% to 50% acetone in heptane) to provide **#94** (90 mg, 60%) as a white solid. LC-MS: m/z 979.8 [$\text{M}+\text{H}^+$], 1002.7 [$\text{M}+\text{Na}^+$], retention time = 1.15 minutes; ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic product signals: δ [8.64 (br d, $J=8.6$ Hz) and 8.86 (br d, $J=8.6$ Hz), total 1H], 7.86-7.91 (m, 2H), [7.77 (d, $J=3.3$ Hz) and 7.79 (d, $J=3.3$ Hz), total 1H], 7.67-7.73 (m, 2H), [7.63 (d, $J=3.3$ Hz) and 7.65 (d, $J=3.3$ Hz), total 1H], 6.87-6.95 (m, 1H), [5.39 (ddd, $J=11$, 8, 4 Hz) and 5.52 (ddd, $J=11.5$, 9, 4 Hz), total 1H], [4.44 (dd, $J=8.4$, 8.4 Hz) and 4.55 (dd, $J=8.4$, 8.4 Hz), total 1H], 3.16, 3.20, 3.21 and 3.25 (4 s, total 6H), 2.96 and 3.06 (2 br s, total 3H), 0.69-0.77 (m, 3H).

[0481] Step 3. Synthesis of N^2 -(3-amino-2,2-dimethylpropanoyl)- N -[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide, trifluoroacetic acid salt (**#95**). To **#94** (86 mg, 0.088 mmol, 1 eq.) in tetrahydrofuran (2 mL, 0.04 M) was added diethylamine (10 mL). After stirring overnight, the reaction was concentrated *in vacuo* and the residue was purified by reverse phase chromatography (Method C) to give **#95** (55 mg, 72%). LC-MS: m/z 757.5 [$\text{M}+\text{H}^+$], retention time = 0.74 minutes; ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ [8.66 (br d, $J=8$ Hz) and 8.92 (br d, $J=9$ Hz), total 1H], [7.91 (br d, $J=8$ Hz) and 7.97 (br d, $J=9$ Hz), total 1H], [7.78 (d, $J=3.3$ Hz) and 7.81 (d, $J=3.1$ Hz), total 1H], 7.65-7.74 (br m, 3H), [7.63 (d, $J=3.3$ Hz) and 7.67 (d, $J=3.3$ Hz), total 1H], 7.12-7.31 (m, 5H), [5.35-5.42 (m) and 5.45-5.52 (m), total 1H], [4.44 (dd, $J=9$, 9 Hz) and 4.55 (dd, $J=9$, 9 Hz), total 1H], 3.17, 3.20, 3.22 and 3.25 (4 s, total 6H), 2.96 and 3.05 (2 br s, total 3H), 1.25 and 1.25 (2 s, total 3H), 1.14 and 1.15 (2 s, total 3H), [1.06 (d, $J=6.6$ Hz) and 1.10 (d, $J=6.4$ Hz), total 3H], 0.72-0.80 (m, 3H).

Reference Example Preparation of N^2 -(3-Amino-2,2-dimethylpropanoyl)- N -{[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide, trifluoroacetic acid salt (#97)}

[0482]



[0483] Step 1. Synthesis of N^2 -(3-[[[9H-fluoren-9-ylmethoxy]carbonyl]amino]-2,2-dimethylpropanoyl)- N -{[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide (#96). To #73 (100 mg, 0.174 mmol, 1 eq.) in dichloromethane (4 mL, 0.04 M) and N,N -dimethylformamide (0.5 mL) was added #93 (59.1 mg, 0.174 mmol, 1 eq.), followed by diisopropylethylamine (92 μ L, 0.52 mmol, 3 eq.) and HATU (102 mg, 0.260 mmol, 1.5 eq.). The reaction was stirred for 18 hours and then concentrated *in vacuo*. The residue was taken up in ethyl acetate (6 mL) and was washed with 1 M aqueous hydrochloric acid solution (2 x 2 mL) and with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. Purification by silica gel chromatography (Gradient: 0% to 50% acetone in heptane) provided #96 (102 mg, 65%) as a white solid. LC-MS: m/z 896.7 [$M+H^+$], 918.8 [$M+Na^+$], retention time = 1.14 minutes; ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic product signals: δ 7.88 (d, $J=7.4$ Hz, 2H), [7.83 (br dd, $J=6, 5$ Hz) and 8.03 (br dd, $J=6, 5$ Hz), total 1H], 7.67-7.73 (m, 2H), 7.36-7.48 (m, 3H), 7.22-7.35 (m, 4H), 7.13-7.21 (m, 3H), 6.86-6.96 (m, 1H), [4.44 (dd, $J=8.6, 8.6$ Hz) and 4.50 (dd, $J=8.6, 8.6$ Hz), total 1H], 3.18, 3.19, 3.26 and 3.29 (4 s, total 6H), 2.96 and 3.11 (2 br s, total 3H), 0.70-0.77 (m, 3H).

[0484] Step 2. Synthesis of N^2 -(3-amino-2,2-dimethylpropanoyl)- N -{[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide, trifluoroacetic acid salt (#97). To #96 (98 mg, 0.11 mmol, 1 eq.) in tetrahydrofuran (2 mL, 0.04 M) was added diethylamine (0.5 mL). After stirring overnight, the reaction was concentrated *in vacuo* and the residue was purified by reverse phase chromatography (Method C) to give #97 (58 mg, 68%). LC-MS: m/z 674.4 [$M+H^+$], 696.4 [$M+Na^+$], retention time = 0.74 minutes; HPLC (Protocol A): 674.5 [$M+H^+$], retention time = 7.072 minutes; ^1H NMR (400 MHz, DMSO- d_6), presumed to be a mixture of rotamers, characteristic signals: δ [7.92 (br d, $J=8$ Hz) and 7.97 (br d, $J=8$ Hz), total 1H], [7.86 (br dd, $J=6, 5$ Hz) and 8.07 (br dd, $J=6, 5$ Hz), total 1H], 7.64-7.74 (br m, 3H), 7.15-7.29 (m, 5H), [4.44 (dd, $J=9, 9$ Hz) and 4.50 (dd, $J=9, 9$ Hz), total 1H], 3.26 and 3.29 (2 s, total 3H), 3.18 and 3.20 (2 s, total 3H), 2.96 and 3.10 (2 br s, total 3H), 1.24 and 1.25 (2 s, total 3H), 1.14 and 1.16 (2 s, total 3H), 1.02-1.07 (m, 3H), 0.73-0.80 (m, 3H).

Preparation of 2-methyl-L-prolyl- N -{[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]- N -methyl-L-valinamide, trifluoroacetic acid salt (#98)}

[0485]



15

25

30



45

55


give **#100** (600 mg, 17% over two steps) as a single enantiomer (retention time = 3.37 minutes, purity >99%). LC-MS: m/z 220.3 $[M+H]^+$, retention time = 2.10 minutes; ^1H NMR (400 MHz, CD_3OD) δ 7.14-7.24 (m, 2H), 7.03-7.09 (m, 2H), 4.59 (d, $J=8.6$ Hz, 1H), 3.87 (ddd, $J=8.5, 5.3, 2.4$ Hz, 1H), 3.35 (dd, $J=14.5, 5.4$ Hz, 1H, assumed; partially obscured by solvent peak), 3.10 (dd, $J=14.4, 2.4$ Hz, 1H), 2.00 (s, 3H). Optical rotation: $[\alpha]_D^{25} +70.9^\circ$ (c 0.67, methanol)

[0490] Step 3. Synthesis of amino(bicyclo[4.2.0]octa-1,3,5-trien-7-yl)acetic acid, hydrochloride salt (**#101**). A mixture of **#100** (200 mg, 0.912 mmol, 1 eq.) and 6 N aqueous hydrochloric acid (12.3 mL, 73.8 mmol, 81 eq.) was heated at reflux overnight. The reaction mixture was concentrated *in vacuo* to give the single enantiomer **#101** (195 mg) as an off-yellow solid, which was used in the next step without further purification.

[0491] Step 4. Synthesis of methyl amino(bicyclo[4.2.0]octa-1,3,5-trien-7-yl)acetate, hydrochloride salt (**#102**). To a mixture of **#101** (195 mg, <0.913 mmol, 1 eq.) in methanol (20 mL, 0.04 M) was added thionyl chloride (0.666 mL, 9.13 mmol, 10 eq.). After two hours at reflux, the reaction mixture was concentrated *in vacuo* to give the single enantiomer **#102** (175 mg, 84% over two steps) as a light-colored solid. LC-MS: m/z 192.3 $[M+H]^+$, retention time = 0.80 minutes; GC-MS: m/z 192 $[M+H]^+$, retention time = 3.206 minutes; ^1H NMR (400 MHz, CD_3OD) δ 7.24-7.33 (m, 2H), 7.11-7.18 (m, 2H), 4.40 (d, $J=6.9$ Hz, 1H), 3.99-4.05 (m, 1H), 3.78 (s, 3H), 3.46 (dd, $J=14.8, 5.4$ Hz, 1H), 3.23 (dd, $J=14.8, 2.5$ Hz, 1H).

Preparation of (2R,3R)-3-Methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanoic acid, hydrochloride salt (**#103**)


[0492]



[0493] To a mixture of **#11** (4.09 g, 14.2 mmol, 1 eq.) in cyclopentyl methyl ether (10 mL, 0.14 M) was added a 4 N solution of hydrogen chloride in dioxane (37 mL, 100 mmol, 7 eq.). After three hours, the reaction mixture was concentrated *in vacuo* and azeotroped three times with heptane to give **#103** (1000 mg, 31%) as a gum, which was used in the next step without further purification. ^1H NMR (400 MHz, $DMSO-d_6$) δ 9.92-10.06 (br s, 1H), 8.66-8.80 (br s, 1H), 3.89 (dd, $J=5.2, 4.9$ Hz, 1H), 3.43-3.53 (m, 1H), 3.39 (s, 3H), 3.06-3.17 (m, 2H), 2.66 (qd, $J=7.1, 4.6$ Hz, 1H), 1.71-2.03 (m, 4H), 1.11 (d, $J=7.1$ Hz, 3H).

Preparation of 2-Methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[1-(bicyclo[4.2.0]octa-1,3,5-trien-7-yl)-2-methoxy-2-oxoethyl] amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#107**) and 2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[bicyclo[4.2.0]octa-1,3,5-trien-7-yl(carboxy)methyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#108**)**

[0494]



[0495] Step 1. Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-3-methoxy-5-methyl-1-oxo-1-(pentafluorophenoxy)heptan-4-yl]-*N*-methyl-L-valinamide (**#104**). To **#32** (4.00 g, 6.56 mmol, 1 eq.) in dichloromethane (20 mL, 0.33 M) and pyridine (1.06 mL, 13.1 mmol, 2 eq.) was added drop-wise pentafluorophenyl trifluoro-

acetate (2.25 mL, 13.1 mmol, 2 eq.). The reaction mixture was stirred for one hour.

[0496] To a second flask containing **#32** (360 mg, 0.59 mmol) in dichloromethane (0.6 mL, 1 M) and pyridine (0.095 mL, 1.2 mmol, 2 eq.) was added drop-wise pentafluorophenyl trifluoroacetate (0.203 mL, 1.18 mmol). This reaction mixture was stirred for 15 minutes.

[0497] The two reaction mixtures were combined, washed twice with 1 N aqueous hydrochloric acid, dried over sodium sulfate, filtered and concentrated *in vacuo*. The resulting yellow oil was dissolved in ethyl acetate, pre-adsorbed onto silica gel and purified by silica gel chromatography (Gradient: 0% to 40% ethyl acetate in heptane) to give **#104** (4.6 g, 83%) as a white foam containing some impurities. LC-MS: *m/z* 798.3 [M+Na⁺], retention time = 1.23 minutes.

[0498] *Step 2.* Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#105**). To a mixture of **#104** (2.00 g, <2.58 mmol, 1 eq.) in dichloromethane (6 mL, 0.4 M) was added a solution of **#103** (483 mg, 2.16 mmol, 1 eq.) in dichloromethane (2 mL) followed by diisopropylethylamine (1.35 mL, 7.73 mmol, 3 eq.). The reaction mixture was stirred for 16 hours, then adsorbed onto silica and purified by silica gel chromatography (Gradient: 0% to 20% methanol in dichloromethane) to give **#105** (1.67 g, 83%) as a white foam. Fractions containing the desired product with impurities (0.571 g) were collected separately.

[0499] The above reaction and purification were repeated in a similar fashion using **#104** (2.60 g, <3.35 mmol, 1 eq.), **#103** (750 mg, 3.35 mmol, 1 eq.), dichloromethane (10 mL, 0.3 M) and diisopropylethylamine (1.35 mL, 7.73 mmol, 2.3 eq.) to give **#105** (2.4 g, 92%) as a tan foam. Fractions containing impure product (1.7 g) were combined with the previous impure fractions and described above to afford additional **#105** (1.30 g, quantitative yield for both reactions over two steps). LC-MS: *m/z* 779.3 [M+H⁺], 802.3 [M+Na⁺], retention time = 1.05 minutes.


[0500] *Step 3.* Synthesis of *N*-[(9*H*-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[[1-(bicyclo[4.2.0]octa-1,3,5-trien-7-yl)-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (**#106**). To a mixture of **#105** (225 mg, 0.289 mmol, 1 eq.) in dichloromethane (15 mL, 0.02 M) and *N,N*-dimethylformamide (1 mL) was added HATU (136 mg, 0.347 mmol, 1.2 eq.). After five minutes, a solution of amine **#102** (72.4 mg, 0.318 mmol, 1 eq.) and diisopropylamine (203 μ L, 1.16 mmol, 3 eq.) in dichloromethane (5 mL) was added. After 24 hours, the reaction mixture was washed with brine, dried over sodium sulfate, filtered, concentrated *in vacuo* onto silica gel, and purified by silica gel chromatography (Gradient: 0% to 50% acetone in heptane) to give the single enantiomer **#106** (210 mg, 76%) as a clear oil. LC-MS: *m/z* 953.1 [M+H⁺], retention time = 3.99 minutes; ¹H NMR (400 MHz, CDCl₃), presumed to be a mixture of rotamers, characteristic signals: 7.76 (d, *J*=7.5 Hz, 2H), 7.57-7.64 (m, 2H), 7.40 (dd, *J*=7.5, 7.4 Hz, 2H), 7.28-7.34 (m, 2H), 4.82-4.88 (m, 1H), 3.95-4.01 (m, 1H), 3.76 and 3.82 (2 s, total 3H), 3.30, 3.31, 3.34 and 3.35 (4 s, total 6H), [1.20 (d, *J*=7.0 Hz) and 1.20 (d, *J*=7.0 Hz), total 3H].

[0501] *Step 4A.* Synthesis of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[[1-(bicyclo[4.2.0]octa-1,3,5-trien-7-yl)-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, trifluoroacetic acid salt (**#107**). According to general procedure A, from **#106** (25 mg, 0.026 mmol, 1 eq.) in dichloromethane (10 mL, 0.003 M) and diethylamine (4 mL) was synthesized the crude desired material, which was purified by reverse phase chromatography (Method C) to give the single enantiomer **#107** (16 mg, 73%) as a solid. LC-MS: *m/z* 730.8 [M+H⁺], retention time = 2.13 minutes; HPLC (Protocol N): retention time = 9.889 minutes.

[0502] *Step 4B.* Synthesis of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[[bicyclo[4.2.0]octa-1,3,5-trien-7-yl(carboxy)methyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide, trifluoroacetic acid salt (**#108**). The single enantiomer **#108** (94.5 mg, 57%) was synthesized from **#106** (190 mg, 0.200 mmol) according to a procedure similar to the one described for synthesis of **#41** from **#40**. LC-MS: *m/z* 716.8 [M+H⁺], retention time = 2.06 minutes; HPLC (Protocol N): retention time = 9.137 minutes.

Preparation of 2-methylalanyl-*N*-[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[[1*S*,2*R*)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-*N*-methyl-L-valinamide (#112**)**

[0503]


25
3035
4045
50

55

minutes (purity > 90%); ^1H NMR (400 MHz, $\text{DMSO}-d_6$), presumed to be a mixture of rotamers, characteristic signals: δ [7.62 (br d, $J=8$ Hz), 7.88 (br d, $J=8$ Hz), 8.07 (br d, $J=9$ Hz) and 8.11 (br d, $J=9$ Hz), total 2H], 7.15-7.34 (m, 5H), [5.34 (d, $J=4$ Hz) and 5.41 (d, $J=5$ Hz), total 1H], 3.18, 3.21, 3.23 and 3.25 (4 s, total 6H), 2.93 and 3.08 (2 br s, total 3H), 1.15, 1.18, 1.21 and 1.25 (4 s, total 6H).

Preparation of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#115).

[0508]




[0509] Step 1. Synthesis of methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate (**#113**). To a stirring mixture of dimer acid#5 (12.1 g, 23.0 mM) and **#67** (11.5 g, 23.0 mM) in 75 mL of dichloromethane under nitrogen, HATU (10.8 g, 27.6 mM) was added followed by Hunig's base (12.1 mL, 69.0 mM). The reaction was allowed to stir at room temperature for 15 hours. Reaction was concentrated to a smaller volume, taken up with ethyl acetate and washed with 1 N HCl two times. The organic layer was then washed with brine, dried over sodium sulfate, filtered, and concentrated *in vacuo*. Residue was then purified by silica gel chromatography (Gradient: 0% to 70% acetone in heptanes), producing **#113** (12.3 g, 62%) as a white solid. LC-MS (Protocol Q): m/z 855.3 [$\text{M}+\text{H}^+$], 877.2 [$\text{M}+\text{Na}^+$], retention time = 2.32 minutes; HPLC (Protocol R): m/z 855.5 [$\text{M}+\text{H}^+$], retention time = 9.596 minutes (purity > 97%).

[0510] Step 2. Synthesis of methyl N-[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(L-valyl)amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]-L-phenylalaninate (**#114**). According to general procedure A, from **#113** (12 g, 14 mmol, 1 eq.), dichloromethane (60 mL, 0.24 M) and diethylamine (40 mL, 390 mM) was synthesized **#114** (5.9 g, 67%) white/slight yellow solid after purification by silica gel chromatography (Gradient: 0% to 25% methanol in dichloromethane). LC-MS (Protocol Q): m/z 633.0 [$\text{M}+\text{H}^+$], retention time = 1.19 minutes. HPLC (Protocol A): m/z 633.5 [$\text{M}+\text{H}^+$], retention time = 7.142 minutes (purity > 98%).

[0511] Step 3. Synthesis of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide-trifluoroacetic acid salt (**#115**). To a stirring mixture of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanine (167 mg, 0.493 mM), **#114** (260 mg, 0.411 mM), and HATU (188 mg, 0.493 mM) in 10 mL of dichloromethane, Hunig's base (0.14 mL, 0.82 mM) was added. The reaction was allowed to stir at room temperature for 1 hour and 20 minutes. Reaction was reduced down. THF (9 mL) was added to crude material and to this stirring mixture lithium hydroxide (49.2 mg, 2.06 mM) dissolved in 3 mL of water was added. The reaction was allowed to stir at room temperature for 4 hours. Reaction was concentrated down followed by purification by medium pressure reverse phase C18 chromatography (Gradient: 5% to 45% water in acetonitrile with 0.02% TFA in each phase) **#115** (218 mg, 64%) white solid. LC-MS (Protocol Q): m/z 718.7 [$\text{M}+\text{H}^+$], 740.6 [$\text{M}+\text{Na}^+$], retention time = 1.21 minutes. HPLC (Protocol A at 45 $^\circ\text{C}$): m/z 718.4 [$\text{M}+\text{H}^+$], retention time = 6.903 minutes. ^1H NMR (400 MHz, $\text{DMSO}-d_6$), δ 8.81-8.95 (m), 8.44-8.50 (m), 8.42 (d), 8.15 (d), 7.14-7.28 (m), 4.71-4.78 (m), 4.57-4.66 (m), 4.49-4.56 (m), 4.41-4.48 (m), 3.94-4.05 (m), 3.72-3.79 (m), 3.39-3.60 (m), 2.95-3.33 (m), 2.78-2.89 (m), 2.69 (s), 2.43-2.50 (m), 2.08-2.42 (m), 1.60-1.92 (m), 1.20-1.57 (m), 0.84-1.11 (m), 0.74-0.83 (m).

Preparation of 2-methyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#117) and 2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#118).

[0512]




[0513] Step 1. Synthesis of 1-(tert-butoxycarbonyl)-2-methyl-L-prolyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (#116). To a stirring solution of #114 (1.02 g, 1.61 mmol, 1.0 eq.) and 1-(tert-butoxycarbonyl)-2-methyl-L-proline (443 mg, 1.93 mmol, 1.2 eq.) in 12 mL of dichloromethane, HATU (735 mg, 1.93 mmol, 1.2 eq.) was added followed by Hunig's base (1.12 mL, 6.45 mmol, 4.0 eq.). The reaction was allowed to stir at room temperature for 2 hours. The reaction was reduced down, diluted with ethyl acetate before being washed with 0.5 N HCl and brine. Organics were then dried over sodium sulfate, reduced to a smaller volume, and then reduced down on silica. Silica chromatography was then performed (Gradient: 0%-45% acetone in heptanes) producing #116 (1.02 g, 74%) as a white solid. LC-MS (Protocol Q): m/z 844.3 [M+H⁺], 867.2 [M+Na⁺], retention time = 2.15 minutes.

[0514] Step 2A. Synthesis of 2-methyl-L-prolyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#117). To a stirring solution of #116 (450 mg, 0.533 mmol, 1.0 eq.) in 7 mL of dichloromethane at 0 °C, TFA (3 mL, 40 mmol, 70 eq.) was added. The reaction was allowed to stir at 0 °C for 5 minutes and then allowed to warm to room temperature while stirring for 20 minutes. Reaction was reduced down, diluted with dichloromethane and a small amount of methanol before being reduced down onto silica. Silica chromatography was then performed (Gradient: 0%-20% methanol in ethyl acetate) producing #117 (396 mg, 89%) as a white solid. LC-MS (Protocol Q): m/z 744.5 [M+H⁺], 767.2 [M+Na⁺], retention time = 1.40 minutes; HPLC (Protocol A at 45 °C): m/z 744.5 [M+H⁺], retention time = 7.149 minutes (purity > 91%). ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.73-9.14 (m), 8.66 (br d), 8.50 (d), 8.22 (d), 7.12-7.25 (m), 4.67-4.74 (m), 4.41-4.63 (m), 3.93-4.00 (m), 3.73 (dd), 3.63 (d), 3.46-3.57 (m), 3.38-3.45 (m), 3.26-3.23 (m), 3.22-3.25 (m), 3.06-3.22 (m), 2.99-3.05 (m), 2.93-2.97 (m), 2.80-2.89 (m), 2.75-2.78 (m), 2.64-2.67 (m), 2.46-2.50 (m), 2.27-2.43 (m), 2.00-2.26 (m), 1.85-1.99 (m), 1.70-1.83 (m), 1.52-1.69 (m), 1.33-1.51 (m), 1.18-1.31 (m), 0.98-1.07 (m), 0.93-0.97 (m), 0.82-0.92 (m), 0.71-0.78 (m).

[0515] Step 2B. Synthesis of 2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#118). To a stirring solution of #116 (435 mg, 0.515 mmol), in 4 mL of THF under nitrogen, LiOH (24.7 mg, 1.03 mmol, 2.0 eq.) dissolved in 2 mL of water was added. The reaction was allowed to stir at room temperature until LC-MS indicated saponification of methyl ester. Reaction was concentrated *in vacuo* and then placed underneath vacuum. Reaction was diluted with dichloromethane and placed underneath nitrogen. To this stirring mixture TFA (3 mL, 40.5 mmol, 80 eq.) was added. Reaction was allowed to stir at room temperature for 30 minutes. Reaction was then reduced down. Residue was purified by medium pressure reverse phase C18 chromatography (Gradient: 5% to 60% acetonitrile in water with 0.02% TFA in each phase) #118 (396 mg, 89%) as a white solid. LC-MS (Protocol Q): m/z 730.2 [M+H⁺], retention time = 1.18 minutes; HPLC (Protocol A at 45 °C): m/z 730.5 [M+H⁺], retention time = 7.088 minutes (purity > 98%). ¹H NMR (400 MHz, DMSO-*d*₆), δ 9.04-9.13 (m), 8.75-8.87 (m), 8.70 (d), 8.38 (d), 8.11 (d), 7.10-7.24 (m), 4.66-4.74 (m), 4.48-4.64 (m), 4.37-4.47 (m), 3.91-3.99 (m), 3.77 (m), 3.47-3.56 (m), 3.33-3.47 (m), 3.08-3.30 (m), 2.93-3.07 (m), 2.75-2.86 (m), 2.63-2.69 (m), 2.45-2.50 (m), 2.28-2.44 (m), 2.03-2.27 (m), 1.88-2.02 (m), 1.68-1.86 (m), 1.55-1.67 (m), 1.30-1.47 (m), 1.17-1.29 (m), 0.98-1.05 (m), 0.93-0.97 (m), 0.83-0.92 (m), 0.71-0.79 (m).

Preparation of 2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#123).

[0516]



[0517] Step 1. Synthesis of (2R,3R)-3-[(2S)-1-[(9H-fluoren-9-ylmethoxy)carbonyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoic acid (**#119**). To a stirring solution of **#11** (2.4 g, 8.4 mmol, 1.0 eq.) in 10 mL of dioxane under nitrogen, 4M HCl in dioxane (20 mL, 80 mM, 10 eq.) was added. The reaction was allowed to stir at room temperature for 3 hours before being concentrated *in vacuo* and placed underneath high vacuum. Crude material was then dissolved with 30 mL of 10% Na₂CO₃. This solution was then added to a stirring solution of 1-[(9H-fluoren-9-ylmethoxy)carbonyl]oxy-pyrrolidine-2,5-dione (2.96 g, 8.77 mmol, 1.05 eq.) in 30 mL of DME. Reaction was allowed to stir at room temperature until TLC (20% methanol/40% ethyl acetate/40% heptanes) indicated the consumption of Boc de-protected starting material. The reaction was concentrated *in vacuo* to a smaller volume, washed twice with ether, acidified to pH 2 using concentrated HCl and then extracted three times with a solution of 90% dichloromethane 10% methanol. The organics were washed with saturated sodium bicarbonate and brine before being dried over sodium sulfate, filtered, and concentrated *in vacuo* to a brown solid **#119** (3.4 g, quant.). LC-MS (Protocol Q): *m/z* 410.0 [M+H⁺], retention time = 1.81 minutes.

[0518] Step 2. Synthesis tert-butyl N-[(2R,3R)-3-[(2S)-1-[(9H-fluoren-9-ylmethoxy)carbonyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate (**#120**). To a stirring solution of tert-butyl L-phenylalaninate, hydrochloride salt (1.67 g, 6.5 mmol, 1.0 eq.) and **#119** (5.9 g, 6.5 mmol, 1.0 eq.) in 50 mL of dichloromethane and 5 mL of DMF, HATU (2.9g, 7.9 mmol, 1.2 eq.) was added followed by Hunig's base (5.6 mL, 32 mmol, 5.0 eq.). The reaction was allowed to stir at room temperature for 45 minutes. Reaction was reduced down, diluted with ethyl acetate, washed with 0.5 N HCl and brine before being concentrated down onto silica. Silica chromatography was then performed (Gradient: 0%-25% acetone in heptane) producing **#120** (3.14 g, 79%) as a white yellow solid. LC-MS (Protocol Q): *m/z* 613.1 [M+H⁺] retention time = 2.37 minutes.

[0519] Step 3. Synthesis of tert-butyl N-[(2R,3R)-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanoyl]-L-phenylalaninate (**#121**). To a stirring solution of **#120** (2.87 g, 4.68 mmol, 1.00 eq.) in 20 mL of dichloromethane, diethylamine (10 mL, 95 mM, 20.5 eq.) was added. The reaction was allowed to stir at room temperature for 2 hours. Another (10 mL, 95 mmol, 20.5 eq.) of diethylamine was added and the reaction was allowed to stir at room temperature for 3 more hours. Reaction was concentrated *in vacuo* and placed underneath high vacuum producing **#121** (1.8 g, quant.) yellow white oil solid mix. LC-MS (Protocol Q): *m/z* 391.1 [M+H⁺] retention time = 1.05 minutes.


[0520] Step 4. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#122**). To a stirring solution of **#121** (0.55 g, 1.0 mmol, 1.0 eq.) in 10 mL of dichloromethane and 1 mL of DMF, **#32** (0.62 g, 1.0 mmol, 1.0 eq.) was added followed by HATU (0.42 g, 1.1 mmol, 1.1 eq.) and Hunig's base (0.72 mL, 4.1 mmol, 4.0 eq.). The reaction was allowed to stir at room temperature for approximately 21 hours. Reaction was reduced down, diluted with ethyl acetate, and then washed with 0.5 N HCl and brine. Organic layer was dried over sodium sulfate, filtered, and concentrated to a smaller volume before being concentrated down onto silica. Silica chromatography was then performed (Gradient: 0%-40% acetone in heptane) producing **#122** (0.62 g, 62%) as a white solid. LC-MS (Protocol Q): *m/z* 982.3 [M+H⁺] retention time = 2.44 minutes.

[0521] Step 5. Synthesis 2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#123**). To a stirring mixture of **#122** (600 mg, 0.611 mmol, 1.00 eq.) in 15 mL of dichloromethane, diethylamine (5 mL, 50 mmol, 80 eq.) was added. The reaction was allowed to stir at room temperature for 3 hours. Reaction was

concentrated *in vacuo* and mixture was purified by Silica Chromatography (Gradient: 0%-40% methanol in dichloromethane) producing **#123** (0.46 g, 99%) as a solid. LC-MS (Protocol Q1): *m/z* 760.3 [M+H⁺] retention time = 0.83 minutes. ¹H NMR (400 MHz, CD₃OD), δ 7.14-7.30 (m), 4.70-4.78 (m), 4.56-4.64 (m), 4.05-4.19 (m), 3.87 (dd), 3.79-3.84 (m), 3.72-3.77 (m), 3.62-3.70 (m), 3.46-3.56 (m), 3.37-3.45 (m), 3.33-3.36 (m), 3.16-3.24 (m), 3.09-3.11 (m), 2.98-3.05 (m), 2.95 (d), 2.91 (d), 2.87 (d), 2.83 (d), 2.73-2.79 (m), 2.40-2.51 (m), 2.29-2.39 (m), 2.16-2.28 (m), 2.04-2.15 (m), 2.01 (s), 1.73-1.96 (m), 1.50-1.68 (m), 1.47-1.49 (m), 1.46 (s), 1.43 (s), 1.38 (s), 1.35 (d), 1.23-1.32 (m), 1.17-1.22 (m), 1.15 (d), 1.04-1.11 (m), 0.94-1.03 (m), 0.82-0.91 (m).

Reference Example Preparation of methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-(3-amino-2,2-dimethylpropanoyl)-L-valyl](methylamino)-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate (#126).

[0522]




[0523] Step 1. Synthesis of 3-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2,2-dimethylpropanoic acid (**#124**). A solution of 3-amino-2,2-dimethylpropanoic acid hydrochloride (1.0 g, 6.5 mmol, 1.0 eq.) in 10 mL of 10% Na₂CO₃ was added to a solution of 1-[[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]pyrrolidine-2,5-dione (2.3 g, 6.5 mmol, 1.0 eq.) in 10 mL of DME. The reaction was allowed to stir at room temperature overnight. Reaction was concentrated to a smaller volume and then washed two times with ether. The aqueous layer was acidified to pH <2 with concentrated HCl and then extracted three times with a 10% methanol 90% dichloromethane solution. The organics were combined before being washed with 1M HCl and brine. The organic layer was dried over sodium sulfate and concentrated *in vacuo* producing **#124** (2.2 g, 98%) as a white solid. LC-MS (Protocol Q1): *m/z* 362.0 [M+Na⁺] retention time = 0.89 minutes.

[0524] Step 2. Synthesis of methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-(3-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2,2-dimethylpropanoyl]-L-valyl](methylamino)-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate (**#125**). To a stirring solution of **#114** (200 mg, 0.316 mmol, 1.00 eq.) in 2 mL of dichloromethane, **#124** (107 mg, 0.316 mmol, 1.00 eq.) was added followed by Hunig's base (0.167 mL, 0.948 mmol, 3.00 eq.) and HATU (149 mg, 0.379 mmol, 1.20 eq.). The reaction was allowed to stir at room temperature for ~12 hours. The reaction was concentrated to a smaller volume, taken up in 10 mL of ethyl acetate, and washed two times with 5 mL of 1M HCl, and once with 5 mL of brine. The organic layer was dried over sodium sulfate and decanted. Organics were concentrated *in vacuo* and the crude material was taken up in dichloromethane. The precipitate was filtered. The organic layer was concentrated *in vacuo* and the residue was purified by silica chromatography (Gradient: 0%-50% acetone in heptane) producing **#125** (235 mg, 78%) as a white solid. LC-MS (Protocol Q): *m/z* 954.2 [M+H⁺] retention time = 2.28 minutes.

[0525] Step 3. Synthesis of methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-(3-amino-2,2-dimethylpropanoyl)-L-valyl](methylamino)-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate (**#126**). To a stirring solution of **#125** (235 mg, 0.246 mmol, 1.00 eq.) in 2 mL of THF, (1 mL, 10 mM, 40.6 eq.) of diethylamine was added. The reaction was allowed to stir at room temperature for 3 hours. Reaction was concentrated *in vacuo* and the residue was purified by silica chromatography (Gradient: 0%-30% methanol in ethyl acetate) producing **#126** (101 mg, 56%) as a white solid. LC-MS (Protocol Q): *m/z* 732.2 [M+H⁺] retention time = 1.32 minutes. ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.51 (dd), 8.28 (d), 7.15-7.29 (m), 5.77 (s), 4.55-4.77 (m), 4.44-4.54 (m), 3.94-4.10 (m), 3.73-3.79 (m), 3.66 (d), 3.49-3.60 (m), 3.40-3.48 (m), 3.10-3.36 (m), 3.00-3.09 (m), 2.83-2.98 (m), 2.57-2.77 (m), 2.19-2.46 (m), 1.87-2.14 (m), 1.61-1.86 (m), 1.36-1.55 (m), 1.23-1.36 (m), 1.12-1.22 (m), 0.97-1.11 (m), 0.82-0.96 (m), 0.73-0.81 (m).

Preparation of N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#130).

[0526]



[0527] Step 1. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-1-tert-butoxy-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#127**). To a round bottom flask containing **#6** (4.7 g, 7.9 mmol, 1.0 eq.) and N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanine (3.2 g, 9.4 mmol, 1.2 eq.) and a stir bar under nitrogen, 50 mL of dichloromethane was added followed by HATU (3.6 g, 9.4 mmol, 1.2 eq.) and Hunig's base (5.5 mL, 32 mmol, 4.0 eq.). The reaction was allowed to stir at room temperature for ~12 hours. Reaction was reduced to a smaller volume, taken up in ethyl acetate, before being washed with 1 N HCl, and brine. Organics were then dried over sodium sulfate, filtered and then reduced down onto silica. Residue was purified by Silica Chromatography (Gradient: 0%-30% acetone in heptane) producing **#127** (4.2 g, 78%) as a white solid. LC-MS (Protocol Q): *m/z* 680.2 [M+H⁺] retention time = 2.52 minutes.


[0528] Step 2. Synthesis N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanyl-N-[(2R,3S,4S)-1-carboxy-2-methoxy-4-methylhexan-3-yl]-N-methyl-L-valinamide, (**#128**). To a stirring solution of **#127** (4.2 g, 6.1 mmol, 1.0 eq.) in 21 mL of dichloromethane under nitrogen, (7 mL, 90 mmol, 10 eq.) of TFA was added. The reaction was allowed to stir at room temperature for ~4 hours. Reaction was concentrated *in vacuo*, azeotroped once with heptane, and then placed underneath high vacuum yielding **#128** as a white slight yellow solid (3.8 g, quant.). LC-MS (Protocol Q): *m/z* 624.2 [M+H⁺] retention time = 2.01 minutes.

[0529] Step 3. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#129**). To a stirring solution of **#128** (1.67 g, 3.1 mmol, 1.0 eq.) in 20 mL of dichloromethane and 2 mL of DMF, **#121** (2.4 g, 3.1 mmol, 1.0 eq.) was added followed by HATU (1.29 g, 3.39 mmol, 1.1 eq.) and then Hunig's base (2.2 mL, 12.3 mmol, 4.0 eq.). The reaction was allowed to stir at room temperature for ~2 hours. Reaction was reduced down, diluted with ethyl acetate before being washed with 0.5 N HCl and brine. Organics were dried over sodium sulfate and then reduced down onto silica. Residue was purified by Silica Chromatography (Gradient: 0%-50% acetone in heptanes) producing **#129** (1.9 g, 62%) as a white solid. LC-MS (Protocol Q): *m/z* 996.3 [M+H⁺] retention time = 2.53 minutes.

[0530] Step 4. Synthesis of N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#130**). To a stirring solution of **#129** (823 mg, 0.826 mmol, 1.00 eq.) in 15 mL of dichloromethane, diethylamine (4 mL, 40 mmol, 50 eq.) was added. The reaction was allowed to stir at room temperature for ~14 ½ hours. The reaction was concentrated *in vacuo* and azeotroped once with heptanes. Residue was diluted with dichloromethane and a small amount of methanol before being reduced down onto silica. Residue was purified by Silica Chromatography (Gradient: 0%-20% methanol in ethyl acetate) producing **#130** (518 mg, 81%) as a white solid. LC-MS (Protocol Q): *m/z* 774.3 [M+H⁺] retention time = 1.48 minutes. HPLC (Protocol A at 25 °C): *m/z* 774.5 [M+H⁺], retention time = 7.733 minutes (purity > 98%). ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.36 (d), 8.14 (d), 7.81 (t), 7.14-7.25 (m), 7.01-7.07 (m), 4.87-4.94 (m), 4.78-4.85 (m), 4.67-4.76 (m), 4.46-4.65 (m), 4.29-4.40 (m), 3.93-4.03 (m), 3.70-3.81 (m), 3.49-3.60 (m), 3.38-3.47 (m), 3.29-3.36 (m), 3.15-3.28 (m), 2.98-3.13 (m), 2.94 (br s), 2.74-2.89 (m), 2.64-2.69 (m), 2.18-2.45 (m), 2.02-2.14 (m), 1.90-2.01 (m), 1.62-1.87 (m), 1.40-1.55 (m), 1.37 (d), 1.20-1.33 (m), 1.16 (d), 1.01-1.10 (m), 0.90-0.98 (m), 0.82-0.89 (m), 0.69-0.79 (m).

Preparation of 2-methyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#131**).**


[0531]



[0532] Step 1. Synthesis of 2-methyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (**#131**). To a stirring solution of **#114** (164 mg, 0.259 mmol, 1.0 eq.) and 1-(tert-butoxycarbonyl)-2-methyl-D-proline (71.3 mg, 0.311 mmol, 1.2 eq.) in 4 mL of dichloromethane, HATU (118 mg, 0.311 mmol, 1.2 eq.) was added followed by Hunig's base (0.180 mL, 1.04 mmol, 4 eq.). The reaction was allowed to stir at room temperature for ~30 minutes. Reaction was reduced down. Reaction was taken up in 3.5 mL of dichloromethane and placed under nitrogen. To this stirring solution, TFA (1.5 mL, 20 mmol, 76 eq.) was added. The reaction was allowed to stir at room temperature for ~1 hour. Reaction was reduced down and placed underneath high vacuum. Purification by (Method J*) affords **#131** (119 mg, 54%) as a white solid. HPLC (Protocol A at 45 °C): *m/z* 744.5 [M+H⁺], retention time = 7.342 minutes (purity > 98%). ¹H NMR (400 MHz, DMSO-*d*₆), δ 9.08-9.18 (m), 8.79-8.89 (m), 8.76 (t), 8.54 (d), 8.29 (d), 7.14-7.31 (m), 4.70-4.79 (m), 4.57- 4.66 (m), 4.45-4.55 (m), 3.96- 4.04 (m), 3.74-3.80, 3.66 (d), 3.48-3.61 (m), 3.40-3.48 (m), 3.09- 3.34 (m), 3.00-3.09 (m), 2.95-3.00 (m), 2.83-2.93 (m), 2.36- 2.53 (m), 2.21-2.35 (m), 2.10-2.19 (m), 1.99-2.10 (m), 1.61-1.09 (m), 1.36-1.53(m), 1.21-1.35 (m), 1.02- 1.10 (m), 0.94- 1.0 (m), 0.86- 0.93 (m), 0.73- 0.82 (m).

Preparation of 2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#134**).**

[0533]



[0534] Step 1. Synthesis of N~2~-(9H-fluoren-9-ylmethoxy)carbonyl]-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#132**). To a flask containing **#5** (1.14 g, 2.17 mmol, 1.0 eq.), 10 mL of dichloromethane was added followed by Hunig's base (1.15 mL, 6.52 mmol, 3.0 eq.), HATU (1.02 g, 2.61 mmol, 1.2 eq.), and **#110** (0.776 g, 2.17 mmol, 1.0 eq.). Reaction was allowed to stir at room temperature for 30 minutes and then concentrated *in vacuo*. Crude material was taken up in 50 mL of ethyl acetate, washed two times with 25 mL of 1 M HCl, and once with 25 mL of brine. Organics were dried over sodium sulfate and decanted. Organics were concentrated *in vacuo*, taken up in 30 mL of dichloromethane, and the resulting precipitate was filtered off. Organics were concentrated *in vacuo* and the residue was purified by silica chromatography (Gradient: 0%-50% acetone in heptanes) producing **#132** (1.33 g, 81%) as a solid. LC-MS (Protocol Q): *m/z* 849.2 [M+Na⁺] retention time = 2.19 minutes.


[0535] Step 2. Synthesis of N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#133**). To a stirring solution of **#132** (1.33 g, 1.60 mmol, 1.0 eq) in 10 mL of THF diethylamine (5 mL, 50 mM, 31.3 eq) was added. The reaction was allowed to stir at room temperature for 4 hours. Reaction was concentrated *in vacuo* and the residue was purified by silica chromatography (Gradient: 0%-30% methanol in ethyl acetate) producing **#133** (418 mg,

43%) as a white solid. LC-MS (Protocol Q1): m/z 605.2 $[M+H]^+$ retention time = 1.48 minutes

[0536] Step 3. Synthesis of 2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#134**). HATU (151 mg, 0.398 mmol, 1.2 eq), **#133** (201 mg, 0.332 mmol, 1.0 eq.) and 1-(tert-butoxycarbonyl)-2-methyl-L-proline (91.3 mg, 0.398 mM, 1.2 eq.) were combined in a round bottom flask containing a stir bar under nitrogen. 5 mL of dichloromethane was added followed by Hunig's base (0.231 mL, 1.33 mmol, 4.0 eq.). The reaction was allowed to stir at room temperature for ~15 hours. Reaction was then concentrated *in vacuo* and placed underneath high vacuum. 4 mL of dioxane was then added to the residue followed by 4M HCl in dioxane (4 mL, 20 mmol, 50 eq.). Reaction was then allowed to stir at room temperature for 1 hour. Reaction was then concentrated *in vacuo* and the residue was purified by medium pressure reverse phase C18 chromatography (Gradient: 5% to 90% acetonitrile in water with 0.02% TFA in each phase) **#134** (237 mg, 86%) as a white solid. LC-MS (Protocol Q): m/z 716.3 $[M+H]^+$, retention time = 1.16 minutes; HPLC (Protocol A at 45 °C): t_r 716.5 $[M+H]^+$, retention time = 6.930 minutes (purity > 98%). ^1H NMR (400 MHz, DMSO- d_6), 9.12-9.21(m), 8.79-8.90 (m), 8.70-8.78 (m), 7.95 (d), 7.64 (d), 7.25-7.36 (m), 7.16- 7.23 (m), 4.74- 4.80 (m), 4.61- 4.69 (m), 4.41- 4.59 (m), 3.91- 4.06 (m), 3.78 (dd), 3.54- 3.64 (m), 3.45- 3.51 (m), 3.17- 3.36 (m), 3.02- 3.15 (m), 3.00 (br s), 2.40-2.48 (m), 2.24- 2.35 (m), 1.91- 2.21 (m), 1.68- 1.90 (m), 1.61-1.68 (m), 1.48- 1.59 (m), 1.22- 1.35 (m), 0.97- 1.09 (m), 0.84- 0.97 (m), 0.74-0.83 (m).

Preparation of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(methylamino)-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#140**), N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-2-amino-1-benzyl-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#141**), N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-oxo-2-(propylamino)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#142**), N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(diethylamino)-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#143**), and N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(tert-butylamino)-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#144**).

[0537]



[0538] Step 1. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-5-methyl-1-oxo-1-(pentafluorophenoxy)heptan-4-yl]-N-methyl-L-valinamide (**#135**). Pentafluorophenyl 3,3,3-trifluoropropanoate (2.44 mL, 13.4 mmol, 2.0 eq.) was added to a solution of **#128** (4.18 g, 6.70 mmol, 1.0 eq.) in 50 mL of dichloromethane followed by pyridine (1.61 mL, 20.1 mmol, 3.0 eq.). Reaction was allowed to stir at room temperature for ~12 hours. Reaction was concentrated *in vacuo* and the residue was purified by silica chromatography (Gradient: 0%-70% acetone in heptanes) producing **#135** (5.2 g, 98%) as a white foam. LC-MS (Protocol Q1): *m/z* 812.1 [M+Na⁺] retention time = 1.24 minutes.

[0539] Step 2. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valina-

mid(**#136**). To a stirring solution of 4M HCl in dioxane (10 mL, 25 mmol, 3.7 eq.) in 10 mL of dioxane **#11** (2.31 g, 8.05 mmol, 1.2 eq.) was added. The reaction was allowed to stir at room temperature for 6 hours. The reaction was concentrated *in vacuo* producing a yellow gum. A solution of **#135** (5.3 g, 6.7 mmol, 1.0 eq.) in 30 mL of dichloromethane was added to the previous residue followed by Hunig's base (3.5 mL, 20 mmol, 3 eq.). The reaction was allowed to stir at room temperature for 4 hours. The reaction was diluted with dichloromethane before being washed with a 1% HCl aqueous solution and then brine. The organics layer was dried over sodium sulfate, concentrated *in vacuo*, and the residue was purified by silica chromatography (Gradient: 20%-50% ethyl acetate in heptanes followed by 93% ethyl acetate 6.6% methanol and 0.4% acetic acid) producing **#136** (4.87 g, 92%) as a off white solid. LC-MS (Protocol Q1): *m/z* 793.3 [M+H⁺] retention time = 1.07 minutes.

[0540] Step 3. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-(pentafluorophenoxy)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#137**). Pentafluorophenyl 3,3,3-trifluoropropanoate (1.3 mL, 7.1 mmol, 2.0 eq.) was added to a solution of **#136** (2.8 g, 3.5 mmol, 1.0 eq.) in 30 mL of dichloromethane followed by the addition of pyridine (0.85 mL, 10.6 mM). The reaction was allowed to stir at room temperature for 2 hours. The reaction was concentrated *in vacuo*, and the residue was purified by silica chromatography (Gradient: 0%-70% acetone in heptane) producing **#137** (3.1 g, 92%) as a white powder. LC-MS (Protocol Q1): *m/z* 959.2 [M+H⁺] retention time = 1.28 minutes.

[0541] Step 4. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide(**#138**). To a stirring solution of **#137** (493 mg, 0.514 mmol, 1.0 eq.) in 4 mL of DMF, L-phenylalanine (84.9 mg, 0.514 mmol, 1.0 eq) was added followed by Hunig's base (0.27 mL, 1.54 mmol, 3.0 eq.). The reaction was allowed to stir at room temperature for ~12 hours. Reaction was concentrated *in vacuo* and residue was purified by silica chromatography (Gradient: 0%-100% ethyl acetate in heptane) producing **#138** (200 mg, 41%) as a white foam. LC-MS (Protocol Q1): *m/z* 940.3 [M+H⁺] retention time = 1.08 minutes.

[0542] Step 5. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-1-(pentafluorophenoxy)-3-phenylpropan-2-yl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#139**). To a stirring solution of **#138** (200 mg, 0.213 mmol, 1.0 eq.) in 5 mL of dichloromethane, Pentafluorophenyl 3,3,3-trifluoropropanoate (126 mg, 0.426 mM, 2.0 eq.) was added followed by pyridine (0.051 mL, 0.64 mmol, 3.0 eq.). The reaction was allowed to stir at room temperature for ~12 hours. Reaction was concentrated *in vacuo* and the residue was purified by silica chromatography (Gradient: 0%-100% ethyl acetate in heptanes) producing **#139** (174 mg, 74%) as a yellow oil. LC-MS (Protocol Q1): *m/z* 1128 [M+Na⁺] retention time = 1.23 minutes.

[0543] Step 6A. Synthesis of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(methylamino)-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#140**). To a stirred solution of **#139** (20 mg, 0.018 mmol, 1.0 eq.) in 1mL of THF methylamine (1M in THF, 0.18 mL, 0.18 mmol, 10 eq.) was added, and the mixture was stirred at room temperature for 3 hours. The reaction was reduced down, and diluted with dmso, and subjected to purification (Method J*). The fractions were collected and concentrated *in vacuo* to give **#140** (4.0 mg, 30%) as a white solid. LC-MS (Protocol Q1): *m/z* 731.2 [M+H⁺], retention time = 0.70 minutes. ¹H NMR (400 MHz, methanol-*d*₄), 7.30-7.41 (m), 4.71-4.78 (m), 4.58-4.69 (m), 4.04-4.15 (m), 3.86-3.98 (m), 3.73-3.78 (m), 3.61-3.70 (m), 3.50-3.58 (m), 3.32-3.47 (m), 3.23-3.26 (m), 3.17-3.22 (m), 3.07-3.15 (m), 2.95-2.98 (m), 2.76-2.91 (m), 2.68-2.75 (m), 2.63-2.66 (m), 2.43-2.51 (m), 2.22-2.28 (m), 1.99-2.11 (m), 1.74-1.96 (m), 1.21-1.31 (m), 1.17-1.20 (m), 0.92-1.10 (m), 0.79-0.89 (m).

[0544] Step 6B. Synthesis of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-2-amino-1-benzyl-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#141**). Following the same procedure as **#140** using **#139** (20 mg, 0.018 mmol, 1.0 eq.), ammonia solution (7M in methanol, 0.026 mL, 0.18 mmol, 10eq.) and purification (Method J*), **#141** (3.0 mg, 20%) was obtained as a white solid. LC-MS (Protocol Q): *m/z* 717.2 [M+H⁺], retention time = 0.79 minutes. ¹H NMR (400 MHz, methanol-*d*₄), 7.22-7.30 (m), 7.14-7.21 (m), 4.57-4.4.80 (m), 4.02-4.17 (m), 3.92-3.98 (m), 3.84-3.91 (m), 3.32-3.74 (m), 3.17-3.27 (m), 3.06-3.14 (m), 2.77-3.05 (m), 2.65 (s), 2.43-2.51 (m), 2.21-2.26 (m), 1.98-2.13 (m), 1.70-1.94 (m), 1.32-1.69 (m), 1.16-1.31 (m), 0.89-1.13 (m), 0.80-0.88 (m).

[0545] Step 6C. Synthesis of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-oxo-2-(propylamino)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#142**). Following the same procedure as **#140** using **#139** (20 mg, 0.018 mmol, 1.0 eq.) n-propylamine (1M in THF, 0.18 mL, 0.18 mmol, 10. eq) and purification (Method J*), **#142** (3.0 mg, 20%) was obtained as a white solid. LC-MS (Protocol Q): *m/z* 759.2 [M+H⁺], retention time = 0.74 minutes. ¹H NMR (400 MHz, methanol-*d*₄), 7.15-7.29 (m), 4.71-4.79 (m), 4.52-4.68 (m), 4.04-4.17 (m), 3.87-3.99 (m), 3.73-3.99 (m), 3.73-3.79 (m), 3.50-3.70 (m), 3.34-3.49 (m), 3.06-3.23 (m), 2.79-2.99 (m), 2.44-2.50 (m), 2.28-2.43 (m), 2.22-2.27 (m), 1.75-2.10 (m), 1.34-1.61 (m), 1.16-1.29 (m), 0.92-1.10 (m), 0.77-0.89 (m).


[0546] Step 6D. Synthesis of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(diethylamino)-2-

oxoethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#143**). Following the same procedure as **#140** using **#139** (20 mg, 0.018 mmol, 1.0 eq.) diethylamine (1M in THF, 0.18 mL, 0.18 mmol, 10 eq.) and purification (Method J*), **#143** (4.0 mg, 30%) was obtained as a white solid. LC-MS (Protocol Q): m/z 773.3 [M+H⁺], retention time = 0.77 minutes. ¹H NMR (400 MHz, methanol-*d*₄), 7.16-7.33 (m), 5.10-5.17 (m), 4.96-5.07 (m), 4.68-4.75 (m), 4.60-4.65 (m), 3.61-4.23 (m), 3.35-3.67 (m), 3.16-3.26 (m), 2.99-3.15 (m), 2.78-2.94 (m), 2.30-2.52 (m), 2.19-2.28 (m), 1.73-2.13 (m), 1.83-1.45 (m), 1.19-1.31 (m), 0.92-1.18 (m), 0.80-0.89 (m).

[0547] Step 6E. Synthesis of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-(tert-butylamino)-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt **#144**. Following the same procedure as **#140** using **#139** (20 mg, 0.018 mmol, 1.0eq.) tert-butylamine (1M in THF, 0.18 mL, 0.18 mmol, 10 eq.) and purification (Method J*), **#144** (3.4 mg, 24%) was obtained as a white solid. LC-MS (Protocol Q1): m/z 773.3 [M+H⁺], retention time = 0.74 minutes. ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.21 (d), 8.03-7.98 (m), 7.92 (d), 7.81-7.62 (m), 7.46-7.16 (m), 4.83-4.69 (m), 4.68-4.56 (m), 4.21-4.07 (m), 3.92-3.86 (m), 3.83-3.80 (m), 3.74-3.65 (m), 3.60-3.48 (m), 3.47-3.36 (m), 3.28-3.13 (m), 3.11-3.01 (m), 2.96-2.82 (m), 2.69-2.62 (m), 2.54-2.43 (m), 2.38-2.12 (m), 2.00-1.76 (m), 1.69-1.161 (m), 1.60-1.53 (m), 1.52-0.98 (m), 0.94-0.86 (m).

Preparation of N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (#145**).**





[0548]



[0549] Step 1. Synthesis of N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#145**). To a stirring solution of **#137** (300 mg, 0.313 mmol, 1.0 eq.) in 3 mL of DMF, (1S,2R)-2-amino-1-phenylpropan-1-ol (54.8 mg, 0.344 mmol, 1.1 eq.) was added followed by Hunig's base (0.164 mL, 0.939 mmol, 3.0 eq). The reaction was allowed to stir at room temperature for ~12 hours. Piperidine 20% solution in DMF (1 mL, 2.2 mmol, 7.0 eq.) was then added and the reaction was allowed to stir at room temperature for 2 hours. Purification (Method J*) followed by concentration of appropriate test tubes produced **#145** (190 mg, 74%) as a white powder. LC-MS (Protocol Q): m/z 704.3 [M+H⁺], retention time = 0.67 minutes. ¹H NMR (400 MHz, CD₃OD), δ 7.97 (d), 7.73 (d), 7.37-7.41 (m), 7.27-7.36 (m), 7.19-7.25 (m), 4.70-4.75 (m), 4.58-4.63 (m), 4.49-4.54 (m), 4.14-4.30 (m), 4.04-4.11 (m), 3.87 (dd), 3.63-3.77 (m), 3.51-3.58 (m), 3.46-3.49 (m), 3.38-3.43 (m), 3.25-3.37 (m), 3.15-3.23 (m), 3.11-3.14 (m), 3.01-3.02 (m), 2.59-2.64 (m), 2.52-2.55 (m), 2.44-2.52 (m), 2.41-2.43 (m), 2.07-2.26 (m), 1.73-2.0 (m), 1.65-1.73 (m), 1.59-1.65 (m), 1.51-1.59 (m), 1.32-1.46 (m), 1.23-1.26 (m), 1.08-1.21 (m), 0.94-1.07 (m), 0.83-0.92 (m).

Preparation of 3-methyl-D-isovalyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (#146**), 3-methyl-L-isovalyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (**#147**), L-isovalyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (**#148**), and D-isovalyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (**#149**).**

[0550]



[0551] Step 1A. Synthesis of 3-methyl-D-isovalyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1S)-1-benzyl-2-methoxy-2-oxoethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide (#146). A solution of #114 (225 mg, 0.356 mmol, 1.0 eq.) in 2 mL of dichloromethane was added to a solution of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-3-methyl-D-isovaline (126 mg, 0.356 mmol, 1.0eq.) in 4 mL of dichloromethane. Hunig's base (0.188 mL, 1.07 mmol, 3.0 eq.) was added followed by HATU (167 mg, 0.427 mmol, 1.2 eq.). The reaction was allowed to stir at room temperature for 12 hours. The reaction was concentrated *in vacuo* and then taken up in ethyl acetate before being washed two times with 1M HCl and once with brine. The organic layer was dried over sodium sulfate and decanted. The organic solvent was removed in a genevac. THF (4 mL) was added followed by diethylamine (2 mL, 19 mmol, 53.4 eq.). The reaction was allowed to stir for ~12 hours. Reaction was concentrated using a genevac followed by silica chromatography (Gradient: 0%-30% methanol in ethyl acetate) producing #146 (183 mg, 69%) as a solid. LC-MS (Protocol Q): *m/z* 746.6 [M+H⁺] retention time = 1.37 minutes. ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.55 (d), 8.26-8.36 (m), 7.88-8.03 (m), 7.81 (d), 7.41-7.53 (m), 7.13-7.30 (m), 7.01 (s), 4.71-4.79 (m), 4.44-4.70 (m), 3.96-4.04 (m), 3.70-3.80 (m), 3.62-3.69 (m), 3.40-3.61 (m), 2.76-3.35 (m), 2.67-2.71 (m), 2.56-2.58 (m), 2.06-2.46 (m), 1.61-1.90 (m), 1.14-1.54 (m), 0.72-1.12 (m).

[0552] Step 1B. Synthesis of 3-methyl-L-isovalyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1S)-1-benzyl-2-methoxy-2-oxoethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide (#147). A solution of #114 (224 mg, 0.354 mmol, 1.0 eq.) in 2 mL of dichloromethane was added to a solution of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-3-methyl-L-isovaline (125 mg, 0.354 mmol, 1.0 eq.) in 4 mL of dichloromethane. Hunig's base (0.187 mL, 1.06 mmol, 3.0 eq.) was added followed by HATU (167 mg, 0.425 mmol, 1.2 eq.). The reaction was allowed to stir at room temperature for 12 hours. The reaction was concentrated *in vacuo* and then taken up in ethyl acetate before being washed two times with 1M HCl and once with brine. The organic layer was dried over sodium sulfate and decanted. The organic solvent was removed in a genevac. THF (4 mL) was added followed by diethylamine (2 mL, 19 mmol, 53.7 eq.). The reaction was allowed to stir for ~12 hours. Reaction was concentrated using a genevac followed by silica chromatography (Gradient: 0%-30% methanol in ethyl acetate) producing #147 (216 mg, 82%) as a solid. LC-MS (Protocol Q): *m/z* 746.6 [M+H⁺] retention time = 1.29 minutes. ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.56 (m), 8.31-8.39 (m), 8.50 (d), 8.30 (br d), 7.87-8.01 (m), 7.80 (d), 7.40-7.53 (m), 7.14-7.30 (m), 4.45-4.78 (m), 3.94-4.04 (m), 3.70-3.79 (m), 3.61-3.69 (m), 3.42-3.59 (m), 2.97-3.37 (m), 2.80-2.92 (m), 2.32-2.49 (m), 2.05-2.30 (m), 1.61-1.89 (m), 1.37-1.56 (m), 1.14-1.135 (m), 0.70-1.11 (m).


[0553] Step 1C. Synthesis of L-isovalyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1S)-1-benzyl-2-methoxy-2-oxoethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide (#148). A solution of #114 (447 mg, 0.707 mmol, 1.0 eq.) in 2 mL of dichloromethane was added to a solution

of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-isovaline (240 mg, 0.707 mmol, 1.0 eq.) in 4 mL of dichloromethane. Hunig's base (0.373 mL, 2.12 mmol, 3.0 eq.) was added followed by HATU (332 mg, 0.425 mmol, 1.2 eq.). The reaction was allowed to stir at room temperature for 12 hours. The reaction was concentrated *in vacuo* and then taken up in ethyl acetate before being washed two times with 1M HCl and once with brine. The organic layer was dried over sodium sulfate and decanted. The organic solvent was removed in a genevac. THF (4 mL) was added followed by diethylamine (2 mL, 19 mmol, 26.9 eq.). The reaction was allowed to stir for ~12 hours. Reaction was concentrated using a genevac followed by silica chromatography (Gradient: 0%-30% methanol in ethyl acetate) producing **#148** (182 mg, 35%) as a solid. LC-MS (Protocol Q1): *m/z* 732.3 [M+H⁺] retention time = 0.71 minutes. ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.56 (d), 8.46-8.52 (m), 8.30 (d), 8.02-8.15 (m), 7.98 (d), 7.80 (d), 7.40-7.53 (m), 7.15-7.30 (m), 4.70-4.80 (m), 4.44-4.69 (m), 3.96-4.05 (m), 3.70-3.79 (m), 3.62-3.69 (m), 3.41-3.59 (m), 2.99-3.35 (m), 2.31-2.95 (m), 2.67-2.71 (m), 2.55-2.59 (m), 2.32-2.48 (m), 2.20-2.31 (m), 1.97-2.19 (m), 1.61-1.88 (m), 1.37-1.56 (m), 1.20-1.34 (m), 1.14-1.19 (m), 1.02-1.11 (m), 0.97-1.01 (m), 0.86-0.96 (m), 0.71-0.83 (m).

[0554] Step 1D. Synthesis of D-isovalyl-N-[(1S,2R)-4-{(2S)-2-[(1R,2R)-3-[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (**#149**). A solution of **#114** (447 mg, 0.707 mmol, 1.0 eq.) in 2 mL of dichloromethane was added to a solution of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-D-isovaline (240 mg, 0.707 mmol, 1.0 eq.) in 4 mL of dichloromethane. Hunig's base (0.373 mL, 2.12 mmol, 3 eq.) was added followed by HATU (332 mg, 0.425 mmol, 1.2 eq.). The reaction was allowed to stir at room temperature for 12 hours. The reaction was concentrated *in vacuo* and then taken up in ethyl acetate before being washed two times with 1M HCl and once with brine. The organic layer was dried over sodium sulfate and decanted. The organic solvent was removed in a genevac. THF (4 mL) was added followed by diethylamine (2 mL, 19 mmol, 26.9 eq.). The reaction was allowed to stir for ~12 hours. Reaction was concentrated using a genevac followed by silica chromatography (Gradient: 0%-30% methanol in ethyl acetate) producing **#149** (154 mg, 30%) as a solid. LC-MS (Protocol Q): *m/z* 732.0 [M+H⁺] retention time = 1.24 minutes. ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.55 (d), 8.38-8.46 (m), 8.29 (d), 8.03-8.14 (m), 7.97 (d), 7.81 (d), 7.40-7.53 (m), 7.14-7.28 (m), 7.02 (s), 4.71-4.79 (m), 4.43-4.69 (m), 3.96-4.05 (m), 3.71-3.80 (m), 3.62-3.70 (m), 3.49-3.60 (m), 3.40-3.48 (m), 3.15-3.34 (m), 3.10-3.14 (m), 3.01-3.09 (m), 2.94-3.00 (m), 2.83-2.93 (m), 2.65-2.71 (m), 2.55-2.59 (m), 2.32-2.48 (m), 2.04-2.31 (m), 1.61-1.89 (m), 1.37-1.52 (m), 1.21-1.35 (m), 1.15-1.20 (m), 1.02-1.10 (m), 0.75-1.01 (m).

Preparation of 1,2-dimethyl-L-prolyl-N-[(1S,2R)-4-{(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (#151**).**

[0555]




[0556] Step 1. Synthesis of 1,2-dimethyl-L-proline (**#150**). A parr flask containing 2-methyl-L-proline (1.0 g, 7.7 mmol, 1.0 eq.), 40 mL of methanol, Formaldehyde 37 wt. % in water (2.1 mL, 77 mmol, 10 eq.), and Palladium 10 wt. % on Carbon (313 mg, 2.94 mmol, 0.38 eq.) was placed on a parr shaker and allowed to shake under 40 psi of hydrogen for ~12 hours. Hydrogen was removed and the reaction was filtered through a pad of celite which was rinsed with a solution of 50% methanol 50% dichloromethane. Residue was concentrated *in vacuo* yielding **#150** (1.1 g, 100%) as a white slight black colored solid. LC-MS (Protocol Q): *m/z* 144.0 [M+H⁺] retention time = 0.17 minutes.

[0557] Step 2. Synthesis of 1,2-dimethyl-L-prolyl-N-[(1S,2R)-4-{(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (**#151**). To a stirring mixture of **#114** (125 mg, 0.198 mmol, 1.0 eq.), **#150** (37 mg, 0.26 mmol, 1.3 eq.), and HATU (98 mg, 0.26 mmol, 1.3 eq.) in 5 mL of dichloromethane, Hunig's base (0.14 mL, 0.80 mmol, 4.1 eq.) was added. The reaction was allowed to stir at room temperature for 1 hour. Reaction was concentrated *in vacuo*. THF (6 mL) was added to crude material. To this stirring mixture LiOH (14 mg, 0.59 mmol, 3.0 eq) dissolved in 2 mL of water was added. Reaction was allowed to stir at room temperature for 90 minutes. Reaction was concentrated *in vacuo* and residue was purified by medium pressure reverse phase C18 chromatography (Gradient: 5% to 40% acetonitrile in water with 0.02% TFA in each phase) **#151** (147 mg, 69%) as a white solid. LC-MS (Protocol Q): *m/z* 744.3 [M+H⁺], retention time = 1.19 minutes; HPLC (Protocol A at 45 °C): *m/z* 744.4 [M+H⁺], retention time = 6.631 minutes (purity > 98%). ¹H NMR (400

MHz, DMSO-*d*₆), δ 9.57-9.71 (m), 8.75 (d), 8.42 (d), 8.15 (d), 7.14-7.29 (m), 4.70-4.79 (m), 4.40-4.68 (m), 3.95-4.03 (m), 3.73-3.80 (m), 3.37-3.61 (m), 2.97-3.31 (m), 2.79-2.88 (m), 2.66-2.76 (m), 2.54-2.58 (m), 2.31-2.43 (m), 1.94-2.29 (m), 1.57-1.91 (m), 1.21-1.52 (m), 0.85-1.10 (m), 0.74-0.82 (m)

Preparation of 1,2-dimethyl-D-prolyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1S)-1-carboxy-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide (#153).

[0558]




[0559] Step 1. Synthesis of 1,2-dimethyl-D-proline (#152). To a parr flask containing 2-methyl-D-proline (432 mg, 3.34 mmol, 1.0 eq.), Formaldehyde 37 wt. % in water (1.0 mL, 37 mM, 11 eq.), 3.5 mL of methanol and 1 mL of water, Palladium 10 wt. % on Carbon (108 mg, 0.304 mmol, 0.304 eq.) was added. The flask was placed on a parr shaker and allowed to shake under 30 psi of hydrogen for ~48 hours. Hydrogen was removed and reaction was washed through a pad of celite, which was subsequently washed with methanol. The organics were concentrated *in vacuo* and then azeotroped with toluene affording #152 (517 mg, 100%) as a solid. ¹H NMR (400 MHz, methanol-*d*₄): δ [3.61-3.56 (m, 1H), 3.07-2.96 (m, 1H), 2.68 (br s, 3H), 2.34-2.22 (m, 1H), 2.01-1.88 (m, 1H), 1.87-1.73 (m, 1H), 1.40 (br s, 3H)].

[0560] Step 2. Synthesis of 1,2-dimethyl-D-prolyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1S)-1-carboxy-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide (#153). To a stirring mixture of #114 (240 mg, 0.379 mmol, 1.0 eq.), #152 (71 mg, 0.49 mmol, 1.3 eq.), and HATU (188 mg, 0.49 mmol, 1.3 eq.) in 10 mL of dichloromethane, Hunig's base (0.27 mL, 4.1 mM, 4.1 eq.) was added. The reaction was allowed to stir at room temperature for 1 hour. Reaction was concentrated *in vacuo*. THF (6 mL) was added to crude material. To this stirring mixture LiOH (36 mg, 1.5 mmol, 4 eq.) dissolved in 2 mL of water was added. Reaction was allowed to stir at room temperature for 1 hour. Reaction was concentrated *in vacuo* and residue was purified by medium pressure reverse phase C18 chromatography (Gradient: 5% to 40% acetonitrile in water with 0.02% TFA in each phase) #153 (220 mg, 78%) as a white solid. LC-MS (Protocol Q): *m/z* 744.8 [M+H]⁺, retention time = 1.16 minutes; HPLC (Protocol A at 45 °C): *t*_r 744.4 [M+H]⁺, retention time = 6.713 minutes (purity > 98%). ¹H NMR (400 MHz, DMSO-*d*₆), δ 9.72-9.85 (m), 8.65 (t), 8.41 (d), 8.14 (d), 7.14-7.28 (m), 4.69-4.79 (m), 4.38-4.53 (m), 3.95-4.04 (m), 3.73-3.79 (m), 3.37-3.62 (m), 3.13-3.33 (m), 2.95-3.10 (m), 2.79-2.89 (m), 2.67-2.75 (m), 2.00-2.46 (m), 1.61-1.90 (m), 1.22-1.54 (m), 1.02-1.09 (m), 0.95-1.01 (m), 0.85-0.94 (m), 0.75-0.83 (m)

Reference Example Preparation of N-2-[[2,2-dimethyl-3-(methylamino)propanoyl]-N-((1S,2R)-2-methoxy-4-((2S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl)amino)propyl)pyrrolidin-1-yl)-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide, trifluoroacetic acid salt (#154).

[0561]




[0562] Step 1. Synthesis of N-2-[[2,2-dimethyl-3-(methylamino)propanoyl]-N-((1S,2R)-2-methoxy-4-((2S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl)amino)propyl)pyrrolidin-1-yl)-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide, trifluoroacetic acid salt (#154). To vial containing #50 (100 mg, 0.152 mmol, 1.0 eq.) and 1 mL of dichloromethane, 2,2-dimethyl-3-(methylamino)propanoic acid (36 mg, 0.152 mmol, 1.0 eq.) was added followed by Hunig's base (0.080 mL, 0.456 mmol, 3.0 eq.) and HATU (66 mg, 0.17 mmol, 1.1 eq.). The reaction was allowed to stir at room temperature for 1 hour. The reaction was concentrated *in vacuo* and then taken up

in ethyl acetate before being washed two times with 1M HCl and once with brine. The organic layer was dried over sodium sulfate and decanted. The reaction was concentrated *in vacuo*. Dioxane (1 ml) was added followed by 4M HCl in dioxane (1.0 mL, 4.0 mmol, 26 eq.). The reaction was allowed to stir at room temperature for ~12 hours. The reaction was concentrated *in vacuo*. The crude material was purified by medium pressure reverse phase C18 chromatography (Gradient: 10% to 100% acetonitrile in water with 0.02% TFA in each phase) yielding **#154** (55.8 mg, 41%) as a solid. LC-MS (Protocol Q): *m/z* 771.8 [M+H⁺]. ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.70 (d), 8.45 (d), 7.90-8.15 (m), 7.82 (d), 7.75 (d), 7.55 (dd), 7.40 (dd), 6.90-7.10 (m), 5.10-5.30 (m), 4.45-4.55 (b), 4.30-4.45 (m), 4.20-4.30 (m), 3.75-3.90 (m), 3.50-3.60 (m), 3.15-3.40 (m), 3.05-3.15 (m), 2.85-3.05 (m), 2.60-2.85 (m), 2.25-2.40 (m), 1.80-2.25 (m), 1.70-1.80 (m), 1.20-1.60 (m), 0.80-1.10 (m), 0.05-0.80 (m).

Reference Example Preparation of methyl N-((2R,3R)-3-[(2S)-1-((3R,4S,5S)-4-[[N-[2,2-dimethyl-3-(methylamino)propanoyl]-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (#155).


[0563]



[0564] Step 1. Synthesis of methyl N-((2R,3R)-3-[(2S)-1-((3R,4S,5S)-4-[[N-[2,2-dimethyl-3-(methylamino)propanoyl]-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (**#155**). To vial containing **#114** (96.2 mg, 0.152 mmol, 1.0 eq.) and 1 mL of dichloromethane, 2,2-dimethyl-3-(methylamino)propanoic acid (36.1 mg, 0.152 mmol, 1.0 eq.) was added followed by Hunig's base (0.080 mL, 0.456 mmol, 3.0 eq.) and HATU (66 mg, 0.17 mmol, 1.1 eq.). The reaction was allowed to stir at room temperature for 1 hour. The reaction was concentrated *in vacuo* and then taken up in ethyl acetate before being washed two times with 1M HCl and once with brine. The organic layer was dried over sodium sulfate and decanted. The reaction was concentrated *in vacuo*. Dioxane (1 ml) was added followed by 4M HCl in dioxane (1.0 mL, 4.0 mmol, 26 eq.). The reaction was allowed to stir at room temperature for ~12 hours. The reaction was concentrated *in vacuo*. The crude material was purified by medium pressure reverse phase C18 chromatography (Gradient: 10% to 100% acetonitrile in water with 0.02% TFA in each phase) yielding **#155** (22.2 mg, 17%). ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.55 (d), 8.22 (d), 8.15-8.35 (m), 7.90-8.05 (m), 7.10-7.25 (m), 4.70-4.80 (m), 4.55-4.65 (m), 4.45-4.52 (m), 3.93-4.00 (m), 3.72-3.78 (m), 3.60-3.70 (m), 3.50-3.60 (m), 3.40-3.50 (m), 2.80-3.30 (m), 2.45-2.60 (m), 2.00-2.45 (m), 1.60-1.80 (m), 1.35-1.50 (m), 1.10-1.35 (m).

Preparation of methyl N-((2R,3R)-3-methoxy-3-[(2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-((2S)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (#158) and methyl N-((2R,3R)-3-methoxy-3-[(2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-((2R)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (#159)

[0565]



[0566] Step 1. (Synthesis of (2S)-1-(tert-butoxycarbonyl)-2-methylpiperidine-2-carboxylic acid (#156) and (2R)-1-(tert-butoxycarbonyl)-2-methylpiperidine-2-carboxylic acid (#157). 1-(tert-butoxycarbonyl)-2-methylpiperidine-2-carboxylic acid (500 mg, 2.06 mmol, 1 eq.) was separated by supercritical fluid chromatography (Column: Chiralcel OJ-H, 250 x 21 mm; Eluent: 90:10 carbon dioxide/ethanol; Flow Rate: 65 g/min; to give the corresponding enantiomers. The first eluting peak (retention time = 1.57 minutes) was isolated to give #156 as a gum (140 mg, 28%) (stereochemistry arbitrarily assigned as the S enantiomer). ¹H NMR (400 MHz, CDCl₃) δ 3.83-3.90 (m, 1H), 2.93-3.01 (m, 1H), 1.87-1.97 (m, 1H), 1.67-1.77 (m, 3H), 1.48-1.66 (m, 2H), 1.46 (s, 3H), 1.44 (s, 9H). Optical rotation: [α]_D²⁵ -21.7° (c 0.40, chloroform). The second eluting peak (retention time = 2.22 minutes) was isolated to give #157 as an oil (255 mg, 51%) (stereochemistry arbitrarily assigned as the R enantiomer). ¹H NMR (400 MHz, CDCl₃) δ 3.83-3.90 (m, 1H), 2.93-3.01 (m, 1H), 1.87-1.97 (m, 1H), 1.67-1.77 (m, 3H), 1.48-1.66 (m, 2H), 1.46 (s, 3H), 1.44 (s, 9H). Optical rotation: [α]_D²⁵ +30.2° (chloroform).


[0567] Step 2A. Synthesis of methyl N-((2R,3R)-3-methoxy-3-((2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-((2S)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)amino]heptanoyl)pyrrolidin-2-yl)-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (#158). To a solution of #156 (8.3 mg, 0.034 mmol, 1 eq.) in dichloromethane (0.3 mL) and *N,N*-dimethylformamide (0.05 mL), was added *N,N*-diisopropylethylamine (0.018 mL, 0.102 mmol, 3 eq.), followed by HATU (16.1 mg, 0.041 mmol, 1.2 eq.). The reaction was stirred for 15 minutes and #114 (23.4 mg, 0.037 mmol, 1.1 eq.) was added and stirred at room temperature for 18 hours. The reaction was diluted with dichloromethane (2.5 mL) and 10 % citric acid (1.5 mL) was added. The layers were separated using a phase separator cartridge and the aqueous layer extracted with dichloromethane (2 X 2.5 mL) and the combined organic layers were concentrated *in vacuo*. The residue was dissolved in dichloromethane (4 mL) and trifluoroacetic acid (0.5 mL) was added. The reaction was stirred at room temperature for 2 hours, then concentrated *in vacuo*. Purification by reverse phase chromatography (method M*) afforded #158 (10.6 mg, 49%). HPLC (Protocol T): *m/z* 758.4 [M+H⁺], retention time = 2.53 minutes (purity >99%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.74-8.90 (m), 8.49-8.55(m), 8.24 (d), 8.08-8.12 (m), 7.94-8.01 (m), 7.14-7.26 (m), 4.71-4.77 (m), 4.57-4.68 (m), 4.44-4.55(m), 3.94-4.0 (m), 3.73-3.78 (m), 3.40-3.72 (m), 3.16-3.32 (m), 2.98-3.16 (m), 2.82-2.92 (m), 2.47-2.56 (m), 2.38-2.44 (m), 2.20-2.37 (m), 2.08-2.19 (m) 1.74-1.88 (m), 1.61-1.73 (m), 1.52-1.59 (m), 1.22-1.52 (m), 1.05 (dd), 0.94-1.00 (m), 0.85-0.93 (m), 0.74-0.79 (m).

[0568] Step 2B. Synthesis of methyl N-((2R,3R)-3-methoxy-3-((2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-((2R)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)amino]heptanoyl)pyrrolidin-2-yl)-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (#159). To a solution of #157 (7.8 mg, 0.032 mmol, 1 eq.) in dichloromethane (0.3 mL) and *N,N*-dimethylformamide (0.05 mL), was added *N,N*-diisopropylethylamine (0.017 mL, 0.096 mmol, 3 eq.) followed by HATU (14.9 mg, 0.038 mmol, 1.2 eq.). The reaction was stirred for 15 minutes and #114 (22.1 mg, 0.035 mmol, 1.1 eq.) was added and stirred at room temperature for 3 hours and then concentrated *in vacuo*. Purification of the residue by silica gel chromatography (Gradient: 0 to 80% acetone in heptane) afforded a white solid which was dissolved in dioxane (0.2 mL) and 4N HCl in dioxane (0.2 mL) was added. The reaction was stirred at room temperature for 2 hours and additional 4N HCl in dioxane (0.1 mL) was added. The reaction was stirred for 2 hours at room temperature, concentrated *in vacuo*. Purification by reverse phase chromatography (Method M*) afforded #159 (6.6 mg, 33 %). HPLC (Protocol T): *m/z* 758.4 [M+H⁺], retention time = 2.46 minutes (purity = 89%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.86-8.95 (m), 8.75-8.84(m), 8.48-8.54 (m), 8.33-8.45 (m), 8.22-8.27 (m), 8.17-8.19 (m), 7.99-8.12 (m), 7.83-7.91 (m), 7.13-7.29

(m), 7.04-7.08 (m), 4.69-4.76 (m), 4.55-4.66 (m), 4.45-4.53 (m), 3.96-4.01 (m), 3.41-3.78 (m), 3.28-3.33 (m), 3.24-3.27 (m), 3.16-3.23 (m), 3.11-3.15 (m), 3.02-3.10 (m), 2.93-3.02 (m), 2.91-2.93 (m), 2.84-2.91 (m), 2.76-2.82 (m), 2.69-2.71 (m), 2.60-2.63 (m), 2.53-2.55 (m), 2.47-2.53 (m), 2.40-2.46 (m), 2.30-2.38 (m), 2.20-2.30 (m), 2.06-2.17 (m), 1.75-1.87 (m), 1.52-1.74 (m), 1.35-1.51 (m), 1.14-1.34 (m), 1.01-1.08 (m), 0.92-1.0 (m), 0.85-0.94 (m), 0.74-0.82 (m).

Preparation of N-((2R,3R)-3-methoxy-3-((2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-((2S)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)amino]heptanoyl)pyrrolidin-2-yl]-2-methylpropanoyl)-L-phenylalanine, trifluoroacetic acid salt (#162) and N-((2R,3R)-3-methoxy-3-((2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-((2R)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)amino]heptanoyl)pyrrolidin-2-yl]-2-methylpropanoyl)-L-phenylalanine, trifluoroacetic acid salt. (#163).

[0569]



[0570] Step 1A. Synthesis of methyl N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((2S)-1-(tert-butoxycarbonyl)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalaninate (**#160**). To a solution of **#156** (106 mg, 0.436 mmol, 1 eq.) in dichloromethane (3 mL) and *N,N*-dimethylformamide (0.5 mL) was added diisopropylethylamine (0.228 mL, 1.31 mmol, 3 eq.) followed by HATU (205 mg, 0.523 mmol, 1.2 eq.). The reaction was stirred for 15 minutes and **#114** (276 mg, 0.436 mmol, 1 eq.) was added and stirred at room temperature for 2 hours. The reaction was diluted with dichloromethane (10 mL) and washed with 10% citric acid (3 X 5 mL). The organic layer was dried over sodium sulfate, filtered and the filtrate concentrated *in vacuo*. Purification of the residue by silica gel chromatography (Gradient: 0 to 80% acetone in heptane) afforded **#160** (145 mg, 39%). LC-MS (protocol Q1): *m/z* 858.8 [M+H⁺], retention time = 1.12 minutes.

[0571] Step 1B. Synthesis of methyl N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((2R)-1-(tert-butoxycarbonyl)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalaninate (**#161**). To a solution of **#157** (109 mg, 0.448 mmol, 1 eq.) in dichloromethane (3 mL) and *N,N*-dimethylformamide (0.5 mL), was added diisopropylethylamine (0.234 mL, 1.34 mmol, 3 eq.) followed by HATU (205 mg, 0.538 mmol, 1.2 eq.). The reaction stirred for 15 minutes and **#114** (284 mg, 0.448 mmol, 1 eq.) was added. After stirring at room temperature for 2 hours, the mixture was diluted with dichloromethane (10 mL), washed with 10 % citric acid (3 X 5 mL). The organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo*. Purification of the residue by silica gel chromatography (Gradient: 0 to 100% acetone in heptane) afforded **#161** (185 mg, 48%). LC-MS (Protocol Q): *m/z* 858.3 [M+H⁺], retention time = 2.25 minutes.

[0572] Step 2A. Synthesis of N-((2R,3R)-3-methoxy-3-((2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-((2S)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)amino]heptanoyl)pyrrolidin-2-yl)-2-methylpropanoyl)-L-phenylalanine, trifluoroacetic acid salt (**#162**). To a solution of **#160** (145 mg, 0.169 mmol, 1 eq.) in tetrahydrofuran (1.25 mL) was added lithium hydroxide (8 mg, 0.338 mmol, 2 eq.) dissolved in water (0.75 mL). The reaction was stirred at room temperature for 2 hours and evaporated to dryness *in vacuo*. The residue was dissolved in dichloromethane (2.5 mL) and trifluoroacetic acid (1 mL) was added. The reaction was stirred for 30 minutes, concentrated *in vacuo* and purified by medium pressure reverse phase C18 chromatography (Gradient: 0% to 100% acetonitrile in water with 0.02% TFA in each phase) to afford the title compound **#162** (145 mg, quantitative) as a white solid. HPLC (Protocol U): *m/z* 744.5 [M+H⁺], retention time = 7.121 minutes (purity = 98%). ¹H NMR (400 MHz, DMSO-*d*₆). δ 8.76-8.96 (m), 8.52-8.58 (m), 8.38-8.43 (m), 8.11-8.16 (m), 7.27-7.30 (m), 7.12-7.27 (m), 7.01-7.05 (m), 4.71-4.79 (m), 4.48-4.67 (m), 4.39-4.47 (m), 3.79-4.22 (m), 3.71-3.78 (m), 3.38-3.57 (m), 3.22-3.30 (m), 3.14-3.23 (m), 3.07-3.13 (m), 2.96-3.06 (m), 2.76-2.87


(m), 2.66-2.68 (m), 2.47-2.57 (m), 2.42-2.44 (m), 2.06-2.40 (m), 1.73-1.89 (m), 1.51-1.72 (m), 1.36-1.49 (m), 1.20-1.35 (m), 1.00-1.09 (m), 0.95-0.99 (m), 0.83-0.94 (m), 0.73-0.80 (m).

[0574] Step 2B. Synthesis of N-((2R,3R)-3-methoxy-3-((2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(N-((2R)-2-methylpiperidin-2-yl)carbonyl)-L-valyl)amino]heptanoyl)pyrrolidin-2-yl)-2-methylpropanoyl)-L-phenylalanine, trifluoroacetic acid salt (**#163**). Compound **#161** (185 mg, 0.216 mmol, 1 eq.) was converted to the crude title compound **#163**,

using the procedure described for the preparation of **#162**. The crude material was purified by medium pressure reverse phase C18 chromatography (Gradient: 0% to 85% acetonitrile in water with 0.02% TFA in each phase) to yield **#163** (127 mg, 68%) as a white solid. HPLC (Protocol U): m/z 744.5 $[M+H]^+$, retention time = 7.077 minutes (purity = 98%). ^1H NMR (400 MHz, DMSO- d_6): δ 8.79-8.99 (m), 8.36-8.49 (m), 8.12-8.17 (m), 7.31-7.34 (m), 7.11-7.27 (m), 7.05-7.09 (m), 4.71-4.77 (m), 4.54-4.68 (m), 4.40-4.53 (m), 3.88-4.39 (m), 3.71-3.77 (m), 3.39-3.58 (m), 3.22-3.32 (m), 3.10-3.22 (m), 3.04-3.09 (m), 2.92-3.03 (m), 2.77-2.88 (m), 2.68-2.71 (m), 2.47-2.57 (m), 2.43-2.45 (m), 2.30-2.42 (m), 2.03-2.29 (m), 1.74-1.88 (m), 1.52-1.73 (m), 1.37-1.51 (m), 1.17-1.37 (m), 1.00-1.07 (m), 0.95-0.99 (m), 0.84-0.93 (m), 0.73-0.81 (m).

Reference Example Preparation of methyl N-((2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[(N-[(3R)-3-fluoropyrrolidin-3-yl]carbonyl)-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (#172**) and Reference Example methyl N-((2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[(N-[(3R)-3-fluoropyrrolidin-3-yl]carbonyl)-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (**#173**).**

[0575]



[0576] Step 1. Synthesis of methyl (3R)-1-benzyl-3-fluoropyrrolidine-3-carboxylate (**#164**) and methyl (3S)-1-benzyl-3-fluoropyrrolidine-3-carboxylate (**#165**). Known (methyl 1-benzyl-3-fluoropyrrolidine-3-carboxylate (3900 mg, 16.4 mmol, 1 eq.) was separated by supercritical fluid chromatography (Column: Chiralpak IC, 250 x 21 mm; Eluent: 95:5 carbon dioxide/propanol; Flow Rate: 65 g/min; to give the corresponding enantiomers. The first eluting peak (retention time = 3.37 minutes) was isolated to afford **#164** (1720 mg, 36%) as a single enantiomer (stereochemistry arbitrarily assigned as R enantiomer). ^1H NMR (400 MHz, TMS- $CDCl_3$): δ 7.17-7.30 (m, 5H), 3.74 (s, 3H), 3.65 (d, J = 12.9 Hz, 1H), 3.63 (d, J = 12.9 Hz, 1H), 2.86-3.03 (m, 3H), 2.61 (q, J = 8.0 Hz, 1H), 2.34-2.46 (m, 1H), 2.13-2.26 (m, 1H). Optical rotation: $[\alpha]_D^{25} +24.7^\circ$ (chloroform). The second eluting peak (retention time = 3.91 minutes) was isolated to afford **#165** (1600 mg, 33%) as a single enantiomer (stereochemistry arbitrarily assigned as S enantiomer). ^1H NMR (400 MHz, $CDCl_3$; $(CH_3)_4Si$): δ 7.17-7.30 (m, 5H), 3.74 (s, 3H), 3.65 (d, J = 12.9 Hz, 1H), 3.63 (d, J = 12.9 Hz, 1H), 2.86-3.03 (m, 3H), 2.61 (q, J = 8.0 Hz, 1H), 2.34-2.46 (m, 1H), 2.13-2.26 (m, 1H). Optical rotation: $[\alpha]_D^{25} -23.3^\circ$ (chloroform).

[0577] Step 2A. Synthesis of 1-tert-butyl 3-methyl (3R)-3-fluoropyrrolidine-1,3-dicarboxylate (**#166**). To a solution containing **#164** (355mg, 1.50 mmol, 1 eq.) and Di-tert-butyl carbonate (400mg, 1.8 mmol, 1.2 eq.) in methanol (15.5 mL) was added 10% Pd/C (70 mg). The reaction was hydrogenated at 45 psi in a Parr shaker at for 22 hours, filtered over celite, and the filtrate concentrated *in vacuo* and purified by silica gel chromatography (Gradient: 0 to 30% ethyl acetate in heptane) to afford **#166** as a clear oil. (272 mg, 74%). ^1H NMR (400 MHz, $CDCl_3$): δ 3.87 (s, 3H), 3.85-3.66 (m, 3H), 3.56 (m, 1H), 2.53-2.28 (m, 2H), 1.51 (s, 9H).

[0578] Step 2B. Synthesis of 1-tert-butyl 3-methyl (3S)-3-fluoropyrrolidine-1,3-dicarboxylate (**#167**). Compound **#165** (362mg, 1.53 mmol, 1 eq.) was converted to **#167** in 63% yield using the method described above for **#164**. ^1H NMR

(400 MHz, CDCl₃), δ 3.87 (s, 3H), 3.85-3.66 (m, 3H), 3.56 (m, 1H), 2.53-2.28 (m, 2H), 1.51 (s, 9H).

[0579] Step 3A. Synthesis of (3R)-1-(tert-butoxycarbonyl)-3-fluoropyrrolidine-3-carboxylic acid (**#168**). To a solution of **#166** (272mg, 1.10 mmol, 1 eq.) dissolved in methanol (2.96 mL) was added an aqueous solution of sodium hydroxide (2.5 M, 0.88 mL) and the reaction was stirred at room temperature for 3.5 hours. The reaction was quenched with 10% aqueous citric acid (5 mL), ethyl acetate (100 mL) was added, and the layers separated. The organic layer was washed with 10% citric acid, water, and brine, dried over sodium sulfate, filtered and concentrated *in vacuo* to afford **#168** as a white solid. (253mg, 99%). ¹H NMR (400 MHz, CDCl₃), δ 3.96-3.69 (m, 3H), 3.59 (m, 1H), 2.59-2.33 (m, 2H), 1.51 (s, 9H). LC-MS (Protocol Q1): *m/z* 232.1 [M-H⁺], retention time = 0.67 minutes. Chiral HPLC retention time: 3.39 min (purity = 99%). (Column: Chiralpak AD-H, 4.6mm x 25cm, mobile phase 5-60% CO₂/Methanol, flow rate 3.0 mL/min); Optical rotation: $[\alpha]_D^{25}$ 4.8 (c= 0.52, MeOH)

[0580] Step 3B. Synthesis of (3S)-1-(tert-butoxycarbonyl)-3-fluoropyrrolidine-3-carboxylic acid (**#169**). To a solution of **#167** (238 mg, 0.963 mmol, 1 eq.) dissolved in methanol (2.6 mL) was added an aqueous solution of sodium hydroxide (2.5 M, 0.88 mL) and the reaction was stirred at room temperature for 3 hours. The reaction was then quenched with 10% aqueous citric acid (5 mL) and ethyl acetate (100 mL) was added, and the layers were separated. The organic layer was washed with 10% citric acid, water, and brine, then dried over sodium sulfate, filtered and concentrated *in vacuo* to afford **#169** as a white solid (221 mg, 99%). ¹H NMR (400 MHz, CDCl₃), δ 3.96-3.69 (m, 3H), 3.59 (m, 1H), 2.59-2.33 (m, 2H), 1.51 (s, 9H). LC-MS (Protocol Q1): *m/z* 232.1 [M-H⁺], retention time = 0.67 minutes. Chiral HPLC retention time: 3.95 min (purity = 98%)(Column: Chiralpak AD-H, 4.6mm x 25cm, mobile phase 5-60% CO₂/Methanol, flow rate 3.0 mL/min); Optical rotation: $[\alpha]_D^{25}$ -3.6 (c= 0.55, MeOH)

[0581] Step 4A. Synthesis of lithium (3R)-1-(tert-butoxycarbonyl)-3-fluoropyrrolidine-3-carboxylate (**#170**). To a solution of **#168** (50 mg, 0.21 mmol, 1 eq.) in methanol (0.2 mL) was added a solution of lithium hydroxide (9.2 mg, 0.38 mmol, 1.8 eq.) dissolved in water (0.1 mL). Next, tetrahydrofuran (0.3 mL) was added and the reaction was stirred at 45 °C for 18 hours. The reaction was concentrated *in vacuo* and the material was azeotroped (3X) with toluene (2 mL) to obtain **#170** (51mg, 100%) as a white solid which was used in the next step without further purification.

[0582] Step 4B. Synthesis of lithium (3S)-1-(tert-butoxycarbonyl)-3-fluoropyrrolidine-3-carboxylate (**#171**). To a solution of **#169** (75 mg, 0.32 mmol, 1 eq.) in methanol (0.3 mL) was added a solution of lithium hydroxide (13.8 mg, 0.572 mmol, 1.8 eq.) in water (0.4 mL). Next, tetrahydrofuran (0.45 mL) was added and the reaction was stirred at 45 °C for 18 hours. The reaction was concentrated *in vacuo* and the material was azeotroped (3X) with toluene (4 mL) to obtain **#171** (77 mg, 100%) as a white solid, which was used in the next step without further purification.


[0583] Step 5A. Synthesis of methyl N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((3R)-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (**#172**). To a suspension of **#168** (36.9 mg, 0.158 mmol, 1 eq.) and **#114** (100 mg, 0.158 mmol, 1.0 eq.) in *N,N*-dimethylformamide (0.8 mL) and dichloromethane (3.6 mL) was added *N,N*-diisopropylethylamine (0.083 mL, 0.474 mmol, 3 eq.) followed by HATU (60.7 mg, 0.158 mmol, 1.0 eq.) and the reaction was stirred at room temperature for 18 hours. The reaction was diluted with ethyl acetate and was washed successively with water, 10% aqueous citric acid (W/V), and brine. The organic layer was dried over sodium sulfate and concentrated *in vacuo* to give 220 mg (164% of theory) of a crude intermediate. A portion of this crude intermediate (50 mg, 23%) was dissolved in dichloromethane (1.5 mL) and trifluoroacetic acid (0.4 mL) was added. The mixture was stirred at room temperature for 2 hours and evaporated to dryness *in vacuo*. Purification by reverse phase chromatography (*Method M**) afforded **#172** (15.8 mg, 51%) LC-MS (Protocol Q): *m/z* 748.9 [M+H⁺] retention time = 1.29 minutes. ¹H NMR (DMSO-*d*₆), δ 9.16-9.43 (m), 8.48-8.53 (m), 8.40-8.44 (m), 8.34-8.39 (m), 8.22-8.30 (m), 8.09-8.16 (m), 7.87-7.91 (m), 7.77-7.83 (m), 7.12-7.24 (m), 4.56-4.72 (m), 4.41-4.54 (m), 3.92-4.00 (m), 3.70-3.75 (m), 3.39-3.66 (m), 3.20-3.25 (m), 3.12-3.20 (m), 2.97-3.11 (m), 2.94 (br s), 2.75-2.89 (m), 2.63-2.69 (m), 2.47-2.54 (m), 2.29-2.45 (m), 2.15-2.27 (m), 2.02-2.15 (m), 1.57-1.87 (m), 1.33-1.51 (m), 1.19-1.30 (m), 1.02 (dd), 0.82-0.97 (m), 0.70-0.79 (m).

[0584] Step 5B. Synthesis of methyl N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((3R)-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalaninate, trifluoroacetic acid salt (**#173**). To a suspension of **#169** (36.9 mg, 0.158 mmol, 1eq.) and **#114** (100.0 mg, 0.158 mmol, 1 eq.) in *N,N*-dimethylformamide (0.8 mL) and dichloromethane (3.6 mL) was added *N,N*-diisopropylethylamine (0.083 mL, 0.474 mmol, 3 eq.) was added, followed by HATU (60.7 mg, 0.158 mmol, 1 eq.). The reaction was stirred at room temperature for 14 hours, diluted with ethyl acetate, and washed successively with water, 10% aqueous citric acid (W/V), and brine. The organic layer was dried over sodium sulfate and concentrated *in vacuo* to give 180 mg (134% of theory) of a crude intermediate. A portion of this crude intermediate (50 mg, 27%) was dissolved in dichloromethane (1.5 mL) and trifluoroacetic acid (0.4 mL) was added and the mixture stirred at room temperature for 2 hours and evaporated to dryness *in vacuo*. Purification by reverse phase chromatography (*Method M**) afforded **#173** (17.6 mg, 45%). LC-MS (Protocol Q): *m/z* 748.9 [M+H⁺] retention time = 1.29 minutes. ¹H NMR (DMSO-*d*₆) δ 9.35-9.50 (m), 9.22-9.34 (m), 8.47-8.52 (m), 8.39-8.45 (m), 8.30-8.37 (m), 8.22-8.24 (m), 8.09-8.13 (m), 7.80-7.85 (m), 7.67-7.72 (m), 7.09-7.24 (m), 6.97-6.98 (m), 4.65-4.72 (m), 4.55-4.64 (m), 4.41-4.50 (m), 3.92-3.99 (m), 3.42-3.75 (m), 3.32-3.39 (m), 3.25-3.31 (m), 3.21-3.24 (m), 3.11-3.20 (m), 3.06-3.11 (m), 2.97-3.05 (m), 2.95 (br s), 2.83-2.88 (m), 2.76-2.82 (m), 2.65-2.70 (m),

2.44-2.54 (m), 2.15-2.42 (m), 2.02-2.14 (m), 1.57-1.84 (m), 1.33-1.48 (m), 1.19-1.30 (m), 1.02 (dd), 0.92-0.97(m), 0.82-0.91 (m), 0.70-0.77 (m).

Preparation of (2S)-N-[(2S)-1-[[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, hydrochloride salt (#178) and (2R)-N-[(2S)-1-[[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, hydrochloride salt (#180).

[0585]



[0586] Step 1. Synthesis of pentafluorophenyl (3R,4S,5S)-4-[[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoate (**#174**). To a solution of **#5** (19.43 g, 37.03 mmol, 1 eq.) in dichloromethane (100 mL) and pyridine (5.86 g, 74.1 mmol, 2 eq.) was added pentafluorophenyl trifluoroacetate (20.7 g, 74.1 mmol, 2 eq.) and the reaction was stirred at room temperature for 1 hour. The reaction was concentrated *in vacuo* and purified by silica gel chromatography (Gradient: 0 to 52% ethyl acetate in heptane) to afford **#174** (23.58 g, 92%) as a yellow oil. LC-MS (Protocol Q1): *m/z* 691.2 [M+H⁺], retention time = 1.23 minutes.

[0587] Step 2. Synthesis of N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N~2~[[9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valinamide (**#175**). To a solution of **#174** (706 mg, 1.02 mmol, 1 eq.) and **#64** (311 mg, 1.02 mmol, 1 eq.) in dichloromethane (3 mL) was added *N,N*-diisopropylethylamine (400 mg, 3.07 mmol, 3 eq.). After 18 hours of stirring at room temperature, the reaction was concentrated *in vacuo* and purified by silica gel chromatography (Gradient: 0 to 100% ethyl acetate in heptane) to afford **#175** (560 mg, 68%) as a white solid. LC-MS (Protocol Q1): *m/z* 611.8 [M+H⁺], retention time = 1.15 minutes.

[0588] Step 3. Synthesis of N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#176**). According to the general procedure A, from **#175** (560 mg, 0.690 mmol, 1 eq.) in dichloromethane (9 mL), and *N,N*-diethylamine (6.0 mL), was synthesized the crude desired compound, which was purified by silica gel chromatography (Gradient: 0 to 50% methanol in dichloromethane) to afford **#176** (351 mg, 87%) as a yellow oil. LC-MS (Protocol Q1): *m/z* 589.5 [M+H⁺], retention time = 0.72 minutes.

[0589] Step 4A. Synthesis of tert-butyl (2S)-2-[[[(2S)-1-[[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]-2-methylpiperidine-1-carboxylate (**#177**). According to the general procedure D, from **#176** (100 mg, 0.170 mmol, 1 eq.), **#156** (53.8 mg, 0.221 mmol, 1.3 eq.), dichloromethane (4.5 mL), HATU (84.9 mg, 0.221 mmol, 1.3 eq.) and *N,N*-diisopropylethylamine (0.123 mL, 0.697 mmol, 4.1 eq.), was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0 to 100% ethyl acetate in heptane) to afford **#177** (145 mg, assume quantitative yield) as a white solid. LC-MS (Protocol Q1): *m/z* 814.7 [M+H⁺], retention time = 1.14 minutes.

[0590] Step 4B. Synthesis of tert-butyl (2R)-2-[[[(2S)-1-[[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]-2-methylpiperidine-1-carboxylate (**#179**). According to the general procedure D, from **#176** (100 mg, 0.170 mmol, 1 eq.), **#157** (53.8 mg, 0.221 mmol, 1.3 eq.), dichloromethane (4.5 mL), HATU (84.9


mg, 0.221 mmol, 1.3 eq.) and *N,N*-diisopropylethylamine (0.123 mL, 0.697 mmol, 4.1 eq.), was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0 to 100% ethyl acetate in heptane) to afford **#179** (155 mg, assume quantitative yield) as a white solid. LC-MS (Protocol Q1): *m/z* 814.7 [M+H⁺], retention time = 1.14 minutes.

[0591] Step 5A. Synthesis of (2S)-N-[(2S)-1-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, hydrochloride salt (**#178**). According to the general procedure C, from **#177** (143 mg, 0.176 mmol, 1 eq.) and 4M solution of hydrochloric acid in dioxane (2.0 mL) was synthesized the desired material as a gum (145 mg). A portion of this crude residue (25 mg) was azeotroped with a mixture of methanol/acetonitrile to afford **#178** (20 mg, 89% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.96-9.07 (m), 8.79-8.96 (m), 8.58 (d), 8.02-8.08 (m), 7.77-7.83 (m), 7.25-7.31 (m), 7.19-7.24 (m), 6.56-6.67 (m), 6.12-6.21 (m), 5.13-5.22 (m), 4.72-4.81 (m), 4.63-4.70 (m), 4.50-4.59 (m), 4.07-4.16 (m), 3.98-4.05 (m), 3.80-3.86 (m), 3.55-3.76 (m), 3.46-3.54 (m), 3.38-3.44 (m), 3.26-3.35 (m), 3.18-3.24 (m), 3.05-3.18 (m), 2.98-3.04 (m), 2.40-2.55 (m), 2.27-2.35 (m), 2.08-2.27 (m), 1.74-1.98 (m), 1.50-1.74 (m), 1.20-1.46 (m), 0.73-1.16 (m). LC-MS (Protocol Q1): *m/z* 714.6 [M+H⁺], retention time = 0.76 minutes. HPLC (Protocol U): *m/z* 714.5 [M+H⁺] retention time = 7.124 minutes (purity = 91%).

[0592] Step 5B. Synthesis of (2R)-N-[(2S)-1-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, hydrochloride salt (**#180**). According to the general procedure C, from **#179** (162 mg, 0.199 mmol, 1 eq.) and 4M solution of hydrochloric acid in dioxane (2.0 mL) was synthesized the desired material as a gum (155 mg). A portion of this gum (25 mg) was azeotroped with a 1/1 mixture of methanol/acetonitrile to afford **#180** (20 mg, 83%) as a solid. ¹H NMR (400 MHz, DMSO-*d*₆), δ 9.02-9.13 (m), 8.83-8.93 (m), 8.39-8.46 (m), 8.00-8.06 (m), 7.78 (t), 7.24-7.30 (m), 7.16-7.21 (m), 6.54-6.65 (m), 6.09-6.19 (m), 5.11-5.18 (m), 4.69-4.78 (m), 4.59-4.68 (m), 4.46-4.56 (m), 4.08-4.13 (m), 3.95-4.03 (m), 3.77-3.85 (m), 3.54-3.73 (m), 3.43-3.53 (m), 3.37-3.42 (m), 3.24-3.33 (m), 3.16-3.22 (m), 3.03-3.15 (m), 2.99-3.02 (m), 2.89-2.98 (m), 2.65-2.76 (m), 2.41-2.54 (m), 2.15-2.39 (m), 2.07-2.15 (m), 1.51-1.94 (m), 1.49 (d), 1.38 (t), 1.20-1.32 (m), 1.02-1.09 (m), 0.84-0.97 (m), 0.73-0.81 (m). LC-MS (Protocol Q1): *m/z* 714.6 [M+H⁺], retention time = 0.76 HPLC (Protocol U): *m/z* 714.4 [M+H⁺], retention time = 7.409 minutes (purity = 90%).

Preparation of 2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, formic acid salt (#182**) and Reference Example N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N~2~[[[(3R)-3-fluoropyrrolidin-3-yl]carbonyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#184**) and Reference Example N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N~2~[[[(3S)-3-fluoropyrrolidin-3-yl]carbonyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#186**).**

[0593]



[0594] Step 1A. Synthesis of 1-(tert-butoxycarbonyl)-2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#181**). According to the general procedure D, from **#176** (100 mg, 0.170 mmol, 1 eq.), (S)-1-(tert-butoxycarbonyl)-2-methyl-L-proline (50.7 mg, 0.221 mmol, 1.3 eq.), dichloromethane (4.3 mL), HATU (84.9 mg, 0.221 mmol, 1.3 eq.) and *N,N*-diisopropylethylamine (0.123 mL, 0.697 mmol, 4.1 eq.), was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0 to 100% ethyl acetate in heptane) to afford **#181** (142 mg, assume quantitative yield). LC-MS (Protocol Q1): *m/z* 800.6 [M+H⁺], retention time = 1.11 minutes.

[0595] Step 1B. Synthesis of tert-butyl (3R)-3-[[[(2S)-1-[[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]-3-fluoropyrrolidine-1-carboxylate (**#183**). To a solution of **#170** (18.2 mg, 0.076 mmol, 1 eq.) in dichloromethane (1.8 mL) and *N,N*-dimethylformamide (0.3 mL) was added *N,N*-diisopropylethylamine (0.040 mL, 0.228 mmol, 3 eq.) followed by HATU (29.2 mg, 0.076 mmol, 1 eq.). After stirring for 10 minutes at room temperature, **#176** (45 mg, 0.076 mmol, 1 eq.) was added. The reaction was stirred at room temperature for 18 hours and additional HATU (29 mg, 0.076 mmol, 1 eq.) was added. After 8 hours the reaction was concentrated *in vacuo* to provide **#183** (61.0 mg, quantitative) which was taken into the next step without further purification. LC-MS (Protocol Q1): *m/z* 826.6 [M+Na⁺], retention time = 1.05 minutes.

[0596] Step 1C. Synthesis of tert-butyl (3S)-3-[[[(2S)-1-[[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]-3-fluorocyclopentanecarboxylate (**#185**). To a solution of **#171** (24 mg, 0.1 mmol, 1 eq.) in dichloromethane (2.35 mL) and *N,N*-dimethylformamide (0.33 mL) was added *N,N*-diisopropylethylamine (0.053 mL, 0.300 mmol, 3 eq.) followed by HATU (38.4 mg, 0.100 mmol, 1 eq.). After stirring at room temperature for 10 minutes, **#176** (58.9 mg, 0.1 mmol, 1 eq.) was added. The reaction was stirred at room temperature for 18 hours and additional quantity of HATU (38.4 mg, 0.100 mmol, 1 eq.) and *N,N*-dimethylformamide (0.2 mL) was added and stirred for an additional 9 hours. The reaction was concentrated *in vacuo* to give **#185** (80 mg, quantitative), which was taken into the next step without further purification. LC-MS (Protocol Q1): *m/z* 804.6 [M+H⁺], retention time = 1.05 minutes.

[0597] Step 2A. Synthesis of 2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, formic acid salt (**#182**). According to the general procedure C, from **#181** (136 mg, 0.170 mmol, 1 eq.) and 4M solution of hydrochloric acid in dioxane (2 mL) was synthesized the desired material as a gum (142 mg). A portion of this crude residue (20 mg, 14%) was azeotroped with a 1/1 mixture of methanol/acetonitrile and then purified by reverse phase chromatography (*Method O*) to obtain **#182** (10 mg, 57% over two steps) as a solid. HPLC (Protocol U): *m/z* 700.4 [M+H⁺], retention time = 7.106 minutes (purity > 90%). ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.25-8.39 (m), 8.20-8.25 (m), 7.96-7.99 (m), 7.74-7.77 (m), 6.55-6.63 (m), 6.10-6.18 (m), 5.11-5.18 (m), 4.66-4.72 (m), 4.51-4.61 (m), 4.46-4.50 (m), 3.96-4.01 (m), 3.37-3.86 (m), 3.20-3.36 (m), 3.11-3.19 (m), 3.03-3.11 (m), 2.98-3.03 (m), 2.90-2.96 (m), 2.77-2.79 (m), 2.65-2.73 (m), 2.57-2.63 (m), 2.47-2.56 (m), 2.36-2.46 (m), 2.26-2.32 (m), 2.14-2.25 (m), 2.03-2.10 (m), 1.92-2.03 (m), 1.72-1.92 (m), 1.64-1.72 (m), 1.60-1.64 (m), 1.50-1.59 (m), 1.39-1.48 (m), 1.23-1.32 (m), 1.18-1.22 (m), 1.12-1.14 (m), 1.01-1.09 (m), 0.83-1.00 (m), 0.74-0.83 (m), 0.70-0.74 (m).


[0598] Step 2B. Synthesis of N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-2-[[[(3R)-3-fluoropyrrolidin-3-yl]carbonyl]-N-methyl-L-valinamide trifluoroacetic acid salt (**#184**). According to the general procedure C, from **#183** (61.1 mg, 0.076 mmol, 1 eq.), dichloromethane (0.3 mL), and a 4M solution of hydrochloric acid in dioxane (0.9 mL) was synthesized the crude desired material (140 mg). A portion of the crude material (98 mg, 69 %) was purified by reverse phase chromatography (*Method M**) to give **#184** (7.6 mg, 20% over two steps). HPLC (Protocol T): *m/z* 704.5 [M+H⁺], retention time = 2.50 minutes (purity = 84%). ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.67-8.71 (m), 8.44-8.48 (m), 8.27-8.33 (m), 8.22-8.27 (m), 7.97-8.03 (m), 7.84-7.89 (m), 7.74-7.81 (m), 7.43-7.48 (m), 7.23-7.29 (m), 7.17-7.21 (m), 6.55-6.66 (m), 6.10-6.19 (m), 5.10-5.19 (m), 4.66-4.75 (m), 4.51-4.63 (m), 3.96-4.04 (m), 3.78-3.85 (m), 3.65-3.73 (m), 3.46-3.62 (m), 3.37-3.45 (m), 3.24-3.37 (m), 3.21-3.24 (m), 3.13-3.21 (m), 3.02-3.13 (m), 2.95-3.00 (m), 2.80-2.82 (m), 2.66-2.71 (m), 2.47-2.57 (m), 2.24-2.46 (m), 2.09-2.24 (m), 1.95-2.05 (m), 1.49-1.93 (m), 1.22-1.34 (m), 1.02-1.09 (m), 0.83-1.01 (m), 0.74-0.82 (m).

[0599] Step 2C. Synthesis of N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-2-[[[(3S)-3-fluoropyrrolidin-3-yl]carbonyl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#186**). According to the general procedure C, from **#185** (80.3 mg, 0.1 mmol, 1 eq.), dichloromethane (0.4 mL), and a 4M solution of hydrochloric acid in dioxane (1.2 mL) was synthesized the crude desired material, in which a portion (94 mg, 53%) was purified by reverse phase chromatography (*Method M**) to give **#186** (11.8 mg, 32% over two steps). ¹H NMR (400 MHz, DMSO-*d*₆), δ 8.85-9.07 (m), 8.29-8.41 (m), 7.99-8.04 (m), 7.76-7.84 (m), 6.56-6.68 (m), 6.12-6.21 (m), 5.12-5.21 (m), 4.87-4.99 (m), 4.69-4.79 (m), 4.49-4.67 (m), 3.98-4.06 (m), 3.80-3.87 (m), 3.64-3.76 (m), 3.55-3.64 (m), 3.47-3.54 (m), 3.39-3.46 (m), 3.26-3.39 (m), 3.22-3.25 (m), 3.18-3.22 (m), 3.06-3.14 (m), 2.98-3.01 (m), 2.55-2.57 (m), 2.42-2.49 (m), 2.11-2.38 (m), 2.09 (s), 1.78-1.97 (m),

1.72-1.77 (m), 1.51-1.71 (m), 1.24-1.36 (m), 1.07 (dd), 0.83-1.03 (m), 0.75- 0.82 (m). HPLC (Protocol T): m/z 704.5 $[M+H^+]$, retention time = 2.48 minutes (purity = 100%).

Preparation of (2S)-N-[(2S)-1-[[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, formate salt (#188) and (2R)-N-[(2S)-1-[[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, formate salt (#190) and Reference Example N~2~-[[(3R)-3-fluoropyrrolidin-3-yl]carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt. (#192) and Reference Example N~2~-[[(3S)-3-fluoropyrrolidin-3-yl]carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt. (#194).

[0600]



[0601] Step 1A. Synthesis of tert-butyl (2S)-2-[[[(2S)-1-[[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]carbonyl]-2-methylpiperidine-1-carboxylate (#187). According to the general procedure D, from #86 (280 mg, 0.4 mmol, 1 eq.), #156 (100 mg, 0.4 mmol, 1 eq.), dichloromethane (5 mL), HATU (182 mg, 0.48 mmol, 1.2 eq.) and *N,N*-diisopropylethylamine (100 mg, 0.8 mmol, 2 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0.01 to 0.05% methanol in dichloromethane) to afford #187 (220 mg, 62%) as a white solid. HPLC (Protocol V): m/z 883.57 $[M+H^+]$, retention time = 3.23 minutes (purity = 95%).

[0602] Step 1B. Synthesis of tert-butyl (2R)-2-[[[(2S)-1-[[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]carbonyl]-2-methylpiperidine-1-carboxylate (#189). According to the general procedure D, from #86 (400 mg, 0.6 mmol, 1 eq.), #157 (146 mg, 0.6 mmol, 1 eq.), dichloromethane (10 mL), HATU (259 mg, 0.72 mmol, 1.2 eq.) and *N,N*-diisopropylethylamine (158 mg, 1.2 mmol, 2 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 0.01 to 0.05% methanol in dichloromethane) to afford #189 (220 mg, 37%) as a white solid. HPLC (Protocol W): m/z 883.7 $[M+H^+]$, retention time = 4.12 minutes (purity = 95%).

[0603] Step 1C. Synthesis of tert-butyl (3R)-3-fluoro-3-[[[(2S)-1-[[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]carbonyl]pyrrolidine-1-carboxylate (#191). According to the general procedure D, from #86 (300 mg, 0.45 mmol, 1 eq.), #168 (106 mg, 0.45 mmol, 1 eq.), dichloromethane (10 mL), HATU (194 mg, 0.54 mmol, 1.2 eq.) and diisopropylethylamine (117 mg, 0.9 mmol, 2 eq.) was synthesized the crude desired material, which was purified by reverse phase chromatography (Method P) to afford #191 (159 mg, 40%) as a white solid. HPLC (Protocol X): m/z 873.4 $[M+H^+]$, retention time = 3.32 minutes (purity = 99%).

[0604] Step 1D. Synthesis of tert-butyl (3S)-3-fluoro-3-[[[(2S)-1-[[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]carbonyl]pyrrolidine-1-carboxylate (#193). According to the general procedure D, from #86 (300 mg, 0.45 mmol, 1 eq.), #169 (106 mg, 0.45 mmol, 1 eq.), dichloromethane (10 mL), HATU (194 mg, 0.54 mmol, 1.2 eq.) and diisopropylethylamine (117 mg, 0.9 mmol, 2 eq.) was synthesized the crude desired material, which was purified by reverse phase chromatography (Method P) to afford #193 (159 mg, 40%) as a white solid. HPLC (Protocol X): m/z 873.4 $[M+H^+]$, retention time = 3.32 minutes (purity = 99%).

oxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methylamino)-3-methyl-1-oxobutan-2-yl]carbonyl]pyrrolidine-1-carboxylate (**#193**). According to the general procedure D, from **#86** (300 mg, 0.45 mmol, 1 eq.), **#169** (106 mg, 0.45 mmol, 1 eq.), dichloromethane (10 mL), HATU (194 mg, 0.54 mmol, 1.2 eq.) and diisopropylethylamine (117 mg, 0.9 mmol, 2 eq.) was synthesized the crude desired material, which was purified by reverse phase chromatography (*Method P*) to afford **#193** (149 mg, 37%) as a white solid. HPLC (Protocol X): *m/z* 873.4 [M+H⁺], retention time = 3.34 minutes (purity = 98%).

[0605] Step 2A. Synthesis of (2S)-N-[(2S)-1-[[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methylamino)-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, formic acid salt (**#188**). According to the general procedure C, from **#187** (20 mg, 0.023 mmol, 1 eq.), dichloromethane (0.1 mL), acetonitrile (0.1 mL) and 4M solution of hydrochloric acid in dioxane (0.26 mL) was synthesized the crude desired material, which was purified by reverse phase chromatography (*Method N**) to obtain **#188** (11.6 mg, 61%); HPLC (Protocol T): *m/z* 783.8 [M+H⁺], retention time = 2.53 minutes (purity = 96%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.82-8.87 (m), 8.60-8.63 (m), 8.26-8.29 (m), 7.84-7.90 (m), 7.75-7.81 (m), 7.60-7.67 (m), 7.21-7.31 (m), 7.14-7.19 (m), 5.49-5.55 (m), 5.37-5.42 (m), 4.69-4.75 (m), 4.59-4.65 (m), 4.50-4.56 (m), 3.95-4.01 (m), 3.77-3.82 (m), 3.54-3.61 (m), 3.47-3.53 (m), 3.24-3.45 (m), 3.14-3.23 (m), 3.03-3.08 (m), 2.96-3.03 (m), 2.78-2.80 (m), 2.64-2.73 (m), 2.60-2.62 (m), 2.47-2.56 (m), 2.31-2.45 (m), 2.13-2.28 (m), 2.00-2.07 (m), 1.92-1.99 (m), 1.71-1.86 (m), 1.58-1.70 (m), 1.50-1.56 (m), 1.38-1.49 (m), 1.15-1.36 (m), 1.08-1.14 (m), 1.03-1.07 (m), 0.90-1.02 (m), 0.83-0.90 (m), 0.73-0.80 (m), 0.70-0.73 (m).


[0606] Step 2B. Synthesis of (2R)-N-[(2S)-1-[[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methylamino)-3-methyl-1-oxobutan-2-yl]-2-methylpiperidine-2-carboxamide, formic acid salt. (**#190**). According to the general procedure C, from **#189** (20 mg, 0.022 mmol, 1 eq.), dichloromethane (0.1 mL), acetonitrile (0.1 mL) and 4M solution of hydrochloric acid in dioxane (0.26 mL) was synthesized the crude desired material, which was purified by reverse phase chromatography (*Method N**) to obtain **#190** (13.2 mg, 73%); HPLC (Protocol T): *m/z* 783.7 [M+H⁺], retention time = 2.5 minutes (purity = 100%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83-8.86 (m), 8.60-8.62 (m), 8.24-8.27 (m), 7.83-7.89 (m), 7.78-7.80 (m), 7.75-7.77 (m), 7.64-7.66 (m), 7.60-7.63 (m), 7.20-7.31 (m), 7.13-7.19 (m), 5.49-5.55 (m), 5.36-5.42 (m), 4.65-4.74 (m), 4.60-4.65 (m), 4.50-4.56 (m), 3.95-4.01 (m), 3.76-3.81 (m), 3.53-3.62 (m), 3.47-3.52 (m), 3.22-3.45 (m), 3.14-3.21 (m), 2.97-3.05 (m), 2.93-2.96 (m), 2.79-2.86 (m), 2.76-2.78 (m), 2.65-2.68 (m), 2.48-2.56 (m), 2.37-2.43 (m), 2.29-2.35 (m), 2.17-2.27 (m), 2.04-2.11 (m), 1.93-2.00 (m), 1.70-1.85 (m), 1.53-1.69 (m), 1.36-1.48 (m), 1.28-1.36 (m), 1.13-1.26 (m), 1.08-1.12 (m), 0.98-1.07 (m), 0.91-0.97 (m), 0.84-0.91 (m), 0.73-0.78 (m).

[0607] Step 2C. Synthesis of N-2-~[[[(3R)-3-fluoropyrrolidin-3-yl]carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt. (**#192**). According to the general procedure C, from **#191** (10 mg, 0.011 mmol, 1 eq.), dichloromethane (0.1 mL), acetonitrile (0.1 mL) and 4M solution of hydrochloric acid in dioxane (0.13 mL) was synthesized the crude desired material, which was purified by reverse phase chromatography (*Method M**) to obtain **#192** (5.1 mg, 60 %); HPLC (Protocol T): *m/z* 773.5 [M+H⁺], retention time = 2.43 minutes (purity = 100%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.32-9.44 (m), 9.17-9.21 (m), 8.91 (d), 8.63-8.69 (m), 8.38-8.43 (m), 8.22-8.27 (m), 7.80 (dd), 7.66 (dd), 7.14-7.33 (m), 5.49-5.57 (m), 5.37-5.45 (m), 4.10-4.78 (m), 3.97-4.06 (m), 3.77-3.83 (m), 3.33-3.65 (m), 3.15-3.29 (m), 2.95-3.09 (m), 2.82-2.83 (m), 2.67-2.71 (m), 2.55-2.57 (m), 2.32-2.54 (m), 2.10-2.31 (m), 2.09 (s), 1.72-1.90 (m), 1.57-1.72 (m), 1.38-1.50 (m), 1.15-1.38 (m), 1.09 (dd), 0.85-1.0 (m), 0.75-0.83 (m).

[0608] Step 2D. Synthesis of N-2-~[[[(3S)-3-fluoropyrrolidin-3-yl]carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt. (**#194**). According to the general procedure C, from **#193** (10 mg, 0.011 mmol, 1 eq.), dichloromethane (0.1 mL), acetonitrile (0.1 mL) and 4M solution of hydrochloric acid in dioxane (0.13 mL) was synthesized the crude desired material, which was purified by reverse phase chromatography (*Method M**) to obtain **#194** (9 mg, 93%); HPLC (Protocol T): *m/z* 773.8 [M+H⁺], retention time = 2.42 minutes (purity = 100%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.39-9.52 (m), 9.21-9.35 (m), 8.90 (d), 8.63-8.69 (m), 8.42-8.48 (m), 8.29-8.34 (m), 7.80 (dd), 7.66 (dd), 7.22-7.33 (m), 7.13-7.21 (m), 5.47-5.57 (m), 5.36-5.44 (m), 4.43-4.93 (m), 3.97-4.05 (m), 3.64-3.83 (m), 3.32-3.61 (m), 3.15-3.29 (m), 3.06-3.09 (m), 2.95-3.05 (m), 2.89-2.95 (m), 2.82-2.84 (m), 2.67-2.72 (m), 2.54-2.56 (m), 2.48-2.53 (m), 2.28-2.48 (m), 2.11-2.28 (m), 2.09 (s), 1.57-1.72 (m), 1.38-1.47 (m), 1.15-1.37 (m), 1.09 (dd), 0.85-0.99 (m), 0.78 (t).

Preparation of 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-aminophenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, formate salt (#200) and 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-aminophenyl)-1-methoxy-1-oxopropan-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, formate salt (#201).

[0609]



[0610] Step 1. Synthesis of 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-tert-butoxy-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#195**). According to the general procedure D, from **#6** (7.75 g, 21.6 mmol, 1 eq.), **#152** (3.88 g, 21.6 mmol, 1 eq.), dichloromethane (100 mL), HATU (9.8 g, 25.9 mmol, 1.2 eq.), and diisopropylethylamine (11.1 g, 86.4 mmol, 4 eq.) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 20 to 55% ethyl acetate in petroleum ether) to afford **#195** (11.1 g, quantitative yield) as a yellow oil.

[0611] Step 2. Synthesis of 1,2-dimethyl-D-prolyl-N-[(2R,3S,4S)-1-carboxy-2-methoxy-4-methylhexan-3-yl]-N-methyl-L-valinamide (**#196**). According to the general procedure B, from **#195** (11.1 g, 21.6 mmol, 1 eq.), dichloromethane (100 mL) and trifluoroacetic acid (40 mL) was synthesized the crude desired material, to obtain **#196** (10.1 g, quantitative yield) which was used in the next step without further purification. LC-MS (Protocol Z): *m/z* 428.5 [*M*+*H*⁺], retention time = 0.9 minutes.

[0612] Step 3. Synthesis of 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-5-methyl-1-oxo-1-(pentafluorophenoxy)heptan-4-yl]-N-methyl-L-valinamide (**#197**). To a cooled solution (0 °C) of **#196** (4.0 g, 9.4 mmol, 1 eq.) in dichloromethane (40 mL) was added dropwise pyridine (2.95 g, 37.6 mmol, 4eq.) followed by a solution of pentafluorophenyl trifluoroacetate (3.9 g, 13.6 mmol, 1.4 eq.) in dichloromethane (5 mL). The mixture was stirred at room temperature for one hour, and the solvent was concentrated *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 1 to 10% methanol in dichloromethane) to afford compound **#197** (4.5 g, 81.2% (over three steps) as white solid.

[0613] Step 4. Synthesis of 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#198**). To a cooled solution (0 °C) of **#197** (4.0 g, 7.4 mmol, 1 eq.) in dichloromethane (25 mL) was added dropwise diisopropylethylamine (3.4 g, 26.3 mmol, 3.5 eq.) followed by a solution **#103** (2.3 g, 7.6 mmol, 1.02 eq.) in dichloromethane (15 mL). After the addition, the mixture was stirred at room temperature for 16 hours and the solvent was removed *in vacuo*. The residue

was purified by silica gel chromatography (Gradient: 1 to 10% methanol in dichloromethane) followed by a second purification by reverse phase chromatography (*Method Q*) to give **#198** (1.57 g, 57.5%) as white solid HPLC (Protocol X): *m/z* 597.49 [M+H⁺] retention time = 8.879 minutes (purity = 98%). Chiral HPLC retention time: 3.328 min (purity = 98%) Column: Column: Chiralcel OJ-H, 250 x 4.6 mm, 5 μ m; Mobile phase: methanol (0.05% diethylamine) in CO₂ from 5% to 40% over 15 minutes; Flow rate: 2.35 mL/minute.


[0614] *Step 5.* Synthesis of 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-(pentafluorophenoxy)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#199**). To a solution of **#198** (280 mg, 0.394 mmol, 1 eq.) in dichloromethane (2 mL) was added pyridine (75 mg, 0.94 mmol, 2.4 eq.) followed by a solution of pentafluorophenyl trifluoroacetate (268 mg, 0.94 mmol, 2.4 eq.) in dichloromethane (1.5 mL). The mixture was stirred at room temperature for 2.5 hours, and the solvent was concentrated *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 1 to 10% methanol in dichloromethane) to afford compound **#199** (279 mg, 39%) as white solid. LC-MS (Protocol Q1): *m/z* 763.5 [M+H⁺], retention time = 0.93 minutes.

[0615] *Step 6A.* Synthesis of 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-(1,2,3,4-tetrahydroquinolin-6-yl)propan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#200**). To a mixture of **#199** (25 mg, 0.033 mmol, 1 eq) and **#215** ((7.7 mg, 0.033 mmol, 1 eq.) in dichloromethane (1.5 mL), *N,N*-diisopropylethylamine (30.2 mg, 2.31 mmol, 7 eq.) was added. The reaction was stirred for 5 minutes and *N,N*-dimethylformamide (0.5 mL) was added. After stirring for 2 ½ hours, additional *N,N*-diisopropylethylamine (30.2 mg, 2.31 mmol, 7 eq.) was added. After 3 ½ hours, more *N,N*-dimethylformamide (0.75 mL) was added and the mixture stirred for 18 hours. Additional *N,N*-diisopropylethylamine (15.1 mg, 1.15 mmol, 3.6 eq.) and *N,N*-dimethylformamide (0.25 mL) were added and reaction stirred at room temperature for 48 hours. The reaction mixture was concentrated *in vacuo* and the crude product was purified by reverse phase chromatography (*Method M**) to give **#200** (12.9 mg, 48 %). HPLC (Protocol T): *m/z* HPLC (*Protocol T*): *m/z* 407.7, double charge [2+], retention time = 1.69 minutes (purity = 100 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.72-9.82 (m), 8.61-8.67 (m), 8.42-8.48 (m), 8.19-8.24 (m), 7.25-7.27 (m), 7.12-7.14 (m), 6.94-7.01 (m), 6.88- 6.94 (m), 6.78- 6.84 (m), 6.67- 6.74 (m), 6.57-6.64 (m), 4.69-4.77 (m), 4.60-4.68 (m), 4.53-4.60 (m), 4.46-4.53 (m), 4.37-4.45 (m), 3.97-4.05 (m), 3.76-3.81 (m), 3.62-3.67 (m), 3.53-3.62 (m), 3.44-3.52 (m), 3.32-3.38 (m), 3.27-3.32 (m), 3.22-3.27 (m), 3.15-3.22 (m), 3.06-3.14 (m), 2.97-3.01 (m), 2.92-2.96 (m), 2.74-2.83 (m), 2.61-2.74 (m), 2.57-2.61 (m), 2.48-2.56 (m), 2.37-2.46 (m), 2.25-2.36 (m), 2.00-2.20 (m), 1.67-1.91 (m), 1.47-1.60 (m), 1.37-1.47 (m), 1.24-1.35 (m), 1.03-1.10 (m), 0.95-1.00 (m), 0.88-0.94 (m), 0.76-0.83 (m).

[0616] *Step 6B.* Synthesis of 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-aminophenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#201**). To a mixture of **#199** (25 mg, 0.033 mmol, 1eq) and the commercially available methyl 4-amino-L-phenylalaninate (8.8 mg, 0.033 mmol, 1 eq.) in dichloromethane (1.5 mL), *N,N*-diisopropylethylamine (30.2 mg, 2.31 mmol, 7 eq.) was added. The reaction was stirred for 5 minutes and *N,N*-dimethylformamide (0.5 mL) was added. After 4 hours, additional *N,N*-diisopropylethylamine (37.75 mg, 2.88 mmol, 8.25 eq.) was added and the mixture stirred for 50 minutes. Additional *N,N*-dimethylformamide (0.75 mL) was added and the reaction was stirred for 66 hours, concentrated *in vacuo* and the crude product was purified by reverse phase chromatography (*Method M**) to give **#201** (14.3 mg, 56 %); HPLC (Protocol T): *m/z* 387.2, double charge [2+], retention time = 1.50 minutes (purity= 100%); ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.68-9.84 (m), 8.57-8.66 (m), 8.46-8.51 (m), 8.23-8.29 (m), 7.18-7.28 (m), 7.11-7.16 (m), 7.03-7.08 (m), 6.97-7.02 (m), 4.67-4.75 (m), 4.58-4.66 (m), 4.34-4.57 (m), 3.95-4.03 (m), 3.85-3.90 (m), 3.73-3.81 (m), 3.66-3.72 (m), 3.57-3.66 (m), 3.50-3.57 (m), 3.42-3.49 (m), 3.32-3.38 (m), 3.14-3.30 (m), 2.95-3.11 (m), 2.84-2.94 (m), 2.78-2.81 (m), 2.63-2.74 (m), 2.46-2.57 (m), 2.34-2.45 (m), 2.19-2.34 (m), 1.97-2.19 (m), 1.67-1.90 (m), 1.45-1.62 (m), 1.34-1.41 (m), 1.21-1.34 (m), 1.01-1.10 (m), 0.82-0.99 (m), 0.72-0.81 (m).

Preparation of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-(1,2,3,4-tetrahydroquinolin-6-yl)propan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, formate salt. (#207**) and 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-aminophenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide formate salt (**#208**) and 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#209**)**

[0617]



[0618] Step 1. Synthesis of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-tert-butoxy-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#202**). According to the general procedure D, from **#6** (4.3 g, 12 mmol, 1 eq.), **#150** (2.15 g, 12 mmol, 1 eq.), dichloromethane (50 mL), HATU (5.46 g, 14 mmol, 1.2 eq.), and diisopropylethylamine (8.17 mL) was synthesized the crude desired material, which was purified by silica gel chromatography (Gradient: 20 to 55% ethyl acetate in petroleum ether) to afford **#202** (5.2 g, 89 %) as a yellow oil.

[0619] Step 2. Synthesis of 1,2-dimethyl-L-prolyl-N-[(2R,3S,4S)-1-carboxy-2-methoxy-4-methylhexan-3-yl]-N-methyl-L-valinamide (**#203**). According to the general procedure B, from **#202** (5.2 g, 10.77 mmol, 1 eq.), dichloromethane (45 mL), and trifluoroacetic acid (20 mL) was synthesized the crude desired material, to obtain **#203** (7 g, quantitative yield) which was used in the next step without further purification.

[0620] Step 3. Synthesis of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-5-methyl-1-oxo-1-(pentafluorophenoxy)heptan-4-yl]-N-methyl-L-valinamide (**#204**). To a cooled solution (0 °C) of **#203** (7.0 g, 10.77 mmol, 1 eq.) in dichloromethane (15 mL) was added dropwise pyridine (3.41 g 43.08 mmol, 4eq.) followed by a solution of pentafluorophenyl trifluoroacetate (6.03 g, 21.54 mmol, 2 eq.) in dichloromethane (7 mL). The mixture was stirred at room temperature for one hour, and the solvent was concentrated *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 1 to 10% methanol in dichloromethane) to afford compound **#204** (8 g, 82% over two steps) as yellow solid.

[0621] Step 4. Synthesis of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#205**). To a cooled solution (0 °C) of **#204** (8.0 g, 10.77 mmol, 1 eq.) in dichloromethane (25 mL) was added dropwise diisopropylethylamine (5.6 g, 43.08 mmol, 4 eq.) followed by a solution of **#103** (3.22 g, 10.77 mmol, 1 eq.) in dichloromethane (15 mL). After the addition, the mixture was stirred at room temperature for 16 hours and the solvent was removed *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 1 to 10% methanol in dichloromethane) to give **#205** (2.2 g, 33 %) as a yellow solid HPLC (Protocol X): m/z 597.42 [$M+H^+$], retention time = 8.729 minutes (purity > 97%), Chiral HPLC retention time: 2.87 min (purity = 89%) Column: Chiralcel OD-3, 150 x 4.6 mm, 3 μm ; Mobile phase: ethanol (0.05% diethylamine) in CO_2 from 5% to 40% over 12 minutes; Flow rate: 2.5 mL/minute.

[0622] Step 5. Synthesis of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-

3-oxo-3-(pentafluorophenoxy)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#206**). To a solution of **#198** (0.28 g, 0.47 mmol, 1 eq.) in dichloromethane (2 mL) was added pyridine (75 mg, 0.94 mmol, 2 eq.) followed by a solution of pentafluorophenyl trifluoroacetate (268 mg, 0.94 mmol, 2 eq.) in dichloromethane (1.5 mL). The mixture was stirred at room temperature for 2.5 hours, and the solvent was concentrated *in vacuo*. The residue was purified by silica gel chromatography (Gradient: 1 to 10% methanol in dichloromethane) to afford compound **#206** (348 mg, 97%) as white solid. LC-MS (protocol Q1): *m/z* 763.5 [M+H⁺], retention time = 0.9 minutes.


[0623] Step 6A. Synthesis of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-(1,2,3,4-tetrahydroquinolin-6-yl)propan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#207**). The title compound was prepared from **#206** (25 mg, 0.033 mmol, 1 eq.) and **#215** (7.7 mg, 0.033 mmol, 1 eq) using the method described above for preparation of **#200**. The crude product was purified by reverse phase chromatography (Method M*) to give **#207** (11.7 mg, 44%). HPLC (Protocol T): *m/z* 407.6, double charge [2+], retention time = 1.59 minutes (purity = 100%). ¹H NMR (DMSO-d₆) δ 9.57-9.69 (m), 8.68-8.76 (m), 8.42-8.47 (m), 8.23-8.29 (m), 8.18-8.23 (m), 7.24-7.27 (m), 6.95-7.01 (m), 6.89-6.94 (m), 6.80-6.86 (m), 6.70-6.78 (m), 6.60-6.67 (m), 4.69-4.77 (m), 4.60-4.68 (m), 4.46-4.60 (m), 4.34-4.46 (m), 3.95-4.03 (m), 3.87-3.91 (m), 3.79-3.85 (m), 3.74-3.79 (m), 3.60-3.66 (m), 3.49-3.60 (m), 3.41-3.49 (m), 3.12-3.35 (m), 3.04-3.12 (m), 2.89-3.04 (m), 2.68-2.83 (m), 2.61-2.67 (m), 2.45-2.55 (m), 2.34-2.44 (m), 2.08-2.33 (m), 2.05-2.08 (m), 1.92-2.05 (m), 1.75-1.91 (m), 1.65-1.75 (m), 1.59-1.64 (m), 1.34-1.58 (m), 1.20-1.31 (m), 1.01-1.09 (m), 0.94-0.99 (m), 0.84-0.93 (m), 0.80-0.83 (m), 0.72-0.80 (m).

[0624] Step 6B. Synthesis of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-aminophenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (**#208**). To a mixture of **#206** (25.0 mg, 0.033 mmol, 1 eq.), and the commercially available methyl 4-amino-L-phenylalaninate (8.8 mg, 0.033 mmol, 1 eq.) in dichloromethane (1.5 mL), *N,N*-diisopropylethylamine (30.2 mg, 2.31 mmol, 7 eq.) was added. The reaction was stirred for 5 minutes and *N,N*-dimethylformamide (0.5 mL) was added. After 2 ½ hours, additional *N,N*-diisopropylethylamine (30.2 mg, 2.31 mmol, 7 eq.) was added. After stirring for 3 1/2 hours, additional *N,N*-dimethylformamide (0.75 mL) was added and The reaction was stirred for 66 hours, concentrated *in vacuo* and the crude product was purified by reverse phase chromatography (Method M*) to give **#208** (13 mg, 51 %); HPLC (Protocol T): *m/z* 387.2, double charge [2+], retention time = 1.58 minutes (purity= 100%); ¹H NMR (400 MHz, DMSO-d₆) δ 9.54-9.69 (m), 8.68-8.75 (m), 8.46-8.50 (m), 8.33-8.37 (m), 8.22-8.31 (m), 8.09-8.14 (m), 7.17-7.27 (m), 7.07-7.16 (m), 6.99-7.05 (m), 6.92-6.99 (m), 4.69-4.75 (m), 4.60-4.68 (m), 4.42-4.59 (m), 4.34-4.42 (m), 3.95-4.03 (m), 3.85-3.90 (m), 3.74-3.80 (m), 3.65-3.72 (m), 3.62-3.65 (m), 3.42-3.62 (m), 3.31-3.36 (m), 3.24-3.30 (m), 3.11-3.24 (m), 3.03-3.11 (m), 2.96-3.03 (m), 2.81-2.92 (m), 2.65-2.76 (m), 2.43-2.55 (m), 2.34-2.43 (m), 2.06-2.33 (m), 1.93-2.05 (m), 1.75-1.89 (m), 1.66-1.74 (m), 1.58-1.65 (m), 1.47-1.57 (m), 1.34-1.43 (m), 1.20-1.32 (m), 1.10-1.14 (m), 1.00-1.09 (m), 0.83-0.99 (m), 0.72-0.81 (m).

[0625] Step 6C. Synthesis of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide, trifluoroacetic acid salt (**#209**). The title compound was prepared from **#206** (25.0 mg, 0.033 mmol, 1 eq.) and methyl-L-phenylalaninate hydrochloride (7.1 mg, 0.033 mmol, 1 eq.) using the method described above for preparation of **#200**. The crude product was purified by reverse phase chromatography (Method M*) to give **#209** (10.3 mg, 41%). HPLC (Protocol T): *m/z* 758.7 [M+H⁺], retention time = 1.787 minutes (purity= 100%). ¹H NMR (DMSO-d₆) δ 9.57-9.70 (m), 8.70-8.75 (m), 8.50-8.56 (m), 8.32-8.42 (m), 8.24-8.26 (m), 8.10-8.15 (m), 7.14-7.27 (m), 7.12-7.13 (m), 6.98-7.00 (m), 4.69-4.77 (m), 4.55-4.67 (m), 4.43-4.53 (m), 3.94-4.02 (m), 3.73-3.78 (m), 3.62-3.68 (m), 3.48-3.60 (m), 3.39-3.48 (m), 3.23-3.33 (m), 3.13-3.22 (m), 3.08-3.13 (m), 3.02-3.08 (m), 2.96-3.01 (m), 2.81-2.94 (m), 2.76-2.80 (m), 2.66-2.75 (m), 2.62-2.66 (m), 2.46-2.55 (m), 2.31-2.45 (m), 2.09-2.29 (m), 2.05-2.09 (m), 1.93-2.04 (m), 1.74-1.88 (m), 1.65-1.74 (m), 1.59-1.65 (m), 1.36-1.52 (m), 1.21-1.35 (m), 1.01-1.08 (m), 0.94-1.00 (m), 0.83-0.94 (m), 0.73-0.81 (m).

Preparation of methyl (2S)-2-amino-3-(1,2,3,4-tetrahydroquinolin-6-yl)propanoate

[0626]



[0627] Step 1. Synthesis of 6-(bromomethyl)quinoline (**#210**). A solution of 6-methylquinoline (5 g, 35 mmol, 1 eq.), N-Bromosuccinimide (8.1 g, 45.5 mmol, 1.3 eq.) and benzoyl peroxide (840 mg, 3.5 mmol, 0.1 eq.) in carbon tetrachloride (100 mL) was stirred at reflux for 3 hours and then cooled to room temperature. The reaction mixture was filtered and the filtrate was concentrated *in vacuo*. The residue was dissolved in tetrahydrofuran (100 mL) and filtered. The filtrate was directly used in the next step without further purification.

[0628] Step 2. Synthesis of 6-[(2S,5R)-3,6-dimethoxy-5-(propan-2-yl)-2,5-dihydropyrazin-2-yl]methylquinoline (**#211**). To a cooled solution (-70 °C) of (2R)-3,6-dimethoxy-2-(propan-2-yl)-2,5-dihydropyrazine (25.8 g, 140 mmol, 2 eq.) in tetrahydrofuran (200 mL) was added dropwise *n*-butyllithium (2.5 M, 64.4 mL, 161 mmol, 2.3 eq.) and then stirred for 30 minutes. A solution of **#210** (15.4 g, 70 mmol, 1 eq.) in tetrahydrofuran (150 mL) was added dropwise at -65 °C and then the solution was stirred for 2 hours at this temperature. The reaction was quenched by saturated aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (100 mL). The organic phase was dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by silica column chromatography (Gradient: 10 to 16% ethyl acetate in petroleum ether) to afford **#211** (7.3 g, 32%, over two steps) as yellow solid. LC-MS (Protocol Z): *m/z* 326.2 [M+H⁺], retention time = 0.88 minutes.

[0629] Step 3. Synthesis of methyl (2S)-2-amino-3-(quinolin-6-yl)propanoate (**#212**). To a solution of **#211** (7.3 g, 22.5 mmol, 1 eq.) in water (25 mL) and acetonitrile (80 mL) was added trifluoroacetic acid (9 mL) at 0 °C and the solution was stirred at 10 °C overnight. The organic layer was removed *in vacuo* and the remaining aqueous layer was basified to pH 9 with sodium carbonate, which was directly used for the next step.


[0630] Step 4. Synthesis of methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(quinolin-6-yl)propanoate (**#213**). To a solution **#212** (5.2 g, 22.5 mmol, 1 eq.) and triethylamine (9.1 g, 90 mmol, 4 eq.) in mixed solvent of methanol (30 mL) and water (50 mL) was added di-*tert*-butyl dicarbonate (17.5 g, 78.75 mmol, 3.5 eq.) at 0 °C and then the solution was stirred at 10 °C overnight. The reaction mixture was filtered and the filter cake was washed with methanol (20 mL X 2). The filtrate was extracted with ethyl acetate (50 mL X 2) and the organic phase was concentrated *in vacuo*. The residue was purified by silica column chromatography (Gradient: 25 to 50% ethyl acetate in petroleum ether) to afford **#213** (5.5 g, 74% over two steps) as yellow oil. LC-MS (Protocol Z): *m/z* 331.2 [M+H⁺], retention time = 0.76 minutes.

[0631] Step 5. Synthesis of methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(1,2,3,4-tetrahydroquinolin-6-yl)propanoate (**#214**). A suspension of **#213** (1.5 g, 4.55 mmol, 1 eq.) and palladium on carbon (150 mg) in ethanol (20 mL) was stirred at 50 °C under 30 psi of hydrogen overnight. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated *in vacuo*. The residue was purified by silica column chromatography (Gradient: 40% ethyl acetate in petroleum ether) to afford **#214** (1.2 g, 80%) as an oil. ¹H NMR (400 MHz, CDCl₃): δ 6.70 (d, 2H), 6.40 (m, 1H), 4.95 (m, 1H), 4.49 (m, 1H), 3.77 (s, 3H), 3.28 (m, 2H), 2.97 (m, 2H), 2.71 (m, 2H), 1.95 (m, 2H), 1.26 (s, 9H). HPLC (Protocol Y): *m/z* 357.0 [M+Na⁺] retention time = 5.304 minutes (purity >98%). Chiral HPLC retention time: 4.64 min (purity = 98%) (Column: Chiralcel OJ-H, 150 x 4.6 mm, 5 μm; Mobile phase: ethanol (0.05% diethylamine) in CO₂ from 5% to 40% over 15 minutes; Flow rate: 2.5 mL/minute).

[0632] Step 6. Synthesis of methyl (2S)-2-amino-3-(1,2,3,4-tetrahydroquinolin-6-yl)propanoate (**#215**). To a solution of **#214** (750 mg, 2.25 mmol, 1 eq.) in dichloromethane (20 mL) was added dropwise trifluoroacetic acid (2 mL) at 0 °C and then the solution was stirred at 20 °C overnight. The reaction mixture was concentrated *in vacuo* and the residue was dissolved in water (20 mL). The solution was basified with sodium carbonate and extracted with ethyl acetate/tetrahydrofuran (30 mL X 3). The organic phase was dried over sodium sulfate and concentrated *in vacuo* to afford **#215** (450 mg, 85%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 6.70 (d, 2H), 6.40 (m, 1H), 3.73 (s, 3H), 3.67 (m, 1H), 3.30 (m, 2H), 2.96 (m, 1H), 2.75 (m, 3H), 1.96 (m, 2H), 1.50 (br, 2H), 1.26 (br, 1H). HPLC (Protocol Y): *m/z* 235.14 [M+H⁺] retention time = 4.35 minutes (purity >96%). Chiral HPLC retention time: 5.71 min (purity = 98%). (Column: Chiralcel OJ-H, 150 x 4.6 mm, 5 μm; Mobile phase: ethanol (0.05% diethylamine) in CO₂ from 5% to 40% over 15 minutes; Flow rate: 2.5 mL/minute).

Reference Example Preparation of N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((3R)-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalanine, trifluoroacetic acid salt (#217) and Reference Example N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((3S)-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalanine, trifluoroacetic acid salt (#219).

[0633]



[0634] Step 1A. Synthesis of methyl N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((3R)-1-(tert-butoxycarbonyl)-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalaninate (#216). To a solution of #168 (36.9 mg, 0.158 mmol, 1 eq.) and #114 (100 mg, 0.158 mmol, 1 eq.) in dichloromethane (3.6 mL) and *N,N*-dimethylformamide (0.8 mL), was added diisopropylethylamine (0.083 mL, 0.474 mmol, 3 eq.) followed by HATU (60.7 mg, 0.158 mmol, 1 eq.). The reaction was allowed to stir at room temperature for 18 hours, diluted with ethyl acetate (25 mL), washed with water (1X), 10% citric acid (1X) and brine (1X). The organic layer was dried over sodium sulfate, filtered, and the filtrate concentrated *in vacuo* to give crude #216 (220 mg, 164% of theory) which was used in next step without further purification. HPLC (protocol Q): *m/z* 848.6 [M+H⁺], retention time = 2.10 minutes.

[0635] Step 1B. Synthesis of methyl N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((3S)-1-(tert-butoxycarbonyl)-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalaninate (#218). To a solution of #169 (36.9 mg, 0.158 mmol, 1 eq.) and #114 (100 mg, 0.158 mmol, 1 eq.) in dichloromethane (3.6 mL) and *N,N*-dimethylformamide (0.8 mL), was added diisopropylethylamine (0.083 mL, 0.474 mmol, 3 eq.) followed by HATU (60.7 mg, 0.158 mmol, 1 eq.). The reaction was allowed to stir at room temperature for 18 hours, diluted with ethyl acetate (25 mL), washed with water (1 X), 10% citric acid (1X) and brine (1X). The organic layer was dried over sodium sulfate, filtered, and the filtrate concentrated *in vacuo* to provide crude #218 (180 mg, 134% of theory) which was used in next step without further purification. HPLC (protocol Q): *m/z* 848.6 [M+H⁺], retention time = 2.10 minutes.


[0636] Step 2A. Synthesis of N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((3R)-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalanine, trifluoroacetic acid salt (#217). To a solution of crude #216 (134 mg) in tetrahydrofuran (4 mL) was added lithium hydroxide (1M, 0.5 mL). The reaction was stirred at room temperature for 18 hours and concentrated *in vacuo*. The residue was dissolved in dichloromethane (2 mL) and trifluoroacetic acid (2 mL) was added. The reaction was stirred for 4 hours and concentrated *in vacuo*. The crude material was purified by reverse phase chromatography (Method M*) to obtain #217 (60 mg, 86% over two steps) as a gum. LC-MS (protocol Q): *m/z* 734.93 [M+H⁺], retention time = 1.19 minutes. ¹H NMR (DMSO-d₆) 12.62-12.83 (m), 9.30-9.43 (m), 9.17-9.28 (m), 8.34-8.41 (m), 8.22-8.31 (m), 8.08-8.15 (m), 7.87-7.93 (m), 7.76-7.81 (m), 7.11-7.23 (m), 4.93-4.99 (m), 4.81-4.88 (m), 4.55-4.71 (m), 4.48-4.54 (m), 4.37-4.45 (m), 3.92-3.99 (m), 3.69-3.75 (m), 3.31-3.65 (m), 3.25-3.30 (m), 3.20-3.24 (m), 3.12-3.19 (m), 3.08-3.10 (m), 2.97-3.07 (m), 2.92-2.97 (m), 2.75-2.84 (m), 2.64-2.70 (m), 2.43-2.57 (m), 2.28-2.43 (m), 2.15-2.26 (m), 2.02-2.15 (m), 1.56-1.87 (m), 1.31-1.48 (m), 1.05-1.30 (m), 0.97-1.06 (m), 0.82-0.97 (m), 0.71-0.79 (m).

[0637] Step 2B. Synthesis of N-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((N-((3S)-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl)(methyl)amino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalanine, trifluoroacetic acid salt (#219). To a solution of crude #218 (100 mg) in tetrahydrofuran (4 mL) was added 1.0 M lithium hydroxide in water (0.5 mL). The reaction was stirred at room temperature for 18 hours and then concentrated *in vacuo*. The crude material was dissolved in dichloromethane (2 mL) and trifluoroacetic acid (2 mL) was added. The reaction was stirred for 4 hours and then concentrated *in vacuo*. The crude material was purified by reverse phase chromatography (Method M*) to obtain #219 as a gum (60 mg, 91% over two steps). LC-MS (protocol Q): *m/z* 734.97 [M+H⁺], retention

time = 1.14 minutes. ^1H NMR (400 MHz, DMSO-d_6), δ 12.62-12.85 (m), 9.32-9.43 (m), 9.13-9.26 (m), 8.39-8.46 (m), 8.30-8.39 (m), 8.25-8.29 (m), 8.08-8.13 (m), 7.79-7.85 (m), 7.67-7.72 (m), 7.10-7.23 (m), 4.94-5.01 (m), 4.83-4.89 (m), 4.64-4.73 (m), 4.56-4.63 (m), 4.44-4.50 (m), 4.37-4.44 (m), 3.92-3.99 (m), 3.60-3.74 (m), 3.24-3.55 (m), 3.11-3.24 (m), 3.07-3.10 (m), 3.02-3.06 (m), 2.98-3.02 (m), 2.93-2.97 (m), 2.75-2.85 (m), 2.68-2.69 (m), 2.63-2.67 (m), 2.45-2.55 (m), 2.26-2.44 (m), 2.15-2.25 (m), 2.03-2.14 (m), 1.55-1.87 (m), 1.31-1.47 (m), 1.15-1.31 (m), 0.98-1.05 (m), 0.91-0.98 (m), 0.82-0.91 (m), 0.71-0.78 (m).

Preparation of 2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(3R,4R,7S)-7-benzyl-4-methyl-18-[(4S,5R)-5-methyl-2-oxoimidazolidin-4-yl]-5,8,13-trioxo-2-oxa-6,9,12-triazaoctadecan-3-yl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (#257).

[0638]



[0639] Step 1. Synthesis of 9H-fluoren-9-ylmethyl [(2S)-1-[(2-[(tert butoxycarbonyl)amino]ethyl)amino]-1-oxo-3-phenylpropan-2-yl]carbamate (**#253**). Following general procedure D using N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-phenylalanine (500 mg, 1.29 mmol, 1.0 eq.), tert-butyl (2-aminoethyl)carbamate (207 mg, 1.29 mmol, 1.0 eq.), HATU (620 mg, 1.55 mmol, 1.2 eq.) and Hunig's base (0.452 mL, 2.58 mmol, 2.0 eq.) in 6 mL of DMF **#253** was yielded as a white solid (620 mg, 91%) following concentration of solvent and recrystallization using ethyl acetate. LC-MS (Protocol Q1): m/z 552.3 $[\text{M}+\text{Na}^+]$, retention time = 1.01 minutes.

[0640] Step 2. Synthesis of N-alpha-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-[2-[(6-[(4S,5R)-5-methyl-2-oxoimidazolidin-4-yl]hexanoyl)amino]ethyl]-L-phenylalaninamide (**#254**). Boc protection was removed using general procedure C using **#251** (88 mg, 0.17 mmol, 1.0 eq.) and 4M HCl (2.0 mL, 8.0 mmol, 48 eq.) followed by concentration *in vacuo*. Coupling reaction was then performed following general procedure D using crude residue, 6-[(4S,5R)-5-methyl-2-oxoimidazolidin-4-yl]hexanoic acid (35.6 mg, 0.166 mmol, 1.0 eq.), HATU (73.2 mg, 0.18 mmol, 1.1 eq.), and Hunig's base (0.087 mL, 0.50 mmol, 3.0 eq.) in 2 mL of DMF followed by purification (Method J) yielding **#254** (35 mg, 34%) as a white solid. LC-MS (Protocol Q1): m/z 626.3 $[\text{M}+\text{H}^+]$, retention time = 0.86 minutes.

[0641] Step 3. Synthesis of N-[2-[(6-[(4S,5R)-5-methyl-2-oxoimidazolidin-4-yl]hexanoyl)amino]ethyl]-L-phenylalaninamide (**#255**). Following general procedure A using **#254** (35 mg, 0.056 mmol, 1.0 eq.), piperidine (0.10 mL, 1.0 mmol, 20 eq.) in 0.5 mL of DMF followed by purification using silica chromatography (0-30% methanol in dichloromethane) affords **#253** (19 mg, 84%). LC-MS (Protocol Q1): m/z 404.2 $[\text{M}+\text{H}^+]$, retention time = 0.48 minutes.


[0642] Step 4. Synthesis of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(3R,4R,7S)-7-benzyl-4-methyl-18-[(4S,5R)-5-methyl-2-oxoimidazolidin-4-yl]-5,8,13-trioxo-2-oxa-6,9,12-triazaoctadecan-3-yl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**#256**). Following general pro-

cedure D using **#105** (36.6 mg, 0.047 mmol, 1.0 eq.), **#255** (19 mg, 0.047 mmol, 1.0 eq.), HATU (22.4 mg, 0.056 mmol, 1.2 eq.) and Hunig's base (0.025 mL, 0.141 mmol) in 1.5 mL of DMF following by purification (Method J) yielded **#256** (15 mg, 27%) as a white solid. LC-MS (Protocol Q1): m/z 1164.8 $[M+H]^+$, retention time = 0.99 minutes.

[0643] Step 5. Synthesis of 2-methylalanyl-N-((3R,4S,5S)-1-[(2S)-2-[(3R,4R,7S)-7-benzyl-4-methyl-18-[(4S,5R)-5-methyl-2-oxoimidazolidin-4-yl]-5,8,13-trioxo-2-oxa-6,9,12-triazaoctadecan-3-yl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N-methyl-L-valinamide (**#257**). Following general procedure A using **#256** (5mg, 0.004 mmol, 1.0 eq.) and piperidine (0.02 mL, 0.2 mmol, 50 eq.) in 0.7 mL of DMF followed by purification (Method J) afforded **#257** (2 mg, 50%) as a colorless glass. LC-MS (Protocol Q1): m/z 1164.8 $[M+H]^+$, retention time = 0.99 minutes. ^1H NMR (400 MHz, DMSO- d_6), δ 8.44-8.52 (m), 8.06-8.20 (m), 7.96-8.01 (m), 7.69-7.83 (m), 7.20-7.28 (m), 7.11-7.19 (m), 3.38-3.83 (m), 3.19-3.26 (m), 3.03-3.12 (m), 2.98 (s), 2.91 (s), 2.75 (s), 2.65-2.70 (m), 2.01-2.36 (m), 1.65-1.87 (m), 1.39-1.57 (m), 1.13-1.37 (m), 1.04-1.08 (m), 0.74-1.01 (m).

Preparation of N-[5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (mv#115).


[0644]



[0645] Step 1. Preparation of N-[5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (**mv#115**). To a stirring solution of 5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentanoic acid (12 mg, 0.061 mM) in 0.4 mL of dichloromethane, and 0.1 mL of DMF, HATU (23.2 mg, 0.061 mM) was added followed by Hunig's base (0.033 mL, 0.188 mM). The reaction was allowed to stir for 5 minutes before **#115** (39 mg, 0.047 mM) was added as a solution in 0.4 mL of dichloromethane, and 0.1 mL of DMF. The reaction was allowed to stir at room temperature for 3 hours and 15 minutes before being quenched through the addition of water containing a small amount of TFA. Reaction was then reduced down. Crude material was dissolved with DMSO and purified by reverse phase chromatography (Method J). The appropriate fractions were concentrated then (Genevac). Material was then further purified by reverse phase chromatography (Method K) with the appropriate fractions being concentrated (Genevac). Material was then transferred to a small vial using dichloromethane and methanol before being reduced down (Genevac) to afford **mv#115** (1.4 mg, 3.3%) oil/solid mix. HPLC (Protocol A at 45 °C): m/z 897.5 $[M+H]^+$, retention time = 9.149 minutes (purity > 97%).

Preparation of N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (mc#115)

[0646]



[0647] Step 1. Synthesis of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl chloride (**#248**). To a stirring solution of 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoic acid (3.15 g, 14.9 mM) in 15 mL of dichloromethane, oxalyl chloride (1.61 mL, 17.9 mM) was added followed by one drop of DMF. The reaction was allowed to stir at room temperature for three hours. The reaction was concentrated *in vacuo*. The residue was dissolved in a one to one solution of heptane and dichloromethane and then concentrated *in vacuo*. This process was repeated two more times producing a solid **#248** (3.43 g, 100%). ¹H NMR (400 MHz, DMSO-*d*₆): δ [7.02 (s, 2H), 3.43 (m, 2H), 2.53 (m, 1H), CH₂.18 (m, 1H), 1.54 (m, 4H), 1.26 (m, 2H).]


[0648] Step 2. Synthesis of N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N,2-dimethylalanine (**#249**). To a stirring solution of **#248** (600 mg, 2.61 mM) in 10 mL of dichloromethane, N,2-dimethylalanine (306 mg, 2.61 mM) was added followed by triethylamine (1.09 mL, 7.84 mM). The reaction was allowed to stir at room temperature for three hours. Dichloromethane was added to the reaction and the organic layer was washed three times with water and two times with brine. The organic layer was separated and then dried over sodium sulfate before being concentrated *in vacuo*. The crude residue was purified by silica chromatography (0-30% methanol in dichloromethane) on silica which had been previously neutralized with triethylamine yielding a white solid **#249** (127 mg, 16%). LC-MS (Protocol Q): *m/z* 309.0 [M-H], retention time = 0.96 minutes.

[0649] Step 3. Synthesis of N-((2R,3R)-3-methoxy-3-((2S)-1-((3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(L-valyl)amino]heptanoyl)pyrrolidin-2-yl)-2-methylpropanoyl)-L-phenylalanine (**#250**). To a stirring solution of **#113** (2.10 g, 2.46 mM) in 10 mL of THF, lithium hydroxide (228 mg, 5.16 mM) was added followed by 3 mL of water. The reaction was allowed to stir at room temperature for 2 hours. The reaction was acidified through the addition of 1 M HCl and then concentrated *in vacuo*. The resulting white solid was taken up in 20 mL of acetonitrile and 5 mL of water. The aqueous layer removed and the organic layer was washed once with water. The organic layer was dried over sodium sulfate, filtered, and concentrated *in vacuo*. Ethyl acetate (20 mL) was then added and the crude solid was allowed to stir for 30 minutes, before being filtered to yield a white solid **#250** (1.42 g, 94%). LC-MS (Protocol Q): *m/z* 619.5 [M+H⁺], retention time = 1.10 minutes. HPLC (Protocol A at 45 °C) *m/z* 619.4 [M+H⁺], retention time = 6.732 minutes.

[0650] Step 4. Synthesis of N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N,2-dimethylalanine-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-((1S)-1-carboxy-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide (**mc#115**). To a stirring solution of **#249** (382 mg, 1.23 mM) in 5 mL of dichloromethane, HATU (482 mg, 1.23 mM) was added followed by triethylamine (0.52 mL, 1.23 mM). The reaction was allowed to stir for 1 hour at room temperature followed by the addition of **#250** (762 mg, 1.23 mM). The reaction was allowed to stir for 3 hours. Reaction was concentrated *in vacuo*. Reverse phase purification (Method L) followed by lyophilization yielded a white solid **mc#120** (124 mg, 11%). HPLC (Protocol A at 45 °C): *m/z* 911.5 [M+H⁺], retention time = 9.676 minutes.

Preparation of N-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (mb#115).


[0651]



[0652] Step 1. Synthesis of N-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (**mb#115**). A stirring solution of 4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoic acid (1.2 equivalents), HATU (1.2 equivalents), and Hunig's base (3 equivalents) in DMF and dichloromethane is allowed to stir for 30 minutes. Compound **#115** (1 equivalent) is then added as a solution in dichloromethane and DMF. Reaction is monitored by LC-MS. Reaction is concentrated down and purification is completed by Isco medium pressure reverse phase chromatography (Gradient: 5%-100% water in acetonitrile).

Preparation of N-[7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)heptanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (me#115).


[0653]



[0654] Step 1. Synthesis of N-[7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)heptanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide (**me#115**). A stirring solution 7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)heptanoic acid (1.2 equivalents), HATU (1.2 equivalents), and Hunig's base (3 equivalents) in DMF and dichloromethane is allowed to stir for 30 minutes. Compound **#115** (1 equivalent) is then added as a solution in dichloromethane and DMF. Reaction is monitored by LC-MS. Reaction is concentrated down and purification is completed by Isco medium pressure reverse phase chromatography (Gradient: 5%-100% water in acetonitrile).

Preparation of N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-5-carbamoyl-N-(4-[(8S,11S,12R)-12-(2-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-oxoethyl)-8-isopropyl-4,5,5,10-tetramethyl-11-[(1S)-1-methylpropyl]-3,6,9-trioxo-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl)-L-ornithinamide (mcValCitPABC#115).

[0655]




[0660] Step 1: Synthesis of methyl N-(tert-butoxycarbonyl)-4-({N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycyl}amino)-L-phenylalaninate (**#251**): To a solution of methyl 4-amino-N-(tert-butoxycarbonyl)-L-phenylalaninate (4.1 g, 15.3 mmol, 1 eq.) in dry *N,N*-dimethylformamide (70 mL) was added *N,N*-Dicyclohexylcarbodiimide (2.9 g, 15.3 mmol, 1 eq.) at 0 °C. The mixture was stirred at 0 °C for 30 minutes. A solution of 2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)acetic acid (3 g, 10.2 mmol, 0.66 eq.) in dry *N,N*-dimethylformamide (20 mL) was added at 0 °C. The mixture was stirred at room temperature for 3 days. The mixture was filtered. The filtrate was poured into ice water (200 mL) and extracted with EtOAc (200 mLX3). The extract was washed with brine (200 mL), dried over Na₂SO₄ and concentrated *in vacuo* to afford **#251** (1.8 g, 32.3% yield) as a light yellow solid. HPLC (Protocol Q2) [M+Na⁺] 567.3, retention time = 1.02 min

[0661] Step 2: Synthesis of methyl 4-({N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycyl}amino)-L-phenylalaninate (**#252**): To a solution of **#251** (800 mg, 1.47 mmol, 1 eq.) in dichloromethane (16 mL) was added TFA (4.8 mL) at 0 °C. The mixture was stirred at room temperature for 2 hours. The mixture was concentrated *in vacuo*. The residue was dissolved in water and filtered. The filtrate was lyophilized to afford **#252** (800 mg, 97.5%) as a white solid. HPLC (Protocol Q3) [M+H⁺] 445.4, retention time = 0.90 min.

[0662] Step 3: Synthesis of 1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-((2S)-2-[(1R,2R)-3-((2S)-3-[4-({N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycyl}amino)phenyl]-1-methoxy-1-oxopropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (**mcGly#201**). To a solution of **#198** (94 mg, 0.13 mmol, 1 eq.) and **#252** (60.3 mg, 0.18 mmol, 1.4 eq.) in *N,N*-dimethylformamide (2 mL) was added HATU (64.2 mg, 0.13 mmol, 1 eq.) followed by *N,N*-diisopropylethylamine (66 mg, 0.52 mmol). The solution was stirred at room temperature for 1 hour. The reaction mixture was neutralized with aq. citric acid and concentrated to give crude product, which was purified by silica gel chromatography (eluted with MeOH/DCM from 1% to 7%), then purified again by preparative TLC (Methanol:dichloromethane = 1:10) to give **mcGly#201** (25 mg, 16.2%) as a white solid: ESI-MS : *m/z* 1023.59 [M+H⁺], HPLC (Protocol EB) retention time = 4.0 minutes (Purity = 96%). ¹H NMR (DMSO-*d*₆) 9.88 (d, 1H), 8.48 (d, 0.5H), 8.24 (d, 0.5H), 8.11 (m, 1H), 7.82 (m, 1H), 7.47 (d, 2H), 7.15 (m, 2H), 7.01 (s, 2H), 4.67 (m, 3H), 3.96 (m, 4H), 3.65 (m, 4H), 3.40 (m, 4H), 3.27 (m, 7H), 3.16 (m, 5H), 2.24 (m, 8H), 1.50 (m, 11H), 1.19 (m, 21H).

Preparation of 1,2-dimethyl-L-propyl-N-[(3R,4S,5S)-1-((2S)-2-[(1R,2R)-3-[(2S)-1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl]amino]-1-oxo-3-phenylpropan-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (MalC6Am#151).

[0663]




[0664] Step 1. Synthesis of 1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-((2S)-2-[(1R,2R)-3-[(2S)-1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl]amino]-1-oxo-3-phenylpropan-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (MalC6Am#151). Following general procedure D using

#151 (20 mg, 0.023 mmol, 1.0 eq.), 1-(6-aminohexyl)-1H-pyrrole-2,5-dione (7.0 mg, 0.030 mmol, 1.3 eq.), HATU (11.4 mg, 0.030 mmol, 1.3 eq.), and Hunig's base (0.016 mL, 0.092 mmol, 1.3 eq.) in 2 mL of dichloromethane, and 0.2 mL of DMF followed by purification using medium pressure reverse phase C18 chromatography (Gradient: 5% to 80% acetonitrile in water with 0.02% TFA in each phase) yielded MalC6Am**#151** (18.4 mg, 86%) as a clear oil/solid mix. LC-MS (Protocol Q): m/z 922.3 $[M+H]^+$, retention time = 1.43 minutes; HPLC (Protocol A at 45 °C): m/z 922.4 $[M+H]^+$, retention time = 7.203 minutes.

Preparation of N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-(4-((6S,9R,10R)-6-benzyl-10-[(2S)-1-((3R,4S,5S)-4-[(1,2-dimethyl-L-prolyl-L-valyl)(methyl)amino]-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl]-9-methyl-3,8-dioxo-2,11-dioxo-4,7-diazadodec-1-yl)phenyl)-N-5-~carbamoyl-L-ornithinamide (mcValCitPABC#246)

[0665]



[0666] Step 1. Synthesis of N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-(4-((6S,9R,10R)-6-benzyl-10-[(2S)-1-((3R,4S,5S)-4-[(1,2-dimethyl-L-prolyl-L-valyl)(methyl)amino]-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl]-9-methyl-3,8-dioxo-2,11-dioxo-4,7-diazadodec-1-yl)phenyl)-N-5-~carbamoyl-L-ornithinamide (mcValCitPABC#246). Following general procedure E using **#246** (29.2 mg, 0.035 mmol, 1.0 eq.), mcValCitPABC-PNP (28.8 mg, 0.039 mmol, 1.1 eq.), 2,6-Lutidine (0.016 mL, 0.14 mmol, 4.0 eq.), Hunig's base (0.025 mL, 0.14 mmol, 4.0 eq.), and HOAT (4.8 mg, 0.035 mmol, 1.0 eq.) in 2.0 mL of DMA followed by purification using medium pressure reverse phase C18 chromatography (Gradient: 5% to 50% acetonitrile in water with 0.02% TFA in each phase) yielded mcValCitPABC**#246** (21 mg, 45%) as a clear oil/solid mix. LC-MS (Protocol Q): m/z 1327.9 $[M+H]^+$, retention time = 1.36 minutes.

HERCEPTIN® *in vitro* and *in vivo* Studies

[0667] It is noted that for the following studies HERCEPTIN® in the absence of conjugated cytotoxic agents shows no significant *in vitro* potency or *in vivo* efficacy at equivalent antibody concentrations.

In vitro Cell Assay Procedure

[0668] Target expressing (BT474 (breast cancer), N87 (gastric cancer), HCC1954 (breast cancer), MDA-MB-361-DYT2 (breast cancer)) or non-expressing (MDA-MB-468) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96® AQ_{ueous} One Solution Cell Proliferation MTS Assay (Promega, Madison WI) 96 hours after treatment. Relative cell viability was determined as percentage of untreated control. IC₅₀ values were calculated using a four parameter logistic model #203 with XLfit v4.2 (IDBS, Guildford, Surrey, UK). Results are shown in **Tables 20, 21A and 21B**.

In vivo MDAMB-361 DYT2 Tumor Xenograft Model

[0669] *In vivo* efficacy studies of antibody-drug conjugates were performed with the Her2+ MDAMB-361 DYT2 cell line. For efficacy studies, 10 million tumor cells in 50% matrigel were implanted subcutaneously into 6-8 week old irradiated nude mice. When the tumor sizes reached between 250-350 mm³ drugs or vehicle were administered through bolus tail vein injection. Mice were injected with 1 mg/kg of antibody drug conjugates treated four times every four days (Q4dx4). Tumor volume is measured twice a week for the first 50 days and once weekly thereafter by a Caliper device and calculated with the following formula: Tumor volume = (length x width²) / 2. Results were compared across studies by normalizing the tumor regression of the drug-treated mice by dividing the tumor volume by the vehicle-treated tumor volume (T/C).

[0670] Six compounds were tested in the three different MDA-MB-361-DYT2 xenograft studies to determine their anti-tumor activity. The results of a representative study with four of the compounds demonstrates significant tumor regression from the vehicle-treated mice over the 50 day observation period (Figure 1). To compare the results of compounds in

the three studies, anti-tumor activity was normalized by dividing the drug-treated tumor volume by the vehicle-treated tumor volume (T/C). A plot of the six T/C values (Figure 2) demonstrates that each of the six compounds causes complete (or almost complete) tumor regression over the observation period which was up to 107 days for one of the studies.

[0671] Results of the testing of H(C)-#D54, H(C)-vcMMAE, H(C)-mcMMAF and H(K)-MCC-DM1 in the MDA-MB-361-DYT2 xenograft studies are shown in Figure 4. Tumor volume in treatment group over control group (T/C) plot allows comparison between conjugates (see Figure 5C). These results demonstrate that H(C)-#D54 displays equivalent efficacy to HERCEPTIN® conjugates with H(C)-vcMMAE, H(C)-mcMMAF and is superior to H(K)-MCC-DM1 in this model.

***In vivo* N87 Tumor Xenograft Model (HERCEPTIN®)**

[0672] *In vivo* efficacy studies of antibody-drug conjugates were performed with target-expressing xenograft models using the N87 cell lines. For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm³. Dosing is done through bolus tail vein injection. Depending on the tumor response to treatment, animals are injected with 1-10 mg/kg of antibody drug conjugates treated four times every four days. All experimental animals are monitored for body weight changes weekly. Tumor volume is measured twice a week for the first 50 days and once weekly thereafter by a Caliper device and calculated with the following formula: Tumor volume = (length x width²) / 2. Animals are humanely sacrificed before their tumor volumes reach 2500 mm³. The tumor size is observed to decrease after the first week of treatment. Animals may be monitored continuously for tumor re-growth after the treatment has discontinued.

[0673] Results of the testing of H(C)-#D54, H(C)-vcMMAE, H(C)-mcMMAF and H(K)-MCC-DM1 in the N87 mouse xenograft *in vivo* screening model are shown in Figures 3 and 5. These results demonstrate that H(C)-#D54 is superior/similar to the H(C)-vcMMAE conjugate and is more potent than the H(C)-mcMMAF and H(K)-MCC-DM1 conjugates in this model.

Pharmacokinetics and Toxicokinetics

[0674] Mouse pharmacokinetics and rat toxicokinetics were determined from single dose mouse pharmacokinetic and rat toxicology studies (see **Tables 22 and 23**). Mouse pharmacokinetics and rat toxicokinetics were determined from single dose mouse pharmacokinetic and rat toxicology studies. Mouse pharmacokinetics were determined from samples collected from nude mice that were administered a single 3 mg/kg dose. Samples were collected for up to 336 h. Rat toxicokinetics were determined in rats (Sprague-Dawley (CrI:CD (SD))) that were administered a single administration of H(C)-vc-MMAE or H(C)-#D54 at doses of 3, 10, and 30 mg/kg, or administered H(C)-mc-MMAD or H(C)-mc-MMAF at 10, 30, and 100 mg/kg. Samples were collected for up to 336 hours. Circulating concentrations of total antibody and ADC were measured using ELISA assays. Area under the curve (AUC) was calculated for the total antibody and ADC for each ADC. ADC to antibody AUC ratios were also calculated.

[0675] Exposure of H(C)-#D54 total antibody and ADC were greater than that observed for H(C)-vc-MMAE in mice at 3 mg/kg and at all doses evaluated in rats. The ADC to Ab AUC ratio for H(C)-#D54 was also greater than that observed for H(C)-vc-MMAE. These results suggest that H(C)-#D54 has greater exposure and that the ADC and/or linker payload are potentially more stable than H(C)-vc-MMAE.

Toxicity

[0676] The target independent toxicity of #D54 and comparator linker-payloads (mcValCitPABC-MMAD and mcVal-CitPABC-MMAE) conjugated to a non-cross reactive monoclonal antibody (IgG1) were assessed in a single-dose rat toxicity study with a two-week observation period. The doses of the antibody drug conjugates (ADCs) were 0, 3, 10 and 30 mg/kg with an n is 5 males/group and the linker-payload loading was similar among the conjugates (3.8, 3.2 and 4, respectively). These studies included at least daily clinical observations, weekly body weights, clinical pathology (end of in-life) and necropsy (Day 15-17) with microscopic examination of 9 or more tissues and any gross lesions.

[0677] Mortality with related body weight changes and signs of morbidity were observed at the 30 mg/kg dose for all conjugates and at the 10 mg/kg dose for the MMAD conjugate. There were no clinical observations or body weight changes in the surviving groups.

[0678] The target organs of the conjugates identified by microscopic examination in the surviving dose groups were as follows. The conjugate at 10 mg/kg had debris in the lumen of the epididymis (5/5, minimal to mild), inflammation at the base of the heart (1/5 rats, minimal) and increased mitosis in the cornea (1/5 rats, minimal). There were no histological findings for the conjugate at 3 mg/kg. For the MMAD conjugate in the surviving dose group at 3 mg/kg, there were changes in and related to the bone marrow and in the testis and epididymis. For the MMAE conjugate at 10 mg/kg, there were changes in the bone marrow, kidney, liver and epididymis. At the 3 mg/kg dose for this conjugate, there were kidney changes and increased mitosis in the liver. Thus, in studies of similar design and in the surviving groups, the conjugate

did not have the bone marrow findings seen with the comparator conjugates and also did not have the liver or kidney findings seen with one of the comparators.

[0679] In summary, the maximum tolerated dose (MTD) of the conjugate and the MMAE conjugate was 10 mg/kg and the MTD of the MMAD conjugate was 3 mg/kg. The no observed adverse effect level (NOAEL) of the conjugate was 3 mg/kg whereas the NOAEL of the comparator linker-payload conjugates was less than 3 mg/kg. This study demonstrates how the toxicological profile for #D54 compares to certain compounds described in the art.

Anti-IL-13R α 2 ADC *In Vitro* and *In Vivo* Studies

Anti-IL-13R α 2 Antibodies and ADCs

[0680] The humanized antibody hu08 specifically binds to the IL-13R α 2 receptor. The amino acid and the nucleotide sequences for hu08 are shown in Table 3. Kabat CDRs are underlined.

Table 3. Amino acid and nucleotide sequences of humanized antibody hu08.

SEQ ID NO	DESCRIPTION	SEQUENCE
9	hu08 heavy chain variable region amino acid sequence (CDRs underlined).	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRNGMSWVR QAPGKGLEWVATVSSGGSYIYYADSVKGRFTISRDNAL NSLYLQMNSLRAEDTAVYYCAR <u>QGT</u> TALATRFEDVWG QGTTLTVSS
10	hu08 light chain variable region amino acid sequence (CDRs underlined).	DIQMTQSPSSLSASVGDRVTITCKASQDVGTAWAYQQ KPGKAPKLLIYSAS <u>YRST</u> GVPSRFSGSGSGTDFTLTISLQ PEDFATYYCQHHSAPWTFGGGTKEIK
11	hu08 heavy chain amino acid sequence (CDRs underlined).	EVQLVESGGGLVQPGGSLRLSCAASGFTFSRNGMSWVR QAPGKGLEWVATVSSGGSYIYYADSVKGRFTISRDNAL NSLYLQMNSLRAEDTAVYYCAR <u>QGT</u> TALATRFEDVWG QGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK DYFPEPVTWNSGALTSGVHTFPAVLQSSGLYSLSSV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW QQGNVFCSCVMHEALHNHYTQKSLSCSPGK
12	hu08 light chain amino acid sequence (CDRs underlined).	DIQMTQSPSSLSASVGDRVTITCKASQDVGTAWAYQQ KPGKAPKLLIYSAS <u>YRST</u> GVPSRFSGSGSGTDFTLTISLQ PEDFATYYCQHHSAPWTFGGGTKEIK TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQ WKVDNALQSGNSQESVTEQDSKDSSTYLSSTLTLSKAD YEKHKVYACEVTHQGLSSPVTKSFNRGEC

(continued)

SEQ ID NO	DESCRIPTION	SEQUENCE
13	hu08-heavy chain nucleotide sequence	GAGGTGCAGCTGGTGGAGTCTGGCGGCGGACTGGTG AGCCTGGCGGCTCTCTGAGACTGTCTTGTGCCGCTCC GGCTTCACCTTCAGTAGGAATGGCATGTCTTGGGTGA GGCAGGCCCTGGCAAGGGCCTGGAGTGGGTGGCCA CCGTTAGTAGTGGTGGTAGTTACATCTACTATGCAGA CAGTGTGAAGGGGCGGTTACCATCTCCAGGGACAAC GCCAAGAAGTCCCTGTACCTCCAGATGAAGTCCCTGA GGGCCGAGGATACCGCCGTGTACTACTGTGCCAGACA AGGGACTACGGCACTAGCTACGAGGTTCTTCGATGTC TGGGGCCAGGGCACCTGGTGACCGTGTCTCTGCGT CGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTC CTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGC TGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG TGTCGTGGAAGTCAAGGCGCCCTGACCAGCGGCGTGCA CACCTTCCCGGCTGTCTACAGTCTCAGGACTCTACT CCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTT GGGCACCCAGACCTACATCTGCAACGTGAATCACAAG CCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC AAATCTTGTGACAAAAGTCAACATGCCCACCGTGCC CAGCACCTGAAGTCTTGGGGGGACCGTCAGTCTTCTC CTTCCCCCAAAACCAAGGACACCCCTCATGATCTCC CGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGA GCCACGAAGACCCCTGAGGTCAAGTCAACTGGTACGT GGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGT CAGCGTCTCACCCTGCTGCACCAGGACTGGCTGAAT GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCC CTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCA AAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGC CCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCA GCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCAG CATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGA GAACAAGTACAAGACCACGCCTCCCGTGTGCTGGACTCC GACGGCTCTTCTTCTCTATAGCAAGCTCACCGTGG ACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCAT GCTCCGTGATGCATGAGGCTCTGCACAACCACTACAC GCAGAAGAGCCTCTCCCTGTCCCCGGGTAAA
14	hu08- light chain nucleotide sequence	GACATCCAGATGACCCAGTCCCCCTCTTCTGTCTGCTGC CTCTGTGGGCGACAGAGTGACCATCACCTGTAAGGCC AGTCAGGATGTAGGTACTGCTGTAGCCTGGTATCAGC AGAAGCCTGGCAAGGCTCCCAAGCTGCTGATCTACTC GGCATCCTACCGGTCCACTGGCGTGCCTTCCAGATTCT CCGGCTCTGGCTCTGGCACCGATTTCACCCTGACCATC TCCTCCCTCCAGCCTGAGGATTTCCGCCACTTACTACTG CCAGCACCATTAAGTGCTCCGTGGACGTTTGGCGGG GGAACAAAGGTGGAGATCAAGACTGTGGCTGCACCA TCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAAGTGCCTCTGTTGTGTGCCTGCTGAATAACT TCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG ATAACGCCCTCCAATCGGGTAACTCCAGGAGAGTGT CACAGAGCAGGACAGCAAGGACAGCACCTACAGCCT CAGCAGCACCCCTGACGCTGAGCAAAGCAGACTACGA GAAACACAAAGTCTACGCTGCGAAGTCACCCATCAG GGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGG GAGAGTGT

[0681] Humanized anti-IL-13R α 2 antibody hu08 was conjugated to various linker-payload combinations of the present invention, as provided in **Table 4**. The antibody drug conjugates were prepared according to the methods of the present

invention.

Table 4 anti-IL-13R α 2 ADCs.

ADC Linker-Payload #	Corresponding ADC Nomenclature
IL13Ra2-AB08-v1010-hG1-(C)_mcValCitPABC-#54	hu08-vc-0101
IL13Ra2-AB08-v1010-hG1-(C)_mc-#115	hu08-mc-3377
IL13Ra2-AB08-v1010-hG1-(C)_mc-0#118	hu08-mc-0131
IL13Ra2-AB08-v1010-hG1-(C)_MalPeg6C2-#117	hu08-Malpeg-6121
IL13Ra2-AB08-v1010-hG1-(C)_Mal(H ₂ O)Peg6C2-0#118	hu08-Malpeg-0131
IL13Ra2-AB08-v1010-hG1-(C)_mc-#117	hu08-mc-6121
IL13Ra2-AB08-v1010-hG1-(C)_mcValCitPABC-#226	hu08-vc-3906
IL13Ra2-AB08-v1010-hG1-(C)_mcValCitPABC-#112	hu08-vc-6780
IL13Ra2-AB08-v1010-hG1-(C)_mc-#69	hu08-mc-8261
IL13Ra2-AB08-v1010-hG1-(C)_mc-#226	hu08-mc-3906
IL13Ra2-AB08-v1010-hG1-(C)_MalPeg6C2-#69	hu08-MalPeg-8261
hulG8.84-mcValCitPABC-#54	hulG8.84-vc0101
hulG8.84-mc-#115	hulG8.84-mc3377

***In Vitro* Cytotoxicity Assay with anti-IL-13R α 2 ADCs**

[0682] Cell lines expressing the IL-13R α 2 antigen and a negative control cell line, were cultured with increasing concentrations of anti-IL-13R α 2 ADCs comprising the hu08 antibody conjugated to various linker payloads of the present invention. After four days, viability of each culture was assessed. IC₅₀ values were calculated by logistic non-linear regression and are presented as ng Ab/mL.

[0683] The data demonstrates that the anti-IL-13R α 2 antibody hu08v1.0/1.0 conjugated to six different auristatin payloads is effective against both of the IL-13R α 2 positive cell lines tested (PC3MM2), having an IC₅₀ ranging from 1.1 to 4.9 ng Ab/mL or 7.3-32.7 pM (**Table 5**). All ADCs were not active against the IL-13R α 2 negative cell line, H460, and the non-IL-13R α 2 binding control ADCs, hulG8.84-vc0101 and hulG8.84-mc3377, were not active against any of the cell lines tested.

Table 5. IC₅₀ (ng Ab/mL) values of humanized anti-IL-13R α 2 ADCs.

ADC	DAR	IC ₅₀ (ng Ab/mL)		
		PC3MM2	A375	H460
hu08-vc0101	3.2	2.5	3.8	>400000
hu08-mc3377	4.3	1.2	2.2	>400000
hu08-mc-0131	3.2	1.3	2.1	>400000
hu08-Malpeg-6121	3.3	3.5	3.4	>400000
hu08-Malpeg-0131	2.9	2.9	4.9	>400000
hu08-mc-6121	3.3	1.1	2.4	>400000
hu08-vc-3906	3	1.5	2.9	>400000
hu08 vc-6780	4	1.2	2.2	>400000
hulG8.84-vc0101	3.7	>400000	>400000	>400000
hulG8.84-mc3377	4.3	>400000	>400000	>400000

In Vivo Subcutaneous Xenograft Models with anti-IL13R α 2 ADCs

[0684] The humanized antibody hu08 specifically binds to the IL-13R α 2 receptor. hu08 ADCs with eleven different linker-payload combinations were tested in an in vivo xenograft model. Female, athymic (nude) mice were injected subcutaneous with PC3MM2. Mice with staged tumors, approximately 0.1 to 0.3 g (n = 8 to 10 mice/treatment group), were administered intravenously q4d x 4 with normal saline (vehicle), hu08v1.0/1.0 ADCs with linker-payloads vc-0101, vc-6780, vc-3906, mc-8261, mc-0131, mc-6121, mc-3377, MalPeg-8261, MalPeg-0131, MalPeg-6121, or MalPeg-3906, and a non-binding Ab (hulgG8.84) conjugated with vc-0101 or mc-3377, at a dose of 2 or 3 mg Ab/kg. The ADCs were dosed based on Ab content. Tumors were measured at least once a week and their size is calculated as mm³ = 0.5 x (tumor width²) x (tumor length).

[0685] The in vivo efficacy results listed in **Table 6** show a range of anti-tumor activity with the various ADCs tested. The relative order of potency is hu08-vc-0101 > hu08-vc-6780 > hu08-mc-0131 > hu08-mc-6121 > hu08-mc-3906 > hu08-MalPeg-0131 > hu08-MalPeg-6121 > hu08-MalPeg-3906 > hu08-mc-8261. At the 3 mg/kg dose level, both hu08-vc-0101 and hu08-mc-3377 demonstrated antitumor activity, whereas the non-binding Ab (hulgG8.84) conjugated with vc-0101 or mc-3377 had no activity and were similar to the vehicle control.

Table 6. Efficacy of anti-IL-13R α 2 ADCs in PC3MM2 xenografts.

ADC	Dose (mg/kg) Q4dx4	PC3MM2 xenograft, tumor volume (mm ³ +/- SEM)							
		Day -1	Day 3	Day 8	Day 16	Day 20	Day 30	Day 42	Day 52
Vehicle	0	638 ± 27	1149 ± 82	1707 ± 133	GT	GT	GT	GT	GT
hu08-MalPeg-3906	2	642 ± 36	1036 ± 60	1176 ± 51	GT	GT	GT	GT	GT
hu08-mc-8261	2	642 ± 51	1088 ± 121	1429 ± 158	GT	GT	GT	GT	GT
hu08-mc-0131	2	637 ± 44	1004 ± 73	778 ± 83	GT	GT	GT	GT	GT
hu08-MalPeg-6121	2	638 ± 36	947 ± 85	1000 ± 126	GT	GT	GT	GT	GT
hu08-MalPeg-0131	2	649 ± 39	1085 ± 54	1040 ± 88	GT	GT	GT	GT	GT
hu08-vc-0101	2	646 ± 36	899 ± 54	557 ± 49	243 ± 28	201 ± 20	113 ± 17	207 ± 49	532 ± 151
hu08-vc-6780	2	641 ± 28	850 ± 100	652 ± 54	279 ± 55	217 ± 45	230 ± 133	GT	GT
hu08-mc-6121	2	636 ± 37	909 ± 63	821 ± 93	GT	GT	GT	GT	GT
hu08-mc-3906	2	637 ± 26	875 ± 48	806 ± 70	GT	GT	GT	GT	GT
hu08-MalPeg-8261	2	645 ± 34	991 ± 71	1220 ± 115	GT	GT	GT	GT	GT
hu08-vc0101	3	339 ± 18	433 ± 45	38 ± 14	6 ± 6	110 ± 110	230 ± 230	GT	GT
hu08-mc3377	3	337 ± 21	385 ± 36	41 ± 12	0 ± 0	78 ± 36	346 ± 147	616 ± 243	902 ± 364

(continued)

ADC	Dose (mg/kg) Q4dx4	PC3MM2 xenograft, tumor volume (mm ³ +/- SEM)							
		Day -1	Day 3	Day 8	Day 16	Day 20	Day 30	Day 42	Day 52
hulG8.84- vc0101	3	365 ± 22	581 ± 47	1017 ± 168	GT	GT	GT	GT	GT
hulG8.84- mc3377	10	328 ± 27	459 ± 63	295 ± 121	544 ± 258	GT	GT	GT	GT
GT= group terminated due to large tumor size									

Anti-Notch ADC *In Vitro* and *In Vivo* Studies**Anti-Notch Antibodies and ADCs**

[0686] Humanized antibodies, hu28 and hu75, and rat-human chimeric antibodies, ch28 and ch75, specifically bind to the Notch receptor. The amino acid and nucleotide sequences for hu28 and hu75 are provided in **Table 7**. Kabat CDRs are underlined.

Table 7. Amino acid and nucleotide sequences of humanized anti-Notch antibodies.

SEQ ID NO.	DESCRIPTION	SEQUENCES
15	hu28 Heavy Chain Variable Region amino acid sequence (CDRs underlined).	EVQLVESGGGLVQPGGSLRLSCAASGFTFRD <u>YGMTWVRQAPGKGL</u> EWVAY <u>YISSGSNYIYYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDT</u> AVYYCARRGPFVLD <u>AWGQGLTVTVSS</u>
16	hu28 Heavy Chain amino acid sequence (CDRs underlined). Human IgG1 Constant Region	EVQLVESGGGLVQPGGSLRLSCAASGFTFRD <u>YGMTWVRQAPGKGL</u> EWVAY <u>YISSGSNYIYYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDT</u> AVYYCARRGPFVLD <u>AWGQGLTVTVSS</u> ASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPG

(continued)

SEQ ID NO.	DESCRIPTION	SEQUENCES
17	hu28 Heavy Chain nucleotide sequence	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGG GGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACTTTCAG GGACTATGGAATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTGGCCTATATTAGTAGTGGTAGCAATTACATCTATT ATGCAGAAGCGGTGAAGGGCCGATTACCATCTCCAGAGACAAC GCCAAGAAGTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGA GGACACGGCTGTGTATTACTGTGCGAGACGAGGCCCGTTTGT GGATGCCTGGGGCCAGGGAACCCCTGGTCACCGTCTCCTCAGCGTC GACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAG CACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACT ACTTCCCCGAACCGGTGACGGTGTCTGTGAACTCAGGCGCCCTGA CCAGCGGCGTGCACACCTTCCCGGTGTCTACAGTCCCTCAGGAC TCTACTCCCTCAGCAGCGTGGTGACCGTGCCTCCAGCAGCTTGG GCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC ACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAAC TCACACATGCCCACCGTGGCCAGCACCTGAACTCCTGGGGGGACC GTCAGTCTTCTCTTCCCCCAAAACCCAAGGACACCCCTCATGAT CTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCC ACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTG GAGGTGCATAATGCCAAGACAAAAGCCGCGGGAGGAGCAGTACA ACAGCACGTACCGTGTGGTCAGCGTCTCACCCTCCTGCACCAGG ACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA GCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAAGCCAAAG GCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCATCCCGGG AGGAGATGACCAAGAACCAGGTGAGCCTGACCTGCCTGGTCAAA GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGG GCAGCCGAGAACTACAAGACCACGCCTCCCGTGTCTGGACT CCGACGGCTCCTTCTTCTCTATAGCAAGCTCACCGTGGACAAGA GCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATG AGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCC CGGGT
18	hu28 Light Chain Variable Region amino acid sequence (CDRs underlined).	DIQMTQSPSSLSASVGRVTITCKASQINRYLHWYQKPKGKAPKLL IYN <u>ANGLQ</u> TGVPSRFSGSGSGTDFTLTISLQPEDFATYYC <u>LQ</u> HNTPW DTFGGGTKVEIK
19	hu28 Light Chain amino acid sequence (CDRs underlined). Human kappa Constant Region	DIQMTQSPSSLSASVGRVTITCKASQINRYLHWYQKPKGKAPKLL IYN <u>ANGLQ</u> TGVPSRFSGSGSGTDFTLTISLQPEDFATYYC <u>LQ</u> HNTPW DTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNFPYPRE AKVQWQVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC
20	hu28 Light Chain nucleotide sequence	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTA GGAGACAGAGTCACCATCACTTGCAAAGCAAGTCAGAGTATTAA CAGGTACTTACACTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTATAATGCAAACGGTTTGCAAACGGGGGTCCCAT CAAGGTTCAAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCA TCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTTTGC AGCATAATACGTGGCCGGACACGTTTGGCGGAGGGACCAAGGTG GAGATCAAACGGACCGTGGCCGCTCCTTCCGTGTTTATCTTCCCC CCTTCCGACGAGCAGCTGAAGTCTGGCACCGCCTCTGTGGTGTGT CTGCTGAACAACCTTACCCCCGGGAGGCCAAGGTGCAGTGGAA GGTGGACAACGCTCTGCAGTCCGGCAACTCCCAGGAGTCTGTGA CCGAGCAGGACTCCAAGGACAGCACCTACTCCCTGTCTCTACCC TGACCTGTCCAAGGCCGACTACGAGAAGCACAAAGGTGTACGCC TGTGAGGTGACCCACCAGGGCCTGTCTCTCCTGTGACCAAGTCC TTCAACCGGGGCGAGTGC

(continued)

SEQ ID NO.	DESCRIPTION	SEQUENCES
21	hu75 Heavy Chain Variable Region amino acid sequence (CDRs underlined).	EVQLVESGGGLVQPGGSLRLSCAASGYAFTDYWMTWVRQAPGKGL EWVVAEISPNSGGTNFNEKFKGRFTISVDNAKNSLYLQMNSLRAEDT AVYYCARGEIRYNWFAYWGQGTLLTVSS
22	hu75 Heavy Chain amino acid sequence (CDRs underlined). Human IgG1 Constant region	EVQLVESGGGLVQPGGSLRLSCAASGYAFTDYWMTWVRQAPGKGL EWVVAEISPNSGGTNFNEKFKGRFTISVDNAKNSLYLQMNSLRAEDT AVYYCARGEIRYNWFAYWGQGTLLTVSSASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFCFSVMHEALHNHYTQKSLSLSPG
23	hu75 Heavy Chain nucleotide sequence	GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGG GGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGTTATGCATTAC TGACTACTGGATGACCTGGGTCCGCCAGGCTCCAGGGAAGGGGC TGGAGTGGGTGGCCGAAATTTCTCCTAACAGTGGTGGTACTAACT TCAATGAAAAGTTCAAGGGCCGATTACCATCTCCGTTGACAACG CCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCCGAG GACACGGCTGTGTATTACTGTGCGAGAGGGGAAATCCGTTACAA TTGGTTTGCTTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC AGCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTC CAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCA AGGACTACTTCCCCGAACCGGTGACGGTGTCTGGAAGTCAAGGC GCCCTGACCAGCGCGTGCACACCTTCCCGGCTGTCTTACAGTCC TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC AGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCC CAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTG ACAAAACCTCACACATGCCCACCGTGCCAGCACCTGAACTCCTGG GGGGACCGTCAGTCTTCTCTTCCCCCAAAACCAAGGACACCC TCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGACG TGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC GGCGTGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC AGTACAACAGCACGTACCGTGTGGTCAGCGTCTCACCCTCCTGC ACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC AACAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAAGC CAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCAT CCCGGGAGGAGATGACCAAGAACCAGGTGACCTGACCTGCCTG GTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAG CAATGGGCAGCCGGAGAACAATAAGACACGCCTCCCGTGC TGGACTCCGACGGCTCTTCTTCTCTATAGCAAGCTCACCGTGG ACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTG ATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTC CCTGTCCCCGGGT
24	hu75 Light Chain Variable Region amino acid sequence (CDRs underlined).	DIQMTQSPSSLSASVGDRVTITCKASQNVGNINIAWYQKPGKAPKL LIYYASNRYTGVPSRFSGSGYGTDFTLTISLQPEDFATYYCQRLYNS PFTFGGGTKVEIK
25	hu75 Light Chain amino acid sequence (CDRs underlined). Human kappa Constant Region	DIQMTQSPSSLSASVGDRVTITCKASQNVGNINIAWYQKPGKAPKL LIYYASNRYTGVPSRFSGSGYGTDFTLTISLQPEDFATYYCQRLYNS PFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR EAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEK HKVYACEVTHQGLSPVTKSFNRGEC

(continued)

SEQ ID NO.	DESCRIPTION	SEQUENCES
26	hu75 Light Chain nucleotide sequence	GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTA GGAGACAGAGTCACCATCACTTGCAAGGCCAGTCAGAATGTGGG TAATAATATAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTA AGCTCCTGATCTATTATGCATCTAACCAGGTACACTGGGGTCCCAT CAAGGTTCAGTGGCAGTGGATATGGGACAGATTTCACTCTCACCA TCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAGC GTCTTTACAATTCTCCATTACGTTTCGGCGGAGGGACCAAGGTGG AGATCAAACGACCGTGGCCGCTCCTTCCGTGTTTCATCTTCCCCC CTTCCGACGAGCAGCTGAAGTCTGGCACCGCCTCTGTGGTGTGTC TGCTGAACAACCTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAG GTGGACAACGCTCTGCAGTCCGGCAACTCCCAGGAGTCTGTGACC GAGCAGGACTCCAAGGACAGCACCTACTCCCTGTCTCTACCCTG ACCCTGTCCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTG TGAGGTGACCCACCAGGGCCTGTCTCTCTGTGACCAAGTCCTT CAACCGGGGCGAGTGC

[0687] Humanized anti-Notch antibodies, hu28 and hu75, and rat-human chimeric anti-Notch antibodies, ch28 and ch75, were conjugated to various linker-payload combinations of the present invention, as provided in **Table 8**. The antibody drug conjugates were prepared according to the methods of the present invention.

Table 8. Anti-Notch ADCs.

ADC Linker-Payload #	Corresponding ADC Nomenclature
Notch-28-v1010-hG1-(C)_mcValCitPABC-#54	hu28-vc0101
Notch-28-v1010-hG1-(C)_mcValCitPABC-#112	hu28-vc6780
Notch-75-v1913-hG1-(C)_mcValCitPABC-#54	hu75-vc0101
Notch-75-v1913-hG1-(C)_mcValCitPABC-#112	hu75-vc6780
Notch-28-cG1-(C)_mcValCitPABC-#54	ch28-vc0101
Notch-28-cG1-(C)_mcValCitPABC-#112	ch28-vc6780
Notch-28-cG1-(C)_mc-#54	ch28-mc0101
Notch-28-cG1-(C)_mc-0#118	ch28-mc0131
Notch-28-cG1-(C)_mc-#115	ch28-mc3377
Notch-28-cG1-(C)_mc-#69	ch28-mc8261
Notch-28-cG1-(C)_MalPeg6C2-0# 118	ch28-MalPeg6C2-0131
Notch-28-cG1-(C)_MalPeg6C2-#69	ch28-MalPeg6C2-8261
Notch-28-cG1-(C)_me-0#118	ch28-me0131
Notch-28-cG1-(C)_m(H ₂ O)c-0#118	ch28-m(H ₂ O)c-0131
Notch-75-cG1-(C)_mcValCitPABC-#54	ch75-vc0101
Notch-75-cG1-(C)_mcValCitPABC-#112	ch75-vc6780
Notch-75-cG1-(C)_mc-0#118	ch75-mc0131
Notch-75-cG1-(C)_mc-#115	ch75-mc3377
Notch-75-cG1-(C)_MalPeg6C2-0#118	ch75-MalPeg6C2-0131
Notch-75-cG1-(C)_MalPeg6C2-#69	ch75-MalPeg6C2-8261
Notch-75-cG1-(C)_me-0#118	ch75-me0131

(continued)

ADC Linker-Payload #	Corresponding ADC Nomenclature
Notch-75-cG1-(C)_m(H2O)c-0#118	ch75-m(H2O)c-0131
huNeg8.8-(C)_mcValCitPABC-#54	huNeg8.8-vc0101
huNeg8.8-(C)_mcValCitPABC-#112	huNeg8.8-vc6780
huNeg8.8-(C)_mc-0#118	huNeg8.8-mc0131
huNeg8.8-(C)_mc-#115	huNeg8.8-mc3377
huNeg8.8-(C)_me-0#118	huNeg8.8-me0131
huNeg8.8-(C)_MalPeg6C2-#69	huNeg8.8-MalPeg6C2-8261
ch2H6-(C)_mc-#69	ch2H6-mc8261

In Vitro Cytotoxicity Assays with Anti-Notch ADCs

[0688] The effects of anti-Notch ADCs were assessed on 1) cell lines endogenously expressing Notch protein: HCC2429 (lung cancer), OVCAR3 (ovarian cancer) and MDA-MB-468 (breast cancer), 2) cell lines engineered to over-express Notch protein: MDA-MB-468/hNotch and U2OS/hNotch, and 3) a negative control cell line (SW900) using an MTS cellular viability indicator (Promega, Madison, WI). These cell lines were cultured with increasing concentrations of anti-Notch ADCs comprising humanized anti-Notch antibodies, hu28 and hu75, and rat-human chimeric anti-Notch antibodies, ch28 and ch75, conjugated to various linker-payload combinations of the present invention. As a specificity control for the anti-Notch-ADCs, non-targeted control-ADCs (huNeg8.8-ADCs or ch2H6-ADCs) were also tested on the same cell lines. After four days, viability of each culture was assessed. IC₅₀ values were calculated by logistic non-linear regression and presented as ng Ab/mL. The drug antibody ratio (DAR) is also provided.

[0689] Table 9 shows IC₅₀ (ng Ab/mL) values of the humanized anti-Notch ADC treatments. HCC2429 and MDA-MB-468/hNotch cell lines had two individual repeats. The data demonstrates that the humanized anti-Notch ADCs with various linker-payloads were active and induced cell death in the Notch expressing and over-expressing cancer cell lines HCC2429, OVCAR3, MDA-MB-468, MDA-MB-468/hNotch, U2OS/hNotch, but not in the negative control cell line SW900 lacking Notch expression. The non-targeted control-ADCs either lacked potency (LP) and therefore IC₅₀ values were not generated as indicated, or were minimally active at the highest doses tested. Anti-Notch ADCs having IC₅₀ values equal to or higher than IC₅₀ values for control-ADCs were considered to lack potency in vitro and indicted as LP.

Table 9. IC₅₀ (ng Ab/mL) values of humanized anti-Notch ADCs.

ADC	DAR	IC ₅₀ (ng Ab/mL) ± S.E.M.							
		HCC2429		OVCAR3	MDA-MB-468	MDA-MB-468/hNotch		U2OS/hNotch	SW900
hu28-vc0101	3.9	473	2940	306	6545	3.2	3	1330	LP
hu75-vc0101	3.8	611	3295	515	7001	37	36	523	LP
huNeg8.8-vc0101	3.7	18417	23978	3770	LP	5122	LP	LP	23379
hu28-vc6780	3.9	148	2050	17	LP	1.3	3	LP	LP
hu75-vc6780	4.2	214	630	254	LP	26	25	LP	LP
huNeg8.8-vc6780	4.2	LP	LP	9238	LP	LP	LP	LP	LP

[0690] Table 10 shows IC₅₀ (ng Ab/mL) values of the rat-human chimeric anti-Notch ADC treatments. For experiments with 2-4 individual repeats, average IC₅₀ values were calculated along with standard error of the mean (S.E.M.). The

data demonstrates that the rat-human chimeric anti-Notch ADCs with various linker-payloads were active and induced cell death in the Notch expressing and over-expressing cancer cell lines HCC2429, OVCAR3, MDA-MB-468, MDA-MB-468/hNotch, U2OS/hNotch. The non-targeted control-ADCs either lacked potency (LP) and therefore IC₅₀ values were not generated as indicated, or were minimally active at the highest doses tested. Anti-Notch ADCs having IC₅₀ values equal to or higher than IC₅₀ values for control-ADCs were considered to lack potency in vitro and indicted as LP.

Table 10. IC₅₀ (ng Ab/mL) values of rat-human chimeric anti-Notch ADCs (nd= not determined).

ADC	DAR	IC ₅₀ (ng Ab/mL) ± S.E.M.				
		HCC2429	OVCAR3	MDA-MB-468	MDA-MB-468/hNotch	U2OS/hNotch
ch28-mc8261	3.7	LP	nd	12147±4806.4	nd	nd
ch2H6-mc8261	4.1	LP	nd	LP	nd	nd
ch28-MalPeg6C2-8261	4.3	LP	nd	83±35.5	nd	nd
ch75-MalPeg6C2-8261	3.8	LP	nd	4255±2375	nd	nd
huNeg8.8-MalPeg6C2-8261	4.1	LP	nd	LP	nd	nd
ch28-mc0131	3.4	251±77.5	6±1.0	35±18.5	nd	3±0.5
ch75-mc0131	3.3	671±406.5	289	8202±2773.0	nd	19
huNeg8.8-mc0131	3.9	Nd	LP	LP	nd	LP
ch28-me0131	3.9	30	8±2.0	24±14.0	nd	3±1.15
ch75-me0131	3.5	Nd	nd	259	nd	nd
huNeg8.8-me0131	3.7	Nd	LP	LP	nd	LP
ch28-mc3377	3.7	LP	14±5.5	27±11.3	nd	3±0.5
ch75-mc3377	3.7	Nd	nd	560	nd	nd
huNeg8.8-mc3377	3.6	Nd	LP	LP	nd	LP
ch28-MalPeg6C2-0131	4.1	LP	10±2.0	10±1.0	nd	3±0.85
ch28-vc0101	3.8	3230±1116.5	635	5443±2630.9	4±0.5	95±18.2
ch75-vc0101	2.7	2112±826.0	LP	4064±1793.9	24±4.0	LP
huNeg8.8-vc0101	3.7	15341	LP	4523±2789.5	8833	LP
ch28-vc6780	4.1	324±78.9	90±48.5	4407±2128.2	3±0.5	LP
ch75-vc6780	2.8	1004±177.0	922	6873±4230.0	21±3.5	LP
huNeg8.8-vc6780	4.1	LP	LP	LP	LP	LP

***In vivo* Human Tumor Xenograft Models with Anti-Notch ADCs**

[0691] Humanized anti-Notch antibodies, hu28 and hu75, and rat-human chimeric anti-Notch antibodies, ch28 and ch75, were conjugated to various linker-payload combinations and tested in 37622A1 non-small cell lung cancer (NSCLC), HCC2429 lung cancer, MDA-MB-468 breast cancer and N87 gastric cancer xenograft models. For each model described below the first dose was given on Day 0. The tumors were measured at least once a week and their volume was calculated with the formula: tumor volume (mm³) = 0.5 x (tumor width²)(tumor length). The mean tumor volumes (± S.E.M.) for each treatment group were calculated having a maximum of 10 animals and a minimum of 6 animals to be included.

A. 37622A1 NSCLC Xenografts

[0692] The effects of anti-Notch ADCs were examined in immunodeficient mice on the in vivo growth of human tumor xenografts that were established from fragments of freshly resected 37622A1 NSCLC tumors obtained in accordance with appropriate consent procedures (Asterand). The 37622A1 NSCLC patient-derived xenografts were subcutaneously passaged in vivo as fragments from animal to animal in nude (Nu/Nu) female mice. When the tumors reached a volume of 150 to 300 mm³, they were staged to ensure uniformity of the tumor size among various treatment groups. The 37622A1 NSCLC model was dosed intravenously four times every four days (Q4dx4) with PBS vehicle, humanized anti-Notch ADCs, control huNeg-8.8 ADCs and cisplatin at the doses provided in **Table 11**.

[0693] Cisplatin is a platinum-based anti-cancer agent used in the treatment of cancer and considered a standard-of-care therapy. Cisplatin cross-links DNA thereby inducing apoptosis and cell growth inhibition. The data demonstrates that anti-Notch ADCs hu28-vc0101, hu28-vc6780, hu75-vc0101 and hu75-vc6780 inhibited growth of 37622A1 NSCLC xenografts. Further, the data shows that anti-Notch ADCs inhibited tumor growth more potently than control huNeg8.8-ADCs. Furthermore, the data shows that anti-Notch ADCs inhibited tumor growth more potently than cisplatin indicating a greater potency than a platinum-based standard-of-care chemotherapeutic drug.

Table 11. Efficacy of anti-Notch ADCs in 37622A1 NSCLC xenografts.

37622A1 NSCLC xenografts, tumor volume (mm ³ ± SEM)								
	PBS	hu28-vc0101	hu28-vc6780	hu75-vc0101	hu75-vc6780	huNeg-8.8-vc0101	huNeg-8.8-vc6780	Cisplatin
Dose mg/kg	0	3	10	3	10	3	10	5
DAY -1	187 ± 10	186 ± 13	182 ± 16	185 ± 17	183 ± 17	184 ± 18	182 ± 17	185 ± 11
DAY 4	227 ± 19	202 ± 16	176 ± 13	200 ± 16	205 ± 23	225 ± 17	226 ± 26	226 ± 15
DAY 7	279 ± 24	202 ± 15	176 ± 19	227 ± 16	195 ± 22	274 ± 18	265 ± 28	280 ± 29
DAY 11	371 ± 42	130 ± 11	122 ± 10	175 ± 20	147 ± 23	309 ± 26	246 ± 30	301 ± 34
DAY 14	419 ± 49	119 ± 11	95 ± 7	156 ± 19	118 ± 18	303 ± 26	277 ± 41	345 ± 47
DAY 18	516 ± 63	71 ± 6	65 ± 6	112 ± 16	93 ± 14	298 ± 28	219 ± 31	309 ± 37
DAY 21	562 ± 65	55 ± 6	56 ± 6	122 ± 27	98 ± 20	320 ± 41	218 ± 42	373 ± 50
DAY 25	610 ± 78	49 ± 6	51 ± 6	137 ± 33	93 ± 24	315 ± 52	264 ± 52	401 ± 58
DAY 28	624 ± 94	41 ± 7	51 ± 8	161 ± 53	99 ± 26	358 ± 61	246 ± 51	446 ± 64
DAY 32	817 ± 99	42 ± 13	72 ± 15	175 ± 52	165 ± 45	398 ± 64	332 ± 77	482 ± 62
DAY 35	900 ± 104	42 ± 11	92 ± 21	271 ± 79	229 ± 59	487 ± 79	384 ± 94	587 ± 80
DAY 39	960 ± 117	62 ± 26	120 ± 31	319 ± 103	294 ± 78	569 ± 102	431 ± 114	591 ± 83
DAY 42	931 ± 108	75 ± 34	151 ± 37	357 ± 113	318 ± 71	590 ± 101	495 ± 128	612 ± 92
DAY 46	1037 ± 102	92 ± 44	172 ± 47	431 ± 137	412 ± 106	743 ± 133	610 ± 165	723 ± 119

(continued)

37622A1 NSCLC xenografts, tumor volume (mm ³ ± SEM)								
	PBS	hu28-vc0101	hu28-vc6780	hu75-vc0101	hu75-vc6780	huNeg-8.8-vc0101	huNeg-8.8-vc6780	Cisplatin
Dose mg/kg	0	3	10	3	10	3	10	5
DAY 49	1119 ±120	120 ±63	248 ±62	519 ±135	521 ±132	810 ±121	718 ±202	853 ±139
DAY 53	1345 ±158	144 ±67	339 ±93	678 ±195	629 ±162	989 ±146	848 ±251	970 ±193
DAY 56	1485 ±185	126 ±51	376 ±100	818 ±251	808 ±196	1149 ±191	776 ±184	1215 ±231
DAY 60	1691 ±220	180 ±85	503 ±138	710 ±162	917 ±209	1287 ±194	964 ±232	1428 ±273
DAY 63	1736 ±193	223 ±111	604 ±160	824 ±191	917 ±147	1503 ±227	1097 ±254	-
DAY 67	-	296 ±152	888 ±272	938 ±202	1116 ±173	1600 ±251	1167 ±260	-
DAY 70	-	312 ±162	773 ±235	953 ±209	1181 ±203	-	1352 ±305	-
DAY 74	-	331 ±160	881 ±264	-	-	-	-	-
DAY 77	-	422 ±210	1029 ±325	-	-	-	-	-
DAY 81	-	510 ±248	-	-	-	-	-	-
DAY 84	-	622 ±322	-	-	-	-	-	-

B. HCC2429 Lung Xenografts

[0694] Similar in vivo experiments were performed with the HCC2429 lung cancer cell line as described above. To generate xenografts, nude (Nu/Nu) female mice were implanted subcutaneously with 3.5x10⁶ HCC2429 cells in 50% Matrigel (BD Biosciences). When the tumors reached a volume of 200 to 400 mm³, the tumors were staged to ensure uniformity of the tumor mass among various treatment groups. The HCC2429 lung model was dosed intravenously Q4dx4 with PBS vehicle, humanized anti-Notch ADCs and control huNeg-8.8 ADCs at the doses provided in **Tables 12 and 13**. The data demonstrates that anti-Notch ADCs hu28-vc0101, hu28-vc6780, hu75-vc0101 and hu75-vc6780 inhibited growth of HCC2429 lung xenografts in a dose-dependent manner. Further, the data shows that anti-Notch ADCs inhibited tumor growth more potently than control huNeg8.8-ADCs at the 1 and 3 mg/kg doses for anti-Notch ADCs with vc0101 linker-payloads and at the 3 and 10 mg/kg doses for anti-Notch ADCs with vc6780 linker-payloads. Furthermore, the data demonstrates that a 3mg/kg dose of hu28-vc0101 was more potent than a 10 mg/kg dose of hu28-vc6780.

Table 12. Efficacy of anti-Notch-vcO 101 ADCs in HCC2429 lung xenografts.

HCC2429 Lung xenografts, tumor volume (mm ³ +/- SEM)										
	PBS	hu28-vc0101			hu75-vc0101			huNeg-8.8-vc0101		
Dose mg/kg	0	3	1	0.3	3	1	0.3	3	1	0.3
DAY -1	245 ±24	245 ±23	246 ±26	246 ±30	245 ±28	246 ±23	247 ±29	244 ±30	245 ±33	246 ±27

EP 2 780 039 B9

(continued)

	HCC2429 Lung xenografts, tumor volume (mm ³ +/- SEM)									
	PBS	hu28-vc0101			hu75-vc0101			huNeg-8.8-vc0101		
Dose mg/kg	0	3	1	0.3	3	1	0.3	3	1	0.3
DAY 1	529 ±52	548 ±52	532 ±36	528 ±50	498 ±39	548 ±37	524 ±66	482 ±59	519 ±72	514 ±50
DAY 3	742 ±73	606 ±78	757 ±68	733 ±78	498 ±44	753 ±93	713 ±74	695 ±91	756 ±	724 ±73
DAY 6	1205 ±120	723 ±101	1095 ±119	1112 ±132	469 ±70	1096 ±146	1078 ±74	1075 ±132	1144 ±100	1207 ±100
DAY 8	1720 ±181	696 ±100	1324 ±173	1617 ±172	407 ±71	1428 ±200	1499 ±115	1404 ±183	1598 ±133	1683 ±165
DAY 10	2312 ±197	620 ±90	1606 ±250	2027 ±233	370 ±81	1611 ±189	1830 ±120	1735 ±253	1974 ±185	2163 ±260
DAY 13	3235 ±120	543 ±92	1717 ±223	2642 ±297	273 ±69	1803 ±208	2408 ±226	2162 ±376	2676 ±346	2589 ±287
DAY 15	-	512 ±111	1865 ±263	-	298 ±88	1871 ±232	-	-	-	-
DAY 17	-	442 ±114	2228 ±333	-	250 ±77	1948 ±228	-	-	-	-
DAY 20	-	428 ±144	-	-	177 ±44	-	-	-	-	-
DAY 23	-	405 ±149	-	-	160 ±35	-	-	-	-	-
DAY 27	-	422 ±164	-	-	174 ±51	-	-	-	-	-
DAY 30	-	394 ±182	-	-	196 ±72	-	-	-	-	-
DAY 34	-	505 ±236	-	-	295 ±121	-	-	-	-	-
DAY 37	-	606 ±283	-	-	433 ±179	-	-	-	-	-
DAY 41	-	750 ±361	-	-	606 ±259	-	-	-	-	-
DAY 45	-	872 ±415	-	-	836 ±359	-	-	-	-	-
DAY 49	-	558 ±303	-	-	732 ±350	-	-	-	-	-
DAY 52	-	571 ±310	-	-	-	-	-	-	-	-
DAY 56	-	704 ±399	-	-	-	-	-	-	-	-

Table 13. Efficacy of anti-Notch-vc6780 ADCs in HCC2429 lung xenografts.

HCC2429 Lung xenografts, tumor volume (mm ³ ± SEM)										
	PBS	hu28-vc6780			hu75-vc6780			huNeg-8.8-vc6780		
Dose mg/kg	0	10	3	1	10	3	1	10	3	1
DAY -1	245 ±28	244 ±22	245 ±24	245 ±27	244 ±19	246 ±30	245 ±16	244 ±22	244 ±26	245 ±20
DAY 1	398 ±50	369 ±31	379 ±45	400 ±66	407 ±43	403 ±51	418 ±34	429 ±56	427 ±49	402 ±53
DAY 3	701 ±102	318 ±31	493 ±65	579 ±113	339 ±36	526 ±74	629 ±65	619 ±62	689 ±83	655 ±97
DAY 5	949 ±140	228 ±28	609 ±82	826 ±191	251 ±33	615 ±98	916 ±97	808 ±101	965 ±114	837 ±117
DAY 7	1345 ±200	172 ±22	638 ±86	1023 ±259	225 ±24	615 ±115	1164 ±131	1072 ±154	1380 ±136	1099 ±172
DAY 10	2045 ±356	143 ±22	784 ±115	1439 ±398	198 ±24	717 ±129	1705 ±184	1452 ±210	2082 ±192	1722 ±363
DAY 12	-	134 ±20	883 ±132	1442 ±487	166 ±22	807 ±130	2029 ±270	1673 ±290	2701 ±228	1586 ±337
DAY 14	-	115 ±16	895 ±175	-	150 ±22	831 ±145	2294 ±287	1809 ±314	-	-
DAY 17	-	127 ±18	1105 ±253	-	158 ±32	1017 ±178	-	-	-	-
DAY 20	-	149 ±27	1219 ±311	-	164 ±48	1297 ±231	-	-	-	-
DAY 24	-	206 ±60	1618 ±468	-	261 ±89	1813 ±343	-	-	-	-
DAY 27	-	290 ±100	-	-	316 ±135	1970 ±462	-	-	-	-
DAY 31	-	378 ±150	-	-	438 ±201	-	-	-	-	-
DAY 34	-	551 ±244	-	-	423 ±177	-	-	-	-	-
DAY 38	-	718 ±332	-	-	504 ±203	-	-	-	-	-
DAY 42	-	1011 ±504	-	-	655 ±266	-	-	-	-	-
DAY 46	-	-	-	-	793 ±320	-	-	-	-	-
DAY 49	-	-	-	-	901 ±351	-	-	-	-	-
DAY 53	-	-	-	-	1228 ±472	-	-	-	-	-

[0695] The HCC2429 lung model was also dosed intravenously Q4dx4 with PBS vehicle, rat-human chimeric anti-Notch ADCs and control huNeg-8.8 ADCs, at a dose of 5mg/kg as provided in **Figure 8A**. The data demonstrates that anti-Notch ADCs with non-cleavable (mc) and cleavable (vc) linkers and various payload combinations inhibited growth

of HCC2429 lung xenografts. Further, the data shows that rat-human chimeric anti-Notch ADCs inhibited tumor growth more potently than control huNeg8.8-ADCs. Furthermore, the data demonstrates that rat-human chimeric anti-Notch ADCs with vc0101 linker-payloads were more potent than the other anti-Notch ADCs tested.

C. MDA-MB-468 Breast Xenografts

[0696] Similar in vivo experiments were performed with the MDA-MB-468 breast cancer cell line as described above. MDA-MB-468 cells are classified as a triple-negative breast cancer (TNBC) basal-like subtype since they lack expression of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) (Lehmann, BD, et al, J Clin Invest. 2011;121(7):2750-2767). To generate xenografts, female SCID Hairless Outbred (SHO) mice were orthotopically implanted with 10×10^6 MDA-MB-468 cells containing 50% Matrigel (BD Biosciences) in the mammary fat pad. When the tumors reached a volume of 250 to 450 mm³, the tumors were staged to ensure uniformity of the tumor mass among various treatment groups. The MDA-MB-468 breast model was dosed intravenously Q4dx4 with PBS vehicle, humanized anti-Notch ADCs and control huNeg8.8 ADCs at the doses provided in **Tables 14 and 15**. The data demonstrates that anti-Notch ADCs hu28-vc0101, hu28-vc6780, hu75-vc0101 and hu75-vc6780 inhibited growth of MDA-MB-468 breast xenografts in a dose-dependent manner. Further, the data shows that anti-Notch ADCs inhibited tumor growth more potently than control huNeg8.8-ADCs at the 1 and 3 mg/kg doses for ADCs with vc0101 linker-payloads and 1, 3 and 10 mg/kg doses for ADC with vc6780 linker-payloads. Furthermore, the data demonstrates that a 1 mg/kg dose of anti-Notch ADCs with vc0101 linker-payloads were more potent than a 3 mg/kg dose of anti-Notch ADCs with vc6780 linker-payloads.

Table 14. Efficacy of anti-Notch-vcO 101 ADCs in MDA-MB-468 breast xenografts.

MDA-MB-468 Breast xenografts, tumor volume (mm ³ ± SEM)										
	PBS	hu28-vc0101			hu75-vc0101			huNeg-8.8-vc0101		
Dose mg/kg	0	3	1	0.3	3	1	0.3	3	1	0.3
DAY 0	343 ± 12	347 ± 15	348 ± 22	336 ± 19	347 ± 20	347 ± 22	348 ± 21	334 ± 23	346 ± 16	344 ± 19
DAY 4	441 ± 24	359 ± 24	439 ± 21	403 ± 28	444 ± 28	410 ± 32	439 ± 31	424 ± 29	447 ± 32	442 ± 19
DAY 7	469 ± 32	326 ± 27	415 ± 25	395 ± 38	338 ± 20	383 ± 33	435 ± 27	411 ± 26	449 ± 20	438 ± 23
DAY 11	495 ± 28	227 ± 27	372 ± 34	412 ± 42	277 ± 22	373 ± 33	504 ± 38	439 ± 36	538 ± 23	496 ± 37
DAY 14	581 ± 35	147 ± 20	314 ± 27	488 ± 45	181 ± 19	350 ± 40	507 ± 30	445 ± 29	592 ± 47	560 ± 36
DAY 18	639 ± 43	77 ± 10	261 ± 33	497 ± 55	90 ± 12	296 ± 33	587 ± 44	479 ± 42	619 ± 42	578 ± 36
DAY 21	638 ± 46	16 ± 8	219 ± 41	509 ± 60	60 ± 9	260 ± 49	590 ± 55	481 ± 34	676 ± 46	627 ± 30
DAY 26	707 ± 41	0 ± 0	253 ± 61	590 ± 66	16 ± 10	267 ± 59	652 ± 64	548 ± 41	793 ± 54	671 ± 56
DAY 29	749 ± 59	0 ± 0	238 ± 64	-	8 ± 8	261 ± 62	675 ± 63	-	819 ± 73	669 ± 37
DAY 32	812 ± 80	0 ± 0	266 ± 67	-	7 ± 7	264 ± 67	738 ± 70	-	913 ± 72	758 ± 44
DAY 35	891 ± 79	0 ± 0	271 ± 73	-	0 ± 0	326 ± 86	821 ± 69	-	1023 ± 96	848 ± 58
DAY 39	892 ± 84	0 ± 0	310 ± 88	-	0 ± 0	324 ± 81	864 ± 74	-	-	884 ± 64

(continued)

	MDA-MB-468 Breast xenografts, tumor volume (mm ³ ± SEM)									
	PBS	hu28-vc0101			hu75-vc0101			huNeg-8.8-vc0101		
Dose mg/kg	0	3	1	0.3	3	1	0.3	3	1	0.3
DAY 42	1037 ±104	0 ±0	349 ±95	-	0 ±0	381 ±94	997 ±84	-	-	1002 ±55
DAY 47	1173 ±134	0 ±0	394 ±123	-	0 ±0	442 ±69	-	-	-	1145 ±78
DAY 50	-	0 ±0	377 ±118	-	0 ±0	484 ±89	-	-	-	1120 ±67
DAY 53	-	0 ±0	414 ±127	-	0 ±0	452 ±78	-	-	-	1229 ±100
DAY 56	-	0 ±0	470 ±128	-	0 ±0	535 ±93	-	-	-	1314 ±120
DAY 60	-	0 ±0	532 ±140	-	0 ±0	603 ±98	-	-	-	-
DAY 63	-	0 ±0	509 ±117	-	0 ±0	-	-	-	-	-
DAY 67	-	0 ±0	611 ±148	-	0 ±0	-	-	-	-	-
DAY 70	-	0 ±0	-	-	0 ±0	-	-	-	-	-

Table 15. Efficacy of anti-Notch-vc6780 ADCs in MDA-MB-468 breast xenografts.

	MDA-MB-468 Breast xenografts, tumor volume (mm ³ ± SEM)									
	PBS	hu28-vc6780			hu75-vc6780			huNeg-8.8-vc6780		
Dose mg/kg	0	10	3	1	10	3	1	10	3	1
DAY 0	342 ±9	335 ±9	342 ±18	342 ±16	343 ±10	344 ±11	340 ±14	339 ±18	341 ±12	346 ±16
DAY 4	466 ±20	395 ±19	394 ±33	462 ±22	418 ±15	406 ±22	423 ±27	432 ±45	457 ±23	466 ±29
DAY 7	481 ±17	350 ±19	399 ±24	452 ±30	370 ±18	378 ±21	434 ±29	449 ±45	529 ±24	528 ±25
DAY 11	611 ±44	248 ±26	380 ±25	512 ±35	302 ±21	403 ±21	471 ±39	504 ±38	599 ±23	621 ±43
DAY 14	610 ±19	154 ±23	401 ±30	507 ±38	228 ±19	370 ±28	470 ±44	503 ±64	622 ±31	639 ±48
DAY 19	707 ±34	65 ±17	438 ±39	538 ±47	112 ±23	339 ±19	536 ±49	437 ±54	697 ±36	713 ±48
DAY 22	-	25 ±16	414 ±41	551 ±48	52 ±21	360 ±17	552 ±44	415 ±54	-	-
DAY 25	-	26 ±19	491 ±37	575 ±55	63 ±25	381 ±23	597 ±48	421 ±76	-	-

(continued)

MDA-MB-468 Breast xenografts, tumor volume (mm ³ ± SEM)										
	PBS	hu28-vc6780			hu75-vc6780			huNeg-8.8-vc6780		
Dose mg/kg	0	10	3	1	10	3	1	10	3	1
DAY 28	-	15 ±15	497 ±68	654 ±74	64 ±26	443 ±33	660 ±53	451 ±84	-	-
DAY 32		0 ±0	524 ±69	653 ±82	71 ±31	437 ±28	634 ±74	456 ±94		
DAY 35	-	0 ±0	-	734 ±89	85 ±38	495 ±33	742 ±80	541 ±108	-	-
DAY 40	-	0 ±0	-	761 ±99	125 ±44	535 ±41	794 ±87	563 ±109	-	-
DAY 43	-	0 ±0	-	816 ±122	134 ±42	619 ±47	878 ±78	581 ±120	-	-
DAY 46	-	0 ±0	-	859 ±126	143 ±42	636 ±38	868 ±99	617 ±116	-	-
DAY 49	-	0 ±0	-	948 ±178	159 ±44	723 ±71	996 ±109	733 ±129	-	-
DAY 53	-	0 ±0	-	1008 ±192	201 ±63	795 ±67	-	758 ±163	-	-
DAY 56	-	0 ±0	-	-	211 ±63	819 ±77	-	-	-	-
DAY 60	-	0 ±0	-	-	240 ±63	976 ±115	-	-	-	-
DAY 63	-	0 ±0	-	-	201 ±57	-	-	-	-	-

[0697] The MDA-MB-468 breast model was also dosed intravenously Q4dx4 with PBS vehicle, rat-human chimeric anti-Notch ADCs and control huNeg-8.8 ADCs, at a dose of 5mg/kg as provided in **Figures 8B and 8C**. The data demonstrates that rat-human chimeric anti-Notch ADCs with non-cleavable (mc) and cleavable (vc) linkers and various payload combinations inhibited growth of MDA-MB-468 breast xenografts. Further, the data shows that rat-human chimeric anti-Notch ADCs inhibited tumor growth more potently than control huNeg8.8-ADCs. Furthermore, the data demonstrates that rat-human chimeric anti-Notch ADCs with vc0101 linker-payloads were more potent than the other rat-human chimeric anti-Notch ADCs tested.

D. N87 Gastric Xenografts

[0698] Similar in vivo experiments were performed with the N87 gastric cancer cell line as described above. To generate xenografts, nude (Nu/Nu) female mice were implanted subcutaneously with 7.5 x10⁶ N87 cells in 50% Matrigel (BD Biosciences). When the tumors reached a volume of 250 to 450 mm³, the tumors were staged to ensure uniformity of the tumor mass among various treatment groups. The N87 gastric model was dosed intravenously Q4dx4 with PBS vehicle, humanized anti-Notch ADCs, control huNeg-8.8 ADCs and cisplatin at the doses provided in **Tables 16 and 17**. The data demonstrates that anti-Notch ADCs hu28-vc0101, hu28-vc6780, hu75-vc0101 and hu75-vc6780 inhibited growth of N87 gastric xenografts in a dose-dependent manner. Further, the data shows that anti-Notch ADCs inhibited tumor growth more potently than control huNeg8.8-ADCs at the 1, 3, 5 mg/kg doses for ADCs with vc0101 linker-payloads and 3 and 10 mg/kg doses for ADCs with vc6780 linker-payloads. Furthermore, the data demonstrates that ADCs with vc0101 linker-payloads were in general more potent than cisplatin standard-of-care therapy and ADCs with vc6780 linker-payloads.

Table 16. Efficacy of anti-Notch-vcO 101 ADCs in N87 gastric xenografts.

N87 Gastric xenografts, tumor volume (mm ³ ± SEM)											
	PBS	hu28-vc0101			hu75-vc0101			huNeg-8.8-vc0101			Cisplatin
Dose mg/kg	0	1	3	5	1	3	5	1	3	5	5
DAY 0	327 ±11	321 ±21	326 ±13	321 ±8	321 ±9	324 ±19	320 ±11	327 ±18	324 ±11	321 ±16	328 ±20
DAY 4	526 ±19	369 ±18	339 ±11	344 ±14	392 ±15	362 ±35	315 ±15	437 ±34	478 ±19	423 ±32	414 ±27
DAY 7	706 ±27	429 ±43	302 ±10	272 ±7	417 ±25	303 ±21	246 ±12	584 ±54	625 ±34	512 ±34	520 ±26
DAY 11	854 ±36	304 ±30	182 ±14	152 ±13	331 ±21	174 ±14	156 ±10	702 ±60	716 ±53	501 ±38	501 ±29
DAY 14	887 ±45	282 ±25	191 ±5	155 ±13	305 ±17	172 ±10	151 ±7	822 ±65	823 ±42	549 ±37	637 ±31
DAY 18	1045 ±68	263 ±24	161 ±7	138 ±11	267 ±17	151 ±10	128 ±6	823 ±73	789 ±33	491 ±51	-
DAY 21	1072 ±76	227 ±23	123 ±15	110 ±9	218 ±23	130 ±5	115 ±7	857 ±78	785 ±35	413 ±50	-
DAY 26	1303 ±140	205 ±32	108 ±16	69 ±16	185 ±24	92 ±14	82 ±10	895 ±126	825 ±62	343 ±63	-
DAY 29	1276 ±139	180 ±30	99 ±14	50 ±13	211 ±37	104 ±16	75 ±12	957 ±126	879 ±72	411 ±89	-
DAY 33	1480 ±183	211 ±43	106 ±17	43 ±14	251 ±53	91 ±18	73 ±12	988 ±180	966 ±98	411 ±89	-
DAY 36	-	215 ±42	122 ±22	52 ±16	272 ±59	86 ±18	85 ±9	884 ±143	1023 ±106	481 ±86	-
DAY 39	-	261 ±54	128 ±23	45 ±14	304 ±72	59 ±16	72 ±13	937 ±167	1142 ±121	535 ±128	-
DAY 42	-	283 ±52	149 ±25	34 ±15	314 ±73	81 ±22	74 ±13	1008 ±179	1240 ±143	596 ±119	-
DAY 47	-	262 ±64	105 ±19	25 ±14	334 ±95	80 ±25	36 ±8	1061 ±210	1380 ±153	621 ±137	-
DAY 53	-	302 ±75	104 ±30	29 ±16	393 ±115	86 ±24	69 ±13	-	-	757 ±189	-
DAY 62	-	415 ±111	116 ±47	33 ±18	463 ±155	106 ±35	50 ±15	-	-	690 ±122	-
DAY 70	-	521 ±135	139 ±54	58 ±30	658 ±241	148 ±54	76 ±22	-	-	852 ±150	-

Table 17. Efficacy of anti-Notch-vc6780 ADCs in N87 gastric xenografts.

N87 Gastric xenografts, tumor volume (mm ³ ± SEM)									
	PBS	hu28-vc6780			hu75-vc6780			huNeg8.8-vc6780	
Dose mg/kg	0	10	3	1	10	3	1	10	3
DAY 0	345 ± 14	350 ± 14	349 ± 10	348 ± 13	349 ± 8	351 ± 20	359 ± 16	356 ± 20	344 ± 14
DAY 4	600 ± 16	434 ± 24	552 ± 24	560 ± 26	468 ± 18	545 ± 37	552 ± 40	581 ± 60	537 ± 36
DAY 8	675 ± 20	379 ± 12	545 ± 37	592 ± 44	351 ± 24	511 ± 31	568 ± 62	605 ± 67	670 ± 45
DAY 11	763 ± 54	315 ± 18	511 ± 25	617 ± 48	316 ± 25	544 ± 43	591 ± 63	636 ± 79	706 ± 38
DAY 14	886 ± 72	292 ± 24	564 ± 29	782 ± 60	269 ± 27	558 ± 36	666 ± 77	775 ± 117	917 ± 36
DAY 18	997 ± 93	199 ± 18	479 ± 29	797 ± 88	224 ± 26	494 ± 41	642 ± 90	665 ± 112	958 ± 57
DAY 21	1041 ± 107	194 ± 20	499 ± 34	839 ± 93	192 ± 19	534 ± 41	710 ± 117	637 ± 119	1002 ± 59
DAY 25	1151 ± 144	181 ± 21	588 ± 40	878 ± 105	227 ± 32	628 ± 58	748 ± 138	647 ± 134	1075 ± 82
DAY 28	1200 ± 155	204 ± 16	672 ± 48	904 ± 123	244 ± 35	645 ± 57	763 ± 145	674 ± 146	1148 ± 77
DAY 33	1481 ± 206	196 ± 27	786 ± 65	1043 ± 152	267 ± 52	730 ± 66	991 ± 239	733 ± 195	1290 ± 128
DAY 36	-	189 ± 37	827 ± 69	1108 ± 185	300 ± 64	850 ± 74	-	817 ± 222	1265 ± 111
DAY 39	-	228 ± 44	847 ± 77	1204 ± 209	323 ± 69	881 ± 88	-	880 ± 247	1429 ± 121
DAY 42	-	257 ± 60	959 ± 81	-	350 ± 78	1020 ± 99	-	797 ± 244	-
DAY 46	-	253 ± 59	1018 ± 94	-	380 ± 78	1097 ± 129	-	874 ± 267	-
DAY 50	-	253 ± 67	1111 ± 95	-	415 ± 77	1162 ± 134	-	-	-
DAY 56	-	298 ± 85	1279 ± 108	-	504 ± 111	1331 ± 187	-	-	-
DAY 63	-	345 ± 93	1368 ± 133	-	581 ± 121	-	-	-	-
DAY 70	-	376 ± 117	1483 ± 154	-	726 ± 163	-	-	-	-
DAY 77	-	388 ± 123	-	-	797 ± 184	-	-	-	-

[0699] The N87 gastric model was also dosed intravenously Q4dx4 with PBS vehicle, rat-human chimeric anti-Notch ADCs and control huNeg-8.8 ADCs, at a dose of 5mg/kg as provided in **Figure 8D**. The data demonstrates that rat-human chimeric anti-Notch ADCs with non-cleavable (mc) and cleavable (vc) linkers and various payload combinations

inhibited growth of N87 gastric xenografts. Further, the data shows that rat-human chimeric anti-Notch ADCs inhibited tumor growth more potently than control huNeg8.8-ADCs. Furthermore, the data demonstrates that rat-human chimeric anti-Notch ADCs with vc0101 linker-payloads were more potent than the other anti-Notch ADCs tested.

[0700] The N87 gastric model was also dosed intravenously Q4dx4 with PBS vehicle and rat-human chimeric anti-Notch ADCs ch28-mc0131, ch75-mc0131, ch28-m(H2O)c-0131 and ch75-m(H2O)c-0131 at a dose of 5mg/kg as provided in **Figure 8E**. The data demonstrates that rat-human chimeric anti-Notch ADCs having mc0131 and m(H2O)c-0131 linker-payloads inhibited growth of N87 gastric xenografts. Further, the data demonstrates that rat-human chimeric anti-Notch ADCs having m(H2O)c-0131 linker-payloads were more potent than rat-human chimeric anti-Notch ADCs having mc0131 linker-payloads.

Table 18A - Selected compounds (cytotoxic peptides with linkers) of the invention and Reference Examples

Linker-Payload #	Preparation method	Purification method	Quantity in mg (Yield)
mcV aLCitP ABC-#34	General procedure E	Method D	4.7 (12%)
MalPeg3C2-#41	General procedure D	Method C	36 (28%)
MalPeg6C2-#42	General procedure D	Method C	125 (88%)
mc-#44	General procedure D	Method C	5.9 (25%)
MalPeg3C2-#44	General procedure D	Method C	10 (28%)
MalPeg6C2-#44	General procedure D	Method C	1.8 (6%)
MalValCitPABC-#44	General procedure E	Method F	4 (10%)
mc-#45	General procedure D	Method C	12.8 (53%)
MalPeg3C2-#45	General procedure D	Method C	7.5 (28%)
MalPeg6C2-#45	General procedure D	Method E1*	13.6 (45%)
mcValCitPABC-#45	General procedure E	Method C & Method EI	5.8 (15%)
mcValCitPABC-#54	General procedure E	Method D	33 (36%)
mc-#69	General procedure D	Method C	30.2 (24%)
MalPeg6C2-#69	General procedure D	Method C	3.6 (13%)
mcValCitPABC-#69	General procedure E	Method I	51 (9%)
mcValCitPABC-#70	General procedure E	Method D	6.9 (12%)
mcValCitPABC-#75	General procedure E	Method H	5.3 (14%)
mc-#79	General procedure D	Method E	5.6 (19%)

EP 2 780 039 B9

(continued)

	Linker-Payload #	Preparation method	Purification method	Quantity in mg (Yield)
5	mcValCitPABC-#79	General procedure E	Method D	5.5 (10%)
	mcValCitPABC-#92	General procedure E	Method E	9.5 (26%)
10	mcValCitP ABC-#112	General procedure E	Method C	11.8 (21%)
	mv-#115	General procedure D	Method J	1.4 (3.3%)
15	mc-#115	-	Method L	124 (11%)
	mb-#1 15	General procedure D	-	-
20	me-#115	General procedure D	-	-
	mcValCitPABC-#115	General procedure E	Method K	4.9 (12%)
25	mc-#51	General procedure D	Method E1	5.5 (42 %)
	mc-#47	General procedure D	Method E1	8.4 (46%)
30	mc-#54	General procedure D	Method E1	12.9 (65%)
	mcValCitPABC-#47	General procedure E	Method E1	3.3 (20%)
35	mcValCitPABC-#26	General procedure E	Method E1	2.3 (20%)
	mc-#26	General procedure D	Method E1	5.4 (10%)
40	mcValCitPABC-#42	General procedure E	Method E1	10.8 (38%)
	mcValCitPABC-#36	General procedure E	Method E1	12.6 (32%)
45	mc-#42	General procedure D	Method E1	7.1 (83%)
	AmPeg6C2-#54	General procedure N	Method J	44 (67%)
50	MalPeg3C2-#54	General procedure D	Method J	19 (69%)
	mcValCitPABCAmPeg6C2-#54	General procedure O	Method J	12 (42%)
55	mcValCitPABCAmPeg3C2-#54	General procedure O	Method J	12.4 (30%)
	MalPeg3C2-#47	General procedure D	Method J*	19 (62%)

EP 2 780 039 B9

(continued)

	Linker-Payload #	Preparation method	Purification method	Quantity in mg (Yield)
5	AmPeg6C2-#47	General procedure N	Method J	50 (77%)
	mcValCitPABCAmPeg3C2-#47	General procedure O	Method J	6.4 (18%)
10	mcValCitPABCAmPeg6C2-#47	General procedure O	Method J	18 (50%)
	MalPeg3C2-#42	General procedure D	Method J	22 (70%)
15	AmPeg6C2-#42	General procedure N	Method J	53 (75%)
	mcValCitPABCAmPeg6C2-#42	General procedure O	Method J	15.4 (43%)
20	mcValCitPABCAmPeg3C2-#42	General procedure O	Method J*	12 (26%)
	MalPeg3C2-#26	General procedure D	Method J*	13.8 (51%)
25	mc-#41	General procedure D	Method J*	9.6 (38%)
	AmPeg6C2-#26	General procedure N	Method J	59 (87%)
30	mcValCitPABCAmPeg3C2-#26	General procedure O	Method J	23.4 (45%)
	MalPeg3C2ValCitPABC-#26	General procedure P	Method J	16 (42%)
35	mcValCitPABCAmPeg6C2-#26	General procedure O	Method J	15 (38%)
	mc-#36	General procedure D	Method J*	26 (80%)
40	MalPeg6C2-#54	General procedure D	Method J	27 (67%)
	MalPeg3C2ValCitPABC-#47	General procedure P	Method J	17 (49%)
45	MalPeg3C2-#36	General procedure D	Method J*	9.2 (33%)
	MalPeg6C2-#47	General procedure D	Method J*	24 (78%)
50	MalPeg6C2-#26	General procedure D	Method J*	29 (75%)
	MalPeg6C2-#36	General procedure D	Method J	18 (58%)
55	mcValCitPABCAmPeg3C2-#36	General procedure O	Method J	16 (51%)
	AmPeg6C2-#36	General procedure N	Method J	51 (78%)

EP 2 780 039 B9

(continued)

	Linker-Payload #	Preparation method	Purification method	Quantity in mg (Yield)
5	mcValCitPABC-#60	General procedure E	Method J	1.9 (4.3%)
	mcValCitPABCAmPeg6C2-#36	General procedure O	Method J	11.6 (35%)
10	mcValCitPABCAmPeg3C2-#41	General procedure O	Method J	5.7 (26%)
	MalPeg6C2-#60	General procedure D	Method J	24 (75%)
15	AmPeg6C2-#60	General procedure N	Method J	31 (80%)
	MalPeg3C2-#60	General procedure D	Method J	17.3 (58%)
20	MalPeg6C2-#41	General procedure D	Method J with AcOH as modifier	11 (28%)
	AmPeg6C2-#66	General procedure N	Method J	5 (10%)
25	mcValCitPABCAmPeg6C2-#60	General procedure O	Method J	12 (34%)
	mc-#70	General procedure D	Method J*	11.2 (46%)
30	2AcAmPeg6C2-#66	General procedure Q	Method J	8 (60%)
	mc-#66	General procedure D	Method J with AcOH as modifier	8.2 (32%)
35	mcValCitPABC-#88	General procedure E	Method J	7.9 (45%)
	mcValCitPABC-#88	General procedure E	Method J	7.5 (39%)
40	mc-#92	General procedure D	Method F	15 (66%)
	mcValCitPABC-#44	General procedure E	Method F	1.6 (4%)
45	mc-#108	General procedure D	Method H without modifier	8.8 (37%)
	mcValCitPABC-#108	General procedure E	Method F	6.1 (14%)
50	NHSCOPeg2C2ValCitPABC-#66	General procedure X2	Method F*	6.8 (32%)
	mcValCitPABC-#98	General procedure E	Method J*	4.8 (11%)
55	mcValCitPABC-#95	General procedure E	Method J*	13 (28%)
	MalPeg3C2-#69	General procedure D	Method K	12.8 (35%)

EP 2 780 039 B9

(continued)

	Linker-Payload #	Preparation method	Purification method	Quantity in mg (Yield)
5	AmPeg6C2-#69	General procedure N	Method J*	71 (69%)
	mcValCitPABC-#84	General procedure E	Method J*	4.9 (11%)
10	AmCapValCitPABC-#54	General procedure R	Method K*	97 (53%)
	mcValCitPABC-#226	General procedure E	Method J*	7.1 (16%)
15	mcValCitP ABC-#117	General procedure E	Method J*	15.8 (36%)
	MalPeg6C2-#98	General procedure D	Method I*	7.4 (22%)
20	mcValCitPABC-#118	General procedure E	Method J*	11.7 (29%)
	mcValCitPABC-#80	General procedure E	Method J*	3.8 (12%)
25	MalPeg6C2-#118	General procedure D	Method J*	11 (4.5%)
	MalPeg6C2-#230	General procedure D	Method H	2.8 (8%)
30	mcValCitP ABC-#232	General procedure E	Method J*	13.6 (29%)
	mc-#1 17	General procedure D	Method J*	9.5 (40%)
35	MalPeg6C2-#117	General procedure D	Method K*	2.3 (8%)
	mv-#69	General procedure D	Method J*	22 (49%)
40	mb-#69	General procedure D	Method J*	12 (28%)
	AmPeg6C2-#234	General procedure N	Method J*	16 (52%)
45	AmPeg6C2-#235	General procedure N	Method J*	16.5 (70%)
	mc-#118	General procedure D	Method J*	41 (38%)
50	MalPeg6C2-#123	General procedure D	Method J*	85 (40%)
	mc-#226	General procedure D	silica chromatography	290(40%)
55	me-#118	General procedure D	Method J*	16.2 (42%)
	mc-#131	General procedure D	Method J*	16.3 (51%)

EP 2 780 039 B9

(continued)

	Linker-Payload #	Preparation method	Purification method	Quantity in mg (Yield)
5	mb-#118	General procedure D	Method J*	7.9 (23%)
	mcValCitPABC-#134	General procedure E	Method J*	17 (33%)
10	mc-#145	General procedure D	Method K	6 (20%)
	MalPeg6C2-#126	General procedure D	Method J*	16.4 (26%)
15	mc-#126	General procedure D	Method K*	16.3 (32%)
	mv-#118	General procedure D	Method J*	11.7 (34%)
20	mc-#172	General procedure D	Method J*	10 (56%)
	MalPeg6C2-#226	General procedure D	Method K*	15 (10%)
25	MalPeg6C2-#145	General procedure D	Method K	1.8 (3.7%)
	mc-#162	General procedure D	Method H* without modifier	1.2 (3.1%)
30	mc-#163	General procedure D	Method K*	9.9 (26%)
	mcValCitPABC-#231	General procedure E	Method J*	0.2 (4%)
35	MalPeg6C2-#238	General procedure D	silica chromatography	240 (77%)
	MalPeg6C2-#239	General procedure D	medium pressure C18 chromatography	104 (39%)
40	mc-#123	General procedure D	silica chromatography	345 (quant.)
	MalC6-#54	General procedure S	Method J*	16.3 (30%)
45	mc-#231	General procedure D	Method J*	10 (60%)
	MalC6-#118	General procedure S	Method J*	5.3 (10%)
50	mcValCitPABC-#123	General procedure E	silica chromatography	179 (60%)
	mc-#237	General procedure D	Method J*	12.6 (47%)
55	mc-#158	General procedure D	Method J*	7.1 (28%)
	MalC6Am-#151	General procedure D	Method J*	18.4 (86%)

EP 2 780 039 B9

(continued)

Linker-Payload #	Preparation method	Purification method	Quantity in mg (Yield)
PFPCOPeg2C2 ValCitPABC-#54	General procedure X3	Method J* AcOH as modifier	70 (68%)
mcValCitPABC-#154	General procedure E	medium pressure C18 chromatography	10 (19%)
MalC6Am-#153	General procedure D	Method K*	18.7 (47%)
PFPCOPeg2C2AmPeg2C2-#69	General procedure X4	Method R*	40 (64%)
mcValCitPABC-#246	General procedure E	medium pressure C18 chromatography	21 (45%)
PFPCOPeg2C2AmPeg2C2-#69	General procedure X4	Method R*	40 (64%)
mc ValCitP ABC-#246	General procedure E	medium pressure C18 chromatography	21 (45%)
PFPCOPeg2C2AlaAlaAsnPABC-#54	General procedure X1	Method R*	16.8 (54%)
PFPCOPeg2C2-#54	General procedure V	Method R*	4.1 (56%)
PFPCOPeg2C2AmPeg2C2PABC-#54	General procedure W	Method R*	1.1 (39%)
AmPeg6C2-#115	General procedure	Method J*	100 (48%)
PFPCOPeg5C2-#115	General procedure V	Method J*	29 (26%)
mcGly-#201	-	silica chromatography	25 (16.2%)
AzCOC2Ph4AmCOPeg2C2-#54	General procedure	Method R*	3.5 (52%)
AzCOC2Ph4AmPeg1C1ValCitPABC-#54	General procedure U	Method R*	93 (43%)
AzCOC2Ph4AmPeg1C1ValCitPABC-#30	General procedure U	Method R*	1.7 (42%)
AzCOC2Ph4AmCOPeg2C2-#69	General procedure	Method R*	88 (62%)
AzCOC2Ph4AmCOPeg2C2-#115	General procedure	Method R*	75 (82%)
AcLysValCitPABC-#54	General procedure	Method J*	86 (40%)

Table 18B - Selected Selected compounds (cytotoxic peptides with linkers) of the invention and Reference Examples

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
mcValCitPABC-#34	HPLC (Protocol M) : 1380.6 [M+Na ⁺], (12.899 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl]-N ⁵ -carbamoyl-L-ornithinamide
MalPeg3C2-#41	LC-MS: 1031.7 [M+H ⁺], 1054.8 [M+Na ⁺] (0.88 minutes); HPLC (Protocol D) : 10.559 minutes	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#42	LC-MS: 1178.2 [M+H ⁺], 1197.4 [M+Na ⁺] (3.50 minutes); HPLC (Protocol Q) : 25.235 minutes	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#44	LC-MS: 913.7 [M+H ⁺] (0.85 minutes); HRMS: Calc: 913.5103 [M+H ⁺], Obsd: 913.5103.	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg3C2-#44	[M+H ⁺](0.82 LC-MS: 1003.8 minutes); HPLC (Protocol A) : 1003.5 [M+H ⁺], 1026.4[M+Na ⁺] (9.095 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#44	LC-MS: 1135.8 [M+H ⁺] (0.83 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalValCitP ABC-#44	LC-MS: 1318.9 [M+H ⁺](0.89 minutes); HPLC (Protocol A) : 1319.6 [M+H ⁺], 1342.6 [M+Na ⁺] (9.132 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl]-N ⁵ -carbamoyl-L-ornithinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
mc-#45	LC-MS: 927.7 [M+H ⁺](0.92 minutes); HRMS: Calc: 927.5260 [M+H ⁺], Obsd: 927.5259.	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg3C2-#45	LC-MS: 1017.8 [M+H ⁺] (0.90 minutes);	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#45	LC-MS: 1149.9 [M+H ⁺] (0.90 minutes); HPLC (Protocol A at 45 °C) : 1150.5 [M+H ⁺], 1171.5 [M+Na ⁺] (9.788 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#45	LC-MS: 1332.8 [M+H ⁺] (1.86 minutes); HPLC (Protocol A at 45 °C) : 1333.6 [M+H ⁺](9.737	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N ⁵ -carbamoyl-L-ornithinamide
mcValCitPABC-#54	HPLC (Protocol A at 45 °C) : 1342.6 [M+H] (9.114 minutes).	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N ⁵ -carbamoyl-L-ornithinamide
mc-#69	LC-MS: 897.7 [M+H ⁺], 919.7 (0.81 minutes); HPLC (Protocol A at 45 °C) : 897.5 [M+H ⁺](9.058 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
MalPeg6C2-#69	HPLC (Protocol A at 45 °C) : 1120.6 [M+H ⁺], 1142.5 (9.076 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc ValCitP ABC-#69	HPLC (ProtocolM) : 1326.6 [M+Na ⁺] (11.962 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#70	HPLC (Protocol A at 45 °C) : 1317.6 [M+H ⁺](9.282 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl]-N ⁵ -carbamoyl-L-ornithinamide
mcValCitPABC-#75	LC-MS: 1273.9 [M+H ⁺](0.82 minutes); HPLC (Protocol A at 45 °C): 1273.6 [M+H ⁺], (8.814 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N ⁵ -carbamoyl-N-{4-[(3-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]carbamoyl)oxetan-3-yl]carbamoyl}oxy)methyl]phenyl]-L-ornithinamide
mc-#79	HPLC (Protocol A at 45 °C) : 941.5 [M+H ⁺], 963.4 [M+Na ⁺] (10.444 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitP ABC-#79	HPLC (Protocol A) : 1346.6 [M+H ⁺], (9.807 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-2-oxoethyl)-4,5,5,10-tetramethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl]-N ⁵ -carbamoyl-L-ornithinamide
mcValCitPABC-#92	LC-MS: 1282.6 [M+H ⁺](0.79 minutes); HPLC (Protocol A at 45 °C): 1282.6 [M+H ⁺](7.953 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-(quinolin-6-ylamino)propyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl]-N ⁵ -carbamoyl-L-ornithinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
mcValCitPABC-#112	HPLC (Protocol M): 1288.6 [M+H ⁺], 1310.6 [M+Na ⁺] (11.757 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N ⁵ -carbamoyl-L-ornithinamide
mv-#115	HPLC (Protocol A at 45 °C): m/z 897.5 [M+H ⁺], (9.149 minutes)	N-[5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
mc-#115	HPLC (Protocol A at 45 °C): m/z 911.5 [M+H ⁺], (9.676 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
mb-#115	-	N-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
me-#115	-	N-[7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)heptanoyl]-N,2-dimethylalanyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
mcValCitPABC-#115	HPLC (Protocol M): m/z 1317.7 [M+H ⁺] (12.261 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-4,5,5,10-tetramethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N ⁵ -carbamoyl-L-ornithinamide
mc-#51	HPLC (Protocol M): m/z 934.5 [M+H ⁺] (11.94 minutes)	N~2~-[1-[(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl)amino]cyclopropyl]carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
mc-#47	HPLC (Protocol M): <i>m/z</i> 962.5 [M+H ⁺] (13.014 minutes)	N-2-~{[(1-~{[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]amino}cyclopentyl)carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-~{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-~{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl] amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl] -N-methyl-L-valinamide
mc-#54	HPLC (Protocol M): <i>m/z</i> 936.5 [M+H ⁺] (9.22 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-~{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-~{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#47	HPLC (Protocol M): <i>m/z</i> 1368.6 [M+H ⁺] (13.157 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-5~-carbamoyl-N-[4-~{[(1-~{[(2S)-1-~{[(3R,4S,5S)-3-methoxy-1-~{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-~{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl] (methyl)amino}-3-methyl-1-oxobutan-2-yl]carbamoyl}cyclopentyl)carbamoyl]oxy)methyl]phen yl] -L-ornithinamide
mcValCitP ABC-#26	HPLC (Protocol M): <i>m/z</i> 1386.6 [M+H ⁺] (16.21 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-~{[(5S,8S,11S,12R)-11-~{(2S)-butan-2-yl]-12-~{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-~{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}-3-t hioxopropyl]pyrrolidin-1-yl}-2-oxoethyl)-4,10-dimethyl-3,6,9-trioxo-5,8-di(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mc-#26	HPLC (Protocol A*): <i>m/z</i> 980.5 [M+H ⁺] (10.628 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-~{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-~{[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}-3-thioxopropyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#42	HPLC (Protocol A*): <i>m/z</i> 1361.7 [M+H ⁺] (9.831 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-~{[(5S,8S,11S,12R)-11-~{(2S)-butan-2-yl]-12-~{(2S)-2-[(1R,2R)-1-methoxy-3-~{[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino}-2-methyl-thioxopropyl]pyrrolidin-1-yl}-2-oxoethyl)-4,10-dimethyl-3,6,9-trioxo-5,8-di(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mcValCitPABC-#36	HPLC (Protocol A*): <i>m/z</i> 1324.6 [M+Na ⁺²³] (9.987 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-~{[(5S,8S,11S,12R)-11-~{(2S)-butan-2-yl]-12-~{2-~{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-~{(2-phenylethyl)amino}-3-thioxopropyl]pyrrolidin-1-yl}-2-oxoethyl)-4,10-dimethyl-3,6,9-trioxo-5,8-di(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed <i>m/z</i> and retention time in minutes: ESI-MS	IUPAC Name
mc-#42	HPLC (Protocol A*): <i>m/z</i> 955.5 [M+H ⁺](10.679 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AmPeg6C2-#54	LC-MS (Protocol H): <i>m/z</i> 1078.7 [M+H ⁺](2.56 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg3C2-#54	LC-MS (Protocol H): <i>m/z</i> 1026.6 [M+H ⁺](3.54 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABCAmPeg6C2-#54	LC-MS (Protocol H): <i>m/z</i> 1677.9 [M+H ⁺](3.48 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(30S,33S,34R)-33-[(2S)-butan-2-yl]-34-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-2-oxoethyl]-27,27,32-trimethyl-3,25,28,31-tetraoxo-30-(propan-2-yl)-2,7,10,13,16,19,22,35-octaoxa-4,26,29,32-tetraazaheptacos-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mcValCitPABCAmPeg3C2-#54	LC-MS (Protocol H): <i>m/z</i> 1545.8 [M+H ⁺](3.48 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(21S,24S,25R)-24-[(2S)-butan-2-yl]-25-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-2-oxoethyl]-18,18,23-trimethyl-3,16,19,22-tetraoxo-21-(propan-2-yl)-2,7,10,13,26-pentaoxa-4,17,20,23-tetraazaheptacos-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
MalPeg3C2-#47	LC-MS (Protocol QI): <i>m/z</i> 1052.7 [M+H ⁺](0.88 minutes)	N~2~-[(1-{[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]amino}cyclopentyl)carbonyl]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AmPeg6C2-#47	LC-MS (Protocol H): <i>m/z</i> 1104.88 [M+H ⁺](2.65 minutes)	1-amino-N-(1-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]carbamoyl)cyclopentyl)-3,6,9,12,15,18-hexaoxahenicosan-21-amide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
mcValCitPABCAmPeg3C2-#47	LC-MS (Protocol H): m/z 1571.8 [M+H ⁺](3.56 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N~5~-carbamoyl-N-(4-{16-[(1-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl] (methyl)amino)-3-methyl-1-oxobutan-2-yl]carbamoyl}cyclopentyl)amino]-3,16-dioxo-2,7,10,13-tetraoxa-4-azahexadec-1-yl]phenyl)-L-ornithin amide
mcValCitPABCAmPeg6C2-#47	HPLC (Protocol H): m/z 1703.8 [M+H ⁺](3.57 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N~5~-carbamoyl-N-(4-{25-[(1-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl] (methyl)amino)-3-methyl-1-oxobutan-2-yl]carbamoyl}cyclopentyl)amino]-3,25-dioxo-2,7,10,13,16,19,22-heptaosa-4-azapentacos-1-yl]phenyl)-L-ornithinamide
MalPeg3C2-#42	LC-MS (Protocol H): m/z 1045.7 [M+H ⁺](3.92 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AmPeg6C2-#42	LC-MS (Protocol H): m/z 1097.7 [M+H ⁺](2.80 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-thioxopropyl]pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABCAmPeg6C2-#42	LC-MS (Protocol H): m/z 1696.8 [M+H ⁺](3.73 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(27S,30S,33S,34R)-33-[(2S)-butan-2-yl]-34-(2-{(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino}-2-methyl-3-thioxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-26,32-dimethyl-3,25,28,31-tetraoxo-27,30-di(propan-2-yl)-2,7,10,13,16,19,22,35-octaoxa-4,26,29,32-tetraazahexatriacont-1-yl]phenyl)-N~5~-carbamoyl-L-ornithin amide
mcValCitPABCAmPeg3C2-#42	LC-MS (Protocol H): m/z 1564.8 [M+H ⁺](3.70 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(18S,21S,24S,25R)-24-[(2S)-butan-2-yl]-25-(2-{(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino}-2-methyl-3-thioxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-17,23-dimethyl-3,16,19,22-tetraoxo-18,21-di(propan-2-yl)-2,7,10,13,26-pentaoxa-4,17,20,23-tetraazaheptacos-1-yl]phenyl)-N~5~-carbamoyl-L-ornithinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
MalPeg3C2-#26	LC-MS (Protocol H): <i>m/z</i> 1070.6 [M+H ⁺](3.94 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy} ethoxy)propanoyl] -N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#41	HPLC (Protocol A): <i>m/z</i> 941.5 [M+H ⁺](9.883 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AmPeg6C2-#26	LC-MS (Protocol H): <i>m/z</i> 1122.6 [M+H ⁺](2.76 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABCAmPeg3C2-#26	LC-MS (Protocol H): <i>m/z</i> 1588.0 [M+H ⁺](3.74 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(18S,21S,24S,25R)-24-[(2S)-butan-2-yl]-25-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl)-2-oxoethyl]-17,23-dimethyl-3,16,19,22-tetraoxo-18,21-di(propan-2-yl)-2,7,10,13,26-pentaoxa-4,17,20,23-tetraazaheptacos-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
MalPeg3C2V alCitP ABC-#26	LC-MS (Protocol H): <i>m/z</i> 1476.8 [M+H ⁺](3.81 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-L-valyl-N-{4-[(5S,8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl)-2-oxoethyl]-4,10-dimethyl-3,6,9-trioxa-5,8-di(propan-2-yl)-2,13-dioxa-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mcValCitPABCAmPeg6C2-#26	LC-MS (Protocol H): <i>m/z</i> 1721.9 [M+H ⁺](3.75 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(27S,30S,33S,34R)-33-[(2S)-butan-2-yl]-34-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl)-2-oxoethyl]-26,32-dimethyl-3,25,28,31-tetraoxo-27,30-di(propan-2-yl)-2,7,10,13,16,19,22,35-octaoxa-4,26,29,32-tetraazahexatriacont-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mc-#36	LC-MS (Protocol Q1): <i>m/z</i> 897.7 [M+H ⁺](1.00 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
MalPeg6C2-#54	LC-MS (Protocol H): <i>m/z</i> 1158.7 [M+H ⁺] (3.55 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg3C2V alCitP ABC-#47	LC-MS (Protocol : <i>m/z</i> 1458.7 H): [M+H ⁺] (3.56 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-L-valyl-N-5-carbamoyl-N-[4-[(1-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methylamino)-3-methyl-1-oxobutan-2-yl] carbamoyl]cyclopentyl)carbamoyl]oxy} methyl)phen yl] -L-omithinamide
MalPeg3C2-#36	LC-MS (Protocol H): <i>m/z</i> 987.7 [M+H ⁺] (3.97 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-N-methyl-L-valyl-N-{(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxoprop yl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#47	LC-MS (Protocol H) : <i>m/z</i> 1184.7 [M+H ⁺] (3.67 minutes)	1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methylamino)-3-methyl-1-oxobutan-2-yl]carbamoyl]cyclopentyl)-3,6,9,12,15,18-hexaoxahenicosan-21-amide
MalPeg6C2-#26	LC-MS (Protocol H): <i>m/z</i> 1202.7 [M+H ⁺] (3.93 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#36	LC-MS (Protocol H): <i>m/z</i> 1118.8 [M-H] (3.96 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-N-methyl-L-valyl-N-{(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
mcValCitPABCAmPeg3C2-#36	LC-MS (Protocol H): <i>m/z</i> 1506.8 [M+H ⁺](3.76 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(18S,21S,24S,25R)-24-[(2S)-butan-2-yl]-25-{2-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidin-1-yl]-2-oxoethyl}-17,23-dimethyl-3,16,19,22-tetraoxo-18,21-di(propan-2-yl)-2,7,10,13,26-pentaoxa-4,17,20,23-tetraazaheptacos-1-yl]phenyl}-N~5~-carbamoyl- L-ornithinamide
AmPeg6C2-#36	LC-MS (Protocol H): <i>m/z</i> 1039.7 [M+H ⁺](2.68 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitP ABC-#60	HPLC (Protocol M): <i>m/z</i> 1307.6 [M+H ⁺](12.696 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxa-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mcValCitPABCAmPeg6C2-#36	LC-MS (Protocol H): <i>m/z</i> 1638.0 [M+H ⁺](3.77 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(27S,30S,33S,34R)-33-[(2S)-butan-2-yl]-34-{2-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(2-phenylethyl)amino]-3-thioxopropyl]pyrrolidin-1-yl]-2-oxoethyl}-26,32-dimethyl-3,25,28,31-tetraoxo-27,30-di(propan-2-yl)-2,7,10,13,16,19,22,35-octaoxa-4,26,29,32-tetraazahexatriacont-1-yl]phenyl}-N~5~-carbamoyl- L-ornithinamide
mcValCitPABCAmPeg3C2-#41	LC-MS (Protocol H): <i>m/z</i> 1550.9 [M+H ⁺](3.53 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(18S,21S,24S,25R)-24-[(2S)-butan-2-yl]-25-(2-{(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-17,23-dimethyl-3,16,19,22-tetraoxo-18,21-di(propan-2-yl)-2,7,10,13,26-pentaoxa-4,17,20,23-tetraazaheptacos-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
MalPeg6C2-#60	LC-MS (Protocol H): <i>m/z</i> 1101.8 [M+H ⁺](3.66 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
AmPeg6C2-#60	LC-MS (Protocol H): <i>m/z</i> 1021.7 [M+H ⁺] (2.57 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg3C2-#60	LC-MS (Protocol H): <i>m/z</i> 969.7 [M+H ⁺] (3.65 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#41	LC-MS (Protocol H): <i>m/z</i> 1163.0 [M-H] (3.70 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[[1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AmPeg6C2-#66	LC-MS (Protocol Q1): <i>m/z</i> 1009.8 [M+H ⁺] (0.72 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABCAmPeg6C2-#60	LC-MS (Protocol H): <i>m/z</i> 1621.0 [M+H ⁺] (3.55 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(30S,33S,34R)-33-[(2S)-butan-2-yl]-34-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[1-phenylcyclopropyl)methyl]amino]propyl]pyrrolidin-1-yl}-2-oxoethyl)-27,27,32-trimethyl-3,25,28,31-tetraoxo-30-(propan-2-yl)-2,7,10,13,16,19,22,35-octa-4,26,29,32-tetraazahexatriacont-1-yl]phenyl)-N-5-carbamoyl-L-ornithinamide
mc-#70	HPLC (Protocol M): <i>m/z</i> 911.5 [M+H ⁺] (11.847 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[[[2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
2AcAmPeg6C2-#66	LC-MS (Protocol Q1): <i>m/z</i> 1129.8 [M+H ⁺] (0.85 minutes)	N-(24-bromo-23-oxo-4,7,10,13,16,19-hexaoxa-22-azatetracosan-1-oyl)-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
mc-#66	LC-MS (Protocol Q1): m/z 867.7 [M+H ⁺] (0.90 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-{2-(cyclohepta-2,4,6-trien-1-yl)ethyl}amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc ValCitP ABC-#88	LC-MS (Protocol Q1): m/z 1355.9 [M+H ⁺] (0.87 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-2-oxoethyl)-4,5,5,10-tetramethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N-5~-carbamoyl-L-ornithinamide
mcValCitPABC-#88	LC-MS (Protocol Q1): m/z 1314.9 [M+H ⁺] (0.91 minutes)	N-{6-[(bromoacetyl)amino]hexanoyl}-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-3-[(2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N-5~-carbamoyl-L-ornithinamide
mc-#92	LC-MS (Protocol Q1): m/z 876.7 [M+H ⁺] (0.75 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-(quinolin-6-ylamino)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#44	HPLC (Protocol A): m/z 1318.6 [M+H ⁺] (9.174 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N-5~-carbamoyl-L-ornithinamide
mc-#108	HPLC (Protocol A): m/z 909.5 [M+H ⁺] (9.063 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(R)-(7S)-bicyclo[4.2.0]octa-1,3,5-trien-7-yl(carboxy)methyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#108	HPLC (Protocol M): m/z 1315.7 [M+H ⁺] (11.89 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-12-(2-{(2S)-2-[(1R,2R)-3-[(R)-(7S)-bicyclo[4.2.0]octa-1,3,5-trien-7-yl(carboxy)methyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-11-[(2S)-butan-2-yl]-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N-5~-carbamoyl-L-ornithinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
NHSCOPeg2C2ValCitPABC-#66	HPLC (Protocol M): <i>m/z</i> 683.3 [M+H ⁺] (10.03 minutes)	N-[3-(2-{3-[(2,5-dioxopyrrolidin-1-yl)oxy]-3-oxopropoxy}ethoxy)propanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-3-{2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mcValCitPABC-#98	HPLC (Protocol M): <i>m/z</i> 1368.6 [M+H ⁺] (12.504 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N~5~-carbamoyl-N-{4-[(2S)-2-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]carbamoyl]-2-methylpyrrolidin-1-yl]carbonyloxy)methyl]phenyl]-L-ornithinamide
mcValCitP ABC-#95	LC-MS (Protocol Q): <i>m/z</i> 1356.5 [M+H ⁺] (1.79 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(9S,12S,13R)-12-[(2S)-butan-2-yl]-13-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-2-oxoethyl)-6,6,11-trimethyl-3,7,10-trioxo-9-(propan-2-yl)-2,14-dioxo-4,8,11-triazapentadec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
MalPeg3C2-#69	HPLC (Protocol M): <i>m/z</i> 987.5 [M+H ⁺] (10.702 minutes)	N-[3-(2-{2-[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy]ethoxy}ethoxy)propanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AmPeg6C2-#69	LC-MS (Protocol H): <i>m/z</i> 1040.1 [M+H ⁺] (2.12 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#84	LC-MS (Protocol Q): <i>m/z</i> 1371.4 [M+H ⁺] (1.89 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}-3-thioxopropyl]pyrrolidin-1-yl)-2-oxoethyl)-4,5,5,10-tetramethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
AmCapValCitPABC-#54	LC-MS (Protocol H): <i>m/z</i> 1262.3 [M+H ⁺] (2.35 minutes)	N-(6-aminohexanoyl)-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl]-N~5~-carbamoyl-L-ornithinamide
mcValCitPABC-#226	LC-MS (Protocol Q): <i>m/z</i> 1330.9 [M+H ⁺] (1.77 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino}-2-methyl-3-oxo propyl]pyrrolidin-1-yl]-2-oxoethyl)-4,5,5,10-tetramethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl]-N~5~-carbamoyl-L-ornithinamide
mcValCitPABC-#117	LC-MS (Protocol Q): <i>m/z</i> 1342.6 [M+H ⁺] (1.80 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N~5~-{4-[[[(2S)-2-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]carbamoyl]-2-methylpyrrolidin-1-yl]carbonyl]oxy)methyl]phenyl]-L-ornithinamide
MalPeg6C2-#98	HPLC (Protocol M): <i>m/z</i> 1185.6 [M+H ⁺] (11.985 minutes)	1-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methyl-L-propyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#118	LC-MS (Protocol Q): <i>m/z</i> 1328.6 [M+H ⁺] (1.68 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N~5~-carbamoyl-N-{4-[[[(2S)-2-[(2S)-1-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]carbamoyl]-2-methylpyrrolidin-1-yl]carbonyl]oxy)methyl]phenyl]-L-ornithinamide
mcValCitPABC-#80	HPLC (Protocol M): <i>m/z</i> 1353.6 [M+Na ⁺] (12.751 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino}-1-methoxy-2-methyl-3-thioxopropyl]pyrrolidin-1-yl]-2-oxoethyl)-4,5,5,10-tetramethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl]-N~5~-carbamoyl-L-ornithinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
MalPeg6C2-#118	LC-MS (Protocol Q): <i>m/z</i> 1145.6 [M+H ⁺] (1.66 minutes)	1-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#230	HPLC (Protocol M): <i>m/z</i> 1146.6 [M+H ⁺] (12.071 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(R)-carboxy(1-phenylcyclopropyl)methyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#232	LC-MS (Protocol Q): <i>m/z</i> 1367.3 [M+H ⁺] (1.81 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N~5~-carbamoyl-N-{4-[[[(2R)-2-[(2S)-1-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl](methyl)amino)-3-methyl-1-oxobutan-2-yl]carbamoyl]-2-methylpyrrolidin-1-yl]carbonyl]oxy)methyl]phenyl]-L-ornithinamide
mc-#117	LC-MS (Protocol Q): <i>m/z</i> 937.4 [M+H ⁺] (1.91 minutes)	1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#117	HPLC (Protocol M): <i>m/z</i> 1161.6 [M+H ⁺] (12.115 minutes)	1-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mv-#69	LC-MS (Protocol Q): <i>m/z</i> 883.3 [M+H ⁺] (1.57 minutes)	N-[5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mb-#69	HPLC (Protocol M): <i>m/z</i> 869.5 [M+H ⁺] (10.874 minutes)	N-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
AmPeg6C2-#234	LC-MS (Protocol Q1): <i>m/z</i> 1514.3 [M+H ⁺] (0.76 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(3R,4R,7S,12S)-7-benzyl-14-[3-chloro-4-(propan-2-yloxy)phenyl]-4-methyl-12-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)benzyl]-5,8,14-trioxo-2,9-dioxo-6,13-diazatetradecan-3-yl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AmPeg6C2-#235	LC-MS (Protocol Q1): <i>m/z</i> 1280.2 [M+H ⁺] (0.87 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-[4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylphenyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#118	LC-MS (Protocol Q): <i>m/z</i> 923.3 [M+H ⁺] (1.73 minutes)	1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-# 123	LC-MS (Protocol Q1): <i>m/z</i> 1175.3 [M+H ⁺] (0.99 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#226	LC-MS (Protocol Q): <i>m/z</i> 925.7 [M+H ⁺] (1.85 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
me-#118	LC-MS (Protocol Q): <i>m/z</i> 937.7 [M+H ⁺] (1.80 minutes)	1-[7-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)heptanoyl]-2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#131	LC-MS (Protocol Q): <i>m/z</i> 937.3 [M+H ⁺] (1.88 minutes)	1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed <i>m/z</i> and retention time in minutes: ESI-MS	IUPAC Name
mb-#118	LC-MS (Protocol Q): <i>m/z</i> 895.3 [<i>M</i> + <i>H</i> ⁺] (1.63 minutes)	1-[4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanoyl]-2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#134	LC-MS (Protocol Q): <i>m/z</i> 1314.3 [<i>M</i> + <i>H</i> ⁺] (1.67 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-5-~carbamoyl-N-{4-[[[(2S)-2-[(2S)-1-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]-2-methylpyrrolidin-1-yl]carbonyl}oxy)methyl]phenyl]-L-ornithinamide
mc-#145	LC-MS (Protocol Q1): <i>m/z</i> 897.34 [<i>M</i> + <i>H</i> ⁺] (0.90 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-# 126	HPLC (Protocol M): <i>m/z</i> 1169.6 [<i>M</i> + <i>Na</i> ⁺] (12.583 minutes)	methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-24,24-dimethyl-21,25-dioxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-25-yl]-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate
mc-#126	HPLC (Protocol M): <i>m/z</i> 925.5 [<i>M</i> + <i>H</i> ⁺] (12.994 minutes)	methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-(3-{6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]amino}-2,2-dimethylpropanoyl)-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate
mv-#118	LC-MS (Protocol Q): <i>m/z</i> 909.2 [<i>M</i> + <i>H</i> ⁺] (1.68 minutes)	1-[5-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentanoyl]-2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#172	LC-MS (Protocol Q1): <i>m/z</i> 941.3 [<i>M</i> + <i>H</i> ⁺] (0.96 minutes)	methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-(((3S)-1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-3-fluoropyrrolidin-3-yl)carbonyl)-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
MalPeg6C2-#226	LC-MS (Protocol Q): <i>m/z</i> 1147.3 [M+H ⁺] (1.76 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#145	LC-MS (Protocol Q1): <i>m/z</i> 1141.3 [M+Na ⁺] (0.87 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#162	LC-MS (Protocol Q): <i>m/z</i> 937.3 [M+H ⁺] (1.50 minutes)	N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-[(2S)-1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylpiperidin-2-yl]carbonyl]-L-valyl](methyl)amino)-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalanine
mc-#163	HPLC (Protocol A): <i>m/z</i> 937.5 [M+H ⁺] (7.855minutes)	N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-[(2R)-1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylpiperidin-2-yl]carbonyl]-L-valyl](methyl)amino)-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalanine
mcValCitPABC-#231	LC-MS (Protocol Q1): <i>m/z</i> 1640.4 [M+Na ²³] (0.94 minutes)	(N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-12-(2-[(2S)-2-[(3R,4R,7S)-7-benzyl-15-{2-[(3,5-dimethyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN)-4-methyl-5,8,13-trioxo-2-oxa-6,9,12-triazapentadecan-3-yl]pyrrolidin-1-yl)-2-oxoethyl)-11-[(2S)-butan-2-yl]-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamidato)(difluoro)boron
MalPeg6C2-#238	LC-MS (Protocol Q1): <i>m/z</i> 1173.3 [M+H ⁺] (0.96 minutes)	N-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-(prop-2-en-1-yloxy)propan-2-yl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalPeg6C2-#239	LC-MS (Protocol Q): <i>m/z</i> 1201.3 [M+H ⁺] (2.02 minutes)	1-[1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-21-oxo-3,6,9,12,15,18-hexaoxahenicosan-21-yl]-2-methyl-L-propyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
mc-#123	LC-MS (Protocol Q1): <i>m/z</i> 953.3 [M+H ⁺] (1.04 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
MalC6-#54	LC-MS (Protocol Q): <i>m/z</i> 922.3 [M+H ⁺] (1.50 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#231	LC-MS (Protocol Q1): <i>m/z</i> 1213.3 [M+H ⁺] (0.98 minutes)	{N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(3R,4R,7S)-7-benzyl-15-{2-[(3,5-dimethyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}-4-methoxy-1,5,8,13-trioxo-2-oxa-6,9,12-triazapentadecan-3-yl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamido} (difluoro)boron
MalC6-#118	LC-MS (Protocol Q1): <i>m/z</i> 909.3 [M+H ⁺] (0.76 minutes)	1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl]-2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#123	LC-MS (Protocol Q1): <i>m/z</i> 1358.3 [M+H ⁺] (0.97 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mc-#237	LC-MS (Protocol Q1): <i>m/z</i> 964.4 [M+H ⁺] (0.96 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mc-#158	HPLC (Protocol M): <i>m/z</i> 951.4 [M+H ⁺] (12.839 minutes)	methyl N-[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[N-((2S)-1-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-2-methylpiperidin-2-yl)carbonyl]-L-valyl](methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]-L-phenylalaninate

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
MalC6Am-#151	LC-MS (Protocol Q): <i>m/z</i> 922.3 [M+H ⁺] (1.43 minutes)	1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-[[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
PFPCOPeg2C2ValCitPABC-#54	LC-MS (Protocol Q): <i>m/z</i> 1502.8 [M+H ⁺] (1.98 minutes)	N-(3-{2-[3-oxo-3-(pentafluorophenoxy)propoxy]ethoxy}propanoyl)-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
mcValCitPABC-#154	LC-MS (Protocol Q1): <i>m/z</i> 1370.2 [M+H ⁺] (0.93 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-{4-[(9S,12S,13R)-12-[(2S)-butan-2-yl]-13-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-2-oxoethyl)-4,6,6,11-tetramethyl-3,7,10-trioxo-9-(propan-2-yl)-2,14-dioxo-4,8,11-triazapentadec-1-yl]phenyl}-N~5~-carbamoyl-L-ornithinamide
MalC6Am-#153	HPLC (Protocol A): <i>m/z</i> 922.5 [M+H ⁺] (7.352 minutes)	1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-[[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
PFPCOPeg2C2AmPeg2C2-#69	HPLC (Protocol BB): <i>m/z</i> 1217.6 [M+H ⁺] (12.936 minutes)	N-[11,20-dioxo-20-(pentafluorophenoxy)-4,7,14,17-tetraoxa-10-azaicosan-1-yl]-2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcValCitPABC-#246	LC-MS (Protocol Q): <i>m/z</i> 1327.9 [M+H ⁺] (1.36 minutes)	N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N-(4-{[(6S,9R,10R)-6-benzyl-10-[(2S)-1-[(3R,4S,5S)-4-[(1,2-dimethyl-L-prolyl-L-valyl)(methyl)amino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-9-methyl-3,8-dioxo-2,11-dioxo-4,7-diazadodec-1-yl}phenyl)-N~5~-carbamoyl-L-rnithinamide
PFPCOPeg2C2AlaAlaAsnPAB C-#54	HPLC (Protocol AB): <i>m/z</i> 1503.6 [M+H ⁺] (8.06 minutes)	N-(3-{2-[3-oxo-3-(pentafluorophenoxy)propoxy]ethoxy}propanoyl)-L-alanyl-L-alanyl-N~1~{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thi azol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-L-aspartamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed <i>m/z</i> and retention time in minutes: ESI-MS	IUPAC Name
PFPCOPeg2C2-#54	HPLC (Protocol AB): <i>m/z</i> 1098.4 [<i>M</i> + <i>H</i> ⁺] (8.44 minutes)	2-methyl-N-(3-{2-[3-oxo-3-(pentafluorophenoxy)propoxy]ethoxy}propanoyl)alanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
PFPCOPeg2C2AmPeg2C2PABC-#54	HPLC (Protocol AB): <i>m/z</i> 1428.2 [<i>M</i> + <i>Na</i> ⁺] (10.32 minutes)	N-[(4-{[11,20-dioxo-20-(pentafluorophenoxy)-4,7,14,17-tetraoxa-10-azaicosan-1-oyl]amino}benzyl)oxycarbonyl]-2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AmPeg6C2-#115	HPLC (Protocol A): <i>m/z</i> 1053.5 [<i>M</i> + <i>H</i> ⁺] (7.35 minutes)	N-(21-amino-4,7,10,13,16,19-hexaoxahenicosan-1-oyl)-N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
PFPCOPeg5C2-#115	LC-MS (Protocol Q) : <i>m/z</i> 1205.1 [<i>M</i> + <i>H</i> ⁺] (1.99 minutes)	N,2-dimethyl-N-[19-oxo-19-(pentafluorophenoxy)-4,7,10,13,16-pentaoxanonadecan-1-oyl]alanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
mcGly-#201	HPLC (Protocol EB): (4.0 minutes) : ESI-MS <i>m/z</i> 1023.59 [<i>M</i> + <i>H</i> ⁺]	1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-[4-({N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycyl)amino]phenyl]-1-methoxy-1-oxopropan-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AzCOC2Ph4AmCOPeg2C2-#54	HPLC (Protocol FB): <i>m/z</i> 1132.4 [<i>M</i> + <i>H</i> ⁺] (10.18 minutes)	2-methyl-N-(3-{2-[3-oxo-3-({4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]phenyl)amino}propoxy]ethoxy}propanoyl)alanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide
AzCOC2Ph4AmPeg1C1ValCitPABC-#54	HPLC (Protocol FB): <i>m/z</i> 1465.8 [<i>M</i> + <i>H</i> ⁺] (10.97 minutes)	N-[(2-oxo-2-({4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]phenyl)amino}ethoxy)acetyl]-L-valyl-N-{4-[(8S,11S,12R)-11-[(2S)-butan-2-yl]-12-(2-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl)-2-oxoethyl)-5,5,10-trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10-triazatetradec-1-yl]phenyl}-N-5-~carbamoyl-L-omithinamide

(continued)

linker with payload #	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ESI-MS	IUPAC Name
AzCOC2Ph4AmPeg1C1ValCitP ABC-#30	HPLC (Protocol FB): <i>m/z</i> 1491.8 [<i>M</i> + <i>H</i> ⁺] (10.56 minutes)	N-[[2-oxo-2-({4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl] phenyl}amino)ethoxy]acetyl]-L-valyl-N~5~-carbamoyl- N-[4-({[(1-((2S)-1-({[(3R,4S,5S)-3-methoxy-1-((2S)- 2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-({[(1S)-2- phenyl-1-(1,3-thiazol-2-yl)ethyl]amino)propyl]pyrrolidin- 1-yl)-5-methyl-1-oxoheptan-4-yl](methyl)ammo}-3- methyl-1-oxobutan-2-yl]carbamoyl)cyclopentyl) carbamoyl]oxy} methyl)phenyl]-L-ornithinamide
AzCOC2Ph4AmCOPeg2C2-#69	HPLC (Protocol AB): <i>m/z</i> 1065.3 [<i>M</i> + <i>H</i> ⁺] (12.02 minutes)	2-methyl-N-(3-{2-[3-oxo-3-({4-[3-oxo-3-(2-oxoazetidin- 1-yl)propyl]phenyl}amino)propoxy]ethoxy}propanoyl) alanyl-N-[(3R,4S,SS)-1-((2S)-2-[(1R,2R)-3-[(1S)-1- carboacy-2-phenylethyl]amino)-1-methoxy-2-methyl-3- oxopropyl]pyrrolidin-1-yl)-3-methoxy-5-methyl-1- oxoheptan-4-yl]-N-methyl-L-valinamide
AzCOC2Ph4AmCOPeg2C2-#115	HPLC (Protocol AA): <i>m/z</i> 1078.6 [<i>M</i> + <i>H</i> ⁺] (12.02 minutes)	N,2-dimethyl-N-(3-{2-[3-oxo-3-({4-[3-oxo-3-(2- oxoazetidin-1-yl)propyl]phenyl} amino)propoxy]ethoxy} propanoyl)alanyl-N-[(3R,4S,5S)-1-((2S)-2-[(1R,2R)-3-[((1S)-1-carboacy-2-phenylethyl]amino)-1-methoxy-2- methyl-3-oxopropyl]pyrrolidin-1-yl)-3-methoxy-5- methyl-1-oxohetan-4-yl]-N-meth-L-valinamide
AcLysValCitPABC-#54	LC-MS (Protocol Q): <i>m/z</i> 1319.3 [<i>M</i> + <i>H</i> ²⁺] (1.34 minutes)	N~2~-acetyl-L-lysyl-L-valyl-N-{4-[(8S,11S,12R)- 11-[(2S)-butan-2-yl]-12-(2-[(2S)-2-[(1R,2R)-1-methoxy- 2-methyl-3-oxo-3-({[(1S)-2-phenyl-1-(1,3-thiazol-2-yl) ethyl]amino)propyl]pyrrolidin-1-yl)-2-oxoethyl)-5,5,10- trimethyl-3,6,9-trioxo-8-(propan-2-yl)-2,13-dioxo-4,7,10- triazatetradec-1-yl]phenyl]-N~5~-carbamoyl-L- ornithinamide, trifluoroacetic acid salt

Table 19A - Selected conjugates of the invention and reference conjugates

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"- phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-(C)_MalPeg3C2-#41	General procedure F	2.3/7.5	1031
H-(C)_MalPeg6C2-#42	General procedure F	2.3/7.5	1177
H-(C)_mc-#44	General procedure F	2.3/7.5	913

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-(C)_MalPeg3C2-#44	General procedure F	2.2/7	1003
H-(C)_MalPeg6C2-#44	General procedure F	2.0/7	1135
H-(C)_mcValCitPABC-#44 procedure	General procedure F	2.5/7.5	1319
H-(C)_Mal-PEG3C2-#45	General procedure F	2.3/7.5	1017
H-(C)_Mal-PEG6C2-#45	General procedure F	2.05/10	1149
H-(C)_mcValCitPABC-#45	General procedure F	2.5/10	1342
H-(C)_mc-#54	General procedure F	2.2/7.5	897
H-(C)_Mal-PEG6C2-#69	General procedure F	2.1/7.5	1119
H-(C)_mcValCitPABC-#69	General procedure F	2.5/7.5	1303
H-(C)_mcValCitPABC-#70	General procedure F	2.0/7	1317
H-(C)_mc-#79	General procedure F	2.0/7	941
H-(C)_mcValCitPABC-#79	General procedure F	2.3/7.5	1345
H-(C)_mc-#115	General procedure F	2.2/6.5	911
H-A114C-(C114)_mc-#51	General procedure G	NA	934.21
H-A114C-(C114)_mc-#47	General procedure G	NA	962.27

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-A114C-(C114)_mc-#54	General procedure G	NA	936.2
H-A114C-(C114)_mcValCitPABC-#47	General procedure H	50/10	1367.72
H-A114C-(C114)_mcValCitPABC-#54	General procedure H	100/10	1341.68
H-A114C-(C114)_mcValCitPABC-#26	General procedure H	50/10	1385.8
H-A114C-(C114)_mc-#26	General procedure H	50/10	980.35
H-A114C-(C114)_mcValCitPABC-#36	General procedure H	50/10	1302.69
H-A114C-(C114)_mcValCitPABC-#42	General procedure H	100/7	1360.73
H-A114C-(C114)_mc-#42	General procedure H	50/10	955.27
H-(C)-mcValCitPABC-#54	General procedure F	2.5/10	1342
H-(C)_mcValCitPABCAmPeg3C2-#54	General procedure F	2.5/9	1544
H-(C)_mcValCitPABCAmPeg6C2-#54	General procedure F	2.6/10	1677
H-(C)_mc-#47	General procedure F	1.9/10	962.27
H-(C)_MalPeg3C2-#54 procedure	General procedure F	1.9/10	1026
H-(C)_mc-#54	General procedure F	2.07/10	936.2
H-(C)_mcValCitPABCAmPeg3C2-#47	General procedure F	2.3/7.5	1569.96

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-(C)_MalPeg3C2-#47	General procedure F	2.3/7.5	1052
H-(C)_mcValCitPABCAmPeg3C2-#42	General procedure F	2.5/7.5	1562.87
H-(C)_mc-#41	General procedure F	2.5/10	941.24
H-(C)_mcValCitPABCAmPeg3C2-#26	General procedure F	2.5/10	1589.04
H-(C)_mcValCitPABCAmPeg6C2-#47	General procedure F	2.4/7	1701.9
H-(C)_MalPeg3C2-#42	General procedure F	2.3/7	1044.58
H-(C)_mcValCitPABCAmPeg6C2-#2 6	General procedure F	2.5/7.5	1719.9
H-(C)_mcValCitPABCAmPeg6C2-#42	General procedure F	2.3/7.5	1696.1
H-(C)_MalPeg6C2-#54	General procedure F	2.3/7.5	1158.5
H-(C)_MalPeg6C2-#47	General procedure F	2.3/7.5	1184.5
H-(C)_MalPeg6C2-#26	General procedure F	2.3/7.5	1202.6
H-(C)-MalPeg6C2-#42	General procedure F	2.3/7.5	1177
H-(C)_mc-#36	General procedure F	2.3/7.5	896
H-(C)_mcValCitPABC-#60	General procedure F	3.0/7	1284.61
H-(C)_MalPeg3C2-#26	General procedure F	2.5/10	1070.42

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-(C)_mcValCitPABCAmPeg3C2-#36	General procedure F	3.0/10	1505.93
H-A114C-(C114) mcValCitPABCAmPeg3C2-#36	General procedure H	50/10	1505.93
H-A114C-(C114)_MalPeg6C2-#54	General procedure H	50/10	1158.5
H-(C)_MalPeg3C2-#60	General procedure F	2.3/7.5	969.23
H-(C)_MalPeg6C2-#60	General procedure F	2.3/7.5	1101.4
H-(C)_MalPeg6C2-#41	General procedure F	2.3/7.5	1163.5
H-(C)-mc-#69	General procedure F	2.2/7.5	897
H-(C)_MalPeg3C2-#36	General procedure F	2.15/1 0	987.31
H-(C)_mcValCitPABCAmPeg6C2-#36	General procedure F	2.25/1 0	1636
H-(C)_MalPeg6C2-#36	General procedure F	2.15/10	1119.5
H-(C)_mcValCitPABCAmPeg3C2-#41	General procedure F	2.5/10	1549.94
H-(C)-MalPeg3C2-#41	General procedure F	2.3/7.5	1031
H-(C)_mcValCitPABCAmPeg6C2-#60	General procedure F	2.5/10	1620
H-A114C-(C114)_mc-#66	General procedure H	50/7	866.5
H-L398C+L443C-(C398+C443) mcValCitPABC-#54	General procedure H	50/7	1341.68

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-K392C+L443C-(C392+C443)_mcValCitPABC-#54	General procedure H	100/10	1341
H-L443C-(C443)_mcValCitPABC-#54	General procedure H	100/10	1341
H-L398C+V422C-(C398+C422)_mcValCitPABC-#54	General procedure H	50/7	1341.68
H-(C)-mc-#44	General procedure F	2.3/7.5	913
H-(C)-Mal-PEG3C2-#45	General procedure F	2.3/7.5	1017
H-(C)_2AcAmPeg6C2-#66	General procedure F	2.4/10	1049.6
H-(C)-Mal-PEG6C2-#45	General procedure F	2.05/10	1149
H-(C)-mc-#79	General procedure F	2.0/7	941
H-(C)-MalPeg3C2-#44	General procedure F	2.2/7	1003
H-(C)-mcValCitPABC-#70	General procedure F	2.0/7	1317
H-(C)-MalPeg6C2-#44	General procedure F	2.0/7	1135
H-A114C-(C114)_mcValCitPABC-#69	General procedure H	100/8.25	1302
H-(C)-mcValCitPABC-#79	General procedure F	2.3/7.5	1345
H-A114C-(C114)_mcValCitPABC-#79	General procedure H	100/7.5	1346
H-(C)-mcValCitPABC-#44	General procedure F	2.5/7.5	1319

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-A114C-(C114)_mcValCitPABC-#88	General procedure H	100/7.5	1355
H-(C)-mcValCitPABC-#69	General procedure F	2.5/7.5	1303
H-(C)_2AcAmCapValCitPABC-#66	General procedure F	2.2/10	1313.49
H-A114C-(C114)_mcValCitPABC-#45	General procedure H	100/7.5	1331.7
H-A114C-(C114)_mcValCitPABC-#34	General procedure H	100/10	1357
H-A114C-(C114) mc-#45	General procedure H	100/10	926
H-A114C-(C114) mc-#70	General procedure H	100/10	911.15
H-(C)_mcValCitPABC-#112	General procedure F	2.3/7.5	1288
H-(C)-Mal-PEG6C2-#69	General procedure F	2.1/7.5	1119
H-Q347C-(C347)_mcValCitPABC-#69	General procedure H	100/10	1302
H-Y373C-(C373)_mcValCitPABC-#69	General procedure H	100/10	1302
H-E388C-(C388)_mcValCitPABC-#69	General procedure H	100/10	1302
H-N421C-(C421)_mcValCitPABC-#69	General procedure H	100/10	1302
H-L443C-(C443)_mcValCitPABC-#69	General procedure H	100/10	1302
H-L443C-(C443)_mcValCitPABC-#79	General procedure H	100/10	1346

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-A114C-(C114)_mcValCitPABC-#95	General procedure H	100/10	1354
H-A114C-(C114)_mcValCitPABC-#98	General procedure H	100/10	1367
H-A114C-(C114)_MalPeg3C2-#69	General procedure H	100/10	987.2
H-N297Q-(Q) _AmPeg6C2-#42	General procedure K	NA	1080
H-N297Q-(Q) _AmPeg6C2-#54	General procedure K	NA	1061
H-N297Q-(Q) _AmPeg6C2-#47	General procedure K	NA	1087
H-N297Q-(Q) _AmPeg6C2-#36	General procedure K	NA	1022
H-N297Q-(Q) _AmPeg6C2-#26	General procedure K	NA	1105
H-N297Q-(Q) _AmPeg6C2-#66	General procedure K	NA	992
H-L443C-(C443)_MalPeg6C2-#69	General procedure H	100/10	1119
H-Q347C-(C347)_MalPeg6C2-#69	General procedure H	100/10	1119
H-E388C-(C388)_MalPeg6C2-#69	General procedure H	100/10	1119
H-N421C-(C421)_MalPeg6C2-#69	General procedure H	100/10	1119
H-E380C-(C380)_MalPeg6C2-#69	General procedure H	100/10	1119
H-L398C+L443C-(C398+C443) MalPeg6C2-#69	General procedure H	100/10	1119

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-K392C+L443C-(C392+C443) MalPeg6C2-#69	General procedure H	100/10	1119
H-kA111C-(kC111)_MalPeg6C2-#69	General procedure H	100/10	1119
H-kK183C-(kC183)_MalPeg6C2-#69	General procedure H	100/10	1119
H-kK207C-(kC207)_MalPeg6C2-#69	General procedure H	100/10	1119
H-A114C-(C114)_mcValCitPABC-#108	General procedure H	100/10	1314.59
H-A114C-(C114)_mcValCitPABC-#84	General procedure H	100/10	1371
H-A11AC-(C114)_mcValCitPABC-#226	General procedure H	100/10	1330
H-A114C-(C114)_mc-#108	General procedure H	100/10	909.12
H-A114C-(C114)_mcValCitPABC-#117	General procedure H	100/10	1342
H-A114C-(C114)_mcValCitPABC-#115	General procedure H	100/10	1316
H-A114C-(C114)_MalPeg6C2-#98	General procedure H	100/10	1184
IL13Ra2-AB08-v1010-hG1-(C) mcValCitPABC-#54	General procedure F	2.2/7	1341.68
IL13Ra2-AB08-v1010-hG1-(C)mc-#69	General procedure F	2.3/7	897.12
IL13Ra2-AB08-v1010-hG1-(C)_ MalPeg6C2-#69	General procedure F	2.3/8	1119
IL13Ra2-AB08-v1010-hG1-(C)_ mcValCitPABC-#69	General procedure F	2.5/8	1302

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-A114C-(C114)_MalPeg6C2-0#118	General procedure H	100/15	1145
H-A114C-(C114)_mcValCitPABC-0#118	General procedure H	100/15	1328
H-A114C-(C114)_mcValCitPABC-#80	General procedure H	100/15	1332
H-A114C-(C114)_mc-#117	General procedure H	100/15	937
H-A114C-(C114)_mcValCitPABC-#232	General procedure H	100/15	1366
H-A114C-(C114)_MalPeg6C2-#230	General procedure H	100/15	1145
H-A114C-(C114)_MalPeg6C2-#117	General procedure H	100/15	1159
H-A114C-(C114)_mc-#115	General procedure H	100/10	911
H-A114C-(C114)_mv-#115	General procedure H	100/10	897
H-A114C-(C114)_mb-#69	General procedure H	100/15	869
H-A114C-(C114)_mv-#69	General procedure H	100/15	883
H-A114C-(C114)_mc-0#118	General procedure H	100/15	923
H-(C)_mc-#117	General procedure F	2.0/6.5	937
H-(C)_MalPeg6C2-#117	General procedure F	2.05/6.5	1159
H-(C)_mc-0#118	General procedure F	2.1/7	923

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-(C)_MalPeg6C2-0#118	General procedure F	2.2/7.5	1145
IL13Ra2-AB08-v1010-hG1-(C)_mc-0#118	General procedure F	2.35/7	923
IL13Ra2-AB08-v1010-hG1-(C)_mc-#226	General procedure F	3.0/10	925
IL13Ra2-AB08-v1010-hG1-(C)_mc-#117	General procedure F	3.0/10	937
IL13Ra2-AB08-v1010-hG1-(C)_MalPeg6C2-#117	General procedure F	3.0/10	1159
IL13Ra2-AB08-v1010-hG1-(C)_MalPeg6C2-0#118	General procedure F	3.0/10	1145
H-A114C-(C114)_MalPeg6C2-#226	General procedure H	100/10	1147
H-A114C-(C114)_mc-#172	General procedure H	100/15	940.53
H-A114C-(C114)_mb-0#118	General procedure H	100/15	895
H-A114C-(C114)_me-0# 118	General procedure H	100/15	937
H-A114C-(C114)_mcValCitPABC-#134	General procedure H	100/15	1314
H-A114C-(C114)_mc-#131	General procedure H	100/15	937
H-A114C-(C114)_MalPeg6C2-#126	General procedure H	100/15	1147
H-A114C-(C114)_MalPeg6C2-#123	General procedure H	100/15	1174
H-A114C-(C114)_mc-#126	General procedure H	100/15	925

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2''-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-A114C-(C114)_mv-0#118	General procedure H	100/15	909
H-(C)_MalPeg6C2-#226	General procedure F	2.4/7	1147
H-(C) mc-#226	General procedure F	2.4/7	925
IL13Ra2-AB08-v1010-hG1-(C)_MalPeg6C2-#226	General procedure F	3.0/10	1147
Notch-28-cG1-(C)_mc-0#118	General procedure F	2.5/7	923
Notch-28-cG1-(C)_mc-#115	General procedure F	2.35/7	911
Notch-28-cG1-(C)_MalPeg6C2-0#118	General procedure F	2.35/7	1145
Notch-28-cG1-(C)_me-0#118	General procedure F	2.4/7	937
Notch-75-cG1-(C)_mc-0#118	General procedure F	2.5/7	923
IL13Ra2-19F9-cG1-(C)_mcValCitPABC-#54	General procedure F	2.5/8	1341.68
IL13Ra2-19F9-cG1-(C)_mcValCitPABC-#112	General procedure F	2.5/7	1288
Notch-28-cG1-(C)_mcValCitPABC-#112	General procedure F	2.3/7	1288
Notch-28-cG1-(C)_MalPeg6C2-#69	General procedure F	2.4/7	1119
Notch-75-cG1-(C)_MalPeg6C2-#69	General procedure F	2.4/7	1119
H-(C)_m(H2O)c-0#118	General procedure I	2.35/7	941

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-(C)_18	General procedure I	2.35/7	1163
H-(C)_Mal(H ₂ O)Peg6C2-#69	General procedure I	2.1/7	1137
H-(C)_m(H ₂ O)c-#69	General procedure I	2.4/7	915
H-(C)_me-0#118	General procedure F	2.2/7	937
H-(C)_mv-0#118	General procedure F	2.2/7	909
H-(C)_mb-0#118	General procedure F	2.1/7	895
H-A114C-(C114)_MalC6-#54	General procedure H	100/5	922.22
H-A114C-(C114)_mc-#231	General procedure H	100/5	1213
H-A114C-(C114)_MalC6-0#118	General procedure H	100/5	909.18
H-(C)_Mal(H ₂ O)Peg6C2-#115	General procedure I	2.4/7	1151
H-A114C-(C114)_mc-#158	General procedure H	100/10	951
H-A114C-(C114)_mcValCitPABC-#231	General procedure H	100/10	1617
H-(C)_m(H ₂ O)c-#115	General procedure I	2.4/7	929
Notch-75-cG1-(C)_mc-#115	General procedure F	3.0/7.0	911.15
Notch-75-cG1-(C)_me-0#118	General procedure F	3.0/7.0	937

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2''-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
Notch-75-cG1-(C)_MalPeg6C2-0#118	General procedure F	3.0/7.0	1144
H-A114C-(C114)_mc-#237	General procedure H	100/10	963
H-A114C-(C114)_mc-#145	General procedure H	100/10	897
H-A114C-(C114)_MalPeg6C2-#145	General procedure H	100/10	1119
H-A114C-(C114)_mc-#162	General procedure H	100/10	937
H-A114C-(C114)_MalC6Am-#151	General procedure H	100/10	905
Notch-28-cG1-(C)_m(H ₂ O)c-0#118	General procedure I	2.2/7	941
Notch-75-cG1-(C)_m(H ₂ O)c-0#118	General procedure I	2.2/7	941
H-(kK1 88)_COPeg2C2ValCitPABC-#54	General procedure J	-	1318
IL13Ra2-AB08-v1010-hG1-(C)_Mal(H ₂ O)Peg6C2-0#118	General procedure F	2.3/7	1163
IL13Ra2-AB08-v1010-hG1-(C)_Mal(H ₂ O)Peg6C2-#115	General procedure F	2.3/7	1151
IL13Ra2-AB08-v1010-hG1-(C)_mc-#115	General procedure F	2.35/7	911
IL13Ra2-AB08-v1010-hG1-(C)_m(H ₂ O)c-0#118	General procedure F	2.8/7	941
H-(C)_mcValCitPABC-0#118	General procedure F	2.2/7	1328
IL13Ra2-AB08-v1010-hG1-(C)_m(H ₂ O)c-#115	General procedure F	2.35/7	929

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-A114C-(C114)_mcValCitPABC-#154	General procedure H	100/5	1369
H-A114C-(C114)_MalC6Am-#153	General procedure H	100/10	921
IL13Ra2-AB08-v1010-Q347C+kK183C-hG1-(C347+kC183)_mcValCitPABC-#54	General procedure H	100/10	1341.68
IL13Ra2-AB08-v1010-Q347C-hG1-(C347)_mcValCitPABC-#54	General procedure H	100/10	1341.68
IL13Ra2-AB08-v1010-hG1-(kK188)_COPeg2C2AmPeg2C2-#69	General procedure J	-	1032
IL13Ra2-AB08-v1010-hG1-(kK188)_COPeg2C2ValCitPABC-#54	General procedure J	-	1318
IL13Ra2-AB08-v1010-L443C-hG1-(C443)_mcValCitPABC-#54	General procedure H	100/10	1341.68
IL13Ra2-AB08-v1010-K392C+L443C-hG1-(C392+C443)_mcValCitPABC-#54	General procedure H	100/10	1341.68
IL13Ra2-AB08-v1010-L443C+kK183C-hG1-(C443+kC183)_mcValCitPABC-#54	General procedure H	100/10	1341.68
H-(C)_mcValCitPABC-#98	General procedure F	2.2/7	1367
H-A114C-(C114)_mcValCitPABC-#246	General procedure H	100/10	1327
H-H435A-(C)_mcValCitPABC-#54	General procedure F	2.2/8	1341.7
H-M428L+N434S-(C)_mcValCitPABC-#70	General procedure F	2.2/8	1316
H-M428L+N434S-(C)_mcValCitPABC-#54	General procedure F	2.2/8	1341.7
H-E388C+N421C-(C388+C421)_mcValCitPABC-#54	General procedure H	100/10	1341

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2"-phosphanetriyltripropanoic acid/ Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/ linker molecular weight
H-Q347C+K392C-(C347+C392)_mcValCitPABC-#54	General procedure H	100/10	1341
H-L443C+kK183C-(C443+kC183)_mcValCitPABC-#54	General procedure H	100/10	1341
H-Q347C+kK183C-(C347+kC183)_mcValCitPABC-#54	General procedure H	100/10	1341
H-Q347C-(C347)_mcValCitPABC-#54	General procedure H	100/10	1341
H-K392C+L443C-(C392+C443)_mc-#115	General procedure H	100/10	911
H-E388C+N421C-(C388+C421)_mc-#115	General procedure H	100/10	911
H-Q347C+K392C-(C347+C392)_mc-#115	General procedure H	100/10	911
H-L443C+kK183C-(C443+kC183)_mc-#115	General procedure H	100/10	911
H-Q347C+kK183C-(C347+kC183)_mc-#115	General procedure H	100/10	911
H-Q347C-(C347)_mc-#115	General procedure H	100/10	911
H-kK183C-(kC183)_mcValCitPABC-#54	General procedure H	100/10	1341
H-E388C-(C388)_mcValCitPABC-#54	General procedure H	100/10	1341
H-kK183C-(kC183)_mc-#115	General procedure H	100/10	911
H-E388C-(C388)_mc-#115	General procedure H	100/10	911
H-L443C-(C443)_mc-#115	General procedure H	100/10	911

(continued)

ADC-Linker-Payload #	Prep. Method	Amount of 2,2',2''-phosphanetriyltripropanoic acid/Linker-Payload or TCEP/ PL (x/y)	Theoretical Δ mass or payload/linker molecular weight
H-N421C-(C421)_mcValCitPABC-#54	General procedure H	100/10	1341
H-N421C-(C421)_mc-#115	General procedure H	100/10	911
H-A114C-(C114)_mcGly-#201	General procedure G	100/10	1023

Table 19B - Selected conjugates of the invention and reference conjugates

ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
H-(C)_MalPeg3C2-#41	SEC (Protocol O): 7.317 minutes; HPLC (Protocol P): HC Δ mass = 1032	4.3
H-(C)_MalPeg6C2-#42	SEC (Protocol O): 7.177 minutes; HPLC (Protocol P): HC Δ mass = 1180	3.9
H-(C)_mc-#44	SEC (Protocol O): 7.195 minutes; HPLC (Protocol P): HC Δ mass = 915	4.4
H-(C)_MalPeg3C2-#44	SEC (Protocol O): 7.247 minutes; HPLC (Protocol P): HC Δ mass = 1005	3.4
H-(C)_MalPeg6C2-#44	SEC (Protocol O): 7.237 minutes; HPLC (Protocol P): HC Δ mass = 1135	3.4
H-(C)_mcValCitPABC-#44	SEC (Protocol O): 7.351 minutes; HPLC (Protocol P): HC Δ mass = 1321	4.2
H-(C)_Mal-PEG3C2-#45	SEC (Protocol O): 7.364 minutes; HPLC (Protocol P): HC Δ mass = 1017	4.3
H-(C)_Mal-PEG6C2-#45	SEC (Protocol O): 7.419 minutes; HPLC (Protocol P): HC Δ mass = 1154	3.9
H-(C)_mcValCitP ABC-#45	SEC (Protocol O): 7.159 minutes; HPLC (Protocol P): HC Δ mass = 1343	4.1
H-(C)_mc-#54	SEC (Protocol O): 7.192 minutes; HPLC (Protocol P): HC Δ mass = 899	4.5
H-(C)_Mal-PEG6C2-#69	SEC (Protocol O): 7.350 minutes; HPLC (Protocol P): HC Δ mass = 1122	3.4
H-(C)_mcValCitPABC-#69	SEC (Protocol O): 7.254 minutes; HPLC (Protocol P): HC Δ mass = 1305	4.5
H-(C)_mcValCitPABC-#70	SEC (Protocol O): 7.466 minutes; HPLC (Protocol P): HC Δ mass = 1318	3.7

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
H-(C)_mc-#79	SEC (Protocol O): 7.478 minutes; HPLC (Protocol P): HC Δ mass = 946	4
H-(C)_mcValCitPABC-#79	SEC (Protocol O): 7.635 minutes; HPLC (Protocol P): HC Δ mass = 1349	3.7
H-(C)_mc-#115	SEC (Protocol O): 7.510 minutes; HPLC (Protocol P): HC Δ mass = 912	3.54
H-A114C-(C114)_mc-#51	-	2.4
H-A114C-(C114)_mc-#47	-	2.3
H-A114C-(C114)_mc-#54	-	2.3
H-A114C-(C114)_mcValCitPABC-#47	-	2
H-A114C-(C114)_mcValCitPABC-#54	-	1.9
H-A114C-(C114)_mcValCitPABC-#26	-	2
H-A114C-(C114)_mc-#26	-	1.9
H-A114C-(C114)_mcValCitPABC-#36	-	2
H-A114C-(C114)_mcValCitPABC-#42	SEC (Protocol P): 7.681 minutes; HPLC (Protocol O): HC Δ mass = 1378	1.95
H-A114C-(C114)mc-#42	-	2
H-(C)-mcValCitPABC-#54	SEC (Protocol P): 7.159 minutes; HPLC (Protocol O): HC Δ mass = 1343	4.1
H-(C) mcValCitPABCAmPeg3C2-#54	-	4.6
H-(C) mcValCitPABCAmPeg6C2-#54	-	4.5
H-(C)_mc-#47	-	4.2
H-(C)_MalPeg3C2-#54	SEC (Protocol P): 7.179 minutes; HPLC (Protocol O): HC Δ mass = 1028	3.7
H-(C)_mc-#54	-	4
H-(C)_mcValCitPABCAmPeg3C2-#47	-	3.7
H-(C)_MalPeg3C2-#47	-	4.3
H-(C)_mcValCitPABCAmPeg3C2-#42	-	4.3
H-(C)_mc-#41	-	3.1
H-(C)_mcValCitPABCAmPeg3C2-#26	-	3
H-(C)_mcValCitPABCAmPeg6C2-#47	-	4.2
H-(C)_MalPeg3C2-#42	SEC (Protocol P): 7.142 minutes; HPLC (Protocol O): HC Δ mass = 1050	4.3
H-(C)_mcValCitPABCAmPeg6C2-#26	-	4.2
H-(C)_mcValCitPABCAmPeg6C2-#42	-	4.1
H-(C)_MalPeg6C2-#54	SEC (Protocol P): 7.254 minutes; HPLC (Protocol O): HC Δ mass = 1161	4.4

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
H-(C)_MalPeg6C2-#47	SEC (Protocol P): 7.303 minutes; HPLC (Protocol O): HC Δ mass = 1182	4.4
H-(C)_MalPeg6C2-#26	-	4.1
H-(C)-MalPeg6C2-#42	SEC (Protocol P): 7.177 minutes; HPLC (Protocol O): HC Δ mass = 1180	3.9
H-(C)_mc-#36	-	4.2
H-(C)_mcValCitPABC-#60	-	3.8
H-(C)_MalPeg3C2-#26	-	3.8
H-(C)_mcValCitPABCAmPeg3C2-#36	-	3.5
H-A114C-(C114)_mcValCitPABCAmPeg3C2-#36	-	1.9
H-A114C-(C114)_MalPeg6C2-#54	-	2
H-(C)_MalPeg3C2-#60	-	4.2
H-(C)_MalPeg6C2-#60	-	4.1
H-(C)_MalPeg6C2-#41	-	4
H-(C)-mc-#69	SEC (Protocol P): 7.192 minutes; HPLC (Protocol O): HC Δ mass = 899	4.5
H-(C)_MalPeg3C2-#36	-	5.2
H-(C)_mcValCitPABCAmPeg6C2-#36	-	4.2
H-(C)_MalPeg6C2-#36	-	5
H-(C)_mcValCitPABCAmPeg3C2-#41	-	4.4
H-(C)-MalPeg3C2-#41	SEC (Protocol P): 7.317 minutes; HPLC (Protocol O): HC Δ mass = 1032	4.3
H-(C)_mcValCitPABCAmPeg6C2-#60	-	4.1
H-A114C-(C114)_mc-#66	-	1.8
H-L398C+L443C-(C398+C443)_mcValCitPABC-#54	-	3.8
H-K392C+L443C-(C392+C443)_mcValCitPABC-#54	-	3.8
H-L443C-(C443)_mcValCitP ABC-#54	SEC (Protocol P): 8.827 minutes; HPLC (Protocol O): HC Δ mass = 1344	2
H-L398C+V422C-(C398+C422)_mcValCitPABC-#54	-	3.4
H-(C)-mc-#44	SEC (Protocol P): 7.195 minutes; HPLC (Protocol O): HC Δ mass = 915	4.4
H-(C)-Mal-PEG3C2-#45	SEC (Protocol P): 7.364 minutes; HPLC (Protocol O): HC Δ mass = 1017	4.3
H-(C) 2AcAmPeg6C2-#66	-	4

EP 2 780 039 B9

(continued)

ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
H-(C)-Mal-PEG6C2-#45	SEC (Protocol P): 7.419 minutes; HPLC (Protocol O): HC Δ mass = 1154	3.9
H-(C)-mc-#79	SEC (Protocol P): 7.478 minutes; HPLC (Protocol O): HC Δ mass = 946	4
H-(C)-MalPeg3C2-#44	SEC (Protocol P): 7.247 minutes; HPLC (Protocol O): HC Δ mass = 1005	3.4
H-(C)-mcValCitPABC-#70	SEC (Protocol P): 7.466 minutes; HPLC (Protocol O): HC Δ mass = 1318	3.7
H-(C)-MalPeg6C2-#44	SEC (Protocol P): 7.237 minutes; HPLC (Protocol O): HC Δ mass = 1135	3.4
H-A114C-(C114)_mcValCitPABC-#69	-	2
H-(C)-mcValCitPABC-#79	SEC (Protocol P): 7.635 minutes; HPLC (Protocol O): HC Δ mass = 1349	3.7
H-A114C-(C114)_mcValCitPABC-#79	-	1.84
H-(C)-mcValCitPABC-#44	SEC (Protocol P): 7.351 minutes; HPLC (Protocol O): HC Δ mass = 1321	4.2
H-A114C-(C114)_mcValCitPABC-#88	-	1.93
H-(C)-mcValCitPABC-#69	SEC (Protocol P): 7.254 minutes; HPLC (Protocol O): HC Δ mass = 1305	4.5
H-(C)_2AcAmCapValCitPABC-#66	-	3.3
H-A114C-(C114)_mcValCitPABC-#45	-	1.92
H-A114C-(C114)_mcValCitPABC-#34	-	2
H-A114C-(C114)_mc-#45	-	1.95
H-A114C-(C114)_mc-#70	-	2
H-(C)_mcValCitPABC-#112	SEC (Protocol P): 7.083 minutes; HPLC (Protocol O): HC Δ mass = 1291	4.4
H-(C)-Mal-PEG6C2-#69	SEC (Protocol P): 7.350 minutes; HPLC (Protocol O): HC Δ mass = 1122	3.4
H-Q347C-(C347)_mcValCitPABC-#69	-	2
H-Y373C-(C373)_mcValCitPABC-#69	-	1.6
H-E388C-(C388)_mcValCitPABC-#69	-	2
H-N421C-(C421)_mcValCitPABC-#69	-	1.95
H-L443C-(C443)_mcValCitPABC-#69	-	2
H-L443C-(C443)_mcValCitPABC-#79	-	2
H-A114C-(C114)_mcValCitPABC-#95	-	2
H-A114C-(C114)_mcValCitPABC-#98	-	2
H-A114C-(C114)_MalPeg3C2-#69	-	2
H-N297Q-(Q)_AmPeg6C2-#42	-	3.2
H-N297Q-(Q)_AmPeg6C2-#54	-	3.04

EP 2 780 039 B9

(continued)

	ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
5	H-N297Q-(Q)_ AmPeg6C2-#47	-	3.16
	H-N297Q-(Q)_ AmPeg6C2-#36	-	3.36
10	H-N297Q-(Q)_ AmPeg6C2-#26	-	3.4
	H-N297Q-(Q)_ AmPeg6C2-#66	-	2.8
15	H-L443C-(C443)_ MalPeg6C2-#69	SEC (Protocol P): 7.012 minutes; HPLC (Protocol O): HC Δ mass =1120	2
	H-Q347C-(C347)_ MalPeg6C2-#69	-	1.9
	H-E388C-(C388)_ MalPeg6C2-#69	-	1.8
	H-N421C-(C421)_ MalPeg6C2-#69	-	1.8
20	H-E380C-(C380)_ MalPeg6C2-#69	-	1.8
	H-L398C+L443C-(C398+C443)_ MalPeg6C2-#69	-	3.9
25	H-K392C+L443C-(C392+C443)_ MalPeg6C2-#69	-	3.5
	H-kA111C-(kC111)_ MalPeg6C2-#69	-	3.7
	H-kK183C-(kC183)_ MalPeg6C2-#69	-	2.1
	H-kK207C-(kC207)_ MalPeg6C2-#69	-	2.3
30	H-A114C-(C114)_ mcValCitPABC-#108	-	2
	H-A114C-(C114)_ mcValCitPABC-#84	-	1.9
	H-A114C-(C114)_ mcValCitPABC-#226	-	1.8
35	H-A114C-(C114)_ mc-#108	-	1.9
	H-A114C-(C114)_ mcValCitPABC-# 117	-	1.8
	H-A114C-(C114)_ mcValCitPABC-#115	-	1.9
	H-A114C-(C114)_ MalPeg6C2-#98	-	1.9
40	IL13Ra2-AB08-v1010-hG1-(C)_ mcValCitPABC-#54	-	3.9
	IL13Ra2-AB08-v1010-hG1-(C)_ mc-#69	-	3.5
45	IL13Ra2-AB08-v1010-hG1-(C)_ MalPeg6C2-#69	-	3.5
	IL13Ra2-AB08-v1010-hG1-(C)_ mcValCitPABC-#69	-	4.4
50	H-A114C-(C114)_ MalPeg6C2-0#118	-	1.9
	H-A114C-(C114)_ mcValCitPABC-0#118	-	1.8
	H-A114C-(C114)_ mcValCitPABC-#80	-	1.8
	H-A114C-(C114)_ mc-#117	-	1.9
55	H-A114C-(C114)_ mcValCitPABC-#232	-	1.8
	H-A114C-(C114)_ MalPeg6C2-#230	-	1.9

(continued)

5	ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
	H-A114C-(C114)_MalPeg6C2-#117	-	1.9
	H-A114C-(C114) mc-#115	-	2
10	H-A114C-(C114)_mv-#115	-	2
	H-A114C-(C114)_mb-#69	-	2
	H-A114C-(C114)_mv-#69	-	2
15	H-A114C-(C114)_mc-0#118	-	2
	H-(C)_mc-#117	SEC (Protocol P): 7.797 minutes; HPLC (Protocol O): HC Δ mass = 937	3.5
	H-(C)_MalPeg6C2-#117	SEC (Protocol P): 8.005 minutes; HPLC (Protocol O): HC Δ mass = 1163	3.56
20	H-(C)_mc-0#118	-	4.1
	H-(C)_MalPeg6C2-0#118	SEC (Protocol P): NA; HPLC (Protocol O): HC Δ mass = 1148	3.9
25	IL13Ra2-AB08-v1010-hG1-(C)_mc-0#118	-	4
	IL13Ra2-AB08-v1010-hG1-(C)_mc-#226	-	4.6
	IL13Ra2-AB08-v1010-hG1-(C)_mc-#117	-	3.3
30	IL13Ra2-AB08-v1010-hG1-(C)_MalPeg6C2-#117	-	3.3
	IL13Ra2-AB08-v1010-hG1-(C)_MalPeg6C2-0#118	-	2.9
	H-A114C-(C114)_MalPeg6C2-#226	-	1.9
35	H-A114C-(C114)_mc-#172	-	1.9
	H-A114C-(C114)_mb-0#118	-	1.9
	H-A114C-(C114)_me-0#118	-	2
40	H-A114C-(C114)mcValCitPABC-#134	-	1.9
	H-A114C-(C114) mc-#131	-	2
	H-A114C-(C114)_MalPeg6C2-#126	-	1.9
	H-A114C-(C114)_MalPeg6C2-#123	-	1.7
45	H-A114C-(C114)_mc-#126	-	2
	H-A114C-(C114)_mv-0#118	-	2
	H-(C)_MalPeg6C2-#226	SEC (Protocol P): 7.501 minutes; HPLC (Protocol O): HC Δ mass = 1150	4.5
50	H-(C)_mc-#226	SEC (Protocol P): 7.418 minutes; HPLC (Protocol O): HC Δ mass = 927	4.5
	IL13Ra2-AB08-v1010-hG1-(C)_MalPeg6C2-#226	-	4.2
55	Notch-28-cG1-(C)_mc-0#118	-	4.6

EP 2 780 039 B9

(continued)

5	ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
	Notch-28-cG1-(C)_mc-#115	SEC (Protocol P): 7.015 minutes; HPLC (Protocol O): HC Δ mass = 911	3.7
10	Notch-28-cG1-(C)_MalPeg6C2-0#118	-	4.1
	Notch-28-cG1-(C)_me-0#118	SEC (Protocol P): 7.182 minutes; HPLC (Protocol O): HC Δ mass = 937	3.9
	Notch-75-cG1-(C)_mc-0#118	-	3.3
15	IL13Ra2-19F9-cG1-(C)_mcValCitPABC-#54	-	4.1
	IL13Ra2-19F9-cG1-(C)_mcValCitPABC-#112	-	4.2
	Notch-28-cG1-(C)_mcValCitPABC-#112	-	4.1
20	Notch-28-cG1-(C)_MalPeg6C2-#69	-	4.3
	Notch-75-cG1-(C)_MalPeg6C2-#69	-	3.8
	H-(C)_m(H ₂ O)c-0#118	SEC (Protocol P): 7.010 minutes; HPLC (Protocol O): HC Δ mass = 942	4.1
25	H-(C)_Mal(H ₂ O)Peg6C2-0#118	SEC (Protocol P): 6.964 minutes; HPLC (Protocol O): HC Δ mass = 1166	4
	H-(C)_Mal(H ₂ O)Peg6C2-#69	-	2.8
30	H-(C)_m(H ₂ O)c-#69	-	3.6
	H-(C)_me-0#118	-	4.4
	H-(C)_mv-0#118	-	4.4
35	H-(C)_mb-0#118	SEC (Protocol P): 7.032 minutes; HPLC (Protocol O): HC Δ mass = 896	4.1
	H-A114C-(C114)_MalC6-#54	-	1.9
	H-A114C-(C114)_mc-#231	-	1.7
40	H-A114C-(C114)_MalC6-0#118	-	2
	H-(C)_Mal(H ₂ O)Peg6C2-#115	SEC (Protocol P): 6.936 minutes; HPLC (Protocol O): HC Δ mass = 1152	4.1
	H-A114C-(C114)_mc-#158	-	2
45	H-A114C-(C114)_mcValCitPABC-#231	-	1.7
	H-(C)_m(H ₂ O)c-#115	SEC (Protocol P): 6.928 minutes; HPLC (Protocol O): HC Δ mass = 930	3.7
	Notch-75-cG1-(C)_mc-#115	-	3.7
50	Notch-75-cG1-(C)_me-0#118	-	3.5
	Notch-75-cG1-(C)_MalPeg6C2-0#118	-	3.8
	H-A114C-(C114)_mc-#237	-	2
	H-A114C-(C114)_mc-#145	-	2
55	H-A114C-(C114)_MalPeg6C2-#145	-	2
	H-A114C-(C114)_mc-#162	-	1.9

EP 2 780 039 B9

(continued)

	ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
5	H-A114C-(C114)_MalC6Am-#151	-	1.9
	Notch-28-cG1-(C)_m(H2O)c-0#118	-	3.7
10	Notch-75-cGI-(C)_m(H2O)c-0#118	-	3
	H-(kK188)_COpeg2C2ValCitPABC-#54	-	2
15	IL13Ra2-AB08-v1010-hG1-(C)_Mal(H2O)Peg6C2-0#118	SEC (Protocol P): 7.766 minutes; HPLC (Protocol O): HC Δ mass = 1164	3.5
	IL13Ra2-AB08-v1010-hG1-(C)_Mal(H2O)Peg6C2-#115	-	3.9
20	IL13Ra2-AB08-v1010-hG1-(C)_mc-#115	SEC (Protocol P): 7.813 minutes; HPLC (Protocol O): HC Δ mass = 911	4.3
	IL13Ra2-AB08-v1010-hG1-(C)_m(H2O)c-0#118	-	3.3
	H-(C)_mcValCitPABC-0#118	-	4.5
25	IL13Ra2-AB08-v1010-hG1-(C)_m(H2O)c-#115	SEC (Protocol P): 7.783 minutes; HPLC (Protocol O): HC Δ mass = 930	3.8
	H-A114C-(C114)_mcValCitPABC-#154	-	1.9
	H-A114C-(C114)_MalC6Am-#153	-	2
30	IL13Ra2-AB08-v1010-Q347C+kK183C-hG1-(C347+kC183)_mcValCitPABC-#54	-	4.3
	IL13Ra2-AB08-v1010-Q347C-hG1-(C347)_mcValCitPABC-#54	-	2.1
35	IL13Ra2-AB08-v1010-hG1-(kK188)_COpeg2C2AmPeg2C2-#69	-	2
	IL13Ra2-AB08-v1010-hG1-(kK188)_COpeg2C2ValCitPABC-#54	-	1.9
40	IL13Ra2-AB08-v1010-L443C-hG1-(C443)_mcValCitPABC-#54	-	2.1
	IL13Ra2-AB08-v1010-K392C+L443C-hG1-(C392+C443)_mcValCitPABC-#54	-	3.7
45	IL13Ra2-AB08-v1010-L443C+kK183C-hG1-(C443+kC183)_mcValCitPABC-#54	-	4
	H-(C)_mcValCitPABC-#98	SEC (Protocol P): 7.232 minutes; HPLC (Protocol O): HC Δ mass = 1371	4.2
50	H-A114C-(C114)_mcValCitPABC-#246	-	1.9
	H-H435A-(C)_mcValCitPABC-#54	-	4
	H-M428L+N434S-(C)_mcValCitPABC-#70	-	4.2
	H-M428L+N434S-(C)_mcValCitPABC-#54	-	4
55	H-E388C+N421C-(C388+C421)_mcValCitPABC-#54	-	3.6

(continued)

ADC-Linker-Payload #	Mass spectra: HPLC-SEC retention time and HPLC Δ mass for the Heavy Chain (HC) portion (up to 6 Da difference with theoretical Δ mass)	Loading or Drug per Antibody ratio (DAR)
H-Q347C+K392C-(C347+C392)_mcValCitPABC-#54	-	3.9
H-L443C+kK183C-(C443+kC183)_mcValCitPABC-#54	-	3.7
H-Q347C+kK183C-(C347+kC183)_mcValCitPABC-#54	SEC (Protocol P): 8.278 minutes; HPLC (Protocol O): HC Δ mass = 1339	3.7
H-Q347C-(C347)_mcValCitPABC-#54	-	1.9
H-K392C+L443C-(C392+C443)_mc-#115	-	4
H-E388C+N421C-(C388+C421)_mc-#115	-	3.8
H-Q347C+K392C-(C347+C392)_mc-#115	-	4
H-L443C+kK183C-(C443+kC183)_mc-#115	-	3.8
H-Q347C+kK183C-(C347+kC183)_mc-#115	-	3.8
H-Q347C-(C347)_mc-#115	-	2
H-kK183C-(kC183)_mcValCitPABC-#54	-	1.9
H-E388C-(C388)_mcValCitPABC-#54	-	2
H-kK183C-(kC183)_mc-#115	-	1.8
H-E388C-(C388)_mc-#115	SEC (Protocol P): 7.364 minutes; HPLC (Protocol O): HC Δ mass = 914	2
H-L443C-(C443)_mc-#115	-	2
H-N421C-(C421)_mcValCitPABC-#54	-	2
H-N421C-(C421)_mc-#115	-	2
H-A114C-(C114)_mcGly-#201	-	1.9

Table 20 - IC₅₀ values for selected compounds (cytotoxic peptides) of the invention and Reference Examples

Example #	BT474 GMEAN IC ₅₀ (nM)	N87GMEAN IC ₅₀ (nM)	MDA-MB-361-DYT2 GMEAN IC ₅₀ (nM)
#26	0.368	0.543	1.045
#30	0.682	6.709	1.853
#34	0.211	1.95	1.119
#36	0.499	1.205	1.111
#41	29.666	33.21	51.784
#42	0.125	0.327	0.195
#44	7.119	14.61	> 16.401
#45	0.15	0.385	0.415
#47	<0.244	<0.256	0.317
#51	<0.599	3.658	-
#54	<0.133	<0.221	0.206

EP 2 780 039 B9

(continued)

	Example #	BT474 GMEAN IC ₅₀ (nM)	N87GMEAN IC ₅₀ (nM)	MDA-MB-361-DYT2 GMEAN IC ₅₀ (nM)
5	#56	0.316	1.256	0.766
	#60	0.524	1.245	0.957
	#66	0.244	0.463	0.334
10	#69	80.191	65.979	40.988
	#70	0.179	0.327	0.225
	#75	>100.000	>100.000	>100.000
	#79	0.079	0.137	0.129
15	#80	20.346	28.204	32.846
	#84	0.246	0.426	0.686
	#115	31.493	50.302	19.870
20	#117	0.096	0.103	0.118
	#118	100.000	100.000	100.000
	#123	0.125	0.089	0.129
	#126	0.315	0.375	0.454
25	#130	0.050	0.076	0.039
	#131	0.072	0.185	0.081
	#134	0.108	0.115	0.134
30	#140	-	-	-
	#141	3.367	3.018	-
	#142	0.279	0.259	-
	#143	-	-	-
35	#144	0.172	0.182	0.174
	#145	0.185	0.167	0.229
	#146	0.435	0.195	0.387
40	#147	0.456	0.144	0.421
	#148	0.429	0.219	0.502
	#149	0.417	0.250	0.428
45	#151	84.867	61.953	84.599
	#153	98.160	47.274	91.350
	#154	0.193	0.572	0.198
	#155	0.323	0.875	0.318
50	#158	0.082	0.115	0.100
	#159	0.070	0.075	0.074
	#162	31.448	21.610	27.824
55	#163	100.000	72.703	99.433
	#172	0.057	0.144	0.086
	#173	0.088	0.099	0.067

EP 2 780 039 B9

(continued)

	Example #	BT474 GMEAN IC ₅₀ (nM)	N87GMEAN IC ₅₀ (nM)	MDA-MB-361-DYT2 GMEAN IC ₅₀ (nM)
5	#178	0.968	1.262	0.911
	#180	0.159	0.117	0.113
	#182	0.153	0.148	0.122
10	#184	2.478	5.098	3.427
	#186	-	-	-
	#188	0.250	0.283	0.404
	#190	0.134	0.066	0.095
15	#192	0.262	0.360	0.408
	#194	0.134	0.212	0.198
	#200	0.048	0.029	0.017
20	#201	0.144	0.150	0.121
	#207	0.219	0.626	0.260
	#208	0.418	0.379	0.336
	#209	0.067	0.067	0.058
25	#217	-	-	-
	#219	-	-	-
	#220	35.163	100.000	100.000
30	#221	32.402	87.857	65.401
	#222	0.158	0.352	0.272
	#223	7.589	13.026	10.863
	#224	0.383	1.563	0.998
35	#225	3.449	10.524	7.575
	#226	0.118	0.478	0.106
	#227	11.008	18.975	12.899
40	#228	0.105	0.090	0.078
	#229	18.372	16.566	10.218
	#230	100.000	89.133	70.236
	#231	3.706	15.127	22.855
45	#232	0.071	0.194	0.095
	#233	1.074	8.413	5.042
	#234	0.684	0.756	2.004
50	#235	0.852	1.320	1.278
	#236	0.020	0.023	0.010
	#237	0.162	0.217	0.278
	#238	0.139	0.077	0.084
55	#239	-	-	-
	#240	11.710	19.930	23.480

EP 2 780 039 B9

(continued)

Example #	BT474 GMEAN IC ₅₀ (nM)	N87GMEAN IC ₅₀ (nM)	MDA-MB-361-DYT2 GMEAN IC ₅₀ (nM)
#241	0.364	0.388	0.494
#242	32.330	41.329	34.529
#243	1.252	1.301	1.284
#244	73.123	100.000	100.000
#245	11.793	33.037	31.856
#246	3.159	10.828	5.430
#247	1.007	2.061	1.334
#257	-	-	-

Table 21A_ - IC₅₀ values for selected conjugates of the invention and reference conjugates

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC50 of Antibody (ng/mL)	IC ₅₀ (nM)	IC50 of Antibody (ng/mL)	IC ₅₀ (nM)	IC50 of Antibody (ng/mL)
H-(C)_MalPeg3C2-#41	0.725	25.592	0.465	16.617	4.02	175.448
H-(C)_MalPeg6C2-#42	0.502	19.855	0.604	24.783	>14.090	>6681.150
H-(C)_mc-#44	3.553	121.414	14.464	493.077	>841.360	>29495.311
H-(C)_MalPeg3C2-#44	2.603	114.847	5.113	225.594	>440.881	>26346.532
H-(C)_MalPeg6C2-#44	1.318	58.155	1.466	64.663	98.174	4873.851
H-(C)_mcValCitPABC-#44	0.188	6.717	0.155	5.329	0.781	28.146
H-(C)_Mal-PEG3C2-#45	2.886	103.762	1.513	52.791	>740.001	>27967.742
H-(C)_Mal-PEG6C2-#45	1.274	49.903	1.423	54.715	111.434	9072.131
H-(C)_mcValCitPABC-#45	0.258	9.997	0.204	7.988	0.417	16.737
H-(C)_mc-#54	0.436	19.821	0.992	45.072	2.45	138.026
H-(C)_Mal-PEG6C2-#69	1.938	5147.54	0.356	12.995	5.743	2427.639
H-(C)_mcValCitPABC-#69	0.18	7.17	0.073	2.878	<0.185	<8.946
H-(C)_mcValCitPABC-#70	0.133	4.522	0.078	2.61	0.249	8.722
H-(C)_mc-#79	0.483	18.097	0.654	24.543	7.576	297.254
H-(C)_mcValCitPABC-#79	0.152	6.634	0.127	5.682	0.469	21.134
H-(C)_mc-#115	0.272	-	0.109	-	0.841	-
H-A114C-(C114)_mc-#51	41.768	-		-	17.297	-
H-A114C-(C114)_mc-#47	3.269	-		-	8.216	-
H-A114C-(C114)_mc-#54	4.294	-		-	7.195	-
H-A114C-(C114)_mcValCitPABC-#47	0.493	-	0.31	-	0.696	-
H-A114C-(C114)_mcValCitPABC-#54	0.174	-	0.17	-	0.189	-
H-A114C-(C114)_mcValCitPABC-#26	2.548	-	28.2	-	4.314	-
H-A114C-(C114)_mc-#26	>60.648	-	>1000.00	-	>980.026	-
H-A114C-(C114)_mcValCitPABC-#36	2.007	-	26.18	-	13.579	-

(continued)

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
H-A114C-(C114) mcValCitPABC-#42	0.283	-	0.16	-	0.524	-
H-A114C-(C114)_mc-#42	0.81	-	1.54	-	44.164	-
H-(C)-mcValCitPABC-#54	0.292	-	0.27	-	0.345	-
H-(C)_mcValCitPABCAmPeg3C2-#54	15.134	-	14.33	-	41.016	-
H-(C)_mcValCitPABCAmPeg6C2-#54	1.898	-	1.4	-	11.71	-
H-(C)_mc-#47	4.429	-	3.52	-	20.007	-
H-(C)_MalPeg3C2-#54	2.181	-	1.54	-	>41.711	-
H-(C)_mc-#54	3.565	-	6.28	-	48.566	-
H-(C)_mcValCitPABCAmPeg3C2-#47	5.228	-	>1000.00	-	>543.852	-
H-(C)_MalPeg3C2-#47	1.467	-	1.29	-	16.856	-
H-(C)_mcValCitPABCAmPeg3C2-#42	1.587	-	4.95	-	>1000.000	-
H-(C)_mc-#41	0.506	-	0.68	-	7.543	-
H-(C)_mcValCitPABCAmPeg3C2-#26	11.211	-	>1000.00	-	>1000.000	-
H-(C)_mcValCitPABCAmPeg6C2-#47	0.935	-	2.46	-	14.283	-
H-(C)_MalPeg3C2-#42	0.517	-	0.51	-	5.479	-
H-(C)_mcValCitPABCAmPeg6C2-#26	10.992	-	>1000.00	-	>1000.000	-
H-(C)_mcValCitPABCAmPeg6C2-#42	1.819	-	1.97	-	75.643	-
H-(C)_MalPeg6C2-#54	2.108	-	1.02	-	>56.928	-
H-(C)_MalPeg6C2-#47	1.637	-	1.42	-	31.762	-
H-(C)_MalPeg6C2-#26	6.385	-	9.55	-	>817.859	-
H-(C)-MalPeg6C2-#42	0.518	-	0.55	-	>7.993	-
H-(C)_mc-#36	>1000.000	-	>1000.00	-	>1000.000	-
H-(C)_mcValCitPABC-#60	0.835	-	6.45	-	14.917	-

(continued)

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
H-(C)_MalPeg3C2-#26	11.506	-	9.43	-	>1000.000	-
H-(C)_mcValCitPABCAmPeg3C2-#36	>1000.000	-	>1000.00	-	>1000.000	-
H-A114C-(C114)_mcValCitPABCAmPeg3 C2-#36	>1000.000	-	>1000.00	-	>325.714	-
H-A114C-(C114)_MalPeg6C2-#54	1.228	-	2.01	-	133.426	-
H-(C)_MalPeg3C2-#60	>1000.000	-	>1000.00	-	>1000.00	-
H-(C)_MalPeg6C2-#60	>1000.000	-	>1000.00	-	>1000.00	-
H-(C)_MalPeg6C2-#41	1.166	-	0.36	-	5.882	-
H-(C)-mc-#69	0.427	-	0.47	-	3.05	-
H-(C)_MalPeg3C2-#36	720.826	-	>1000.00	-	>1000.000	-
H-(C)_mcValCitPABCAmPeg6C2-#36	>1000.000	-	>1000.00	-	>1000.000	-
H-(C)_MalPeg6C2-#36	878.903	-	159.1	-	>1000.000	-
H-(C)_mcValCitPABCAmPeg3C2-#41	2.363	-	2.28	-	18.728	-
H-(C)-MalPeg3C2-#41	0.725	-	0.54	-	4.004	-
H-(C)_mcValCitPABCAmPeg6C2-#60	979.982	-	>1000.00	-	392.905	-
H-A114C-(C114)_mc-#66	17.235	-	>1000.00	-	>1000.000	-
H-L398C+L443C-(C398+C443)_mcValCitPABC-#54	0.249	-	0.27	-	0.678	-
H-K392C+L443C-(C392+C443)_mcValCitPABC-#54	<0.195	-	0.42	-	<0.254	-
H-L443C-(C443)_mcValCitPABC-#54	<0.130	-	0.32	-	<0.267	-
H-L398C+V422C-(C398+C422)_mcValCitPABC-#54	0.387	-	0.27	-	0.504	-
H-(C)-mc-#44	3.553	-	>507.23	-	>878.489	-
H-(C)-Mal-PEG3C2-#45	2.886	-	68.41	-	>834.717	-

(continued)

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC50 of Antibody (ng/mL)	IC ₅₀ (nM)	IC50 of Antibody (ng/mL)	IC ₅₀ (nM)	IC50 of Antibody (ng/mL)
H-(C)_2AcAmPeg6C2-#66	703.419	-	>1000.00	-	>1000.000	-
H-(C)-Mal-PEG6C2-#45	1.274	-	2.74	-	>268.047	-
H-(C)-mc-#79	0.483	-	0.65	-	7.576	-
H-(C)-MalPeg3C2-#44	2.603	-	5.11	-	>440.881	-
H-(C)-mcValCitP ABC-#70	0.188	-	0.09	-	<0.179	-
H-(C)-MalPeg6C2-#44	1.318	-	1.47	-	98.174	-
H-A114C-(C114)_ mcValCitPABC-#69	0.174	-	0.06	-	0.207	-
H-(C)-mcV alCitP ABC-#79	0.152	-	0.15	-	0.469	-
H-A114C-(C114)_ mcValCitPABC-#79	0.124	-	0.12	-	0.386	-
H-(C)-mcValCitPABC-#44	0.252	-	0.18	-	0.732	-
H-A114C-(C114)_ mcValCitPABC-#88	8.127	-	>1000.00	-	62.825	-
H-(C)-mcValCitPABC-#69	0.133	-	0.1	-	0.249	-
H-(C)_2AcAmCapValCitPABC-#66	0.436	-	0.99	-	2.45	-
H-A114C-(C114)_ mcValCitPABC-#45	0.217	-	0.2	-	0.496	-
H-A114C-(C114)_ mcValCitPABC-#34	3.724	-	>1000.00	-	18.422	-
H-A114C-(C114)_mc-#45	6.431	-	>1000.00	-	148.852	-
H-A114C-(C114)_mc-#70	0.349	-	0.62	-	7.208	-
H-(C)_mcValCitPABC-#112	0.226	-	0.24	-	0.469	-
H-(C)-Mal-PEG6C2-#69	0.453	-	0.54	-	1.8	-
H-Q347C-(C347)_ mcValCitPABC-#69	0.368	-	0.06	-	0.22	-
H-Y373C-(C373)_ mcValCitPABC-#69	0.359	-	0.06	-	0.295	-
H-E388C-(C388)_ mcValCitPABC-#69	0.427	-	0.06	-	0.314	-
H-N421C-(C421)_ mcValCitPABC-#69	0.434	-	0.09	-	0.244	-

(continued)

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
H-L443C-(C443)_ mcValCitPABC-#69	0.239	-	0.05	-	0.272	-
H-L443C-(C443)_ mcValCitPABC-#79	0.3	-	0.15	-	0.412	-
H-A114C-(C114)_ mcValCitPABC-#95	0.381	-	0.36	-	0.852	-
H-A114C-(C114)_ mcValCitPABC-#98	0.171	-	0.24	-	0.258	-
H-A114C-(C114)_ MalPeg3C2-#69	0.221	-	0.58	-	1.589	-
H-N297Q-(Q)_ AmPeg6C2-#42	0.466	-	0.36	-	5.42	-
H-N297Q-(Q)_ AmPeg6C2-#54	0.557	-	0.37	-	6.899	-
H-N297Q-(Q)_ AmPeg6C2-#47	0.346	-	0.43	-	4.337	-
H-N297Q-(Q)_ AmPeg6C2-#36	3.003	-	>1000.00	-	284.267	-
H-N297Q-(Q)_ AmPeg6C2-#26	0.991	-	1.07	-	35.331	-
H-N297Q-(Q)_ AmPeg6C2-#66	13.812	-	>1000.00	-	>1000.000	-
H-L443C-(C443)_ MalPeg6C2-#69	0.251	-	0.25	-	1.989	-
H-Q347C-(C347)_ MalPeg6C2-#69	0.267	-	0.3	-	0.887	-
H-E388C-(C388)_ MalPeg6C2-#69	0.382	-	0.46	-	3.035	-
H-N421C-(C421)_ MalPeg6C2-#69	0.35	-	0.45	-	1.329	-
H-E380C-(C380)_ MalPeg6C2-#69	0.482	-	0.49	-	5.588	-
H-L398C+L443C-(C398+C443)_ MalPeg6C2-#69	0.226	-	0.3	-	1.346	-
H-K392C+L443C-(C392+C443)_ MalPeg6C2-#69	0.268	-	0.31	-	1.63	-
H-KA111C-(KC111)_ MalPeg6C2-#69	0.297	-	0.34	-	1.635	-
H-KK183C-(KC183)_ MalPeg6C2-#69	0.257	-	0.5	-	2.23	-
H-KK207C-(KC207)_ MalPeg6C2-#69	0.252	-	0.41	-	1.744	-
H-A114C-(C114)_ mcValCitPABC-#108	0.212	-	0.12	-	0.777	-
H-A114C-(C114)_ mcValCitPABC-#84	0.627	-	12.2	-	1.733	-

(continued)

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
H-A114C-(C114)_mcValCitPABC-#226	0.2	-	0.1	-	0.239	-
H-A114C-(C114)_mc-#108	>1000.000	-	>1000.00	-	113.889	-
H-A114C-(C114)_mcValCitPABC-#117	0.242	-	0.17	-	0.239	-
H-A114C-(C114)_mcValCitPABC-#115	0.202	-	0.2	-	0.211	-
H-A114C-(C114)_MalPeg6C2-#98	0.576	-	0.47	-	1.46	-
H-A114C-(C114)_MalPeg6C2-0#118	0.257	-	0.17	-	0.505	-
H-A114C-(C114)_mcValCitPABC-0#118	0.251	-	0.24	-	0.398	-
H-A114C-(C114)_mcValCitPABC-#80	0.341	-	0.31	-	0.887	-
H-A114C-(C114)_mc-#117	0.197	-	0.14	-	0.465	-
H-A114C-(C114)_mcValCitPABC-#232	0.376	-	1.31	-	1.367	-
H-A114C-(C114)_MalPeg6C2-#230	0.504	-	0.85	-	3.179	-
H-A114C-(C114)_MalPeg6C2-#117	0.335	-	0.21	-	0.792	-
H-A114C-(C114)_mc-#115	0.243	-	0.23	-	0.45	-
H-A114C-(C114)_mv-#115	0.21	-	0.15	-	0.65	-
H-A114C-(C114)_mb-#69	0.256	-	0.43	-	2.137	-
H-A114C-(C114)_mv-#69	0.215	-	0.27	-	1.043	-
H-A114C-(C114)_mc-0#118	0.151	-	0.1	-	0.342	-
H-(C) mc-#117	0.162	-	0.06	-	0.314	-
H-(C)_MalPeg6C2-#117	0.283	-	0.07	-	0.515	-
H-(C)_mc-0#118	0.18	-	<0.10	-	0.303	-
H-(C)_MalPeg6C2-0#118	0.269	-	0.15	-	0.499	-
H-A114C-(C114)_MalPeg6C2-#226	0.28	-	0.22	-	0.685	-
H-A114C-(C114)_mc-#172	0.296	-	0.41	-	0.694	-

(continued)

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
H-A114C-(C114)_mb-0#118	0.318	-	0.33	-	0.709	-
H-A114C-(C114)_me-0#118	0.256	-	0.33	-	0.64	-
H-A114C-(C114)_mcValCitPABC-#134	0.301	-	0.34	-	0.501	-
H-A114C-(C114)_mc-#131	0.357	-	0.76	-	1.614	-
H-A114C-(C114)_MalPeg6C2-#126	0.284	-	0.36	-	1.377	-
H-A114C-(C114)_MalPeg6C2-#123	0.362	-	0.34	-	1.867	-
H-A114C-(C114)_mc-#126	0.319	-	0.49	-	3.294	-
H-A114C-(C114)_mv-0#118	0.209	-	0.25	-	0.719	-
H-(C) MalPeg6C2-#226	0.575	-	0.22	-	1.126	-
H-(C)_mc-#226	0.359	-	0.18	-	0.69	-
H-(C)_m(H2O)c-0#118	0.26	-	0.11	-	0.448	-
H-(C)_Mal(H2O)Peg6C2-0#118	0.482	-	0.19	-	0.9	-
H-(C)_Mal(H2O)Peg6C2-#69	0.832	-	0.51	-	5.769	-
H-(C)_m(H2O)c-#69	0.418	-	0.28	-	1.529	-
H-(C)_me-0#118	0.186	-	0.11	-	0.218	-
H-(C)_mv-0#118	0.201	-	0.14	-	0.265	-
H-(C)_mb-0#118	0.222	-	0.13	-	0.267	-
H-A114C-(C114)_MalC6-#54	0.662	-	5.11	-	8.003	-
H-A114C-(C114)_mc-#231	>1000.000	-	>1000.00	-	>1000	-
H-A114C-(C114)_MalC6-0#118	0.976	-	113	-	15.407	-
H-(C)_Mal(H2O)Peg6C2-#115	1.06	-	0.28	-	3.439	-
H-A114C-(C114)_mc-#158	0.247	-	0.35	-	0.739	-
H-A114C-(C114)_mcValCitPABC-#231	1.178	-	24.41	-	13.447	-

(continued)

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
H-(C)_m(H ₂ O)c-#115	0.393	-	0.17	-	0.498	-
H-A114C-(C114)_mc-#237	0.97	-	0.68	-	27.907	-
H-A114C-(C114)_mc-#145	4.681	-	585.59	-	643.391	-
H-A114C-(C114)_MalPeg6C2-#145	12.856	-	190.59	-	89.125	-
H-A114C-(C114)_mc-#162	0.377	-	0.15	-	1.144	-
H-A114C-(C114)_MalC6Am-#151	0.42	-	0.1	-	0.694	-
H-(kK188)_CO Peg2C2ValCitPAB C-#54		-		-		-
H-(C)_mcValCitPABC-0#118	0.227	-	0.14	-	0.182	-
H-A114C-(C114)_mcValCitPABC-#154	0.323	-	0.32	-	0.363	-
H-A114C-(C114)_MalC6Am-#153	0.377	-	0.27	-	0.34	-
H-(C)_mcValCitPABC-#98	0.211	-	0.14	-	0.162	-
H-A114C-(C114)_mcValCitPABC-#246	0.357	-	0.65	-	3.197	-
H-H435A-(C)_mcValCitPABC-#54	0.358	-	0.17	-	0.237	-
H-M428L+N434S-(C)_mcValCitPABC-#70	0.322	-	0.1	-	0.114	-
H-M428L+N434S-(C)_mcValCitPABC-#54	0.354	-		-	0.217	-
H-E388C+N421C-(C388+C421)_mcValCitPABC-#54	1.38	-	0.99	-	0.855	-
H-Q347C+K392C-(C347+C392)_mcValCitPABC-#54	0.276	-	0.29	-	0.147	-
H-L443C+kK183C-(C443+kC183)_mcValCitPABC-#54	<0.129	-	0.37	-	<0.111	-
H-Q347C+kK183C-(C347+kC183)_mcValCitPABC-#54	0.146	-	0.25	-	0.08	-
H-Q347C-(C347)_mcValCitPABC-#54	0.153	-	0.33	-	0.111	-
H-K392C+L443C-(C392+C443)_mc-#115	0.323	-	0.1	-	0.304	-

(continued)

ADC-Linker-Payload #	BT474		HCC1954		N87	
	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
H-E388C-N421C-(C388+C421)_mc-#115	1.251	-	0.42	-	0.997	-
H-Q347C+K392C-(C347+C392)_mc-#115	0.342	-	0.1	-	0.219	-
H-L443C+kK183C-(C443+kC183)_mc-#115	0.319	-	0.1	-	0.268	-
H-Q347C+kK183C-(C347+kC183)_mc-#115	0.347	-	0.1	-	0.403	-
H-Q347C-(C347)_mc-#115	0.272	-	0.18	-	0.278	-
H-kK183C-(kC183)_mcValCitPABC-#54	0.287	-	0.34	-	0.194	-
H-E388C-(C388)_mcValCitPABC-#54	0.098	-	0.38	-	0.084	-
H-kK183C-(kC183)_mc-#115	0.28	-	0.27	-	0.269	-
H-E388C-(C388)_mc-#115	0.302	-	0.15	-	0.301	-
H-L443C-(C443)_mc-#115	0.222	-	0.1	-	0.259	-
H-N421C-(C421)_mcValCitPABC-#54	<0.051	-	0.42	-	<0.051	-
H-N421C-(C421)_mc-#115	0.312	-	0.23	-	0.306	-
H-A114C-(C114)_mcGly-#201	0.321	-		-		-

Table 21B - IC₅₀ values for selected conjugates of the invention and reference conjugates

	ADC-Linker-Payload #	DYT2		MDA-MB-468	
		IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
5	H-(C) MalPeg3C2-#41	>69.685	>17528.581	-	>35714.286
	H-(C)_MalPeg6C2-#42	33.396	5455.61	>629.281	>25857.971
10	H-(C)_mc-#44	>1000.000	>34090.909	>1000.000	>34090.909
	H-(C)_MalPeg3C2-#44	>1000.000	>44117.647	>1000.000	>44117.647
	H-(C)_MalPeg6C2-#44	>1000.000	>44117.647	>1000.000	>44117.647
15	H-(C)_mcValCitPABC-#44	0.203	7.246	>1000.000	>35714.286
	H-(C)_Mal-PEG3C2-#45	>1000.000	>34883.721	>1000.000	>34883.721
	H-(C)_Mal-PEG6C2-#45	>1000.000	>38461.538	>1000.000	>38461.538
	H-(C)_mcValCitPABC-#45	0.371	14.304	613.294	24435.914
20	H-(C)_mc-#54	>1000.000	>45454.545	>1000.000	>45454.545
	H-(C)_Mal-PEG6C2-#69	>467.163	>29849.279	>1000.000	>35714.286
	H-(C)_mcValCitPABC-#69	0.156	7.54	547.953	21860.354
25	H-(C)_mcValCitPABC-#70	0.098	3.332	>1000.000	>33333.333
	H-(C)_mc-#79	>1000.000	>37500.000	978.508	36694.065
	H-(C)_mcValCitPABC-#79	0.212	9.528	351.392	15383.462
	H-(C)_mc-#115	0.21	-	-	-
30	H-A114C-(C114)_mc-#51	>1000.000	-	>1000.000	-
	H-A114C-(C114)_mc-#47	>1000.000	-	>1000.000	-
	H-A114C-(C114)_mc-#54	>1000.000	-	>1000.000	-
35	H-A114C-(C114)_mcValCitPABC-#47	383.667	-	445.014	-
	H-A114C-(C114)_mcValCitPABC-#54	0.372	-	362.213	-
	H-A114C-(C114)_mcValCitPABC-#26	>1000.000	-	>930.555	-
	H-A114C-(C114)_mc-#26	>1000.000	-	>1000.000	-
40	H-A114C-(C114)_mcValCitPABC-#36	>927.422	-	>1000.000	-
	H-A114C-(C114)_mcValCitPABC-#42	0.436	-	530.596	-
	H-A114C-(C114)_mc-#42	>727.245	-	567.735	-
45	H-(C)-mcValCitPABC-#54	0.275	-	471.905	-
	H-(C)_mcValCitPABCAmPeg3C2-#54	>1000.000	-	>1000.000	-
	H-(C) mcValCitPABCAmPeg6C2-#54	>1000.000	-	>1000.000	-
	H-(C)_mc-#47	>1000.000	-	>1000.000	-
50	H-(C)_MalPeg3C2-#54	>1651.007	-	>1651.007	-
	H-(C)_mc-#54	>1000.000	-	>1000.000	-
	H-(C)_mcValCitPABCAmPeg3C2-#47	>1000.000	-	>1000.000	-
55	H-(C)_MalPeg3C2-#47	>1000.000	-	>1000.000	-
	H-(C)_mcValCitPABCAmPeg3C2-#42	>1000.000	-	>1000.000	-
	H-(C)_mc-#41	>1000.000	-	>1000.000	-

EP 2 780 039 B9

(continued)

		DYT2		MDA-MB-468	
	ADC-Linker-Payload #	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
5	H-(C)_mcValCitPABCAmPeg3C2-#26	>1000.000	-	>1000.000	-
	H-(C)_mcValCitPABCAmPeg6C2-#47	>1000.000	-	>1000.000	-
10	H-(C)_MalPeg3C2-#42	9.675	-	358.435	-
	H-(C)_mcValCitPABCAmPeg6C2-#26	>1000.000	-	>1000.000	-
	H-(C)_mcValCitPABCAmPeg6C2-#42	>1000.000	-	>1000.000	-
	H-(C)_MalPeg6C2-#54	>1731.544	-	>1731.544	-
15	H-(C)_MalPeg6C2-#47	>1651.007	-	>1651.007	-
	H-(C)_MalPeg6C2-#26	>1000.000	-	>1000.000	-
	H-(C)_MalPeg6C2-#42	5.705	-	>642.029	-
20	H-(C)_mc-#36	>1000.000	-	>1000.000	-
	H-(C)_mcValCitPABC-#60	>699.241	-	>544.495	-
	H-(C)_MalPeg3C2-#26	>1000.000	-	>1000.000	-
	H-(C)_mcValCitPABCAmPeg3C2-#36	>1000.000	-	> 1000.000	-
25	H-A114C-(C114) _mcValCitPABCAmPeg3C2-#36	>1000.000	-	> 1000.000	-
	H-A114C-(C114)_MalPeg6C2-#54	>1000.000	-	>1000.000	-
30	H-(C)_MalPeg3C2-#60	>1000.000	-	>1000.000	-
	H-(C)_MalPeg6C2-#60	>1000.000	-	>1000.000	-
	H-(C)_MalPeg6C2-#41	>1000.000	-	>1000.000	-
	H-(C)-mc-#69	>71.831	-	>899.249	-
35	H-(C)_MalPeg3C2-#36	>1000.000	-	>1000.000	-
	H-(C)_mcValCitPABCAmPeg6C2-#36	>1000.000	-	>1000.000	-
	H-(C)_MalPeg6C2-#36	>1000.000	-	>1000.000	-
40	H-(C)_mcValCitPABCAmPeg3C2-#41	>1000.000	-	>1000.000	-
	H-(C)-MalPeg3C2-#41	>69.685	-	>1000.000	-
	H-(C)_mcValCitPABCAmPeg6C2-#60	>1000.000	-	>1000.000	-
	H-A114C-(C114)_mc-#66	>1000.000	-	>1000.000	-
45	H-L398C+L443C-(C398+C443)_ mcValCitPABC-#54	0.463	-	801.354	-
	H-K392C+L443C-(C392+C443)_ mcValCitPABC-#54	<0.171	-	565.01	-
50	H-L443C-(C443)_mcValCitPABC-#54	0.371	-	500.958	-
	H-L398C+V422C-(C398+C422)_ mcValCitPABC-#54	0.48	-	610.884	-
	H-(C)_mc-#44	>1000.000	-	>1000.000	-
55	H-(C)_Mal-PEG3C2-#45	>1000.000	-	>1000.000	-
	H-(C)_ 2AcAmPeg6C2-#66	>1000.000	-	>1000.000	-

EP 2 780 039 B9

(continued)

		DYT2		MDA-MB-468	
	ADC-Linker-Payload #	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
5	H-(C)-Mal-PEG6C2-#45	>1000.000	-	>1000.000	-
	H-(C)_mc-#79	>1000.000	-	978.508	-
10	H-(C)_MalPeg3C2-#44	>1000.000	-	>1000.000	-
	H-(C)-mcValCitPABC-#70	0.116	-	547.953	-
	H-(C)-MalPeg6C2-#44	>1000.000	-	>1000.000	-
15	H-A114C-(C114)_mcValCitPABC-#69	0.083	-	>1000.000	-
	H-(C)-mcValCitPABC-#79	0.212	-	351.392	-
	H-A114C-(C114)_mcValCitPABC-#79	0.199	-	472.593	-
	H-(C)-mcValCitPABC-#44	0.248	-	>1000.000	-
20	H-A114C-(C114)_mcValCitPABC-#88	>1000.000	-	>1000.000	-
	H-(C)-mcValCitPABC-#69	0.098	-	>1000.000	-
	H-(C)_ 2AcAmCapValCitPABC-#66	>1000.000	-	>1000.000	-
25	H-A114C-(C114)_mcValCitPABC-#45	2.37	-	>968.025	-
	H-A114C-(C114)_mcValCitPABC-#34	>1000.000	-	>1000.000	-
	H-A114C-(C114)_mc-#45	>1000.000	-	>1000.000	-
	H-A114C-(C114)_mc-#70	>1000.000	-	>1000.000	-
30	H-(C)_mcValCitPABC-#112	0.185	-	>563.999	-
	H-(C)-Mal-PEG6C2-#69	0.963	-	748.275	-
	H-Q347C-(C347)_mcValCitPABC-#69	0.094	-	>1000.000	-
35	H-Y373C-(C373)_mcValCitPABC-#69	0.156	-	>1000.000	-
	H-E388C-(C388)_mcValCitPABC-#69	0.117	-	>1000.000	-
	H-N421C-(C421)_mcValCitPABC-#69	0.162	-	>1000.000	-
	H-L443C-(C443)_mcValCitPABC-#69	0.1	-	>1000.000	-
40	H-L443C-(C443)_mcValCitPABC-#79	0.303	-	370.53	-
	H-A114C-(C114)_mcValCitPABC-#95	61.8	-	>1000.000	-
	H-A114C-(C114)_mcValCitPABC-#98	0.218	-	609.904	-
45	H-A114C-(C114)_MalPeg3C2-#69	>1000.000	-	>1000.000	-
	H-N297Q-(Q)_ AmPeg6C2-#42	>1000.000	-	>1000.000	-
	H-N297Q-(Q)_ AmPeg6C2-#54	>1000.000	-	>1000.000	-
	H-N297Q-(Q)_ AmPeg6C2-#47	>1000.000	-	>1000.000	-
50	H-N297Q-(Q)_ AmPeg6C2-#36	>1000.000	-	>1000.000	-
	H-N297Q-(Q)_ AmPeg6C2-#26	>1000.000	-	>1000.000	-
	H-N297Q-(Q)_ AmPeg6C2-#66	>1000.000	-	>1000.000	-
55	H-L443C-(C443)_ MalPeg6C2-#69	>1000.000	-	758.157	-
	H-Q347C-(C347)_ MalPeg6C2-#69	1.752	-	832.08	-
	H-E388C-(C388)_ MalPeg6C2-#69	6.883	-	>973.529	-

EP 2 780 039 B9

(continued)

		DYT2		MDA-MB-468	
	ADC-Linker-Payload #	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
5	H-N421C-(C421)_MalPeg6C2-#69	1.027	-	472.466	-
	H-E380C-(C380)_MalPeg6C2-#69	>65.641	-	873.254	-
10	H-L398C+L443C-(C398+C443)_MalPeg6C2-#69	0.827	-	846.418	-
	H-K392C+L443C-(C392+C443)_MalPeg6C2-#69	>32.438	-	804.407	-
15	H-kA111C-(kC111)_MalPeg6C2-#69	0.423	-	740.791	-
	H-kK183C-(kC183)_MalPeg6C2-#69	>1000.000	-	749.154	-
	H-kK207C-(kC207)_MalPeg6C2-#69	>138.618	-	586.857	-
20	H-A114C-(C114)_mcValCitPABC-#108	>1000.000	-	873.831	-
	H-A114C-(C114)_mcValCitPABC-#84	976.796	-	>1000.000	-
	H-A114C-(C114)_mcValCitPABC-#226	0.101	-	385.851	-
	H-A114C-(C114)_mc-#108	>1000.000	-	>1000.000	-
25	H-A114C-(C114)_mcValCitPABC-#117	0.107	-	469.882	-
	H-A114C-(C114)_mcValCitPABC-#115	0.142	-	989.147	-
	H-A114C-(C114)_MalPeg6C2-#98	355.331	-	>1000.000	-
	H-A114C-(C114)_MalPeg6C2-0#118	0.126	-	>865.455	-
30	H-A114C-(C114)_mcValCitPABC-0#118	0.215	-	>1000.000	-
	H-A114C-(C114)_mcValCitPABC-#80	0.432	-	>1000.000	-
	H-A114C-(C114)_mc-#117	0.107	-	>414.892	-
35	H-A114C-(C114)_mcValCitPABC-#232	38.422	-	959.259	-
	H-A114C-(C114)_MalPeg6C2-#230	>1000.000	-	>1000.000	-
	H-A114C-(C114)_MalPeg6C2-#117	0.179	-	>1000.000	-
	H-A114C-(C114)_mc-#115	0.238	-	>699.755	-
40	H-A114C-(C114)_mv-#115	0.322	-	>668.891	-
	H-A114C-(C114)_mb-#69	>1000.000	-	>1000.000	-
	H-A114C-(C114)_mv-#69	>1000.000	-	>1000.000	-
45	H-A114C-(C114)_mc-0#118	0.098	-	432.816	-
	H-(C)_mc-#117	<0.093	-	194.684	-
	H-(C)_MalPeg6C2-#117	<0.080	-	361.061	-
	H-(C)_mc-0#118	<0.073	-	541.542	-
50	H-(C)_MalPeg6C2-0#118	0.074	-	465.455	-
	H-A114C-(C114)_MalPeg6C2-#226	0.513	-	574.794	-
	H-A114C-(C114)_mc-#172	1.48	-	500.864	-
55	H-A114C-(C114)_mb-0#118	0.208	-	506.604	-
	H-A114C-(C114)_me-0#118	0.236	-	903.571	-
	H-A114C-(C114)_mcValCitPABC-#134	1.434	-	648.066	-

EP 2 780 039 B9

(continued)

		DYT2		MDA-MB-468	
	ADC-Linker-Payload #	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
5	H-A114C-(C114)_mc-#131	>1000.000	-	480.901	-
	H-A114C-(C114)_MalPeg6C2-#126	54.268	-	656.645	-
10	H-A114C-(C114)_MalPeg6C2-#123	>1000.000	-	543.693	-
	H-A114C-(C114)_mc-#126	>1000.000	-	749.49	-
	H-A114C-(C114)_mv-0#118	0.147	-	490.276	-
15	H-(C)_MalPeg6C2-#226	0.206	-	582.309	-
	H-(C)_mc-#226	0.219	-	477.622	-
	H-(C)_m(H2O)c-0#118	0.071	-	306.626	-
	H-(C)_Mal(H2O)Peg6C2-0#118	<0.059	-	441.766	-
20	H-(C)_Mal(H2O)Peg6C2-#69	0.203	-	459.502	-
	H-(C)_m(H2O)c-#69	0.315	-	740.334	-
	H-(C)_me-0#118	<0.061	-	455.314	-
25	H-(C)_mv-0#118	0.084	-	531.617	-
	H-(C)_mb-0#118	0.076	-	584.327	-
	H-A114C-(C114)_MalC6-#54	52.056	-	65.721	-
	H-A114C-(C114)_mc-#231	>1000.000	-	>1000.000	-
30	H-A114C-(C114)_MalC6-0#118	>1000.000	-	>1000.000	-
	H-(C)_Mal(H2O)Peg6C2-#115	0.095	-	698.101	-
	H-A114C-(C114)_mc-#158	0.164	-	329.554	-
35	H-A114C-(C114)_mcValCitPABC-#231	>1000.000	-	>1000.000	-
	H-(C) m(H2O)c-#115	<0.069	-	534.743	-
	H-A114C-(C114)_mc-#237	>1000.000	-	646.464	-
	H-A114C-(C114)_mc-#145	>1000.000	-	>1000.000	-
40	H-A114C-(C114)_MalPeg6C2-#145	>1000.000	-	>1000.000	-
	H-A114C-(C114)_mc-#162	0.201	-	676.764	-
	H-A114C-(C114)_MalC6Am-#151	0.469	-	75.696	-
45	H-(kK188)_ COPEG2C2ValCitPABC-#54	-	-	-	-
	H-(C)_mcValCitPABC-0#118	0.081	-	>1000.000	-
	H-A114C-(C114)_mcValCitPABC-#154	1.708	-	566.056	-
	H-A114C-(C114)_MalC6Am-#153	0.114	-	69.259	-
50	H-(C)_mcValCitPABC-#98	0.23	-	270.019	-
	H-A114C-(C114)_mcValCitPABC-#246	>1000.000	-	>1000.000	-
	H-H435A-(C)_mcValCitPABC-#54	0.208	-	339.77	-
55	H-M428L+N434S-(C)_mcValCitPABC-#70	0.069	-	380.393	-
	H-M428L+N434S-(C)_mcValCitPABC-#54	0.178	-	-	-

(continued)

	ADC-Linker-Payload #	DYT2		MDA-MB-468	
		IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)	IC ₅₀ (nM)	IC ₅₀ of Antibody (ng/mL)
5	H-E388C+N421C-(C388+C421)_mcValCitPABC-#54	1.033	-	826.243	-
10	H-Q347C+K392C-(C347+C392)_mcValCitPABC-#54	0.103	-	390.7	-
	H-L443C+kK183C-(C443+kC183)_mcValCitPABC-#54	<0.103	-	395.707	-
15	H-Q347C+kK183C-(C347+kC183)_mcValCitPABC-#54	<0.051	-	384.028	-
	H-Q347C-(C347)_mcValCitPABC-#54	2.89	-	393.412	-
	H-K392C+L443C-(C392+C443)_mc-#115	0.07	-	542.081	-
20	H-E388C+N421C-(C388+C421)_mc-#115	0.227	-	>1000.000	-
	H-Q347C+K392C-(C347+C392)_mc-#115	0.068	-	934.867	-
25	H-L443C+kK183C-(C443+kC183)_mc-#115	0.071	-	757.604	-
	H-Q347C+kK183C-(C347+kC183)_mc-#115	0.073	-	741.434	-
30	H-Q347C-(C347)_mc-#115	0.098	-	888.128	-
	H-kK183C-(kC183)_mcValCitPABC-#54	1.329	-	160.012	-
	H-E388C-(C388)_mcValCitPABC-#54	0.658	-	287.88	-
35	H-kK183C-(kC183)_mc-#115	0.179	-	775.698	-
	H-E388C-(C388)_mc-#115	0.124	-	958.96	-
	H-L443C-(C443)_mc-#115	0.108	-	451.857	-
	H-N421C-(C421)_mcValCitPABC-#54	0.601	-	263.107	-
40	H-N421C-(C421)_mc-#115	0.108	-	668.857	-
	H-A114C-(C114)_mcGly-#201	0.073	-	-	-

Table 22 - Selected pharmacokinetic values in rats for conjugates of the invention and selected pharmacokinetic values in rats for conjugates comprising MMAD, MMAE or MMAF. AUCs were calculated at a 0-last of 0-336 h except where noted.

	ADC	Dose	AUC (0-last) (µg*Hours/mL)		ADC/Ab Ratio
			ADC	Ab	
50	H(C)-#D54	3	3390 ¹	4560 ¹	74
		10	13200 ¹	16400 ¹	80
55		30	37800 ²	41700 ¹	91

(continued)

		AUC (0-last) (μg*Hours/mL)		
ADC	Dose	ADC	Ab	ADC/Ab Ratio
H(C)-#A69	10	14140	20840	68
	30	44040	63480	69
	100	146000	212000	69
H(C)-MalPEG6C2-MMAD	10	13300	15780	84
	30	56180	60280	93
	100	134400	146800	92
H(C)-mc-MMAD	10	7650	14500	53
	30	20700	43800	47
	100	58000	121000	48
H(C)-vc-MMAE	3	1080 ³	2950 ³	37
	10	3930 ³	10600 ³	37
	30	13400 ³	18400 ³	-
H(C)-mc-MMAF	10	10700	24500	44
	30	32000	71500	45
	100	83600	176000	48
H(K)-MCC-DM1	3	3800	5200	73
	10	12800	16200	79
	30	39100	49600	79
¹ denotes a 0-last of 0-312 hours ² denotes a 0-last of 0-168 hours ³ denotes a 0-last of 0-96 hours				

Table 23 - Selected pharmacokinetic values in mice for conjugates of the invention and for conjugates comprising MMAD, MMAE or MMAF. AUCs were calculated at a 0-last of 0-336 h except where noted.

	ADC	Dose	AUC (0-last) ($\mu\text{g}\cdot\text{Hours/mL}$)		ADC/Ab Ratio
			ADC	Ab	
40	H(C)-#D44	3	1070 ¹	2720 ¹	39
	H(C)-#D70	3	2240	4890	46
45	H(C)-#D69	3	2490	4770	52
	H(C)-#A69	3	3594	5722	63
	H(C)-MalPEG6C2-MMAD	3	2641	5415	49
50	H(C)-mc-MMAD	3	3580	4970	72
	H(C)-vc-MMAE	3	1600	3290	49
	H(C)-mc-MMAF	3	3080	4800	64
¹ denotes a 0-last of 0-168 hours					

Table 24 - Data showing stability of conjugates prepared using ring-opened versus ring closed succinimide-based linkers.

Herceptin ADC		GSH stability (6d) (%loading remaining on day 6)	Mouse ADC AUC (ug*h/mL)	Mouse PK ADC/Ab
mc-#118	ring-closed	65%	2160	55%
	ring-opened	87%	3490	65%
MalPeg6C2-#118	ring-closed	82%	2010	70%
	ring-opened	100%	3000	77%
mc-#8261	ring-closed	51%	3590	52%
	ring-opened	96%	4470	73%
MalPeg6C2-#8261	ring-closed	61%	2950	72%
	ring-opened	104%	-	-
mc-#115	ring-closed	-	1930	58%
	ring-opened	-	2330	68%

Table 25A - Selected payloads and their methods of synthesis

Example	Prepared in the Same Manner as or Preparation Method	Purification Method	Quantity in mg (Yield)
#220	example #107	Method M	10.5 mg (43%)
#221	example #107	Method M	15.2 mg (76%)
#222	General procedure L	Method J*	14 mg (39%)
#223	General procedure L	Method J*	16.6 mg (42%)
#224	General procedure L	Method J*	18.8 mg (68%)
#225	General procedure L	Method J*	17.3 mg (64%)
#226	example #146	silica chromatography	354 mg (78%)
#227	General procedure L	Method J*	19.4 mg (77%)
#228	example #131	Method E1*	30 mg (51%)
#229	example #151	Method J*	16 mg (61%)
#230	General procedure L	Method J*	69 mg (42%)
#231	General procedure L*	Method J*	4.2 mg (44%)
#232	example #98	Method J*	113 mg (50%)
#233	example #146	silica chromatography	88 mg (82%)

(continued)

Example	Prepared in the Same Manner as or Preparation Method	Purification Method	Quantity in mg (Yield)
#234	General procedure L	Method J*	8.5 mg (78%)
#235	General procedure L*	Method J*	27 mg (77%)
#236	example #131	achiral	3.7 mg (14%)
#237	example #145	silica chromatography	38.6 mg (93%)
#238	example #145	silica chromatography	419mg (81%)
#239	example #130	silica chromatography	315 mg (48%)
#240	example #142	Method E1*	6 mg (20%)
#241	example #142	Method E1*	6 mg (20%)
#242	example #145	Method J*	8 mg (10%)
#243	example #145	Method J*	12 mg (22%)
#244	example #145	Method J*	9.6 mg (20%)
#245	General procedure M	medium pressue	38 mg (55%)
#246	example #130	medium pressue	78 mg (80%)
#247	example #178	Method M*	10.5 mg (57%)

Table 25B - Selected payloads and their IUPAC name and characterization data

Example	IUPACNAME	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) unless indicated otherwise
#220	2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2R,4S)-4-carboxy-1-phenylpentan-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	HPLC (Protocol CB): <i>m/z</i> 746.51 [M+H ⁺] (1.57 minutes)
#221	2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-(bicyclo[1.1.1]pent-1-ylamino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	HPLC (Protocol DB): <i>m/z</i> 622.42 [M+H ⁺] (1.57 minutes)
#222	2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(1R)-2-methoxy-2-oxo-1-(1-phenylcyclopropyl)ethyl]amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol H): <i>m/z</i> 744.9 [M+H ⁺] (2.19 minutes). ¹ H NMR (400 MHz, CDCl ₃) δ 7.16-7.22 (m), 6.99-7.08 (m), 6.42-6.51 (m), 6.10-6.17 (m), 4.87-4.96 (m), 4.65-4.79 (m), 4.27-4.36 (m), 4.04-4.27 (m), 3.95-4.02 (m), 3.87-3.93 (m), 3.64-3.84 (m), 3.44-3.57 (m), 3.22-3.42 (m), 3.08-3.17 (m), 2.98-3.07 (m), 2.90-2.93 (m), 2.85-2.89 (m), 2.53-2.57 (m), 2.35-2.51 (m), 2.19-2.27 (m), 2.02-2.16 (m), 1.93-2.00 (m), 1.77-1.90 (m), 1.57-1.70 (m), 1.35-1.52 (m), 1.26-1.33 (m), 1.19-1.25 (m), 1.11-1.16 (m), 1.03-1.11 (m), 0.83-1.02 (m), 0.79-0.88 (m).

(continued)

Example	IUPACNAME	Mass spectrum: LC-MS or HPLC observed <i>m/z</i> and retention time in minutes: ¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) unless indicated otherwise
#223	2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(1S)-2-methoxy-2-oxo-1-(1-phenylcyclopropyl)ethyl]amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol H): <i>m/z</i> 744.4 [M+H ⁺] (2.17 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 8.19-8.24 (m), 7.87-7.92 (m), 7.20-7.38 (m), 4.71-5.04 (m), 4.61-4.71 (m), 4.47-4.52 (m), 4.38-4.44 (m), 4.05-4.13 (m), 3.99-4.04 (m), 3.90-3.98 (m), 3.64-3.73 (m), 3.52-3.60 (m), 3.46-3.52 (m), 3.37-3.46 (m), 3.35-3.37 (m), 3.29-3.35 (m), 3.24-3.28 (m), 3.15-3.19 (m), 3.08-3.14 (m), 3.01-3.06 (m), 2.84-2.87 (m), 2.43-2.63 (m), 1.96-2.20 (m), 1.68-1.95 (m), 1.60-1.66 (m), 1.52-1.57 (m), 1.33-1.44 (m), 1.27-1.32 (m), 1.23-1.27 (m), 1.12-1.17 (m), 1.04-1.10 (m), 0.96-1.03 (m), 0.90-0.96 (m), 0.82-0.90 (m).
#224	2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1R)-1-[(7R)-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]-2-methoxy-2-oxoethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol H): <i>m/z</i> 730.8 [M+H ⁺] (2.15 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 7.09-7.18 (m), 6.95-7.08 (m), 4.88-4.93 (m), 4.75-4.85 (m), 4.72-4.74 (m), 4.62-4.70 (m), 4.50-4.59 (m), 4.09-4.16 (m), 3.96-4.06 (m), 3.82-3.90 (m), 3.67-3.76 (m), 3.58-3.67 (m), 3.58-3.67 (m), 3.45-3.54 (m), 3.33-3.44 (m), 3.33-3.44 (m), 3.28-3.33 (m), 3.10-3.27 (m), 3.00-3.10 (m), 2.93-3.00 (m), 2.75-2.78 (m), 2.56-2.65 (m), 2.36-2.45 (m), 2.17-2.35 (m), 1.94-2.16 (m), 1.67-1.94 (m), 1.48-1.67 (m), 1.27-1.33 (m), 1.23-1.27 (m), 1.17-1.26 (m), 1.08-1.17 (m), 0.98-1.07 (m), 0.86-0.98 (m), 0.77-0.84 (m).
#225	2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-[(7S)-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]-2-methoxy-2-oxoethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol H): <i>m/z</i> 730.9 [M+H ⁺] (2.19 minutes)
#226	N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q): <i>m/z</i> 732.4 [M+H ⁺] (1.24 minutes). ¹ H NMR δ 8.47-8.53 (m), 8.24-8.29 (m), 7.81-7.91 (m), 7.14-7.27 (m), 4.54-4.75 (m), 4.44-4.54 (m), 3.94-4.02 (m), 3.72-3.78 (m), 3.61-3.69 (m), 3.28-3.36 (m), 3.14-3.28 (m), 2.99-3.08 (m), 2.81-2.97 (m), 2.29-2.57 (m), 2.16-2.29 (m), 1.91-2.16 (m), 1.60-1.87 (m), 1.35-1.53 (m), 0.99-1.33 (m), 0.80-0.99 (m), 0.71-0.80 (m).
#227	2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-[(7R)-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]-2-methoxy-2-oxoethyl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q): <i>m/z</i> 730.4 [M+H ⁺] (1.29 minutes)

(continued)

Example	IUPACNAME	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) unless indicated otherwise
#228	N,N,2-trimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	HPLC (Protocol A*): <i>m/z</i> 746.5 [M+H ⁺] (7.103 minutes)
#229	N,N,2-trimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1S)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 732.3 [M+H ⁺] (0.70 minutes)
#230	2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(R)-carboxy(1-Phenylcyclopropyl)methyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	HPLC (Protocol G): <i>m/z</i> 730.4 [M+H ⁺] (1.25 minutes)
#231	difluoro {2-methylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(3R,4R,7S)-7-benzyl-15-{2-[(3,5-dimethyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}-4-methyl-5,8,13-trioxo-2-oxa-6,9,12-triazapentadecan-3-yl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamidato}boron	LC-MS (Protocol Q1): <i>m/z</i> 1020.6 [M+H ⁺] (0.83 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 8.19-8.23 (m), 7.99-8.07 (m), 7.93-7.98 (m), 7.41-7.45 (m), 7.23-7.31 (m), 7.17-7.22 (m), 7.00-7.04 (m), 6.32-6.37 (m), 6.20-6.24 (m), 4.72-4.93 (m), 4.61-4.69 (m), 4.05-4.17 (m), 3.88-3.93 (m), 3.72-3.81 (m), 3.63-3.70 (m), 3.56-3.62 (m), 3.48-3.56 (m), 3.25-3.44 (m), 3.16-3.25 (m), 3.09-3.14 (m), 2.98-3.09 (m), 2.81-2.90 (m), 2.54-2.67 (m), 2.39-2.53 (m), 2.09-2.32 (m), 1.75-1.97 (m), 1.60-1.69 (m), 1.52-1.59 (m), 1.32-1.44 (m), 1.28-1.32 (m), 1.16-1.21 (m), 0.98-1.09 (m), 0.86-0.98 (m), 0.79-0.90 (m).
#232	2-methyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q): <i>m/z</i> 769.3 [M+H ⁺] (1.34 minutes). ¹ H NMR δ 9.04-9.17 (m), 8.88-8.94 (m), 8.70-8.86 (m), 8.62-8.67 (m), 7.79-7.84 (m), 7.76-7.79 (m), 7.65-7.69 (m), 7.61-7.64 (m), 7.20-7.31 (m), 7.12-7.20 (m), 5.44-5.52 (m), 5.34-5.46 (m), 4.70-4.78 (m), 4.56-4.67 (m), 4.47-4.54 (m), 3.94-4.04 (m), 3.76-3.83 (m), 3.52-3.61 (m), 3.36-3.52 (m), 3.28-3.35 (m), 3.10-3.27 (m), 2.93-3.08 (m), 2.77-2.80 (m), 2.64-2.70 (m), 2.35-2.54 (m), 2.09-2.34 (m), 1.96-2.09 (m), 1.54-1.88 (m), 1.38-1.52 (m), 1.18-1.36 (m), 1.03-1.13 (m), 0.81-1.01 (m), 0.68-0.81 (m).

(continued)

Example	IUPACNAME	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) unless indicated otherwise
#233	methyl N-((2R,3R)-3-[(2S)-1-((3R,4S,5S)-4-[(N-[(3-aminooxetan-3-yl)carbonyl]-L-valyl])(methyl)amino)-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)-L-phenylalaninate	LC-MS (Protocol Q): <i>m/z</i> 732.2 [M+H ⁺] (1.28 minutes). ¹ H NMR δ 8.48- 8.53 (m), 8.22-8.28 (m), 7.80-7.92 (m), 7.14-7.28 (m), 4.74-4.79 (m), 4.54-4.72 (m), 4.43-4.52 (m), 4.24-4.35 (m), 4.07-4.12 (m), 3.94-4.02 (m), 3.72-3.78 (m), 3.61-3.69 (m), 3.48-3.58 (m), 3.40-3.48 (m), 3.11-3.35 (m), 2.98-3.11 (m), 2.75-2.97 (m), 2.64-2.69 (m), 2.30-2.55 (m), 2.17-2.28 (m), 2.03-2.14 (m), 1.92-2.02 (m), 1.59-1.87 (m), 1.35-1.54 (m), 1.21-1.33 (m), 1.112-1.20 (m), 1.00-1.09 (m), 0.70-0.98 (m).
#234	2-methylalanyl-N-((3R,4S,5S)-1-[(2S)-2-((3R,4R,7S, 12S)-7-benzyl-14-[3-chloro-4-(propan-2-yloxy)phenyl]-4-methyl-12-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)benzyl]-5,8,14-trioxo-2,9-dioxo-6,13-diazatetr adecan-3-yl]pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N-methyl-L-valinamide	LC-MS (Protocol H): <i>m/z</i> 589.9 [M+H ²⁺] (2.29 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 8.55-8.61 (m), 8.40- 8.45 (m), 8.34-8.39 (m), 8.23-8.28 (m), 8.14-8.19 (m), 7.84-7.95 (m), 7.79-7.84 (m), 7.71-7.77 (m), 7.61-7.68 (m), 7.46-7.52 (m), 7.34-7.40 (m), 7.09-7.27 (m), 7.03-7.09 (m), 4.77-4.90 (m), 4.58-4.77 (m), 4.43-4.55 (m), 4.17-4.33 (m), 4.07-4.16 (m), 4.00-4.07 (m), 3.79-3.85 (m), 3.58-3.70 (m), 3.44-3.52 (m), 3.12-3.40 (m), 2.80-3.12 (m), 2.64-2.71 (m), 2.62-2.64 (m), 2.38-2.47 (m), 2.00-2.33 (m), 1.66-2.00 (m), 1.46-1.63 (m), 1.29-1.44 (m), 1.07-1.16 (m), 0.91-1.07 (m), 0.79-0.87 (m).
#235	2-methylalanyl-N-[(3R,4S,5S)-1-((2S)-2-[(1R,2R)-3-[(2S)-1-[[4-(5-fluoro-1,3-benzothiazol-2-yl)-2-methylphenyl]amino}-1-oxo-3-phenylpropan-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 944.3 [M+H ⁺] (0.84 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 8.54-8.59 (m), 8.29- 8.33 (m), 7.87-8.02 (m), 7.80-7.87 (m), 7.68-7.74 (m), 7.62-7.67 (m), 7.20-7.38 (m), 4.98-5.06 (m), 4.84-4.97 (m), 4.66-4.79 (m), 4.61-4.66 (m), 4.13-4.19 (m), 3.98-4.04 (m), 3.91-3.96 (m), 3.79-3.85 (m), 3.64-3.73 (m), 3.38-3.56 (m), 3.34-3.38 (m), 3.28-3.34 (m), 3.17-3.27 (m), 3.12-3.16 (m), 3.03-3.11 (m), 2.99-3.03 (m), 2.86-2.87 (m), 2.80-2.82 (m), 2.69-2.71 (m), 2.31-2.54 (m), 2.27-2.31 (m), 2.06-2.27 (m), 1.88-2.00 (m), 1.74-1.88 (m), 1.64-1.74 (m), 1.59-1.64 (m), 1.50-1.59 (m), 1.27-1.48 (m), 1.19-1.26 (m), 1.11-1.16 (m), 1.06-1.11 (m), 0.96-1.05 (m), 0.86-0.94 (m), 0.77-0.83 (m).
#236	1,2-dimethyl-D-prolyl-N-[(3R,4S,5S)-3-methoxy-1-((2S)-2-[(1R,2R)-1-methoxy-3-[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 758.3 [M+H ⁺] (0.74 minutes)

(continued)

Example	IUPACNAME	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ¹ H NMR (400 MHz, DMSO-d ₆) unless indicated otherwise
#237	N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 771.2 [M+H ⁺] (0.67 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 7.95-7.96 (m), 7.48-7.55 (m), 7.45-7.48 (m), 7.26-7.31 (m), 6.94-7.18 (m), 5.45-5.49 (m), 5.19-5.22 (m), 5.11-5.17 (m), 4.97-5.00 (m), 4.78-4.87 (m), 4.68-4.77 (m), 4.59-4.64 (m), 4.27-4.34 (m), 3.99-4.16 (m), 3.84-3.92 (m), 3.78-3.82 (m), 3.62-3.78 (m), 3.49-3.59 (m), 3.41-3.49 (m), 3.20-3.41 (m), 2.99-3.20 (m), 2.95-2.98 (m), 2.82-2.86 (m), 2.77-2.79 (m), 2.62-2.68 (m), 2.28-2.49 (m), 2.19-2.27 (m), 1.98-2.16 (m), 1.56-1.91 (m), 1.31-1.49 (m), 1.19-1.30 (m), 1.15-1.19 (m), 1.06-1.13 (m), 0.88-1.03 (m), 0.79-0.87 (m).
#238	N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-(prop-2-en-1-yloxy)propan-2-yl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 758.84 [M+H ⁺] (0.71 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 7.15-7.32 (m), 5.86-6.00 (m), 5.28-5.40 (m), 5.17-5.27 (m), 4.97-5.04 (m), 4.69-4.91 (m), 4.57-4.69 (m), 4.05-4.21 (m), 3.91-3.96 (m), 3.79-3.88 (m), 3.71-3.78 (m), 3.62-3.70 (m), 3.25-3.56 (m), 3.15-3.24 (m), 3.08-3.14 (m), 2.90-3.02 (m), 2.79-2.87 (m), 2.42-2.52 (m), 2.20-2.38 (m), 2.12-2.20 (m), 2.03-2.12 (m), 2.00-2.03 (m), 1.71-2.1.96 (m), 1.33-1.70 (m), 1.23-1.32 (m), 1.17-1.23 (m), 1.12-1.17 (m), 1.05-1.10 (m), 0.94-1.05 (m), 0.82-0.89 (m).
#239	2-methyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-tert-butoxy-1-oxo-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q): <i>m/z</i> 786.6 [M+H ⁺] (1.46 minutes). ¹ H NMR δ 8.35-8.42 (m), 8.21-8.31 (m), 8.14-8.20 (m), 7.15-7.29 (m), 4.66-4.76 (m), 4.53-4.65 (m), 4.46-4.53 (m), 4.32-4.42 (m), 4.07-4.15 (m), 3.96-4.04 (m), 3.76-3.82 (m), 3.41-3.61 (m), 3.30-3.38 (m), 3.16-3.30 (m), 3.08-3.15 (m) 2.99-3.08 (m), 2.92-2.96 (m), 2.78-2.90 (m), 2.63-2.78 (m), 2.37-2.58 (m), 2.18-2.36 (m), 2.03-2.13 (m), 1.89-2.01 (m), 1.64-1.88 (m), 1.35-1.62 (m), 1.31-1.35 (m), 1.17-1.31 (m), 1.03-1.14 (m), 0.70-1.01 (m).
#240	N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-[(1H-1,2,3-triazol-4-ylmethyl)amino]propan-2-yl]amino)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 798.2 [M+H ⁺] (0.66 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 8.43-8.49 (m), 7.50-7.53 (m), 7.42-7.48 (m), 7.06-7.20 (m), 4.21-4.83 (m), 3.95-4.13 (m), 3.76-3.88 (m), 3.53-3.67 (m), 3.16-3.47 (m), 3.08-3.15 (m) 3.00-3.16 (m), 2.77-2.90 (m), 2.70-2.73 (m), 2.62-2.69 (m), 2.45-2.58 (m), 2.34-2.41 (m), 2.21-2.29 (m), 2.12-2.21 (m), 1.55-2.09 (m), 1.39-1.54 (m), 1.16-1.36 (m), 1.04-1.14 (m), 0.85-0.99 (m), 0.73-0.80 (m), 0.00-0.02 (m).

(continued)

Example	IUPACNAME	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ¹ H NMR (400 MHz, DMSO-d ₆) unless indicated otherwise
#241	N,2-dimethylalanyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 755.1 [M+H ⁺] (0.69 minutes). ¹ H NMR (400 MHz, CD ₃ OD) δ 8.36-8.67 (m), 7.26-7.50 (m), 7.10-7.26 (m), 5.13-5.17 (m), 4.95-4.99 (m), 4.67-4.84 (m), 4.61-4.66 (m), 4.50-4.60 (m), 3.77-4.12 (m), 3.69-3.75 (m), 3.56-3.66 (m), 3.44-3.54 (m), 3.19-3.44 (m), 3.12-3.19 (m), 3.03-3.12 (m), 2.74-2.94 (m), 2.37-2.60 (m), 2.14-2.36 (m), 1.60-2.13 (m), 1.47-1.59 (m), 1.19-1.40 (m), 1.11-1.16 (m), 0.88-1.11 (m), 0.75-0.84 (m), 0.02-0.06 (m).
#242	N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(1H-imidazol-4-yl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 722.95 [M+H ⁺] (0.52 minutes) ¹ H NMR (400 MHz, CD ₃ OD) δ 8.78-8.86 (m), 8.71-8.73 (m), 7.96-8.00 (m), 7.34-7.40 (m), 4.74-4.91 (m), 4.67-4.71 (m), 4.55-4.63 (m), 4.13-4.22 (m), 4.04-4.10 (m), 3.97-4.01 (m), 3.84-3.92 (m), 3.66-3.82 (m), 3.42-3.64 (m), 3.26-3.42 (m), 3.11-3.21 (m), 2.90-2.92 (m), 2.83-2.84 (m), 2.59-2.64 (m), 2.48-2.56 (m), 2.32-2.41 (m), 2.09-2.24 (m), 1.99-2.08 (m), 1.68-1.95 (m), 1.59-1.66 (m), 1.51-1.58 (m), 1.35-1.45 (m), 1.22-1.26 (m), 1.17-1.21 (m), 0.95-1.12 (m), 0.83-0.89 (m).
#243	N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-3-(4-hydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 748.2 [M+H ⁺] (0.52 minutes) ¹ H NMR (400 MHz, CD ₃ OD), δ 8.91-8.99 (m), 8.42-8.46 (m), 8.15-8.20 (m), 7.92-8.01 (m), 7.00-7.10 (m), 6.64-6.74 (m), 5.22-5.26 (m), 5.06-5.09 (m), 4.79-4.95 (m), 4.65-4.79 (m), 4.59-4.65 (m), 4.12-4.21 (m), 4.05-4.12 (m), 3.91-3.99 (m), 3.84-3.90 (m), 3.67-3.79 (m), 3.60-3.66 (m), 3.39-3.57 (m), 3.34-3.39 (m), 3.29-3.34 (m), 3.12-3.27 (m), 2.98-3.00 (m), 2.78-2.88 (m), 2.61-2.65 (m), 2.55-2.57 (m), 2.46-2.53 (m), 2.10-2.36 (m), 1.68-1.96 (m), 1.61-1.68 (m), 1.55-1.60 (m), 1.35-1.53 (m), 1.19-1.24 (m), 1.14-1.18 (m), 1.08-1.13 (m), 0.98-1.08 (m), 0.84-0.92 (m).
#244	N,2-dimethylalanyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(1R)-1-carboxy-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q1): <i>m/z</i> 718.4 [M+H ⁺] (0.66 minutes) ¹ H NMR (400 MHz, CD ₃ OD), δ 7.87-7.92 (m), 7.71-7.76 (m), 7.46-7.53 (m), 7.40-7.46 (m), 7.19-7.33 (m), 4.81-4.96 (m), 4.68-4.77 (m), 4.60-4.65 (m), 4.47-4.53 (m), 4.01-4.17 (m), 3.94-3.98 (m), 3.81-3.86 (m), 3.68-3.76 (m), 3.56-3.64 (m), 3.40-3.50 (m), 3.36-3.40 (m), 3.26-3.35 (m), 3.23-3.26 (m), 3.16-3.22 (m), 3.12-3.16 (m), 2.94-3.06 (m), 2.91-2.93 (m), 2.86-2.88 (m), 2.41-2.66 (m), 2.32-2.41 (m), 1.97-2.23 (m), 1.85-1.97 (m), 1.71-1.85 (m), 1.62-1.68 (m), 1.50-1.61 (m), 1.37-1.46 (m), 0.98-1.14 (m), 0.85-0.92 (m).

(continued)

Example	IUPACNAME	Mass spectrum: LC-MS or HPLC observed m/z and retention time in minutes: ¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) unless indicated otherwise
#245	1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2S)-1-oxo-3-phenyl-1-(piperazin-1-yl)propan-2-yl]amino}propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q): <i>m/z</i> 835.0 [M+Na ⁺] (0.87 minutes) ¹ H NMR δ 9.58-9.69 (m), 8.84-9.16 (m), 8.69-8.77 (m), 8.54-8.60 (m), 8.44-8.50 (m), 8.32-8.42 (m), 8.25-8.30 (m), 7.13-7.31 (m), 7.00-7.01 (m), 4.97-5.06 (m), 4.88-4.97 (m), 4.57-4.75 (m), 4.45-4.57 (m), 3.84-4.45 (m), 3.62-3.84 (m), 3.40-3.62 (m), 3.13-3.33 (m), 2.77-3.10 (m), 2.67-2.75 (m), 2.47-2.57 (m), 2.38-2.45 (m), 1.92-2.35 (m), 1.58-1.88 (m), 1.37-1.55 (m), 1.22-1.32 (m), 0.97-1.06 (m), 0.84-0.97 (m), 0.73-0.81 (m).
#246	1,2-dimethyl-L-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(2S)-1-amino-3-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	LC-MS (Protocol Q): <i>m/z</i> 366.2 [M+H ²⁺] (0.91 minutes) ¹ H NMR δ 9.56-9.65 (m), 8.70-8.76 (m), 8.05-8.09 (m), 7.77-7.92 (m), 7.14-7.30 (m), 4.60-4.72 (m), 4.46-4.57 (m), 3.61-4.39 (m), 3.41-3.61 (m), 3.11-3.33 (m), 2.97-3.09 (m), 2.79-2.94 (m), 2.63-2.74 (m), 2.38-2.56 (m), 2.13-2.37 (m), 1.93-2.13 (m), 1.45-1.89 (m), 1.21-1.32 (m), 1.09-1.14 (m), 1.03-1.08 (m), 0.84-0.95 (m), 0.73-0.80 (m).
#247	2-methyl-D-prolyl-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[2-(cyclohepta-2,4,6-trien-1-yl)ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide	HPLC (Protocol DB): <i>m/z</i> 700.51 [M+H ⁺] (2.56 minutes)

SEQUENCE LISTING

[0701]

<110> Pfizer Inc.
Doroski, Matthew

<120> CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF

<130> PC71886

<160> 26

<170> PatentIn version 3.5

<210> 1

<211> 106

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<222> (45)..(45)

<223> xaa at position 45 is Ala or Val

<220>

EP 2 780 039 B9

<221> MISC_FEATURE

<222> (83)..(83)

<223> xaa at position 83 is Leu or Val

5 <400> 1

10

15

20

25

30

35

40

45

50

55

```

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
1      5      10      15

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
20      25      30

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Xaa Leu Gln Ser
35      40      45

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
50      55      60

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
65      70      75      80

His Lys Xaa Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
85      90      95

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100      105

```

<210> 2

<211> 106

<212> PRT

<213> Homo sapiens

<400> 2

EP 2 780 039 B9

	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	
	1				5					10					15		
5	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	
				20					25					30			
10	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Val	Leu	Gln	Ser	
			35					40					45				
15	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	
		50					55					60					
20	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	
	65					70					75					80	
25	His	Lys	Leu	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	
					85					90					95		
30	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys							
				100					105								
	<210> 3																
	<211> 106																
	<212> PRT																
	<213> Homo sapiens																
	<400> 3																
35	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	
	1				5					10					15		
40	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	
				20					25					30			
45	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	
			35					40					45				
50	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	
		50					55					60					
55	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	
	65					70					75					80	
	His	Lys	Leu	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	
					85					90					95		
	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys							

EP 2 780 039 B9

100

105

5 <210> 4
 <211> 106
 <212> PRT
 <213> Homo sapiens

10 <400> 4

1	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln
					5					10					15	
15	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr
				20					25					30		
20	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser
			35					40					45			
25	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr
		50					55					60				
30	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys
	65					70					75					80
35	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro
					85					90					95	
40	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys						
				100					105							

40 <210> 5
 <211> 112
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic peptide sequence

45 <400> 5

50

55

EP 2 780 039 B9

	Glu	Leu	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ser	Ser	Gln	Ser	Leu	Leu	His	Thr
				20					25					30		
10	Tyr	Gly	Ser	Pro	Tyr	Leu	Asn	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Ser
			35					40					45			
15	Pro	Lys	Leu	Leu	Ile	Tyr	Lys	Val	Ser	Asn	Arg	Phe	Ser	Gly	Val	Pro
		50					55					60				
20	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile
	65					70					75					80
25	Ser	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Val	Tyr	Phe	Cys	Ser	Gln	Gly
					85					90					95	
30	Thr	His	Leu	Pro	Tyr	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys
				100					105					110		

<210> 6

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide sequence

<400> 6

EP 2 780 039 B9

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asn	Tyr	
				20					25					30			
10	Trp	Met	Ser	Trp	Val	Arg	Gln	Ser	Pro	Glu	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
15	Ser	Glu	Ile	Arg	Leu	Arg	Ser	Asp	Asn	Tyr	Ala	Thr	His	Tyr	Ala	Glu	
		50					55					60					
20	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	
	65					70					75					80	
25	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Gly	Ile	Tyr	
					85					90					95		
30	Tyr	Cys	Lys	Thr	Tyr	Phe	Tyr	Ser	Phe	Ser	Tyr	Trp	Gly	Gln	Gly	Thr	
				100					105					110			
35	Leu	Val	Thr	Val	Ser	Ser											
				115													
40	<210> 7																
	<211> 219																
	<212> PRT																
	<213> Artificial Sequence																
45	<220>																
	<223> Synthetic peptide sequence																
50	<400> 7																

EP 2 780 039 B9

	Glu	Leu	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	
	1				5					10					15		
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ser	Ser	Gln	Ser	Leu	Leu	His	Thr	
				20					25					30			
10	Tyr	Gly	Ser	Pro	Tyr	Leu	Asn	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Ser	
			35					40					45				
15	Pro	Lys	Leu	Leu	Ile	Tyr	Lys	Val	Ser	Asn	Arg	Phe	Ser	Gly	Val	Pro	
		50					55					60					
20	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	
	65					70					75					80	
25	Ser	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Val	Tyr	Phe	Cys	Ser	Gln	Gly	
					85					90					95		
30	Thr	His	Leu	Pro	Tyr	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys	
				100					105					110			
35	Arg	Thr	Val	Ala	Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	
			115					120					125				
40	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	
		130					135					140					
45	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	
	145					150					155					160	
50	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	
					165					170					175		
55	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	
				180					185					190			
60	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	
			195					200					205				
65	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys						
		210					215										

<210> 8

<211> 448

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide sequence

<400> 8

5

10

15

20

25

30

35

40

45

50

55

EP 2 780 039 B9

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Asn	Tyr	
				20					25					30			
10	Trp	Met	Ser	Trp	Val	Arg	Gln	Ser	Pro	Glu	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
15	Ser	Glu	Ile	Arg	Leu	Arg	Ser	Asp	Asn	Tyr	Ala	Thr	His	Tyr	Ala	Glu	
		50					55					60					
20	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	
	65					70					75					80	
25	Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Gly	Ile	Tyr	
					85					90					95		
30	Tyr	Cys	Lys	Thr	Tyr	Phe	Tyr	Ser	Phe	Ser	Tyr	Trp	Gly	Gln	Gly	Thr	
				100					105					110			
35	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	
			115					120					125				
40	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	
		130					135					140					
45	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	
	145					150					155					160	
50	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	
					165					170					175		
55	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	
				180					185					190			
60	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	
			195					200					205				
65	Asn	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	
		210					215					220					
70	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	
	225					230					235					240	

EP 2 780 039 B9

	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	
					245					250					255		
5	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	
				260					265					270			
10	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	
			275					280					285				
15	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	
		290					295					300					
20	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	
	305					310					315					320	
25	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	
					325					330					335		
30	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	
				340					345					350			
35	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	
			355					360					365				
40	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	
		370					375					380					
45	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	
	385					390					395					400	
50	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	
					405					410					415		
55	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	
				420					425					430			
60	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	
			435					440					445				
65	<210> 9																
70	<211> 122																
75	<212> PRT																
80	<213> Artificial Sequence																
85	<220>																
90	<223> Synthetic peptide sequence																
95	<400> 9																

EP 2 780 039 B9

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn
 20 25 30
 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Thr Val Ser Ser Gly Gly Ser Tyr Ile Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Gln Gly Thr Thr Ala Leu Ala Thr Arg Phe Phe Asp Val Trp
 100 105 110
 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120
 <210> 10
 <211> 107
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Synthetic peptide sequence
 <400> 10
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
 20 25 30
 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Ser Ala Ser Tyr Arg Ser Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

EP 2 780 039 B9

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His His Tyr Ser Ala Pro Trp
85 90 95

5 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 11

<211> 452

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide sequence

15

<400> 11

20

25

30

35

40

45

50

55

EP 2 780 039 B9

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Arg	Asn	
				20					25					30			
10	Gly	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
15	Ala	Thr	Val	Ser	Ser	Gly	Gly	Ser	Tyr	Ile	Tyr	Tyr	Ala	Asp	Ser	Val	
		50					55					60					
20	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr	
	65					70					75					80	
25	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
30	Ala	Arg	Gln	Gly	Thr	Thr	Ala	Leu	Ala	Thr	Arg	Phe	Phe	Asp	Val	Trp	
				100					105					110			
35	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	
			115					120					125				
40	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	
		130					135					140					
45	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	
	145					150					155					160	
50	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	
				165						170					175		
55	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	

EP 2 780 039 B9

	180	185	190
5	Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn 195 200 205		
10	His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser 210 215 220		
15	Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 225 230 235 240		
20	Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255		
25	Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270		
30	His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285		
35	Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 290 295 300		
40	Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 305 310 315 320		
45	Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 325 330 335		
50	Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350		
55	Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val 355 360 365		
	Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380		
	Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 385 390 395 400		
	Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 405 410 415		
	Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 420 425 430		

EP 2 780 039 B9

Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Cys
435 440 445

5 Ser Pro Gly Lys
450

<210> 12

<211> 213

10 <212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide sequence

15

<400> 12

20

25

30

35

40

45

50

55

EP 2 780 039 B9

	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asp	Val	Gly	Thr	Ala
				20					25					30		
10	Val	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
15	Tyr	Ser	Ala	Ser	Tyr	Arg	Ser	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
20	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	His	His	Tyr	Ser	Ala	Pro	Trp
					85					90					95	
30	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys	Thr	Val	Ala	Ala	Pro
				100					105					110		
35	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr
			115					120					125			
40	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys
		130					135					140				
45	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu
	145					150					155					160
50	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser
					165					170					175	
55	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala
				180					185					190		
	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe
			195					200					205			
	Asn	Arg	Gly	Glu	Cys											
		210														
55	<210>	13														
	<211>	1356														
	<212>	DNA														
	<213>	Artificial Sequence														

EP 2 780 039 B9

<220>

<223> Synthetic nucleotide sequence

<400> 13

5

	gaggtgcagc tgggtggagtc tggcggcgga ctggtgcagc ctggcggctc tctgagactg	60
	tcttgtgccg cctccggctt caccttcagt aggaatggca tgtcttgggt gaggcaggcc	120
10	cctggcaagg gcctggagtg ggtggccacc gttagtagtg gtggtagtta catctactat	180
	gcagacagtg tgaaggggag gttcaccatc tccagggaca acgccaagaa ctccctgtac	240
	ctccagatga actccctgag ggccgaggat accgccgtgt actactgtgc cagacaaggg	300
15	actacggcac tagctacgag gttcttcgat gtctggggcc agggcaccct ggtgaccgtg	360
	tcctctgctg cgaccaaggg cccatcggtc tccccctgg caccctctc caagagcacc	420
20	tctgggggca cagcggccct gggctgcctg gtcaaggact acttccccga accggtgacg	480
	gtgtcgtgga actcaggcgc cctgaccagc ggcgtgcaca ccttcccgcc tgtcctacag	540
	tcctcaggac tctactccct cagcagcgtg gtgaccgtgc cctccagcag cttgggcacc	600
25	cagacctaca tctgcaacgt gaatcacaa cccagcaaca ccaagggtga caagaaagtt	660
	gagcccaaat cttgtgacaa aactcacaca tgcccaccgt gccccagcacc tgaactcctg	720
	gggggaccgt cagtcttctt cttcccccca aaaccaagg acaccctcat gatctcccg	780
30	accctgagg tcacatgctg ggtggtggac gtgagccacg aagaccctga ggtcaagttc	840
	aactggtacg tggacggcgt ggaggtgcat aatgccaaaga caaagccgcg ggaggagcag	900
35	tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat	960
	ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat cgagaaaacc	1020
	atctccaaag ccaaagggca gccccgagaa ccacagggtg acaccctgcc cccatcccgg	1080
40	gaggagatga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc	1140
	gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct	1200
	cccgtgctgg actccgacgg ctccttcttc ctctatagca agctcaccgt ggacaagagc	1260
45	aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac	1320
	tacacgcaga agagcctctc cctgtccccg ggtaaa	1356

50

<210> 14

<211> 639

<212> DNA

<213> Artificial Sequence

55

<220>

<223> Synthetic nucleotide sequence

EP 2 780 039 B9

<400> 14

```

gacatccaga tgaccagtc cccctcttct ctgtctgcct ctgtgggcga cagagtgacc      60
5  atcacctgta aggccagtca ggatgtaggt actgctgtag cctggatatca gcagaagcct      120
   ggcaaggctc ccaagctgct gatctactcg gcatactacc ggtccactgg cgtgccttcc      180
   agattctccg gctctggctc tggcaccgat ttcacctga ccatctcctc cctccagcct      240
10  gaggatttcg ccacctaata ctgccagcac cattatagtg ctccgtggac gtttggcggc      300
   ggaacaaagg tggagatcaa gactgtggct gcaccatctg tcttcatctt cccgccatct      360
   gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc      420
15  agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag      480
   agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg      540
20  agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg      600
   agctcgcccc tcacaaagag cttcaacagg ggagagtgt      639

```

<210> 15

<211> 117

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide sequence

<400> 15

```

35  Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
    1           5           10           15

    Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asp Tyr
    20           25           30

    Gly Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
    35           40           45

45  Ala Tyr Ile Ser Ser Gly Ser Asn Tyr Ile Tyr Tyr Ala Glu Ala Val
    50           55           60

50  Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

```

55

EP 2 780 039 B9

	65		70		75		80									
5	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95		
10	Ala	Arg	Arg	Gly	Pro	Phe	Val	Leu	Asp	Ala	Trp	Gly	Gln	Gly	Thr	Leu
				100					105					110		
	Val	Thr	Val	Ser	Ser											
				115												
15	<210> 16															
	<211> 446															
	<212> PRT															
	<213> Artificial Sequence															
20	<220>															
	<223> Synthetic peptide sequence															
	<400> 16															
25																
30																
35																
40																
45																
50																
55																

EP 2 780 039 B9

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Arg	Asp	Tyr	
				20					25					30			
10	Gly	Met	Thr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
15	Ala	Tyr	Ile	Ser	Ser	Gly	Ser	Asn	Tyr	Ile	Tyr	Tyr	Ala	Glu	Ala	Val	
	50						55					60					
20	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr	
	65					70					75					80	
25	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
				85						90				95			
30	Ala	Arg	Arg	Gly	Pro	Phe	Val	Leu	Asp	Ala	Trp	Gly	Gln	Gly	Thr	Leu	
				100					105					110			
35	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	
			115					120					125				
40	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	
		130					135					140					
45	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	
	145					150					155					160	

EP 2 780 039 B9

	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	
					165					170					175		
5	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	
				180					185					190			
10	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	
			195					200					205				
15	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	
		210					215					220					
20	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	
	225					230					235					240	
25	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	
					245					250					255		
30	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	
				260					265					270			
35	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	
			275					280					285				
40	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	
		290					295					300					
45	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	
	305					310					315					320	
50	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	
					325					330					335		
55	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	
				340					345					350			
60	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	
			355					360					365				
65	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	
		370					375					380					
70	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	
	385					390					395					400	
75	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	

EP 2 780 039 B9

405

410

415

5

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430

10

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
435 440 445

<210> 17

<211> 1338

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Synthetic nucleotide sequence

20

<400> 17

25

30

35

40

45

50

55

EP 2 780 039 B9

	gaggtgcagc tgggtggagtc tgggggagggc ttggtccagc ctgggggggtc cctgagactc	60
	tcctgtgcag cctctggatt cactttcagg gactatggaa tgacctgggt ccgccaggct	120
5	ccaggaagg ggctggagtg ggtggcctat attagtagtg gtagcaatta catctattat	180
	gcagaagcgg tgaagggccg attcaccatc tccagagaca acgccaagaa ctcaactgtat	240
10	ctgcaaatac acagcctgag agccgaggac acggctgtgt attactgtgc gagacgaggc	300
	ccgtttgttt tggatgcctg gggccaggga accctgggtca ccgtctcctc agcgtcgacc	360
	aagggcccat cggctcttccc cctggcacc cctccaaga gcacctctgg gggcacagcg	420
15	gccctgggct gcctgggtcaa ggactacttc cccgaaccgg tgacgggtgc gtggaactca	480
	ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac	540
	tccctcagca gcgtgggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc	600
20	aacgtgaatc acaagcccag caacaccaag gtggacaaga aagttgagcc caaatcttgt	660
	gacaaaactc acacatgccc accgtgccc gcacctgaac tcctgggggg accgtcagtc	720
25	ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca	780
	tgcgtgggtg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac	840
	ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac	900
30	cgtgtgggtc gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag	960
	tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa	1020
	gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag	1080
35	aaccagggtc gcctgacctg cctgggtcaaa ggcttctatc ccagcgacat cgccgtggag	1140
	tgggagagca atgggcagcc ggagaacaac tacaagacca cgctcccgt gctggactcc	1200
40	gacggctcct tcttcctcta tagcaagctc accgtggaca agagcagggt gcagcagggg	1260
	aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc	1320
45	ctctccctgt ccccggt	1338
	<210> 18	
	<211> 107	
	<212> PRT	
	<213> Artificial Sequence	
50	<220>	
	<223> Synthetic peptide sequence	
55	<400> 18	

EP 2 780 039 B9

1	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
					5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Ser	Ile	Asn	Arg	Tyr
				20					25					30		
10	Leu	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
15	Tyr	Asn	Ala	Asn	Gly	Leu	Gln	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
20	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Leu	Gln	His	Asn	Thr	Trp	Pro	Asp
					85					90					95	
30	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys					
				100					105							

<210> 19

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide sequence

<400> 19

1	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
					5					10					15	
40	Asp	Arg	Val	Thr	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Ser	Ile	Asn	Arg	Tyr
				20					25					30		
45	Leu	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			

EP 2 780 039 B9

	Tyr	Asn	Ala	Asn	Gly	Leu	Gln	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50						55					60				
5	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
10	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Leu	Gln	His	Asn	Thr	Trp	Pro	Asp
					85					90					95	
15	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala
				100					105					110		
20	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly
			115					120					125			
25	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala
		130					135					140				
30	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln
	145					150					155					160
35	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser
					165					170					175	
40	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr
				180					185					190		
45	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser
			195					200					205			
50	Phe	Asn	Arg	Gly	Glu	Cys										
	210															

<210> 20

<211> 642

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic nucleotide sequence

<400> 20

EP 2 780 039 B9

	gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc	60
	atcacttgca aagcaagtca gagtattaac aggtacttac actggtatca gcagaaacca	120
5	gggaaagccc ctaagctcct gatctataat gcaaacgggt tgcaaacggg ggtcccatca	180
	aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct	240
10	gaagattttg caacttacta ctgtttgcag cataatacgt ggccggacac gtttggcgga	300
	gggaccaagg tggagatcaa acggaccgtg gccgctcctt ccgtgttcat cttccccct	360
	tccgacgagc agctgaagtc tggcaccgcc tctgtggtgt gtctgctgaa caacttctac	420
15	ccccgggagg ccaaggtgca gtggaagggt gacaacgctc tgcagtccgg caactcccag	480
	gagtctgtga ccgagcagga ctccaaggac agcacctact ccctgtcctc taccctgacc	540
20	ctgtccaagg ccgactacga gaagcacaag gtgtacgcct gtgagggtgac ccaccagggc	600
	ctgtcctctc ctgtgaccaa gtccttcaac cggggcgagt gc	642

	<210> 21
	<211> 119
25	<212> PRT
	<213> Artificial Sequence
	<220>
	<223> Synthetic peptide sequence
30	
	<400> 21

35

40

45

50

55

EP 2 780 039 B9

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Tyr	Ala	Phe	Thr	Asp	Tyr	
				20					25					30			
10	Trp	Met	Thr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
15	Ala	Glu	Ile	Ser	Pro	Asn	Ser	Gly	Gly	Thr	Asn	Phe	Asn	Glu	Lys	Phe	
		50					55					60					
20	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Val	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr	
	65					70					75					80	
25	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
				85						90					95		
30	Ala	Arg	Gly	Glu	Ile	Arg	Tyr	Asn	Trp	Phe	Ala	Tyr	Trp	Gly	Gln	Gly	
				100					105					110			
35	Thr	Leu	Val	Thr	Val	Ser	Ser										
			115														
40																	
	<210> 22																
	<211> 448																
	<212> PRT																
	<213> Artificial Sequence																
45																	
	<220>																
	<223> Synthetic peptide sequence																
50																	
	<400> 22																
55																	

EP 2 780 039 B9

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	
	1				5					10					15		
5	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Tyr	Ala	Phe	Thr	Asp	Tyr	
				20					25					30			
10	Trp	Met	Thr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
			35					40					45				
15	Ala	Glu	Ile	Ser	Pro	Asn	Ser	Gly	Gly	Thr	Asn	Phe	Asn	Glu	Lys	Phe	
		50					55					60					
20	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Val	Asp	Asn	Ala	Lys	Asn	Ser	Leu	Tyr	
	65					70					75					80	
25	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
				85						90					95		
30	Ala	Arg	Gly	Glu	Ile	Arg	Tyr	Asn	Trp	Phe	Ala	Tyr	Trp	Gly	Gln	Gly	
				100					105					110			
35	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	
			115					120					125				
40	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	
		130					135					140					
45	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	
	145					150					155					160	
50	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	
				165						170					175		
55	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	
				180					185					190			
60	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro	
			195					200					205				
65	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	
		210					215					220					
70	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	
	225					230					235					240	

EP 2 780 039 B9

	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	
					245					250					255		
5	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	
				260					265					270			
10	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	
			275					280					285				
15	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	
		290					295					300					
20	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	
	305					310					315					320	
25	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	
					325					330					335		
30	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	
				340					345					350			
35	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	
			355					360					365				
40	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	
		370					375					380					
45	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	
		385				390					395					400	
50	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	
				405						410					415		
55	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	
				420					425					430			
60	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	
			435					440					445				
65	<210> 23																
70	<211> 1344																
75	<212> DNA																
80	<213> Artificial Sequence																
85	<220>																
90	<223> Synthetic nucleotide sequence																
95	<400> 23																

	gaggtgcagc tgggtggagtc tgggggaggc ttggtccagc ctgggggggtc cctgagactc	60
5	tcctgtgcag cctctggtta tgcattcact gactactgga tgacctgggt ccgccaggct	120
	ccagggaagg ggctggagtg ggtggccgaa atttctccta acagtgggtg tactaacttc	180
	aatgaaaagt tcaagggccg attcaccatc tccgttgaca acgccaagaa ctactgtat	240
10	ctgcaaata acagcctgag agccgaggac acggctgtgt attactgtgc gagaggggaa	300
	atccgttaca attggtttgc ttactggggc cagggaaccc tggtcaccgt ctccctcagcg	360
15	tcgaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc	420
	acagcggccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg	480
	aactcaggcg ccctgaccag cggcgtgcac accttccccg ctgtcctaca gtcctcagga	540
20	ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac	600
	atctgcaacg tgaatcacia gccagcaac accaaggtgg acaagaaagt tgagcccaa	660
	tcttgtgaca aaactcacac atgccaccg tgcccagcac ctgaactcct ggggggaccg	720
25	tcagtcttcc tcttcccccc aaaaccaag gacaccctca tgatctcccg gaccctgag	780
	gtcacatgcg tgggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac	840
	gtggacggcg tggaggtgca taatgccaaag acaaagccgc gggaggagca gtacaacagc	900
30	acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag	960
	tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa	1020
35	gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggaggagatg	1080
	accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc	1140
	gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccggtgctg	1200
40	gactccgacg gtccttctt cctctatagc aagctcaccg tggacaagag caggtggcag	1260
	caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag	1320
45	aagagcctct ccctgtcccc ggggt	1344
	<210> 24	
	<211> 107	
	<212> PRT	
	<213> Artificial Sequence	
50	<220>	
	<223> Synthetic peptide sequence	
55	<400> 24	

EP 2 780 039 B9

1	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
					5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asn	Val	Gly	Asn	Asn
				20					25					30		
10	Ile	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
15	Tyr	Tyr	Ala	Ser	Asn	Arg	Tyr	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
20	Ser	Gly	Tyr	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Arg	Leu	Tyr	Asn	Ser	Pro	Phe
					85					90					95	
30	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys					
				100					105							

<210> 25

<211> 214

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide sequence

<400> 25

EP 2 780 039 B9

	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
	1				5					10					15	
5	Asp	Arg	Val	Thr	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asn	Val	Gly	Asn	Asn
				20					25					30		
10	Ile	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
			35					40					45			
15	Tyr	Tyr	Ala	Ser	Asn	Arg	Tyr	Thr	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
		50					55					60				
20	Ser	Gly	Tyr	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
	65					70					75					80
25	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Arg	Leu	Tyr	Asn	Ser	Pro	Phe
					85					90					95	
30	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala
				100					105					110		
35	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly
			115					120					125			
40	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala
45																
50																
55																
	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln
	145					150					155					160
40	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser
					165					170					175	
45	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr
				180					185					190		
50	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser
			195					200					205			
55	Phe	Asn	Arg	Gly	Glu	Cys										
				210												
	<210>	26														
	<211>	642														
	<212>	DNA														
	<213>	Artificial Sequence														

<220>


<223> Synthetic nucleotide sequence

<400> 26

5
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60
atcacttgca aggccagtc gaatgtgggt aataatatag cctggatatca gcagaaacca 120
10 gggaaagccc ctaagctcct gatctattat gcactaacc ggtacactgg ggtcccatca 180
aggttcagtg gcagtggata tgggacagat ttcactctca ccatcagcag tctgcaacct 240
gaagattttg caacttacta ctgtcagcgt ctttacaatt ctccattcac gttcggcgga 300
15 gggaccaagg tggagatcaa acggaccgtg gccgctcctt ccgtgttcat cttccccct 360
tccgacgagc agctgaagtc tggcaccgcc tctgtggtgt gtctgctgaa caacttctac 420
20 ccccgggagg ccaaggtgca gtggaaggtg gacaacgctc tgcagtccgg caactcccag 480
gagtctgtga ccgagcagga ctccaaggac agcacctact ccctgtcctc taccctgacc 540
ctgtccaagg ccgactacga gaagcacaag gtgtacgcct gtgaggtgac ccaccagggc 600
25 ctgtcctctc ctgtgaccaa gtccttcaac cggggcgagt gc 642

Claims


30 1. A compound of formula I:



I

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,


W is



R¹ is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;
R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;
R^{3A} and R^{3B} are either of the following:


- (i) R^{3A} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; and R^{3B} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; or
- (ii) R^{3A} and R^{3B} taken together are either C_2 - C_8 alkylene, which C_2 - C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1 - C_8 heteroalkylene, which C_1 - C_8 heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R^5 is



C_1 - C_{10} heterocyclyl, C_3 - C_8 carbocycl and C_6 - C_{14} aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of $-C_1$ - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')_2$, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1-C_8\text{alkyl})$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl;

or R^5 is



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -C₁-C₈ alkyl-N(R')₂, -C₁-C₈ alkyl-C(O)R', -C₁-C₈ alkyl-C(O)OR', -O-(C₁-C₈ alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R', -SR' and arylene-R', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ heterocyclyl, C₁-C₁₀alkylene-C₃-C₈heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C₁-C₁₀ heterocyclyl;


R⁶ is hydrogen, -C₁-C₈ alkyl, -C₂-C₈ alkenyl, -C₂-C₈ alkynyl or -C₁-C₈ haloalkyl;

R¹² is hydrogen, C₁-C₄ alkyl, C₁-C₁₀ heterocyclyl or C₆-C₁₄ aryl;

R¹³ is C₁-C₁₀ heterocyclyl; and

X is O.


2. A compound of formula IIa:




IIa

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,



W is



R¹ is



Z is




40

R^{3A} and R^{3B} are either of the following:


(ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R^5 is

5




10




15

20



25

30




35

C_1 - C_{10} heterocyclyl, C_3 - C_8 carbocyclyl and C_6 - C_{14} aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of - C_1 - C_8 alkyl, - C_1 - C_8 alkyl- $N(R')$ ₂, - C_1 - C_8 alkyl- $C(O)R'$, - C_1 - C_8 alkyl- $C(O)OR'$, - O -(C_1 - C_8 alkyl)- $C(O)R'$, - $OC(O)R'$, - $C(O)OR'$, - $C(O)N(R')$ ₂, - $NHC(O)R'$, - $S(O)_2R'$, - $S(O)R'$, -OH, halogen, - N_3 , - $N(R')$ ₂, -CN, - $NHC(=NH)NH_2$, - $NHCONH_2$, - $S(=O)_2R'$ and - SR' , wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl; or R^5 is

40

45



50

55

optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, - C_1 - C_8 alkyl- $N(R')$ ₂, - C_1 - C_8 alkyl- $C(O)R'$, - C_1 - C_8 alkyl- $C(O)OR'$, - O -(C_1 - C_8 alkyl)- $C(O)R'$, - $OC(O)R'$, - $C(O)OR'$, - $C(O)N(R')$ ₂, - $NHC(O)R'$, - $S(O)_2R'$, - $S(O)R'$, -OH, halogen, - N_3 , - $N(R')$ ₂, -CN, - $NHC(=NH)NH_2$, - $NHCONH_2$, - $S(=O)_2R'$, - SR' and arylene- R' , wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl, C_1 - C_{10} alkylene- C_3 - C_8 heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10}

heterocyclyl;

R⁶ is hydrogen, -C₁-C₈alkyl, -C₂-C₈alkenyl, -C₂-C₈alkynyl or -C₁-C₈haloalkyl;

R¹² is hydrogen, C₁-C₄alkyl, C₁-C₁₀heterocyclyl or C₆-C₁₄aryl;

R¹³ is C₁-C₁₀heterocyclyl; and


R⁷ is independently selected for each occurrence from the group consisting of F, Cl, I, Br, NO₂, CN and CF₃;

R¹⁰ is hydrogen, -C₁-C₁₀alkyl, -C₃-C₈carbocyclyl, -aryl, -C₁-C₁₀heteroalkyl, -C₃-C₈heterocyclo, -C₁-C₁₀alkylene-aryl, -arylene-C₁-C₁₀alkyl, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo), -(C₃-C₈ carbocyclo)-C₁-C₁₀alkyl, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo), and -(C₃-C₈ heterocyclo)-C₁-C₁₀alkyl, where aryl on R₁₀ comprising aryl is optionally substituted with [R₇]_h;

h is 1, 2, 3, 4 or 5; and

X is O.


3. A compound of formula IIIa:



IIIa

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is



R¹ is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;


R^{3A} and R^{3B} are either of the following:





(i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and

R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or


(ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R⁵ is








or



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -NH₂, -NH(R'), -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl and unsubstituted aryl;

R¹¹ is








or

;

Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈heterocyclo-, -C₁-C₁₀alkylene-arylene-, -arylene-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo)-, -(C₃-C₈carbocyclo)-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀alkylene-;

Z is





or -NH₂;


G is halogen, -OH, -SH, or -S-C₁-Cealkyl;

R⁷ is independently selected for each occurrence from the group consisting of F, Cl, I, Br, NO₂, CN and CF₃;

h is 1, 2, 3, 4 or 5; and

X is O.


4. A compound of formula IIb:




IIb

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is




R¹ is



Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈heterocyclo-,
 -C₁-C₁₀alkylene-arylene-, -arylene-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo)-,
 -(C₃-C₈carbocyclo)-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀alkylene-;

Z is



or -NHL;

L is an antibody;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;


R^{3A} and R^{3B} are either of the following:


(i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and

R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or


(ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R⁵ is





C_1 - C_{10} heterocyclyl, C_3 - C_8 carbocycl and C_6 - C_{14} aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of $-C_1$ - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')_2$, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl; or R^5 is



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')_2$, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$, $-SR'$ and arylene- R' , wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl, C_1 - C_8 heterocyclyl, C_1 - C_{10} alkylene- C_3 - C_8 heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl;


R^6 is hydrogen, $-C_1$ - C_8 alkyl, $-C_2$ - C_8 alkenyl, $-C_2$ - C_8 alkynyl or $-C_1$ - C_8 haloalkyl;

R^{12} is hydrogen, C_1 - C_4 alkyl, C_1 - C_{10} heterocyclyl or C_6 - C_{14} aryl;

R^{13} is C_1 - C_{10} heterocyclyl; and

X is O .


5. A compound of formula IIIb:



IIIb

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is



R¹ is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;

R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;


R^{3A} and R^{3B} are either of the following:

(i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and


R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or

(ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R⁵ is





or





optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -NH₂, -NH(R'), -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl and unsubstituted aryl;

R¹¹ is




Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈heterocyclo-,
 -C₁-C₁₀alkylene-arylene-, -arylene-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo)-,
 -(C₃-C₈carbocyclo)-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀alkylene-;
 Z is



or -NHL;
 L is an antibody;
 X is O.


6. A compound of formula **IIC**:



IIc


or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

R^{1'} is



Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈ heterocyclo-, -C₁-C₁₀ alkylene-arylene-, -arylene-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ carbocyclo)-, -(C₃-C₈ carbocyclo)-C₁-C₁₀ alkylene-, -C₁-C₁₀ alkylene-(C₃-C₈ heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀ alkylene-;


Z' is




or -NH-;

L is an antibody;

D is absent;


$R^{2'}$ is hydrogen, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, or is absent if  is present;
 $R^{3A'}$ and $R^{3B'}$ are either of the following:

(i) $R^{3A'}$ is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; and

$R^{3B'}$ is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen, or $R^{3B'}$ is C_2 - C_4 alkylene and forms a saturated 5 to 6 member ring as indicated by ; or

(ii) $R^{3A'}$ and $R^{3B'}$ taken together are either C_2 - C_8 alkylene, which C_2 - C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1 - C_8 heteroalkylene, which C_1 - C_8 heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;


R^5 is



C_1 - C_{10} heterocyclyl, C_3 - C_8 carbocyclyl and C_6 - C_{14} aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of $-C_1$ - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')_2$, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl)- $C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$,

halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl;

or R^5 is



optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')_2$, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O$ -(C_1 - C_8 alkyl), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$, $-SR'$ and arylene- R' , wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl, C_1 - C_8 heterocyclyl, C_1 - C_{10} alkylene- C_3 - C_8 heterocyclyl and aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl;


R^6 is hydrogen, $-C_1$ - C_8 alkyl, $-C_2$ - C_8 alkenyl, $-C_2$ - C_8 alkynyl or $-C_1$ - C_8 haloalkyl;

R^{12} is hydrogen, C_1 - C_4 alkyl, C_1 - C_{10} heterocyclyl or C_6 - C_{14} aryl;

R^{13} is C_1 - C_{10} heterocyclyl; and

X is O.


7. A compound of formula IIIc:



IIIc

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

W is



R^1 is hydrogen, C_1 - C_8 alkyl or C_1 - C_8 haloalkyl;

R^2 is hydrogen, C_1 - C_8 alkyl or C_1 - C_8 haloalkyl;

R^{3A} and R^{3B} are either of the following:


(i) R^{3A} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; and

R^{3B} is C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, C_3 - C_8 carbocyclyl, or halogen; or


(ii) R^{3A} and R^{3B} taken together are either C_2 - C_8 alkylene, which C_2 - C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1 - C_8 heteroalkylene, which C_1 - C_8

heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R⁵ is




or




optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C₁-C₈ alkyl, -O-(C₁-C₈alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogen, -N₃, -NH₂, -NH(R'), -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' and -SR', wherein each R' is independently selected from the group consisting of hydrogen, C₁-C₈ alkyl and unsubstituted aryl;

R^{11'} is



Y is -C₂-C₂₀ alkylene-, -C₂-C₂₀ heteroalkylene-, -C₃-C₈ carbocyclo-, -arylene-, -C₃-C₈heterocyclo-, -C₁-C₁₀alkylene-arylene-, -arylene-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈carbocyclo)-, -(C₃-C₈carbocyclo)-C₁-C₁₀alkylene-, -C₁-C₁₀alkylene-(C₃-C₈heterocyclo)-, or -(C₃-C₈ heterocyclo)-C₁-C₁₀alkylene-;

Z' is




or -NH-;

L is an antibody;

X is O.

8. A compound of formula **IId**:



IId

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,

L is an antibody;

[linker] is a divalent linker;


D is absent;

R² is hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, or is absent if  is present;


R^{3A'} and R^{3B'} are either of the following:

(i) R^{3A'} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and

R^{3B'} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or R^{3B'} is C₂-C₄ alkylene and forms a saturated 5

to 6 member ring as indicated by ; or


(ii) R^{3A'} and R^{3B'} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring; R⁵ is



35 C_1 - C_{10} heterocyclyl, C_3 - C_8 carbocyclyl and C_6 - C_{14} aryl optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of $-C_1$ - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')$ ₂, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl)- $C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')$ ₂, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')$ ₂, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl, or two R' can, together with the nitrogen to which they are attached, form a C_1 - C_{10} heterocyclyl;

40


or R^5 is



55 optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, $-C_1$ - C_8 alkyl- $N(R')$ ₂, $-C_1$ - C_8 alkyl- $C(O)R'$, $-C_1$ - C_8 alkyl- $C(O)OR'$, $-O-(C_1$ - C_8 alkyl)- $C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')$ ₂, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-N(R')$ ₂, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$, $-SR'$ and arylene- R' , wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl, C_1 - C_8 heterocyclyl, C_1 - C_{10} alkylene- C_3 - C_8 heterocyclyl and aryl, or two R' can, together with the

nitrogen to which they are attached, form a C₁-C₁₀ heterocyclyl;
 R⁶ is hydrogen, -C₁-C₈ alkyl, -C₂-C₈ alkenyl, -C₂-C₈ alkynyl or -C₁-C₈ haloalkyl;
 R¹² is hydrogen, C₁-C₄ alkyl, C₁-C₁₀ heterocyclyl or C₆-C₁₄ aryl;
 R¹³ is C₁-C₁₀ heterocyclyl; and
 X is O.


9. A compound of formula III d:



III d

or a pharmaceutically acceptable salt or solvate thereof, wherein, independently for each occurrence,


W is








R¹ is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;
 R² is hydrogen, C₁-C₈ alkyl or C₁-C₈ haloalkyl;
 R^{3A} and R^{3B} are either of the following:


- (i) R^{3A} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; and R^{3B} is C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₃-C₈ carbocyclyl, or halogen; or
- (ii) R^{3A} and R^{3B} taken together are either C₂-C₈ alkylene, which C₂-C₈ alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C₁-C₈ heteroalkylene, which C₁-C₈ heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring;

R⁵ is





or




optionally substituted with 1, 2, 3, 4 or 5 groups independently selected from the group consisting of C_1 - C_8 alkyl, $-O-(C_1-C_8\text{alkyl})$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogen, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ and $-SR'$, wherein each R' is independently selected from the group consisting of hydrogen, C_1 - C_8 alkyl and unsubstituted aryl;

[linker] is a divalent linker;


L is an antibody;

X is O.

10. The compound, salt or solvate of any of claims 1-5, 7 and 9, wherein W is



11. The compound, salt or solvate of any of claims 1-5, 7 and 9, wherein W is



12. The compound, salt or solvate of any of claims 1-5, 7 and 9, wherein R^2 is hydrogen, or C_1 - C_8 alkyl.

13. The compound, salt or solvate of any of claims 1-5, 7 and 9, wherein R^{3A} is C_1 - C_8 alkyl, preferably methyl.

14. The compound, salt or solvate of any of claims 1-5, 7 and 9, wherein R^{3A} and R^{3B} taken together are either C_2 - C_8 alkylene, which C_2 - C_8 alkylene when taken together with the carbon to which it is bound, forms a saturated carbocyclic ring; or C_1 - C_8 heteroalkylene, which C_1 - C_8 heteroalkylene, together with the carbon to which it is bound, forms a saturated heterocyclic ring.


15. The compound, salt or solvate of claim 14, wherein R^{3A} and R^{3B} taken together are $-CH_2CH_2-$, which $-CH_2CH_2-$

when taken together with the carbon to which it is bound forms cyclopropyl.

16. The compound, salt or solvate of claim 14, wherein R^{3A} and R^{3B} taken together are $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$, which $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ when taken together with the carbon to which it is bound forms cyclopentyl.


17. The compound, salt or solvate of claim 14, wherein R^{3A} and R^{3B} taken together are $-\text{CH}_2\text{OCH}_2-$, which $-\text{CH}_2\text{OCH}_2-$ when taken together with the carbon to which it is bound forms oxetanyl.

18. The compound, salt or solvate of any of claims 1-2, 4, 6 and 8, wherein R^5 is




19. The compound, salt or solvate of any of claims 4-9 wherein antibody is selected from trastuzumab, oregovomab, edrecolomab, cetuximab, a humanized monoclonal antibody to the vitronectin receptor ($\alpha_v\beta_3$); alemtuzumab; a humanized anti-HLA-DR antibody for the treatment of non-Hodgkin's lymphoma; 131I Lym-1; a murine anti-HLA-Dr10 antibody for the treatment of non-Hodgkin's lymphoma; a humanized anti-CD2 mAb for the treatment of Hodgkin's Disease or non-Hodgkin's lymphoma; labetuzumab; bevacizumab; ibritumomab tiuxetan; ofatumumab; panitumumab; rituximab; tositumomab; ipilimumab; gemtuzumab; an anti-IL13 antibody; and an anti-Notch antibody.


20. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to Claim 1 selected from:




5




10




15




20



30




35




40


45




50


55









and




21. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to Claim 1 selected from:








5






10





15




20





25




30




35



40




45




50


5



10




15




20

25




30




35

40




45




50


55




5




10



15



20



25

and


22. A payload-linker or an antibody-drug-conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to any one of Claims 2 to 9, comprising a radical of a compound of claim 20 or 21.

30

23. An antibody drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, comprising a radical of a compound of claims 1-3.


24. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to any one of Claims 2 or 3 selected from:

35




40

45




50

55




5




10

15




20

25




30

35




40


45




50

55







5




10



15




20




25

30




35




40


45




50

55







5




10




15




20




25




30



40




45




50

55


5



10




15




20

25




30




35

40




45

50




55


5




10




15




20




25



35




45




50

55

5




10




15

20




25




30


35



40




45




50


55




5




10




15




20



25




30




35


40



45




50




55


5




10



15




20




25

30




35




40

45




50




55


5




10



15




20




25

30




35




40

45




50


55




5




10



15




20




25

30




35

40





45




50

55






and




25. An antibody-drug-conjugate or a pharmaceutically acceptable salt or solvate thereof, according to any one of Claims 4, 5, 7 or 9 comprising a radical of a compound of claim 24.


26. A compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is




27. A compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is




28. A compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is




29. A compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is




30. A compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is




31. A compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is



32. A compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is




33. A compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is




34. A payload-linker or an antibody-drug-conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 2 to 9, comprising a radical of a compound of claims 26-33.


35. A compound of claim 24, or a pharmaceutically acceptable salt or solvate thereof, which is




36. A compound of claim 24, or a pharmaceutically acceptable salt or solvate thereof, which is




37. A compound of claim 24, or a pharmaceutically acceptable salt or solvate thereof, which is



38. A compound of claim 24, or a pharmaceutically acceptable salt or solvate thereof, which is



39. A compound of claim 24, or a pharmaceutically acceptable salt or solvate thereof, which is




40. An antibody-drug-conjugate, or a pharmaceutically acceptable salt or solvate thereof, according to any one of claims 4, 5, 7 or 9, comprising a radical of a compound of claims 35-39.

41. A pharmaceutical composition comprising a compound of any one of claims 1-40, or a pharmaceutically acceptable salt or solvate thereof, and pharmaceutically acceptable excipient.

42. A compound of any one of claims 1-40, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of claim 41, for use in the treatment of cancer.


Patentansprüche

1. Verbindung der Formel I:



oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:

W ist



R¹ ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;

R^2 ist Wasserstoff, C_1 - C_8 -Alkyl oder C_1 - C_8 -Halogenalkyl;


R^{3A} und R^{3B} sind eines der folgenden:

(i) R^{3A} ist C_1 - C_8 -Alkyl, C_1 - C_8 -Halogenalkyl, C_3 - C_8 -Carbocyclyl oder Halogen; und

R^{3B} ist C_1 - C_8 -Alkyl, C_1 - C_8 -Halogenalkyl, C_3 - C_8 -Carbocyclyl oder Halogen; oder

(ii) R^{3A} und R^{3B} sind zusammengekommen entweder C_2 - C_8 -Alkyl, welches C_2 - C_8 -Alkyl, wenn zusammengekommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C_1 - C_8 -Heteroalkyl, welches C_1 - C_8 -Heteroalkyl, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;

R^5 ist



C_1 - C_{10} -Heterocyclyl, C_3 - C_8 -Carbocyclyl und C_6 - C_{14} -Aryl, optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen, die unabhängig ausgewählt sind aus der Gruppe, bestehend aus $-C_1$ - C_8 -Alkyl, $-C_1$ - C_8 -Alkyl- $N(R')_2$, $-C_1$ - C_8 -Alkyl- $C(O)R'$, $-C_1$ - C_8 -Alkyl- $C(O)OR'$, $-O(-C_1-C_8-Alkyl)$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, Halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(O)_2R'$ und $-SR'$, wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C_1 - C_8 -Alkyl und nicht substituiertem Aryl, oder zwei R' können, zusammen mit dem Stickstoff, an den sie gebunden sind, ein C_1 - C_{10} -Heterocyclyl bilden; oder R^5 ist



15

20

25

30

CN(C)C(=O)[C@H](C)C[C@@H](OC)[C@H](C)CC(=O)N1CCCC1[C@H](C)C(=O)[C@H](C)C(=O)NR5

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:

35





45

50



Y ist -C₂-C₂₀-Alkylen-, -C₂-C₂₀-Heteroalkylen-, -C₃-C₈-Carbocyclo-, -Arylen-, -C₃-C₈-Heterocyclo-, -C₁-C₁₀-Alkylen-arylen-, Arylen-C₁-C₁₀-alkylen-, -C₁-C₁₀-Alkylen- (C₃-C₈-carbocyclo)-, -(C₃-C₈-Carbocyclo)-C₁-C₁₀-alkylen-, -C₁-C₁₀-Alkylen- (C₃-C₈-heterocyclo)- oder - (C₃-C₈-Heterocyclo)-C₁-C₁₀-alkylen-;
Z ist



oder -NH₂;

G ist Halogen, -OH, -SH oder -S-C₁-C₆-Alkyl;

R² ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;



R^{3A} und R^{3B} sind eines der folgenden:


i) R^{3A} ist -C₁-C₈-Alkyl, -C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl, oder Halogen; und

R^{3B} ist C₁-C₈-Alkyl, C₃-C₈-Carbocyclyl oder Halogen; oder


(ii) R^{3A} und R^{3B} sind zusammengekommen entweder C₂-C₈-Alkylen, welches C₂-C₈-Alkylen, wenn zusammengekommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C₁-C₈-Heteroalkylen, welches C₁-C₈-Heteroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;

R⁵ ist





C_1 - C_{10} -Heterocyclyl, C_3 - C_8 -Carbocyclyl und C_6 - C_{14} -Aryl, optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen, die unabhängig ausgewählt sind aus der Gruppe, bestehend aus - C_1 - C_8 -Alkyl, - C_1 - C_8 -Alkyl- $N(R')_2$, - C_1 - C_8 -Alkyl- $C(O)R'$, - C_1 - C_8 -Alkyl- $C(O)OR'$, -O-(- C_1 - C_8 -Alkyl), - $C(O)R'$, -OC(O) R' , - $C(O)OR'$, - $C(O)N(R')_2$, -NHC(O) R' , -S(O) $_2R'$, -S(O) R' , -OH, Halogen, - N_3 , - $N(R')_2$, -CN, -NHC(=NH)NH $_2$, -NHCONH $_2$, -S(O) $_2R'$ und -SR', wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C_1 - C_8 -Alkyl und nicht substituiertem Aryl, oder zwei R' können, zusammen mit dem Stickstoff an den sie gebunden sind, ein C_1 - C_{10} -Heterocyclyl bilden; oder R^5 ist



optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen unabhängig ausgewählt aus der Gruppe, bestehend aus - C_1 - C_8 -Alkyl, - C_1 - C_8 -Alkyl- $N(R')_2$, - C_1 - C_8 -Alkyl- $C(O)R'$, - C_1 - C_8 -Alkyl- $C(O)OR'$, -O-(- C_1 - C_8 -Alkyl), - $C(O)R'$, -OC(O) R' , - $C(O)OR'$, - $C(O)N(R')_2$, -NHC(O) R' , -S(O) $_2R'$, -S(O) R' , -OH, Halogen, - N_3 , - $N(R')_2$, -CN, -NHC(=NH)NH $_2$, -NHCONH $_2$, -S(O) $_2R'$, -SR' und Arylen- R' , wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C_1 - C_8 -Alkyl, C_1 - C_8 -Heterocyclyl, C_1 - C_{10} -Alkyl- C_3 - C_8 -heterocyclyl und Aryl, oder zwei R' können, zusammen mit dem Stickstoff, an den sie gebunden sind, ein C_1 - C_{10} -Heterocyclyl bilden;

R^6 ist Wasserstoff, - C_1 - C_8 -Alkyl, - C_2 - C_8 -Alkenyl, - C_2 - C_8 -Alkinyl oder - C_1 - C_8 -Halogenalkyl;

R^{12} ist Wasserstoff, - C_1 - C_4 -Alkyl, - C_1 - C_{10} -Heterocyclyl oder - C_6 - C_{14} -Aryl;

R^{13} ist - C_1 - C_{10} -Heterocyclyl; und


R^7 ist unabhängig ausgewählt für jedes Vorkommen aus der Gruppe, bestehend aus F, Cl, I, Br, NO $_2$, CN und CF $_3$;

R^{10} ist Wasserstoff, - C_1 - C_{10} -Alkyl, - C_3 - C_8 -Carbocyclyl, -Aryl, - C_1 - C_{10} -Heteroalkyl, - C_3 - C_8 -Heterocyclo, - C_1 - C_{10} -Alkyl-aryl, -Arylen- C_1 - C_{10} -alkyl, - C_1 - C_{10} -Alkyl- (C $_3$ -C $_8$)carbocyclo, - (C $_3$ -C $_8$ -Carbocyclo)- C_1 - C_{10} -alkyl, - C_1 - C_{10} -Alkyl- (C $_3$ -C $_8$ -heterocyclo) und - (C $_3$ -C $_8$ -Heterocyclo), - C_1 - C_{10} -Alkyl, wobei Aryl an R_{10} enthaltend Aryl optional mit [R $_7$] $_h$ substituiert ist;

h ist 1, 2, 3, 4 oder 5; und


X ist O.

3. Verbindung der Formel IIIa:

**IIIa**

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:

W ist



oder

R¹ ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;

R² ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;


R^{3A} und R^{3B} sind eines der folgenden:

(i) R^{3A} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; und


R^{3B} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; oder

(ii) R^{3A} und R^{3B} sind zusammengekommen entweder C₂-C₈-Alkylen, welches C₂-C₈-Alkylen, wenn zusammengekommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C₁-C₈-Heteroalkylen, welches C₁-C₈-Heteroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;



R⁵ ist



oder





optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen unabhängig ausgewählt aus der Gruppe, bestehend aus C_1 - C_8 -Alkyl, $-O-(C_1-C_8\text{-Alkyl})$, $-C(O)R'$, $-OC(O)R'$, $C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, Halogen, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ und $-SR'$, wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C_1 - C_8 -Alkyl und nicht substituiertem Aryl;
 R^{11} ist



oder

Y ist $-C_2-C_{20}$ -Alkylen-, $-C_2-C_{20}$ -Heteroalkylen-, $-C_3-C_8$ -Carbocyclo-, $-Arylen$ -, $-C_3-C_8$ -Heterocyclo-, $-C_1-C_{10}$ -Alkylen-arylen-, $-Arylen-C_1-C_{10}$ -alkylen-, $-C_1-C_{10}$ -Alkylen- $(C_3-C_8\text{-carbocyclo})$ -, $-(C_3-C_8\text{-Carbocyclo})-C_1-C_{10}$ -alkylen-, $-C_1-C_{10}$ -Alkylen- $(C_3-C_8\text{-heterocylo})$ - oder $(C_3-C_8\text{-Heterocylo})-C_1-C_{10}$ -alkylen-;
 Z ist





oder -NH₂;


G ist halogen, -OH, -SH oder -S-C₁-C₆-Alkyl;

R⁷ ist für jedes Vorkommen unabhängig ausgewählt aus der Gruppe, bestehend aus F, Cl, I, Br, NO₂, CN und CF₃;

h ist 1, 2, 3, 4 oder 5; und

X ist O.


4. Verbindung der Formel IIb:



IIb


oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:

W ist




oder

R¹ ist



Y ist -C₂-C₂₀-Alkylen-, -C₂-C₂₀-Heteroalkylen-, -C₃-C₈-Carbocyclo-, -Arylen-, -C₃-C₈-Heterocyclo-, -C₁-C₁₀-Alkylen-arylen-, -Arylen-C₁-C₁₀-alkylen-, -C₁-C₁₀-Alkylen-(C₃-C₈-carbocyclo)-, -(C₃-C₈-Carbocyclo)-C₁-C₁₀-alkylen-, -C₁-C₁₀-Alkylen-(C₃-C₈-heterocylo) - oder (C₃-C₈-Heterocylo)-C₁-C₁₀-alkylen-;
Z ist



oder -NHL;

L ist ein Antikörper;

R² ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;


R^{3A} und R^{3B} sind eines der folgenden:


(i) R^{3A} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; und

R^{3B} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; oder

(ii) R^{3A} und R^{3B} sind zusammengenommen entweder C₂-C₈-Alkylen, welches C₂-C₈-Alkylen, wenn zusammengenommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C₁-C₈-Heteroalkylen, welches C₁-C₈-Heteroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;


$\mathbb{R}^5$ ist





25 C_1 - C_{10} -Heterocyclyl, C_3 - C_8 -Carbocyclyl und C_6 - C_{14} -Aryl, optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen, die unabhängig ausgewählt sind aus der Gruppe, bestehend aus $-C_1$ - C_8 -Alkyl, $-C_1$ - C_8 -Alkyl- $N(R')_2$, $-C_1$ - C_8 -Alkyl- $C(O)R'$, $-C_1$ - C_8 -Alkyl- $C(O)OR'$, $-O(-C_1-C_8-Alkyl)$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, Halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(O)_2R'$ und $-SR'$, wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C_1 - C_8 -Alkyl und nicht substituiertem Aryl, oder zwei R' können, zusammen mit dem Stickstoff an den sie gebunden sind, ein C_1 - C_{10} -Heterocyclyl bilden; oder R^5 ist

30



optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen unabhängig ausgewählt aus der Gruppe, bestehend aus $-C_1$ - C_8 -Alkyl, $-C_1$ - C_8 -Alkyl- $N(R')_2$, $-C_1$ - C_8 -Alkyl- $C(O)R'$, $-C_1$ - C_8 -Alkyl- $C(O)OR'$, $-O(-C_1-C_8-Alkyl)$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, Halogen, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(O)_2R'$, $-SR'$ und Arylen- R' , wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C_1 - C_8 -Alkyl, C_1 - C_8 -Heterocyclyl, C_1 - C_{10} -Alkylen- C_3 - C_8 -heterocyclyl und Aryl, oder zwei R' können, zusammen mit dem Stickstoff, an den sie gebunden sind, ein C_1 - C_{10} -Heterocyclyl bilden;

45

R^6 ist Wasserstoff, $-C_1$ - C_8 -Alkyl, $-C_2$ - C_8 -Alkenyl, $-C_2$ - C_8 -Alkynyl oder $-C_1$ - C_8 -Halogenalkyl;

R^{12} ist Wasserstoff, $-C_1$ - C_4 -Alkyl, $-C_1$ - C_{10} -Heterocyclyl oder $-C_6$ - C_{14} -Aryl;


R^{13} ist $-C_1$ - C_{10} -Heterocyclyl; und

X ist O.

50

5. Verbindung der Formel IIIb:


55



IIIb

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:

W ist



R¹ ist Wasserstoff, -C₁-C₈-Alkyl, oder

-C₁-C₈-Halogenalkyl;

R² ist Wasserstoff, -C₁-C₈-Alkyl, oder -C₁-C₈-Halogenalkyl;


R^{3A} und R^{3B} sind eines der folgenden:

(i) R^{3A} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; und


R^{3B} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; oder

(ii) R^{3A} und R^{3B} sind zusammengekommen entweder C₂-C₈-Alkylen, welches C₂-C₈-Alkylen, wenn zusammengekommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C₁-C₈-Heteroalkylen, welches C₁-C₈-Heteroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;

R⁵ ist





oder



optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen unabhängig ausgewählt aus der Gruppe, bestehend aus C₁-C₈-Alkyl, -O-(C₁-C₈-Alkyl), -C(O)R', -OC(O)R', C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, Halogen, -N₃, -NH₂, -NH(R'), -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' und -SR', wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C₁-C₈-Alkyl und nicht substituiertem Aryl;

R¹¹ ist




oder


;

Y ist -C₂-C₂₀-Alkylen-, -C₂-C₂₀-Heteroalkylen-, -C₃-C₈-Carbocyclo-, -Arylen-, -C₃-C₈-Heterocyclo-, -C₁-C₁₀-Alkylen-arylen-, -Arylen-C₁-C₁₀-alkylen-, -C₁-C₁₀-Alkylen- (C₃-C₈-carbocyclo)-, -(C₃-C₈-Carbocyclo)-C₁-C₁₀-alkylen-, -C₁-C₁₀-Alkylen-(C₃-C₈-heterocylo) - oder (C₃-C₈-Heterocylo)-C₁-C₁₀-alkylen-;


Z ist




,



,




,



oder -NHL;
L ist ein Antikörper;
X ist O.


6. Verbindung der Formel IIc:



IIc

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:


R^{1'} ist



oder

Y ist -C₂-C₂₀-Alkylen-, -C₂-C₂₀-Heteroalkylen-, -C₃-C₈-Carbocyclo-, -Arylen-, -C₃-C₈-Heterocyclo-,
-C₁-C₁₀-Alkylen-arylen-, -Arylen-C₁-C₁₀-alkylen-, -C₁-C₁₀-Alkylen-(C₃-C₈-carbocyclo)-, -(C₃-C₈-Carbocyclo)-C₁-C₁₀-alkylen-, -C₁-C₁₀-(C₃-C₈-heterocyclo) - oder (C₃-C₈-Heterocyclo)-C₁-C₁₀-alkylen-;
Z' ist


5



10

15

20



oder -NH-;


25

L ist ein Antikörper;

D ist nicht vorhanden;

R^{2'} ist Wasserstoff, -C₁-C₈-Alkyl, -C₁-C₈-Halogenalkyl oder ist nicht vorhanden, wenn

30



vorhanden ist;


R^{3A'} und R^{3B'} sind eines der folgenden:

35

(i) R^{3A'} ist -C₁-C₈-Alkyl, -C₁-C₈-Halogenalkyl, -C₃-C₈-Carbocyclyl oder Halogen; und

R^{3B'} ist -C₁-C₈-Alkyl, -C₁-C₈-Halogenalkyl, -C₃-C₈-Carbocyclyl oder Halogen, oder R^{3B'} ist C₂-C₄-Alkylen und bildet einen gesättigten 5 bis 6 gliedrigen Ring, bezeichnet mit

40




oder

(ii) R^{3A'} und R^{3B'} sind zusammengekommen entweder C₂-C₈-Alkylen, welches C₂-C₈-Alkylen, wenn zusammengekommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C₁-C₈-Heteroalkylen, welches C₁-C₈-Heteroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;


45

R⁵ ist


50



55



$\text{C}_1\text{-C}_{10}$ -Heterocyclyl, $\text{C}_3\text{-C}_8$ -Carbocyclyl und $\text{C}_6\text{-C}_{14}$ -Aryl, optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen, die unabhängig ausgewählt sind aus der Gruppe, bestehend aus $-\text{C}_1\text{-C}_8\text{-Alkyl}$, $-\text{C}_1\text{-C}_8\text{-Alkyl-N(R')}_2$, $-\text{C}_1\text{-C}_8\text{-Alkyl-C(O)R'}$, $-\text{C}_1\text{-C}_8\text{-Alkyl-C(O)OR'}$, $-\text{O-(-C}_1\text{-C}_8\text{-Alkyl)}$, $-\text{C(O)R'}$, $-\text{OC(O)R'}$, $-\text{C(O)OR'}$, $-\text{C(O)N(R')}_2$, $-\text{NHC(O)R'}$, $-\text{S(O)}_2\text{R'}$, $-\text{S(O)R'}$, $-\text{OH}$, Halogen, $-\text{N}_3$, $-\text{N(R')}_2$, $-\text{CN}$, $-\text{NHC(=NH)NH}_2$, $-\text{NHCONH}_2$, $-\text{S(O)}_2\text{R'}$ und $-\text{SR'}$, wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, $\text{C}_1\text{-C}_8\text{-Alkyl}$ und nicht substituiertem Aryl, oder zwei R' können, zusammen mit dem Stickstoff, an den sie gebunden sind, ein $\text{C}_1\text{-C}_{10}$ -Heterocyclyl bilden; oder R^5 ist



optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen unabhängig ausgewählt aus der Gruppe, bestehend aus $-\text{C}_1\text{-C}_8\text{-Alkyl}$, $-\text{C}_1\text{-C}_8\text{-Alkyl-N(R')}_2$, $-\text{C}_1\text{-C}_8\text{-Alkyl-C(O)R'}$, $-\text{C}_1\text{-C}_8\text{-Alkyl-C(O)OR'}$, $-\text{O-(-C}_1\text{-C}_8\text{-Alkyl)}$, $-\text{C(O)R'}$, $-\text{OC(O)R'}$, $-\text{C(O)OR'}$, $-\text{C(O)N(R')}_2$, $-\text{NHC(O)R'}$, $-\text{S(O)}_2\text{R'}$, $-\text{S(O)R'}$, $-\text{OH}$, Halogen, $-\text{N}_3$, $-\text{N(R')}_2$, $-\text{CN}$, $-\text{NHC(=NH)NH}_2$, $-\text{NHCONH}_2$, $-\text{S(O)}_2\text{R'}$, $-\text{SR'}$ und Arylen- R' , wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, $\text{C}_1\text{-C}_8\text{-Alkyl}$, $\text{C}_1\text{-C}_8\text{-Heterocyclyl}$, $\text{C}_1\text{-C}_{10}\text{-Alkylen-C}_3\text{-C}_8\text{-heterocyclyl}$ und Aryl, oder zwei R' können, zusammen mit dem Stickstoff, an den sie gebunden sind, ein $\text{C}_1\text{-C}_{10}$ -Heterocyclyl bilden;


R^6 ist Wasserstoff, $-\text{C}_1\text{-C}_8\text{-Alkyl}$, $-\text{C}_2\text{-C}_8\text{-Alkenyl}$, $-\text{C}_2\text{-C}_8\text{-Alkynyl}$ oder $-\text{C}_1\text{-C}_8\text{-Halogenalkyl}$;

R^{12} ist Wasserstoff, $-\text{C}_1\text{-C}_4\text{-Alkyl}$, $-\text{C}_1\text{-C}_{10}\text{-Heterocyclyl}$ oder $-\text{C}_6\text{-C}_{14}\text{-Aryl}$;

R^{13} ist $-\text{C}_1\text{-C}_{10}\text{-Heterocyclyl}$; und

X ist O.


7. Verbindung der Formel IIIc:



IIIc

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:

W ist



R¹ ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;

R² ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;


R^{3A} und R^{3B} sind eines der folgenden:


(i) R^{3A} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; und

R^{3B} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; oder


(ii) R^{3A} und R^{3B} sind zusammengekommen entweder C₂-C₈-Alkylen, welches C₂-C₈-Alkylen, wenn zusammengekommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C₁-C₈-Heteroalkylen, welches C₁-C₈-Heteroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;

R⁵ ist






oder




optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen, unabhängig ausgewählt aus der Gruppe, bestehend aus C_1 - C_8 -Alkyl, $-O-(C_1-C_8\text{-Alkyl})$, $-C(O)R'$, $-OC(O)R'$, $C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, Halogen, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ und $-SR'$, wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C_1 - C_8 -Alkyl und nicht substituiertem Aryl;


$R^{11'}$ ist



Y ist $-C_2-C_{20}$ -Alkylen-, $-C_2-C_{20}$ -Heteroalkylen-, $-C_3-C_8$ -Carbocyclo-, -Arylen-, $-C_3-C_8$ -Heterocyclo-, $-C_1-C_{10}$ -Alkylen-arylen-, -Arylen- $-C_1-C_{10}$ -alkylen-, $-C_1-C_{10}$ -Alkylen- ($-C_3-C_8$ -carbocyclo) -, - ($-C_3-C_8$ -Carbocyclo) - $-C_1-C_{10}$ -alkylen-, $-C_1-C_{10}$ -Alkylen ($-C_3-C_8$ -heterocyclo) - oder - ($-C_3-C_8$ -Heterocyclo) - $-C_1-C_{10}$ -alkylen-;

Z' ist






oder -NH-;

L ist ein Antikörper;
X ist O.

8. Verbindung der Formel IId:



IId

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:

L ist ein Antikörper;
[linker] ist ein divalenter Linker;
D ist nicht vorhanden;
R^{2'} ist Wasserstoff, -C₁-C₈-Alkyl, -C₁-C₈-Halogenalkyl oder ist nicht vorhanden, wenn


vorhanden ist;
R^{3A'} und R^{3B'} sind eines der folgenden:

- (i) R^{3A'} ist -C₁-C₈-Alkyl, -C₁-C₈-Halogenalkyl, -C₃-C₈-Carbocyclyl oder Halogen; und
R^{3B'} ist -C₁-C₈-Alkyl, -C₁-C₈-Halogenalkyl, -C₃-C₈-Carbocyclyl oder R^{3B'} ist C₂-C₄-Alkylen und bildet ein gesättigten 5 bis 6 gliedrigen Ring, bezeichnet mit


oder

- (ii) R^{3A'} und R^{3B'} sind zusammengekommen entweder C₂-C₈-Alkylen, welches C₂-C₈-Alkylen, wenn zusammengekommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet;

oder C₁-C₈-Heteroalkylen, welches C₁-C₈-Heteroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;
R⁵ ist



C₁-C₁₀-Heterocyclyl, C₃-C₈-Carbocyclyl und C₆-C₁₄-Aryl, optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen, die unabhängig ausgewählt sind aus der Gruppe, bestehend aus -C₁-C₈-Alkyl, -C₁-C₈-Alkyl-N(R')₂, -C₁-C₈-Alkyl-C(O)R', -C₁-C₈-Alkyl-C(O)OR', -O-(-C₁-C₈-Alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, Halogen, -N₃, -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(O)₂R' und -SR', wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C₁-C₈-Alkyl und nicht substituiertem Aryl, oder zwei R' können, zusammen mit dem Stickstoff, an den sie gebunden sind, ein C₁-C₁₀-Heterocyclyl bilden; oder R⁵ ist



optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen unabhängig ausgewählt aus der Gruppe, bestehend aus -C₁-C₈-Alkyl, -C₁-C₈-Alkyl-N(R')₂, -C₁-C₈-Alkyl-C(O)R', -C₁-C₈-Alkyl-C(O)OR', -O-(-C₁-C₈-Alkyl), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, Halogen, -N₃, -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(O)₂R', -SR' und Arylen-R', wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C₁-C₈-Alkyl, C₁-C₈-Heterocyclyl, C₁-C₁₀-Alkylen-C₃-C₈-heterocyclyl und

Aryl, oder zwei R' können, zusammen mit dem Stickstoff, an den sie gebunden sind, ein C₁-C₁₀-Heterocyclyl bilden;


R⁶ ist Wasserstoff, -C₁-C₈-Alkyl, -C₂-C₈-Alkenyl, -C₂-C₈-Alkynyl oder -C₁-C₈-Halogenalkyl;

R¹² ist Wasserstoff, -C₁-C₄-Alkyl, -C₁-C₁₀-Heterocyclyl oder -C₆-C₁₄-Aryl;

R¹³ ist -C₁-C₁₀-Heterocyclyl; und

X ist O.


9. Verbindung der Formel III d:



III d

oder ein pharmazeutisch annehmbares Salz oder Solvat davon, wobei, unabhängig für jedes Vorkommen, gilt:

W ist



R¹ ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;

R² ist Wasserstoff, C₁-C₈-Alkyl oder C₁-C₈-Halogenalkyl;










R^{3A} und R^{3B} sind eines der folgenden:

(i) R^{3A} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; und


R^{3B} ist C₁-C₈-Alkyl, C₁-C₈-Halogenalkyl, C₃-C₈-Carbocyclyl oder Halogen; oder

(ii) R^{3A} und R^{3B} sind zusammengekommen entweder C₂-C₈-Alkylen, welches C₂-C₈-Alkylen, wenn zusammengekommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C₁-C₈-Heteroalkylen, welches C₁-C₈-Heteroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet;

R⁵ ist




oder




optional substituiert mit 1, 2, 3, 4 oder 5 Gruppen unabhängig ausgewählt aus der Gruppe, bestehend aus C_1 - C_8 -Alkyl, $-O-(C_1-C_8\text{-Alkyl})$, $-C(O)R'$, $-OC(O)R'$, $C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, Halogen, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ und $-SR'$, wobei jedes R' unabhängig ausgewählt ist aus der Gruppe, bestehend aus Wasserstoff, C_1 - C_8 -Alkyl und nicht substituiertem Aryl;
[linker] ist ein divalentener Linker;
L ist ein Antikörper;
X ist O.

10. Verbindung, Salz oder Solvat nach einem der Ansprüche 1 bis 5, 7 und 9, wobei W




ist.

11. Verbindung, Salz oder Solvat nach einem der Ansprüche 1 bis 5, 7 und 9, wobei W



ist.


12. Verbindung, Salz oder Solvat nach einem der Ansprüche 1 bis 5, 7 und 9, wobei R^2 Wasserstoff oder C_1 - C_8 -Alkyl ist.
13. Verbindung, Salz oder Solvat nach einem der Ansprüche 1 bis 5, 7 und 9, wobei R^{3A} C_1 - C_8 -Alkyl, bevorzugt Methyl ist.
14. Verbindung, Salz oder Solvat nach einem der Ansprüche 1 bis 5, 7 und 9, wobei gilt: R^{3A} und R^{3B} sind zusammenge-
nommen entweder C_2 - C_8 -Alkylen, welches C_2 - C_8 -Alkylen, wenn zusammenge-
nommen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten carbocyclischen Ring bildet; oder C_1 - C_8 -Heteroalkylen, welches C_1 - C_8 -He-
teroalkylen, zusammen mit dem Kohlenstoff, an den es gebunden ist, einen gesättigten heterocyclischen Ring bildet.
15. Verbindung, Salz oder Solvat nach Anspruch 14, wobei R^{3A} und R^{3B} zusammenge-
nommen $-CH_2CH_2-$ sind, welches $-CH_2CH_2-$, wenn zusammenge-
nommen mit dem Kohlenstoff, an den es gebunden ist, Cyclopropyl bildet.
16. Verbindung, Salz oder Solvat nach Anspruch 14, wobei R^{3A} und R^{3B} zusammenge-
nommen $-CH_2CH_2CH_2CH_2-$ sind, welches $-CH_2CH_2CH_2CH_2-$, wenn zusammenge-
nommen mit dem Kohlenstoff, an den es gebunden ist, Cyclopentyl bildet.
17. Verbindung, Salz oder Solvat nach Anspruch 14, wobei R^{3A} und R^{3B} zusammenge-
nommen $-CH_2OCH_2-$ sind, wel-
ches $-CH_2OCH_2-$, wenn zusammenge-
nommen mit dem Kohlenstoff, an den es gebunden ist, Oxetanyl bildet.
18. Verbindung, Salz oder Solvat nach einem der Ansprüche 1 bis 2, 4, 6, und 8, wobei R^5




ist.

19. Verbindung, Salz oder Solvat nach einem der Ansprüche 4 bis 9, wobei der Antikörper ausgewählt ist aus Trastu-
zumab, Oregovomab, Edrecolomab, Cetuximab, einem humanisierten monoklonalen Antikörper für den Vitronec-
tinrezeptor ($\alpha_v\beta_3$); Alemtuzumab; einem humanisierten Anti-HLD-DR-Antikörper zur Behandlung von non-Hodgkin-
Lymphom; ^{131}I Lym-1; einem murinen Anti-HLA-Dr10-Antikörper zur Behandlung von non-Hodgkin-Lymphom;
einem humanisierten Anti-CD2 mAb für die Behandlung von Hodgkin-Krankheit oder non-Hodgkin-Lymphom; La-
betuzumab; Bevacizumab; Ibritumomab tiuxetan; Ofatumumab; Panitumumab; Rituximab; Tositumomab; Ipili-
mumab; Gemtuzumab; einem Anti-IL13-Antikörper; und einem Anti-Notch-Antikörper.
20. Verbindung oder ein pharmazeutisch annehmbares Salz oder Solvat davon, nach Anspruch 1, ausgewählt aus:


5




10




15




20




25




30



35




45




50

55

5




10



15


20



25




30




35


40



45



50




55








5




10






15




20





25






30






35




40




45




50




55







21. Verbindung oder pharmazeutisch annehmbares Salz oder Solvat davon, nach Anspruch 1, ausgewählt aus:




5




10



15




20




25

30




35




40

45




50


55



5




10




15


20




25



30




35



40





45




50

55













22. Payload-Linker oder Antikörperarzneimittelkonjugat, oder pharmazeutisch annehmbares Salz oder Solvat davon, nach einem der Ansprüche 2 bis 9, umfassend einen Rest einer Verbindung nach Anspruch 20 oder 21.

23. Antikörperarzneimittelkonjugat oder pharmazeutisch annehmbares Salz oder Solvat davon, umfassend einen Rest einer Verbindung nach Ansprüche 1 bis 3.


24. Verbindung oder pharmazeutisch annehmbares Salz oder Solvat davon, nach einem der Ansprüche 2 oder 3, ausgewählt aus:



5




10




15

20




25

30




35

40












45




50

55







5




10




15




20




25



30




35




40










45











50




55







5




10



15




20




25


30



35




40























45










50











55











und




25. Antikörperarzneimittelkonjugat oder pharmazeutisch annehmbares Salz oder Solvat davon, nach einem der Ansprüche 4, 5, 7 oder 9, enthaltend einen Rest einer Verbindung nach Anspruch 24.

26. Verbindung nach Anspruch 1 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche




ist.

27. Verbindung nach Anspruch 1 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche




ist.

28. Verbindung nach Anspruch 1 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche




ist.

29. Verbindung nach Anspruch 1 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche




ist.

30. Verbindung nach Anspruch 1 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche




ist.

31. Verbindung nach Anspruch 1 oder pharmazeutisch/ annehmbares Salz oder Solvat davon, welche




ist.

32. Verbindung nach Anspruch 1 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche



ist.


33. Verbindung nach Anspruch 1 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche



ist.


34. Payload-Linker oder Antikörperarzneimittelkonjugat oder pharmazeutisch annehmbares Salz oder Solvat davon, nach einem der Ansprüche 2 bis 9, umfassend einen Rest einer Verbindung nach Ansprüche 26 bis 33.

35. Verbindung nach Anspruch 24 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche




ist.

36. Verbindung nach Anspruch 24 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche




ist.

37. Verbindung nach Anspruch 24 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche




ist.

38. Verbindung nach Anspruch 24 oder pharmazeutisch annehmbares Salz oder Solvat davon, welche



ist.

39. Verbindung nach Anspruch 24 oder ein pharmazeutisch annehmbares Salz oder Solvat davon, welche



ist.


40. Antikörperarzneimittelkonjugat oder pharmazeutisch annehmbares Salz oder Solvat davon, nach einem der Ansprüche 4, 5, 7 oder 9, umfassend einen Rest der Verbindung nach Ansprüchen 35 bis 39.

41. Pharmazeutische Zusammensetzung umfassend einer Verbindung nach einem der Ansprüche 1 bis 40 oder ein pharmazeutisch annehmbares Salz oder Solvat davon und pharmazeutisch annehmbaren Hilfsstoffe.

42. Verbindung nach einem der Ansprüche 1 bis 40 oder ein pharmazeutisch annehmbares Salz oder Solvat davon, oder pharmazeutische Zusammensetzung nach Anspruch 41 zur Verwendung in der Behandlung von Krebs.

Revendications


1. Composé de formule I :



I

ou solvate ou sel pharmaceutiquement acceptable de celui-ci, dans lequel, indépendamment pour chaque occurrence,

W est



R¹ est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;

R² est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;

R^{3A} et R^{3B} sont l'un ou l'autre des suivants :

(i) R^{3A} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; et


R^{3B} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; ou

(ii) R^{3A} et R^{3B} pris ensemble sont soit C₂-C₈ alkylène, lequel C₂-C₈ alkylène lorsqu'il est pris conjointement

avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C₁-C₈ hétéroalkylène, lequel

C₁-C₈ hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé ;


R⁵ est



C₁-C₁₀ hétérocyclyle, C₃-C₈ carbocycly et C₆-C₁₄ aryle optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en -C₁-C₈ alkyle, -C₁-C₈ alkyle-N (R')₂, -C₁-C₈ alkyle-C (O)R', -C₁-C₈ alkyle-C(O)OR', -O-(C₁-C₈alkyle), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogène, -N₃, -N(R')₂, -CN, -NHC (=NH) NH₂, -NHCONH₂, -S(=O)₂R' et -SR', dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C₁-C₈ alkyle et aryle

non substitué, ou deux R' peuvent, conjointement avec l'azote auquel ils sont attachés, former un C₁-C₁₀ hétérocycle ;
ou R⁵ est

5



optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en C₁-C₈ alkyle, -C₁-C₈ alkyle-N(R')₂, -C₁-C₈ alkyle-C (O)R', -C₁-C₈ alkyle-C (O)OR', -O-(C₁-C₈alkyle), -C(O)R', -OC(O)R', -C(O)OR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogène, -N₃, -N(R')₂, -CN, -NHC (=NH)NH₂, -NHCONH₂, -S(=O)₂R', -SR' et arylène-R', dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C₁-C₈ alkyle, C₁-C₈hétérocyclyle, C₁-C₁₀alkylène-C₃-C₈hétérocyclyle et aryle, ou deux R' peuvent, conjointement avec l'azote auquel ils sont attachés, former un C₁-C₁₀ hétérocyclyle ;

R⁶ est hydrogène, -C₁-C₈ alkyle, -C₂-C₈ alcényle, -C₂-C₈ alcynyle ou -C₁-C₈ halogénoalkyle ;


R¹² est hydrogène, C₁-C₄ alkyle, C₁-C₁₀ hétérocyclyle ou C₆-C₁₄ aryle ;

R¹³ est C₁-C₁₀ hétérocyclyle ; et

X est O.

2. Composé de formule IIa :

25




IIa

ou solvate ou sel pharmaceutiquement acceptable de celui-ci, dans lequel, indépendamment pour chaque occurrence.

West

40



ou

 R^1 est

50

55



15



25

30

35


40

45

50


55






C_1 - C_{10} hétérocyclyle, C_3 - C_8 carbocyclyle et C_6 - C_{14} aryle optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en $-C_1$ - C_8 alkyle, $-C_1$ - C_8 alkyle-N (R')₂, $-C_1$ - C_8 alkyle-C (O) R' , $-C_1$ - C_8 alkyle-C (O)OR', $-O$ -(C_1 - C_8 alkyle), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogène, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ et $-SR'$, dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C_1 - C_8 alkyle et aryle non substitué, ou deux R' peuvent, conjointement avec l'azote auquel ils sont attachés, former un C_1 - C_{10} hétérocyclyle ;

ou R^5 est



ou



optionnellement substitué par 1, 2, 3, 4 ou 5 groupes choisis indépendamment dans le groupe consistant en $-C_1$ - C_8 alkyle, $-C_1$ - C_8 alkyle-N(R')₂, $-C_1$ - C_8 alkyle-C (O) R' , $-C_1$ - C_8 alkyle-C (O)OR', $-O$ -(C_1 - C_8 alkyle), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogène, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$, $-SR'$ et arylène- R' , dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C_1 - C_8 alkyle, C_1 - C_8 hétérocyclyle, C_1 - C_{10} alkylène- C_3 - C_8 hétérocyclyle et aryle, ou deux R' peuvent, conjointement avec l'azote auquel ils sont attachés, former un C_1 - C_{10} hétérocyclyle ;

R^6 est hydrogène, $-C_1$ - C_8 alkyle, $-C_2$ - C_8 alcényle, $-C_2$ - C_8 alcynyle ou $-C_1$ - C_8 halogénoalkyle ;

R^{12} est hydrogène, C_1 - C_4 alkyle, C_1 - C_{10} hétérocyclyle ou C_6 - C_{14} aryle ;

R^{13} est C_1 - C_{10} hétérocyclyle ; et


R^7 est indépendamment choisi, pour chaque occurrence, dans le groupe consistant en F, Cl, I, Br, NO_2 , CN et CF_3 ;

R¹⁰ est hydrogène, -C₁-C₁₀alkyle, -C₃-C₈carbocyclyle, -aryle, -C₁-C₁₀hétéroalkyle, -C₃-C₈hétérocyclo, -C₁-C₁₀alkylène-aryle, -arylène-C₁-C₁₀alkyle, -C₁-C₁₀alkylène- (C₃-C₈) carbocyclo), -(C₃-C₈carbocyclo) -C₁-C₁₀alkyle, -C₁-C₁₀alkylène- (C₃-C₈hétérocyclo), et - (C₃-C₈hétérocyclo) -C₁-C₁₀alkyle, où aryle sur R₁₀ comprenant aryle est optionnellement substitué par [R₇]_h ;

h vaut 1, 2, 3, 4 ou 5 ; et

X est O.


3. Composé de formule IIIa :



IIIa

ou solvate ou sel pharmaceutiquement acceptable de celui-ci, dans lequel, indépendamment pour chaque occurrence,

W est



R¹ est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;

R² est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;


R^{3A} et R^{3B} sont l'un ou l'autre des suivants :


(i) R^{3A} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; et

R^{3B} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; ou


(ii) R^{3A} et R^{3B} pris ensemble sont soit C₂-C₈ alkylène, lequel C₂-C₈ alkylène lorsqu'il est pris conjointement avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C₁-C₈ hétéroalkylène, lequel C₁-C₈ hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé ;

R⁵ est








ou



optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en C₁-C₈ alkyle, -O-(C₁-C₈alkyle), -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH₂, -C(O)NHR', -C(O)N(R')₂, -NHC(O)R', -S(O)₂R', -S(O)R', -OH, halogène, -N₃, -NH₂, -NH(R'), -N(R')₂, -CN, -NHC(=NH)NH₂, -NHCONH₂, -S(=O)₂R' et -SR', dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C₁-C₈ alkyle et aryle non substitué ;


R¹¹ est


ou



Y est -C₂-C₂₀ alkylène-, -C₂-C₂₀ hétéroalkylène- ; -C₃-C₈ carbocyclo-, -arylène-, -C₃-C₈ hétérocyclo-, -C₁-C₁₀alkylène-arylène-, -arylène-C₁-C₁₀alkylène-, -C₁-C₁₀-alkylène- (C₃-C₈carbocyclo)-, (C₃-C₈carbocyclo)-C₁-C₁₀alkylène-, -C₁-C₁₀alkylène- (C₃-C₈hétérocyclo)- ou - (C₃-C₈hétérocyclo)-C₁-C₁₀alkylène- ;

Z est





ou -NH_2 ;


G est halogène, -OH , -SH ou $\text{S-C}_1\text{-C}_6$ alkyle ;

R^7 est indépendamment choisi, pour chaque occurrence, dans le groupe consistant en F, Cl, I, Br, NO_2 , CN et CF_3 ;

h vaut 1, 2, 3, 4 ou 5 ; et

X est O.


4. Composé de formule IIb :



IIb


ou solvate ou sel pharmaceutiquement acceptable de celui-ci, dans lequel, indépendamment pour chaque occurrence,

W est



ou


R^1 est



ou

Y est $\text{-C}_2\text{-C}_{20}$ alkylène-, $\text{-C}_2\text{-C}_{20}$ hétéroalkylène-; $\text{-C}_3\text{-C}_8$ carbocyclo-, -arylène-, $\text{-C}_3\text{-C}_8$ hétérocyclo-, $\text{-C}_1\text{-C}_{10}$ alkylène-arylène-, -arylène- $\text{-C}_1\text{-C}_{10}$ alkylène-, $\text{-C}_1\text{-C}_{10}$ -alkylène- ($\text{-C}_3\text{-C}_8$ carbocyclo-), ($\text{-C}_3\text{-C}_8$ carbocyclo)

-C₁-C₁₀alkylène-, -C₁-C₁₀alkylène- (C₃-C₈hétérocyclo) - ou -(C₃-C₈hétérocyclo)-C₁-C₁₀alkylène- ;
Z est



ou -NHL ;

L est un anticorps ;

R² est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;


R^{3A} et R^{3B} sont l'un ou l'autre des suivants :

(i) R^{3A} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; et

R^{3B} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; ou

(ii) R^{3A} et R^{3B} pris ensemble sont soit C₂-C₈ alkylène, lequel C₂-C₈ alkylène lorsqu'il est pris conjointement avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C₁-C₈ hétéroalkylène, lequel C₁-C₈ hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé ;

R⁵ est





15



25


34



45

50

54



R^1 est hydrogène, C_1 - C_8 alkyle ou C_1 - C_8 halogénoalkyle ;

R^2 est hydrogène, C_1 - C_8 alkyle ou C_1 - C_8 halogénoalkyle ;


R^{3A} et R^{3B} sont l'un ou l'autre des suivants :

(i) R^{3A} est C_1 - C_8 alkyle, C_1 - C_8 halogénoalkyle, C_3 - C_8 carbocyclyle ou halogène ; et


R^{3B} est C_1 - C_8 alkyle, C_1 - C_8 halogénoalkyle, C_3 - C_8 carbocyclyle ou halogène ; ou

(ii) R^{3A} et R^{3B} pris ensemble sont soit C_2 - C_8 alkylène, lequel C_2 - C_8 alkylène lorsqu'il est pris conjointement avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C_1 - C_8 hétéroalkylène, lequel C_1 - C_8 hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé ;

R^5 est




ou



optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en C_1 - C_8 alkyle, $-O-(C_1-C_8\text{alkyle})$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogène, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ et $-SR'$, dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C_1 - C_8 alkyle et aryle non substitué ;


R^{11} est



5

10

15




ou

20

Y est -C₂-C₂₀ alkylène-, -C₂-C₂₀ hétéroalkylène-, -C₃-C₈ carbocyclo-, -arylène-, -C₃-C₈ hétérocyclo-,
 -C₁-C₁₀alkylène-arylène-, -arylène-C₁-C₁₀alkylène-, -C₁-C₁₀-alkylène-(C₃-C₈carbocyclo)-,
 -(C₃-C₈carbocyclo)-C₁-C₁₀alkylène-, -C₁-C₁₀alkylène-(C₃-C₈hétérocyclo)- ou
 -(C₃-C₈hétérocyclo)-C₁-C₁₀alkylène- ;
 Z est


25



30

35

40




45

ou -NHL ;
 L est un anticorps ;
 X est O.

50

6. Composé de formule IIc :


55



IIc


ou solvate ou sel pharmaceutiquement acceptable de celui-ci, dans lequel, indépendamment pour chaque occurrence,

R^{1'} est



ou

Y est -C₂-C₂₀ alkylène-, -C₂-C₂₀ hétéroalkylène-; -C₃-C₈ carbocyclo-, -arylène-, -C₃-C₈ hétérocyclo-,
 -C₁-C₁₀alkylène-arylène-, -arylène-C₁-C₁₀alkylène-, -C₁-C₁₀-alkylène-(C₃-C₈carbocyclo)-,
 -(C₃-C₈carbocyclo)-C₁-C₁₀alkylène-, -C₁-C₁₀alkylène-(C₃-C₈hétérocyclo)- ou -
 (C₃-C₈hétérocyclo)-C₁-C₁₀alkylène-;
 Z' est



ou -NH-;

L est un anticorps;


D est absent;

R^{2'} est hydrogène, C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, ou est absent si est présent;

R^{3A'} et R^{3B'} sont l'un ou l'autre des suivants:


- (i) $R^{3A'}$ est C_1 - C_8 alkyle, C_1 - C_8 halogénoalkyle, C_3 - C_8 carbocycle ou halogène ; et $R^{3B'}$ est C_1 - C_8 alkyle, C_1 - C_8 halogénoalkyle, C_3 - C_8 carbocycle ou halogène, ou $R^{3B'}$ est C_2 - C_4 alkylène et forme un cycle saturé à 5 à 6 chaînons comme indiqué par ou
- (ii) $R^{3A'}$ et $R^{3B'}$ pris ensemble sont soit C_2 - C_8 alkylène, lequel C_2 - C_8 alkylène lorsqu'il est pris conjointement avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C_1 - C_8 hétéroalkylène, lequel C_1 - C_8 hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé ;

R^5 est



C_1 - C_{10} hétérocycle, C_3 - C_8 carbocycle et C_6 - C_{14} aryle optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en $-C_1$ - C_8 alkyle, $-C_1$ - C_8 alkyle- $N(R')$, $-C_1$ - C_8 alkyle- $C(O)R'$, $-C_1$ - C_8 alkyle- $C(O)OR'$, $-O-(C_1$ - C_8 alkyle), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogène, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ et $-SR'$, dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C_1 - C_8 alkyle et aryle non substitué, ou deux R' peuvent, conjointement avec l'azote auquel ils sont attachés, former un C_1 - C_{10} hétérocycle ;


ou R^5 est



optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en C_1 - C_8 alkyle, $-C_1$ - C_8 alkyle- $N(R')$, $-C_1$ - C_8 alkyle- $C(O)R'$, $-C_1$ - C_8 alkyle- $C(O)OR'$, $-O-(C_1$ - C_8 alkyle), $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogène, $-N_3$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$

NH₂, -NHCONH₂, -S(=O)₂R', -SR' et arylène-R', dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C₁-C₈ alkyle, C₁-C₈hétérocyclyle, C₁-C₁₀alkylène-C₃-C₈hétérocyclyle et aryle, ou deux R' peuvent, conjointement avec l'azote auquel ils sont attachés, former un C₁-C₁₀ hétérocyclyle ;
 R⁶ est hydrogène, -C₁-C₈ alkyle, -C₂-C₈ alcényle, -C₂-C₈ alcynyle ou -C₁-C₈ halogénoalkyle ;
 R¹² est hydrogène, C₁-C₄ alkyle, C₁-C₁₀ hétérocyclyle ou C₆-C₁₄ aryle ;
 R¹³ est C₁-C₁₀ hétérocyclyle ; et
 X est O.


7. Composé de formule IIIc :



IIIc

ou solvate ou sel pharmaceutiquement acceptable de celui-ci, dans lequel, indépendamment pour chaque occurrence,

W est



R¹ est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;

R² est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;


R^{3A} et R^{3B} sont l'un ou l'autre des suivants :


(i) R^{3A} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; et

R^{3B} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; ou


(ii) R^{3A} et R^{3B} pris ensemble sont soit C₂-C₈ alkylène, lequel C₂-C₈ alkylène lorsqu'il est pris conjointement avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C₁-C₈ hétéroalkylène, lequel C₁-C₈ hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé ;

R⁵ est






ou



optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en C_1 - C_8 alkyle, $-O-(C_1-C_8\text{alkyle})$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogène, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ et $-SR'$, dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C_1 - C_8 alkyle et aryle non substitué ;



$R^{11'}$ est



ou


Y est $-C_2-C_{20}$ alkylène-, $-C_2-C_{20}$ hétéroalkylène- ; $-C_3-C_8$ carbocyclo-, -arylène-, $-C_3-C_8$ hétérocyclo-, $-C_1-C_{10}$ alkylène-arylène-, -arylène- $-C_1-C_{10}$ alkylène-, $-C_1-C_{10}$ -alkylène- (C_3-C_8 carbocyclo)-, $-(C_3-C_8\text{carbocyclo})-C_1-C_{10}$ alkylène-, $-C_1-C_{10}$ alkylène- (C_3-C_8 hétérocyclo)- ou $-(C_3-C_8\text{hétérocyclo})-C_1-C_{10}$ alkylène- ;

Z' est



ou -NH- ;
L est un anticorps ;
X est O.


8. Composé de formule IId :



IId

ou solvate ou sel pharmaceutiquement acceptable de celui-ci, dans lequel, indépendamment pour chaque occurrence,


L est un anticorps ;
[lieur] est un lieu divalent ;
D est absent ;
R² est hydrogène, C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, ou est absent si



est présent ;
R^{3A'} et R^{3B'} sont l'un ou l'autre des suivants :

(i) R^{3A'} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocycle ou halogène ; et


R^{3B'} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocycle, ou R^{3B'} est C₂-C₄ alkylène et forme un cycle saturé à 5 à 6 chaînons comme indiqué par




ou

(ii) R^{3A'} et R^{3B'} pris ensemble sont soit C₂-C₈ alkylène, lequel C₂-C₈ alkylène lorsqu'il est pris conjointement avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C₁-C₈ hétéroalkylène, lequel C₁-C₈ hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé ;


R⁵ est






$\text{C}_1\text{-C}_{10}$ hétérocyclyle, $\text{C}_3\text{-C}_8$ carbocyclyle et $\text{C}_6\text{-C}_{14}$ aryle optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en $-\text{C}_1\text{-C}_8$ alkyle, $-\text{C}_1\text{-C}_8$ alkyle- $\text{N}(\text{R}')_2$, $-\text{C}_1\text{-C}_8$ alkyle- $\text{C}(\text{O})\text{R}'$, $-\text{C}_1\text{-C}_8$ alkyle- $\text{C}(\text{O})\text{OR}'$, $-\text{O}(\text{C}_1\text{-C}_8\text{alkyle})$, $-\text{C}(\text{O})\text{R}'$, $-\text{OC}(\text{O})\text{R}'$, $-\text{C}(\text{O})\text{OR}'$, $-\text{C}(\text{O})\text{N}(\text{R}')_2$, $-\text{NHC}(\text{O})\text{R}'$, $-\text{S}(\text{O})_2\text{R}'$, $-\text{S}(\text{O})\text{R}'$, $-\text{OH}$, halogène, $-\text{N}_3$, $-\text{N}(\text{R}')_2$, $-\text{CN}$, $-\text{NHC}(\text{=NH})\text{NH}_2$, $-\text{NHCONH}_2$, $-\text{S}(\text{=O})_2\text{R}'$ et $-\text{SR}'$, dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, $\text{C}_1\text{-C}_8$ alkyle et aryle non substitué, ou deux R' peuvent, conjointement avec l'azote auquel ils sont attachés, former un $\text{C}_1\text{-C}_{10}$ hétérocyclyle ;

ou R^5 est



ou



optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en $\text{C}_1\text{-C}_8$ alkyle, $-\text{C}_1\text{-C}_8$ alkyle- $\text{N}(\text{R}')_2$, $-\text{C}_1\text{-C}_8$ alkyle- $\text{C}(\text{O})\text{R}'$, $-\text{C}_1\text{-C}_8$ alkyle- $\text{C}(\text{O})\text{OR}'$, $-\text{O}(\text{C}_1\text{-C}_8\text{alkyle})$, $-\text{C}(\text{O})\text{R}'$, $-\text{OC}(\text{O})\text{R}'$, $-\text{C}(\text{O})\text{OR}'$, $-\text{C}(\text{O})\text{N}(\text{R}')_2$, $-\text{NHC}(\text{O})\text{R}'$, $-\text{S}(\text{O})_2\text{R}'$, $-\text{S}(\text{O})\text{R}'$, $-\text{OH}$, halogène, $-\text{N}_3$, $-\text{N}(\text{R}')_2$, $-\text{CN}$, $-\text{NHC}(\text{=NH})\text{NH}_2$, $-\text{NHCONH}_2$, $-\text{S}(\text{=O})_2\text{R}'$, $-\text{SR}'$ et arylène- R' , dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, $\text{C}_1\text{-C}_8$ alkyle, $\text{C}_1\text{-C}_8$ hétérocyclyle, $\text{C}_1\text{-C}_{10}$ alkylène- $\text{C}_3\text{-C}_8$ hétérocyclyle et aryle, ou deux R' peuvent, conjointement avec l'azote auquel ils sont attachés, former un $\text{C}_1\text{-C}_{10}$ hétérocyclyle ;

R^6 est hydrogène, $\text{C}_1\text{-C}_8$ alkyle, $\text{C}_2\text{-C}_8$ alcényle, $\text{C}_2\text{-C}_8$ alcynyle ou $\text{C}_1\text{-C}_8$ halogénoalkyle ;

R^{12} est hydrogène, $\text{C}_1\text{-C}_4$ alkyle, $\text{C}_1\text{-C}_{10}$ hétérocyclyle ou $\text{C}_6\text{-C}_{14}$ aryle ;


R^{13} est $\text{C}_1\text{-C}_{10}$ hétérocyclyle ; et

X est O.

9. Composé de formule IIIId :

5

10



IIIId


15

ou solvate ou sel pharmaceutiquement acceptable de celui-ci, dans lequel, indépendamment pour chaque occurrence,

W est

20

25



ou

30

R¹ est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;

R² est hydrogène, C₁-C₈ alkyle ou C₁-C₈ halogénoalkyle ;

R^{3A} et R^{3B} sont l'un ou l'autre des suivants :

35

(i) R^{3A} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; et

R^{3B} est C₁-C₈ alkyle, C₁-C₈ halogénoalkyle, C₃-C₈ carbocyclyle ou halogène ; ou

(ii) R^{3A} et R^{3B} pris ensemble sont soit C₂-C₈ alkylène, lequel C₂-C₈ alkylène lorsqu'il est pris conjointement avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C₁-C₈ hétéroalkylène, lequel C₁-C₈ hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé ;


R⁵ est

40


45

50

55




ou




optionnellement substitué par 1, 2, 3, 4 ou 5 groupes indépendamment choisis dans le groupe consistant en C_1-C_8 alkyle, $-O-(C_1-C_8\text{alkyle})$, $-C(O)R'$, $-OC(O)R'$, $-C(O)OR'$, $-C(O)NH_2$, $-C(O)NHR'$, $-C(O)N(R')_2$, $-NHC(O)R'$, $-S(O)_2R'$, $-S(O)R'$, $-OH$, halogène, $-N_3$, $-NH_2$, $-NH(R')$, $-N(R')_2$, $-CN$, $-NHC(=NH)NH_2$, $-NHCONH_2$, $-S(=O)_2R'$ et $-SR'$, dans lequel chaque R' est indépendamment choisi dans le groupe consistant en hydrogène, C_1-C_8 alkyle et aryle non substitué ;
 [lieur] est un lieu divalent ;
 L est un anticorps ;
 X est O.

10. Composé, sel ou solvate selon l'une quelconque des revendications 1 à 5, 7 et 9, dans lequel W est



11. Composé, sel ou solvate selon l'une quelconque des revendications 1 à 5, 7 et 9, dans lequel W est



12. Composé, sel ou solvate selon l'une quelconque des revendications 1 à 5, 7 et 9, dans lequel R^2 est hydrogène ou C_1-C_8 alkyle.

13. Composé, sel ou solvate selon l'une quelconque des revendications 1 à 5, 7 et 9, dans lequel R^{3A} est C_1-C_8 alkyle, de préférence méthyle.


14. Composé, sel ou solvate selon l'une quelconque des revendications 1 à 5, 7 et 9, dans lequel R^{3A} et R^{3B} pris ensemble sont soit C_2-C_8 alkylène, lequel C_2-C_8 alkylène lorsqu'il est pris conjointement avec le carbone auquel il est lié, forme un cycle carbocyclique saturé ; soit C_1-C_8 hétéroalkylène, lequel C_1-C_8 hétéroalkylène, conjointement avec le carbone auquel il est lié, forme un cycle hétérocyclique saturé.

15. Composé, sel ou solvate selon la revendication 14, dans lequel R^{3A} et R^{3B} pris ensemble sont $-CH_2CH_2-$, lequel $-CH_2CH_2-$ lorsqu'il est pris conjointement avec le carbone auquel il est lié forme cyclopropyle.

16. Composé, sel ou solvate selon la revendication 14, dans lequel R^{3A} et R^{3B} pris ensemble sont $-CH_2CH_2CH_2CH_2-$, lequel $-CH_2CH_2CH_2CH_2-$ lorsqu'il est pris conjointement avec le carbone auquel il est lié forme cyclopentyle.


17. Composé, sel ou solvate selon la revendication 14, dans lequel R^{3A} et R^{3B} pris ensemble sont $-CH_2OCH_2-$, lequel $-CH_2OCH_2-$ lorsqu'il est pris conjointement avec le carbone auquel il est lié forme oxétanyle.

18. Composé, sel ou solvate selon l'une quelconque des revendications 1 et 2, 4, 6 et 8, dans lequel R⁵ est




19. Composé, sel ou solvate selon l'une quelconque des revendications 4 à 9, dans lequel l'anticorps est choisi parmi trastuzumab, orégovomab, édrécolomab, cétuximab, un anticorps monoclonal humanisé pour le récepteur de vitronectine ($\alpha_v\beta_3$) ; alemtuzumab ; un anticorps anti-HLA-DR humanisé pour le traitement d'un lymphome non hodgkinien ; 1211 Lym-1 ; un anticorps anti-HLA-Dr10 murin pour le traitement d'un lymphome non hodgkinien ; un mAb anti-CD2 humanisé pour le traitement de la maladie de Hodgkin ou d'un lymphome non hodgkinien ; labétuzumab ; bévacizumab ; ibritumomab tiuxétan ; ofatumumab ; panitumumab ; rituximab ; tositumomab ; ipilimumab ; gemtuzumab ; un anticorps anti-IL13 ; et un anticorps anti-Notch.


20. Composé, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, selon la revendication 1, choisi parmi :




5




10




15




20




25




35




40




45



50



55



,


5



,

,


10



,


,

15




,


20



,




,




,

25




,


30



,




,




,


35



,




,




,


40



,




,




,


45



,




,




,

55


5




10




15




20



25




30



35


40



45

et


50




21. Composé, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, selon la revendication 1, choisi parmi :

55


5




10




15




20




25




30



35




45




50

55


5



10




15




20


25




30




35




40



45




50




55


5




10




15




20




25



30




35




40



45



50







55




22. Lieux de charge utile ou conjugué anticorps-médicament, ou solvate ou sel pharmaceutiquement acceptable de ceux-ci, selon l'une quelconque des revendications 2 à 9, comprenant un radical d'un composé de la revendication 20 ou 21.

23. Conjugué anticorps-médicament, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, comprenant un radical d'un composé des revendications 1 à 3.


24. Composé, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, selon l'une quelconque des revendications 2 ou 3 choisi parmi :



5




10




15

20




25

30




35

40




45




50

55




5




10


15




20



25




30




35


40



45




50




55


5




10



15




20




25

30




35




40


45




50




55







5




10




15




20




25




30



35




45




55

5




10




15

20




25


30



35




40




45

50




55

5




10




15

20




25

30




35




40

45




50




55


5




10



15




20




25


30



35




40




45

50




55


5




10




15




20




25




30




35












40















50




55








et




25. Conjugué anticorps-médicament ou solvate ou sel pharmaceutiquement acceptable de celui-ci, selon l'une quelconque des revendications 4, 5, 7 ou 9 comprenant un radical d'un composé de la revendication 24.


26. Composé selon la revendication 1, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




27. Composé selon la revendication 1, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




28. Composé selon la revendication 1, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




29. Composé selon la revendication 1, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




30. Composé selon la revendication 1, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




31. Composé selon la revendication 1, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est



32. Composé selon la revendication 1, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




33. Composé selon la revendication 1, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




34. Lieur de charge utile ou conjugué anticorps-médicament, ou solvate ou sel pharmaceutiquement acceptable de ceux-ci, selon l'une quelconque des revendications 2 à 9, comprenant un radical d'un composé des revendications 26 à 33.


35. Composé selon la revendication 24, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




36. Composé selon la revendication 24, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est




37. Composé selon la revendication 24, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est



38. Composé selon la revendication 24, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est



39. Composé selon la revendication 24, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, qui est



40. Conjugué anticorps-médicament, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, selon l'une quelconque des revendications 4, 5, 7 ou 9, comprenant un radical d'un composé des revendications 35 à 39.

41. Composition pharmaceutique comprenant un composé de l'une quelconque des revendications 1 à 40, ou un solvate ou sel pharmaceutiquement acceptable de celui-ci, et un excipient pharmaceutiquement acceptable.

42. Composé selon l'une quelconque des revendications 1 à 40, ou solvate ou sel pharmaceutiquement acceptable de celui-ci, ou composition pharmaceutique selon la revendication 41, à utiliser dans le traitement du cancer.

Figure 1





Figure 2


Figure 3

Figure 4A




Figure 4B









Figure 4C












Figure 6

Figure 7




Figure 8A

Efficacy of rat-human chimeric anti-Notch ADC's dosed at 5mg/kg in HCC2429 lung xenografts

HCC2429 Lung xenografts, tumor volume (mm ³ +/- SEM)													
Day	PBS	ch28- mc0101	ch28- mc0131	ch28- MALPEG6 C2-0131	ch75- mc0131	ch28- vc0101	ch75- vc0101	ch75- vc0780	huNeg8.8 -mc0131	huNeg8.8 -mc0377	huNeg8.8 -mc0131	huNeg8.8 -vc0101	huNeg8.8 -vc0780
-2	192 +44	195 +37	195 +39	196 +47	195 +35	195 +33	195 +25	205 +35	195 +43	195 +45	195 +42	209 +45	195 +43
2	503 +106	457 +73	525 +101	505 +128	483 +96	395 +54	450 +48	420 +66	503 +119	500 +127	543 +115	580 +136	516 +117
4	838 +187	506 +96	554 +136	536 +192	522 +125	238 +46	366 +47	430 +92	845 +149	637 +175	745 +168	845 +201	739 +177
6	1008 +229	562 +126	600 +152	750 +207	634 +158	258 +33	318 +48	474 +108	1117 +171	939 +243	1016 +225	1118 +270	988 +229
8	1618 +265	552 +133	787 +177	1020 +213	620 +129	177 +24	217 +30	502 +125	1773 +264	1346 +284	1506 +187	1548 +394	1449 +304
11	1805± 228	761 +166	941 +314	1302 +257	737 +162	189 +22	198 +33	601 +155	1986 +170	1608 +259	1873 +283	1532 +407	1682 +316
13	2033± 293	865 +176	1534 +339	1599 +274	802 +184	122 +15	166 +33	755 +186	2535 +228	2257 +350	1631 +400	-	-
16	-	917 +207	949 +190	1556 +300	878 +200	97 +13	120 +26	781 +210	-	-	-	-	-
19	-	1222 +275	1322 +276	1986 +414	1051 +247	88 +14	102 +28	770 +153	-	-	-	-	-
23	-	1634 +401	-	-	1354 +340	79 +25	72 +25	355 +156	-	-	-	-	-
26	-	-	-	-	-	77 +47	64 +28	1153 +253	-	-	-	-	-
30	-	-	-	-	-	109 +86	36 +20	1270 +205	-	-	-	-	-
33	-	-	-	-	-	136 +128	36 +34	1628±30 9	-	-	-	-	-
37	-	-	-	-	-	210 +199	48 +45	-	-	-	-	-	-
40	-	-	-	-	-	323 +311	58 +57	-	-	-	-	-	-
44	-	-	-	-	-	17 +17	108 +107	-	-	-	-	-	-
51	-	-	-	-	-	43 +43	201 +200	-	-	-	-	-	-
58	-	-	-	-	-	82 +82	040	-	-	-	-	-	-
65	-	-	-	-	-	138 +138	040	-	-	-	-	-	-
73	-	-	-	-	-	301 +301	040	-	-	-	-	-	-
79	-	-	-	-	-	-	040	-	-	-	-	-	-
89	-	-	-	-	-	-	040	-	-	-	-	-	-
96	-	-	-	-	-	-	040	-	-	-	-	-	-

Figure 8B

Efficacy of rat-human chimeric anti-Notch ADCs dosed at 5mg/kg in MDA-MB-468 breast xenografts

MDA-MB-468 Breast xenografts, tumor volume (mm ³ ± SEM)									
Day	PBS	ch75- mc3377	ch75-me0131	ch75-MALPEG6 C2-0131	ch75-me0131	huNeg8- me0131	huNeg8- mc3377	huNeg8- me0131	
-1	303 ±10	304 ±19	303 ±18	308 ±22	306 ±14	306 ±14	302 ±21	306 ±21	
2	344 ±14	315 ±26	348 ±21	375 ±16	354 ±7	340 ±16	353 ±25	343 ±26	
5	360 ±17	339 ±25	339 ±16	325 ±23	346 ±14	349 ±19	366 ±31	349 ±31	
8	439 ±28	340 ±20	352 ±21	346 ±27	368 ±15	437 ±35	431 ±25	421 ±36	
12	533 ±37	337 ±22	311 ±26	312 ±31	350 ±18	492 ±27	449 ±30	486 ±41	
15	542 ±40	304 ±23	291 ±22	271 ±18	322 ±22	543 ±42	484 ±48	523 ±35	
19	608 ±46	234 ±20	228 ±25	204 ±20	283 ±19	552 ±37	516 ±28	542 ±45	
22	544 ±34	240 ±20	210 ±26	156 ±21	261 ±22	602 ±38	561 ±38	586 ±47	
26	707 ±58	256 ±22	169 ±14	127 ±14	252 ±25	616 ±65	604 ±34	664 ±52	
29	785 ±72	278 ±33	191 ±19	119 ±16	285 ±27	761 ±53	641 ±42	695 ±57	
33	822 ±78	320 ±45	203 ±23	133 ±22	315 ±31	755 ±80	737 ±57	759 ±66	
36	840 ±87	308 ±53	220 ±18	119 ±20	320 ±30	786 ±55	855 ±54	788 ±81	
40	894 ±80	346 ±51	276 ±39	143 ±20	367 ±41	882 ±90	946 ±69	863 ±77	
44	1040 ±104	373 ±49	312 ±34	152 ±29	421 ±29	1050 ±109	1055 ±54	1002 ±82	
48	1174 ±146	459 ±69	362 ±58	193 ±31	455 ±42	1138 ±131	1148 ±36	1066 ±92	
51	1266 ±144	539 ±83	418 ±49	237 ±31	563 ±48	1301 ±127	1368 ±57	1164 ±98	
54	1244 ±155	543 ±93	427 ±45	220 ±37	592 ±52	1288 ±134	1321 ±56	1206 ±30	
57	1366 ±161	594 ±97	474 ±85	280 ±36	665 ±56	1380 ±151	1530 ±23	1132 ±102	
61	1492 ±129	659 ±100	497 ±80	275 ±36	690 ±52	1380 ±149	1607 ±39	-	
64	-	718 ±117	519 ±93	363 ±45	758 ±64	1420 ±160	1580 ±47	-	
68	-	872 ±152	636 ±117	368 ±48	-	1552 ±198	1550 ±71	-	
71	-	837 ±151	705 ±102	377 ±65	-	-	-	-	
78	-	-	906 ±137	511 ±74	-	-	-	-	

Figure 8C

Efficacy of rat-human chimeric anti-Notch ADCs dosed at 5mg/kg in MDA-MB-468 breast xenograft

MDA-MB-468 Breast xenografts, tumor volume (mm ³ ± SEM)													
Day	PBS	ch28-mc0131	ch28-mc377	ch28-mc0131	ch28-mc0131	ch75-mc0131	ch28-vd0101	ch28-vd0101	ch75-vd0101	ch75-vd0101	ch75-vd0101	huNe08.8-mc0131	huNe08.8-mc377
-1	309 ±11	314 ±12	313 ±20	314 ±15	311 ±22	307 ±19	313 ±22	309 ±23	312 ±7	308 ±8	313 ±21	310 ±15	312 ±18
4	306 ±20	308 ±19	321 ±20	320 ±19	331 ±26	337 ±16	333 ±21	323 ±20	328 ±21	341 ±17	353 ±27	333 ±19	333 ±18
8	414 ±25	315 ±18	297 ±17	306 ±14	295 ±25	315 ±14	241 ±24	203 ±21	297 ±23	323 ±21	334 ±33	391 ±28	349 ±22
11	452 ±31	262 ±15	297 ±15	266 ±12	238 ±22	324 ±22	149 ±17	237 ±25	219 ±16	306 ±25	422 ±33	408 ±31	350 ±35
18	578 ±48	143 ±11	121 ±10	173 ±21	115 ±9	257 ±28	38 ±8	136 ±19	108 ±12	237 ±35	496 ±45	479 ±40	310 ±22
21	515 ±46	107 ±9	119 ±10	145 ±19	68 ±6	214 ±27	24 ±7	138 ±23	70 ±10	232 ±43	499 ±47	569 ±49	275 ±66
28	591 ±89	113 ±16	132 ±15	95 ±18	26 ±10	171 ±24	14 ±7	163 ±28	37 ±11	228 ±50	584 ±51	638 ±72	251 ±66
35	835 ±87	131 ±25	191 ±20	127 ±19	15 ±8	206 ±29	7 ±5	176 ±33	26 ±9	340 ±58	662 ±64	758 ±101	279 ±72
39	968 ±103	179 ±37	234 ±18	148 ±33	32 ±12	267 ±36	0 ±0	229 ±41	13 ±8	400 ±74	702 ±56	882 ±110	361 ±99
42	1034 ±112	158 ±35	236 ±22	174 ±37	32 ±13	240 ±42	0 ±0	242 ±41	10 ±8	420 ±72	753 ±75	345 ±123	362 ±90
46	1140 ±126	191 ±43	230 ±27	188 ±48	44 ±16	233 ±35	0 ±0	243 ±41	11 ±8	442 ±77	834 ±77	1016 ±148	377 ±101
49	1211 ±92	233 ±56	333 ±33	207 ±45	37 ±17	334 ±46	0 ±0	295 ±52	7 ±7	495 ±86	696 ±90	1114 ±150	439 ±115
57	1402 ±112	298 ±67	447 ±37	273 ±59	72 ±28	403 ±53	0 ±0	369 ±65	13 ±13	652 ±110	1093 ±106	1355 ±189	577 ±155
60	-	328 ±69	513 ±42	335 ±67	69 ±28	472 ±59	0 ±0	373 ±61	25 ±16	688 ±118	1108 ±97	1236 ±158	483 ±88
63	-	320 ±70	516 ±44	354 ±67	67 ±29	498 ±58	0 ±0	415 ±76	21 ±14	709 ±114	1092 ±113	1375 ±137	579 ±148
67	-	319 ±85	538 ±49	371 ±77	85 ±37	563 ±63	0 ±0	462 ±94	21 ±15	798 ±136	1203 ±121	-	655 ±165
74	-	431 ±98	632 ±57	382 ±47	114 ±47	565 ±74	0 ±0	493 ±91	47 ±27	928 ±143	-	-	715 ±216
77	-	470 ±113	-	423 ±42	122 ±51	-	0 ±0	-	45 ±26	-	-	-	-
84	-	-	-	-	177 ±72	-	0 ±0	-	67 ±37	-	-	-	-
98	-	-	-	-	162 ±75	-	0 ±0	-	58 ±37	-	-	-	-
104	-	-	-	-	-	-	0 ±0	-	-	-	-	-	-
112	-	-	-	-	-	-	0 ±0	-	-	-	-	-	-
117	-	-	-	-	-	-	0 ±0	-	-	-	-	-	-
126	-	-	-	-	-	-	0 ±0	-	-	-	-	-	-

Figure 8D

Efficacy of rat-human chimeric anti-Neureg1 in N87 gastric xenograft

Day	PBS	N87 Gastric xenografts, tumor volume (mm ³ ± SEM)					
		Det28-mc0131	ch28-vc0101	ch28-vc6780	ch75-vc0101	huNeg8.8-vc0101	huNeg8.8-vc6780
-1	388 ±16	391 ±11	384 ±16	388 ±17	391 ±8	385 ±18	393 ±16
3	815 ±48	609 ±35	538 ±20	484 ±72	536 ±38	631 ±31	711 ±31
6	907 ±56	583 ±41	488 ±48	522 ±41	611 ±27	672 ±40	733 ±43
11	1335 ±67	623 ±50	313 ±28	416 ±48	437 ±29	568 ±74	1019 ±56
14	1260 ±85	452 ±45	206 ±21	297 ±52	275 ±18	447 ±87	988 ±86
18	1393 ±101	468 ±55	183 ±20	285 ±65	228 ±17	419 ±91	997 ±88
21	1701 ±117	528 ±61	189 ±25	314 ±80	221 ±28	462 ±121	1202 ±168
25	-	531 ±72	194 ±30	305 ±84	224 ±44	430 ±131	1151 ±119
28	-	579 ±78	173 ±26	291 ±88	230 ±56	427 ±133	1247 ±137
31	-	597 ±75	176 ±32	349 ±110	256 ±62	458 ±148	1370 ±180
36	-	671 ±89	214 ±45	380 ±121	326 ±72	490 ±177	1465 ±237
39	-	762 ±98	256 ±53	406 ±133	416 ±109	514 ±186	-
46	-	873 ±115	279 ±68	493 ±158	549 ±225	603 ±248	-
50	-	1020 ±149	341 ±80	573 ±178	630 ±187	806 ±285	-
56	-	1055 ±153	374 ±83	560 ±174	715 ±207	800 ±238	-
62	-	1193 ±207	379 ±85	653 ±204	806 ±253	649 ±254	-
69	-	-	490 ±106	773 ±254	-	766 ±313	-
77	-	-	534 ±126	722 ±269	-	-	-
83	-	-	627 ±156	-	-	-	-
90	-	-	813 ±197	-	-	-	-
96	-	-	903 ±207	-	-	-	-
101	-	-	901 ±213	-	-	-	-

Figure 8E

Efficacy of rat-human chimeric anti-Notch ADCs dosed at 5mg/kg in N87 gastric xenografts

Day	N87 Gastric xenografts, tumor volume (mm ³ ± SEM)			
	PBS	ch28-mc0131	ch28-m(H2O)c-0131	ch75-m(H2O)c-0131
-1	372 ±8	371 ±18	371 ±17	364 ±12
4	589 ±28	473 ±41	469 ±41	461 ±33
7	706 ±56	479 ±39	446 ±34	466 ±28
11	837 ±71	442 ±37	391 ±29	468 ±33
14	969 ±98	395 ±43	308 ±24	430 ±33
18	1069 ±106	328 ±36	231 ±27	424 ±41
21	1252 ±123	337 ±48	232 ±29	448 ±42
25	1230 ±112	324 ±55	230 ±38	422 ±45
28	1352 ±132	363 ±62	256 ±41	487 ±52
32		381 ±66	255 ±49	530 ±56
35		419 ±85	283 ±52	541 ±56
39		453 ±87	315 ±65	570 ±55
42		522 ±108	347 ±71	619 ±66
46		559 ±119	381 ±87	629 ±68
49		637 ±139	418 ±96	697 ±87
53		681 ±149	441 ±107	755 ±91
56		713 ±167	479 ±113	753 ±90
63		783 ±192	542 ±139	869 ±112
70		847 ±219	535 ±148	827 ±107
77		1081 ±273	726 ±191	1041 ±139
84			855 ±230	1172 ±165
91			722 ±194	1332 ±194
98			757 ±204	1125 ±198

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- EP 0404097 A [0023]
- WO 9311161 A [0023]
- US 4816567 A [0178]
- US 4816397 A [0178]
- US 5585089 A [0178]
- WO 8702671 A [0178]
- EP 0184187 A [0178]
- EP 0171496 A [0178]
- EP 0173494 A [0178]
- WO 8601533 A [0178]
- EP 012023 A [0178]
- US 5225539 A [0178]
- US 5625126 A [0179]
- US 5633425 A [0179]
- US 5569825 A [0179]
- US 5661016 A [0179]
- US 5545806 A [0179]
- WO 9734631 A [0183]
- US 180204 A [0220]
- WO 2012007896 A [0220]
- US 2006205670 A [0227]
- EP 624377 A [0334]
- WO 2012007896 A1 [0339]
- WO 2012059882 A2 [0340]
- WO 9633212 A [0359]
- WO 9509864 A [0359]
- EP 0695758 A [0359]
- WO 078848 A [0359]
- WO 0118032 A [0359]
- WO 0948967 A [0359]
- WO 09117531 A [0359]
- WO 088603 A [0359]
- US 7750116 B [0359]
- US 5985837 A [0359]
- US 20059751 B [0359]
- WO 37622 A1 [0691]

Non-patent literature cited in the description

- **JANEWAY et al.** Immuno. Biology. Garland Publishing, 2001 [0012]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. Public Health Service, National Institutes of Health, 1991 [0021]
- **CHOTHIA ; LESK.** *J. Mol. Biol.*, 1987, vol. 196, 901-917 [0021]
- **PLUCKTHUN.** The Pharmacology of Monoclonal Antibodies. Springer-Verlag, 1994, vol. 113, 269-315 [0022]
- **HOLLINGER et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0023]
- **JONES et al.** *Nature*, 1986, vol. 321, 522-525 [0024]
- **RIECHMANN et al.** *Nature*, 1988, vol. 332, 323-329 [0024]
- **PRESTA.** *Curr. Op. Struct. Biol.*, 1992, vol. 2, 593-596 [0024]
- **S. P. PARKER.** McGraw-Hill Dictionary of Chemical Terms. McGraw-Hill Book Company, 1984 [0056]
- **ELIEL ; WILEN.** Stereochemistry of Organic Compounds. John Wiley & Sons, Inc, 1994 [0056]
- **T. W. GREENE ; P. G. M. WUTS.** Protective Groups in Organic Synthesis. John Wiley & Sons, 1999 [0059]
- **HARRISON ; HARRISON et al.** Compendium of Synthetic Organic Methods. John Wiley and Sons, 1971, 1-8 [0059]
- **LAGUZZA et al.** *J. Med. Chem.*, 1989, vol. 32 (3), 548-55 [0171]
- **COLIGAN et al.** Current Protocols in Protein Science. John Wiley & Sons, 2002, vol. 2 [0171]
- **TENG et al.** *Proc. Natl. Acad. Sci. USA.*, 1983, vol. 80, 7308-7312 [0174]
- **KOZBOR et al.** *Immunology Today*, 1983, vol. 4, 72-79 [0174]
- **OLSSON et al.** *Meth. Enzymol.*, 1982, vol. 92, 3-16 [0174]
- **KABAT et al.** Sequences of Proteins of Immunological Interest. National Institute of Health, 1991 [0176]
- **KABAT E et al.** *J. Immunology*, 1980, vol. 125 (3), 961-969 [0176]
- **BERTER et al.** *Science*, 1988, vol. 240, 1041-1043 [0178]
- **LIU et al.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 3439-3443 [0178]
- **LIU et al.** *J. Immunol.*, 1987, vol. 139, 3521-3526 [0178]
- **SUN et al.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 214-218 [0178]
- **NISHIMURA et al.** *Cancer. Res.*, 1987, vol. 47, 999-1005 [0178]
- **WOOD et al.** *Nature*, 1985, vol. 314, 446-449 [0178]
- **SHAW et al.** *J. Natl. Cancer Inst.*, 1988, vol. 80, 1553-1559 [0178]

- **MORRISON.** *Science*, 1985, vol. 229, 1202-1207 [0178]
- **Ol et al.** *BioTechniques*, 1986, vol. 4, 214 [0178]
- **JONES et al.** *Nature*, 1986, vol. 321, 552-525 [0178]
- **VERHOEYAN et al.** *Science*, 1988, vol. 239, 1534 [0178]
- **BEIDLER et al.** *J. Immunol.*, 1988, vol. 141, 4053-4060 [0178]
- **LONBERG ; HUSZAR.** *Int. Rev. Immunol.*, 1995, vol. 13, 65-93 [0179]
- **JESPERS et al.** *Biotechnology*, 1994, vol. 12, 899-903 [0180]
- **HOOGENBOOM ; WINTER.** *J. Mol. Biol.*, 1991, vol. 227, 381 [0180]
- **MARKS et al.** *J. Mol. Biol.*, 1991, vol. 222, 581 [0180]
- The rise of monoclonal antibodies as therapeutics. **QUAN ; CARTER.** *Anti-IgE and Allergic Disease.* Marcel Dekker, 2002, 427-469 [0180]
- **SCHRODER ; LUBKE.** *The Peptides.* Academic Press, 1965, vol. 1, 76-136 [0196]
- **GOODSON.** *Medical Applications of Controlled Release*, 1984, vol. 2, 115-138 [0246]
- **LANGER.** *Science*, 1990, vol. 249, 1527-1533 [0246]
- **E. W. MARTIN.** *Remington's Pharmaceutical Sciences* [0248]
- **MalcValCitPABC-PNP.** *Eur. Pat. Appl.*, 1994 [0334]
- *Bioorganic and Medicinal Chemistry Letters*, 2012, vol. 22, 4249-4253 [0349]
- **PETIT et al.** *J. Am. Chem. Soc.*, 1989, vol. 111, 5463 [0359]
- **PETIT et al.** *AntiCancer Drug Design*, 1998, vol. 13, 243 [0359]
- **PETIT et al.** *J. Nat. Prod.*, 2011, vol. 74, 962 [0359]
- **LEHMANN, BD et al.** *J Clin Invest.*, 2011, vol. 121 (7), 2750-2767 [0696]